{
	"questions": [
		{
			"body": "What is the effect of ranolazine in diastolic heart failure?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/21538388",
				"http://www.ncbi.nlm.nih.gov/pubmed/22767404",
				"http://www.ncbi.nlm.nih.gov/pubmed/22343711",
				"http://www.ncbi.nlm.nih.gov/pubmed/19403851",
				"http://www.ncbi.nlm.nih.gov/pubmed/19333133",
				"http://www.ncbi.nlm.nih.gov/pubmed/23596505",
				"http://www.ncbi.nlm.nih.gov/pubmed/18439620",
				"http://www.ncbi.nlm.nih.gov/pubmed/17027025",
				"http://www.ncbi.nlm.nih.gov/pubmed/7873471",
				"http://www.ncbi.nlm.nih.gov/pubmed/19752362",
				"http://www.ncbi.nlm.nih.gov/pubmed/20924097",
				"http://www.ncbi.nlm.nih.gov/pubmed/24251065",
				"http://www.ncbi.nlm.nih.gov/pubmed/22465693"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/21538388",
				"http://www.ncbi.nlm.nih.gov/pubmed/22767404",
				"http://www.ncbi.nlm.nih.gov/pubmed/22343711",
				"http://www.ncbi.nlm.nih.gov/pubmed/19403851",
				"http://www.ncbi.nlm.nih.gov/pubmed/19333133",
				"http://www.ncbi.nlm.nih.gov/pubmed/23596505",
				"http://www.ncbi.nlm.nih.gov/pubmed/18439620",
				"http://www.ncbi.nlm.nih.gov/pubmed/17027025",
				"http://www.ncbi.nlm.nih.gov/pubmed/7873471",
				"http://www.ncbi.nlm.nih.gov/pubmed/19752362",
				"http://www.ncbi.nlm.nih.gov/pubmed/20924097",
				"http://www.ncbi.nlm.nih.gov/pubmed/24251065",
				"http://www.ncbi.nlm.nih.gov/pubmed/22465693"
			],
			"type": "summary",
			"id": "532f05a5d6d3ac6a34000025",
			"snippets": [
				{
					"offsetInBeginSection": 253,
					"offsetInEndSection": 383,
					"text": "Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21538388",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 71,
					"offsetInEndSection": 384,
					"text": "Ranolazine is an innovative anti-ischemic and antianginal agent that inhibits the late Na current, thereby reducing the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. In addition, ranolazine seems to exert beneficial effects on diastolic cardiac function. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 103,
					"text": "Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22343711",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1569,
					"offsetInEndSection": 1799,
					"text": "Diastolic dysfunction could be reversed by ranolazine, probably resulting from a direct effect on myofilaments, indicating that cardiac oxidative stress may mediate diastolic dysfunction through altering the contractile apparatus.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22343711",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 748,
					"offsetInEndSection": 981,
					"text": "Ranolazine (10 microM) significantly reduced the PC-induced increase in LVEDP by 72 +/- 6% (n = 6, p < 0.001), reduced left ventricular wall stiffness, and attenuated the PC-induced increase of CPP by 53 +/- 10% (n = 6-7, p < 0.05). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19403851",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 685,
					"offsetInEndSection": 804,
					"text": " Ranolazine, a specific inhibitor of late INa, reduces Na influx and hence ameliorates disturbed Na and Ca homeostasis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19333133",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1120,
					"offsetInEndSection": 1288,
					"text": "New clinical and experimental studies even point to potential antiarrhythmic effects, beneficial effects in diastolic heart failure, and under hyperglycemic conditions.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19333133",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1776,
					"offsetInEndSection": 1917,
					"text": "In addition, Lovelock et al. [26] could describe an effect of ranolazine on myofilament Ca sensitivity, thereby improving diastolic function.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 519,
					"offsetInEndSection": 743,
					"text": "Almost 20Β years ago, there was an elegant in vivo study showing an improved diastolic function in noninfarcted ischemic hearts in a small number of patients before and in the presence of intravenous application of ranolazine",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 958,
					"offsetInEndSection": 1367,
					"text": "In addition, a recent echocardiographic study investigated the effects of ranolazine in patients with stable angina with preserved ejection fraction [29β€Άβ€Ά]. After 2Β months deceleration time E, isovolumic contraction time, and isovolumic relaxation time decreased, whereas ejection time increased. Global left ventricular function also improved, as indicated by a decrease in the myocardial performance index.\n",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1979,
					"offsetInEndSection": 2162,
					"text": "First, in dogs with heart failure, acute infusion of ranolazine significantly reduced left ventricular end diastolic pressure, and increased ejection fraction as well as stroke volume",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 2879,
					"offsetInEndSection": 3082,
					"text": "Addition of ranolazine did not cause negative inotropy but significantly ameliorated disturbed intracellular ion handling and reduced the increase in diastolic tension (ie, improved diastolic dysfunction",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 3802,
					"offsetInEndSection": 4129,
					"text": "This increase in NCX forward mode displays the link between ranolazine-modulated cytosolic Na and Ca in such a way that both stimuli of the reverse NCX mode in heart failure, elevated [Na]i and prolonged action potential duration, become attenuated by exposure to ranolazine, leading to improved Ca elimination during diastole.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 4130,
					"offsetInEndSection": 4462,
					"text": "The results of this in vitro study led us to initiate the Ranolazine in Diastolic Heart Failure (RALI-DHF) trial (NCT01163734) to investigate intravenous ranolazine application in vivo followed by 2Β weeks oral treatment in patients with diastolic dysfunction due to severe HFpEF in a small proof-of-concept placebo-controlled study ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 488,
					"text": "In summary, there are increasingly experimental and preclinical data for a beneficial role of ranolazine in diastolic dysfunction and cardiac arrhythmias in addition to its current antianginal role. We believe that further experimental studies and future clinical trials will shed light onto the potential impact and future indications for ranolazine to treat patients possibly with certain arrhythmias, forms of heart failure most likely with diastolic dysfunction and HFpEF.",
					"beginSection": "sections.5",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404",
					"endSection": "sections.5"
				}
			]
		},
		{
			"body": "Which are the musculoskeletal manifestations of Marfan syndrome?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/19726741",
				"http://www.ncbi.nlm.nih.gov/pubmed/17620463",
				"http://www.ncbi.nlm.nih.gov/pubmed/6481730",
				"http://www.ncbi.nlm.nih.gov/pubmed/21971724",
				"http://www.ncbi.nlm.nih.gov/pubmed/20686061"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/19726741",
				"http://www.ncbi.nlm.nih.gov/pubmed/17620463",
				"http://www.ncbi.nlm.nih.gov/pubmed/6481730",
				"http://www.ncbi.nlm.nih.gov/pubmed/21971724",
				"http://www.ncbi.nlm.nih.gov/pubmed/20686061"
			],
			"type": "list",
			"id": "532f0b2cd6d3ac6a3400002c",
			"snippets": [
				{
					"offsetInBeginSection": 220,
					"offsetInEndSection": 329,
					"text": "Musculoskeletal manifestations include scoliosis, dural ectasia, protrusio acetabuli, and ligamentous laxity.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19726741",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 460,
					"offsetInEndSection": 587,
					"text": "Scoliosis, pectus excavatum and carinatum, arachnodactyly, and acetabular protrusion are common musculoskeletal manifestations.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17620463",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 135,
					"offsetInEndSection": 308,
					"text": "Two cases are described in which protrusio acetabuli was a major problem. Otto pelvis should be considered as one of the musculoskeletal manifestations of Marfan's syndrome.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/6481730",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1415,
					"offsetInEndSection": 1594,
					"text": "The following musculoskeletal abnormalities were found: pectus in 3 patients (11%), pectus and scoliosis in 19 (73%), dolichostenomelia in 11 (42%) and arachnodactyly in 21 (80%).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21971724",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1815,
					"offsetInEndSection": 2179,
					"text": "Musculoskeletal clinicians should be aware of the diagnostic features of Marfan syndrome. Patients with three to four physically evident features, or two highly specific features (e.g., thumb and wrist signs, craniofacial features, dural ectasia, or protrusio), should be carefully reexamined and possibly referred for an echocardiogram or a genetics consultation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20686061",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Are patients with marfan syndrome at increased risk of arrhythmias?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22738784",
				"http://www.ncbi.nlm.nih.gov/pubmed/17597390",
				"http://www.ncbi.nlm.nih.gov/pubmed/12535830"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22738784",
				"http://www.ncbi.nlm.nih.gov/pubmed/17597390",
				"http://www.ncbi.nlm.nih.gov/pubmed/12535830"
			],
			"type": "yesno",
			"id": "532f0c4ed6d3ac6a3400002e",
			"snippets": [
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 183,
					"text": "Marfan syndrome (MFS) is a variable, autosomal-dominant disorder of the connective tissue. In MFS serious ventricular arrhythmias and sudden cardiac death (SCD) can occur.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22738784",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 127,
					"offsetInEndSection": 191,
					"text": "Marfan's patients carry increased risk for cardiac arrhythmias. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17597390",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 774,
					"offsetInEndSection": 935,
					"text": "Ventricular arrhythmias were present in 21% and were associated with increased left ventricular size, mitral valve prolapse, and abnormalities of repolarization.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12535830",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 949,
					"offsetInEndSection": 1277,
					"text": "Cardiac complications are rare in young patients with Marfan syndrome receiving medical therapy and close clinical follow-up. Sudden death still occurs, and appears more common in patients with a dilated left ventricle. Left ventricular dilation may predispose to alterations of repolarization and fatal ventricular arrhythmias.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12535830",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which is the prognostic meaning of delayed enhancement documented in patients hypertrophic cardiomyopathy?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20339815",
				"http://www.ncbi.nlm.nih.gov/pubmed/20079992",
				"http://www.ncbi.nlm.nih.gov/pubmed/19808288",
				"http://www.ncbi.nlm.nih.gov/pubmed/22498326",
				"http://www.ncbi.nlm.nih.gov/pubmed/21498307",
				"http://www.ncbi.nlm.nih.gov/pubmed/19474054",
				"http://www.ncbi.nlm.nih.gov/pubmed/18562248",
				"http://www.ncbi.nlm.nih.gov/pubmed/18208827",
				"http://www.ncbi.nlm.nih.gov/pubmed/23376948",
				"http://www.ncbi.nlm.nih.gov/pubmed/21234292",
				"http://www.ncbi.nlm.nih.gov/pubmed/22348519",
				"http://www.ncbi.nlm.nih.gov/pubmed/19740409",
				"http://www.ncbi.nlm.nih.gov/pubmed/18204915",
				"http://www.ncbi.nlm.nih.gov/pubmed/12224720",
				"http://www.ncbi.nlm.nih.gov/pubmed/20102955",
				"http://www.ncbi.nlm.nih.gov/pubmed/19477402",
				"http://www.ncbi.nlm.nih.gov/pubmed/22128204",
				"http://www.ncbi.nlm.nih.gov/pubmed/19784900",
				"http://www.ncbi.nlm.nih.gov/pubmed/15861263",
				"http://www.ncbi.nlm.nih.gov/pubmed/22135401",
				"http://www.ncbi.nlm.nih.gov/pubmed/20667520",
				"http://www.ncbi.nlm.nih.gov/pubmed/20688032",
				"http://www.ncbi.nlm.nih.gov/pubmed/22687593",
				"http://www.ncbi.nlm.nih.gov/pubmed/22935464"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20339815",
				"http://www.ncbi.nlm.nih.gov/pubmed/20079992",
				"http://www.ncbi.nlm.nih.gov/pubmed/19808288",
				"http://www.ncbi.nlm.nih.gov/pubmed/22498326",
				"http://www.ncbi.nlm.nih.gov/pubmed/21498307",
				"http://www.ncbi.nlm.nih.gov/pubmed/19474054",
				"http://www.ncbi.nlm.nih.gov/pubmed/18562248",
				"http://www.ncbi.nlm.nih.gov/pubmed/18208827",
				"http://www.ncbi.nlm.nih.gov/pubmed/23376948",
				"http://www.ncbi.nlm.nih.gov/pubmed/21234292",
				"http://www.ncbi.nlm.nih.gov/pubmed/22348519",
				"http://www.ncbi.nlm.nih.gov/pubmed/19740409",
				"http://www.ncbi.nlm.nih.gov/pubmed/18204915",
				"http://www.ncbi.nlm.nih.gov/pubmed/12224720",
				"http://www.ncbi.nlm.nih.gov/pubmed/20102955",
				"http://www.ncbi.nlm.nih.gov/pubmed/19477402",
				"http://www.ncbi.nlm.nih.gov/pubmed/22128204",
				"http://www.ncbi.nlm.nih.gov/pubmed/19784900",
				"http://www.ncbi.nlm.nih.gov/pubmed/15861263",
				"http://www.ncbi.nlm.nih.gov/pubmed/22135401",
				"http://www.ncbi.nlm.nih.gov/pubmed/20667520",
				"http://www.ncbi.nlm.nih.gov/pubmed/20688032",
				"http://www.ncbi.nlm.nih.gov/pubmed/22687593",
				"http://www.ncbi.nlm.nih.gov/pubmed/22935464"
			],
			"type": "factoid",
			"id": "5339ecf4d6d3ac6a3400005f",
			"snippets": [
				{
					"offsetInBeginSection": 1208,
					"offsetInEndSection": 1466,
					"text": " It is possible to conclude that there is a high prevalence of myocardial fibrosis in hypertrophic cardiomyopathy patients with high-risk or recovered from cardiac sudden death, like those with clinical indication to implantable cardioverter -defibrillator. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20339815",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 927,
					"offsetInEndSection": 1018,
					"text": "AF in HCM is related with myocardial fibrosis detected by DE-CMR and dilatation of the LA. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20079992",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1183,
					"offsetInEndSection": 1388,
					"text": "Over the follow-up period, the annualized adverse cardiovascular event rate in patients with DE exceeded that in patients without DE but did not achieve statistical significance (5.5% versus 3.3%; P=0.5). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19808288",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1452,
					"offsetInEndSection": 1780,
					"text": "Late gadolinium enhancement by CMR has prognostic value in predicting adverse cardiovascular events among HCM patients. There are significant relationships between LGE and cardiovascular mortality, heart failure death, and all-cause mortality in HCM. Additionally, LGE and SCD/aborted SCD displayed a trend toward significance. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22498326",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1185,
					"offsetInEndSection": 1364,
					"text": "The hyperenhanced apical myocardium had a lower percentage of systolic myocardial thickening, and was associated with serious symptoms (e.g. syncope) and ventricular arrhythmias. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21498307",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1221,
					"offsetInEndSection": 1413,
					"text": "A semi-quantitative index of DCE is a significant multivariable predictor of both clinical VT/VF and of risk for SCD and may contribute to risk assessment in borderline or controversial cases.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19474054",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1419,
					"offsetInEndSection": 1509,
					"text": "Myocardial scar imaged by CE-CMR is common in patients with HCM, and is predictive of VT. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18562248",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which is the clinical meaning of the presence of delayed enhancement in patients with hypertrophic cardiomyopathy?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23097128",
				"http://www.ncbi.nlm.nih.gov/pubmed/22641976",
				"http://www.ncbi.nlm.nih.gov/pubmed/21498307",
				"http://www.ncbi.nlm.nih.gov/pubmed/20102955",
				"http://www.ncbi.nlm.nih.gov/pubmed/19808288",
				"http://www.ncbi.nlm.nih.gov/pubmed/19477402",
				"http://www.ncbi.nlm.nih.gov/pubmed/18552138",
				"http://www.ncbi.nlm.nih.gov/pubmed/18387438"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23097128",
				"http://www.ncbi.nlm.nih.gov/pubmed/22641976",
				"http://www.ncbi.nlm.nih.gov/pubmed/21498307",
				"http://www.ncbi.nlm.nih.gov/pubmed/20102955",
				"http://www.ncbi.nlm.nih.gov/pubmed/19808288",
				"http://www.ncbi.nlm.nih.gov/pubmed/19477402",
				"http://www.ncbi.nlm.nih.gov/pubmed/18552138",
				"http://www.ncbi.nlm.nih.gov/pubmed/18387438"
			],
			"type": "factoid",
			"id": "5339edd6d6d3ac6a34000061",
			"snippets": [
				{
					"offsetInBeginSection": 1464,
					"offsetInEndSection": 1664,
					"text": "The extent of regional myocardial fibrosis is associated with regional myocardial function independently of morphological changes of the myocardium, and the correlation extended to global LV function.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23097128",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1606,
					"offsetInEndSection": 1785,
					"text": "Occurrence of myocardial fibrosis in hypertrophic cardiomyopathy is associated with left atrial and ventricular dysfunction as well as with the severity of heart failure symptoms.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22641976",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1376,
					"offsetInEndSection": 1595,
					"text": "Patients with symptomatic apical HCMshowed myocardial hyperenhancement involving the subendocardial layer, which might be related to regional systolic dysfunction, serious clinical symptoms, and ventricular arrhythmias.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21498307",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1100,
					"offsetInEndSection": 1269,
					"text": "In conclusion, late gadolinium enhancement was associated with nonsustained ventricular tachycardia, arrhythmic risk factors, and worse New York Heart Association class.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20102955",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 666,
					"offsetInEndSection": 798,
					"text": "The presence of DE was related to occurrence of heart failure symptoms (P=0.05) and left ventricular systolic dysfunction (P=0.001).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19808288",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1066,
					"offsetInEndSection": 1183,
					"text": "DE (7%+/-7% of left ventricle) was present in 54 patients who were asymptomatic (and with normal ejection fraction). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19808288",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1122,
					"offsetInEndSection": 1330,
					"text": "In HCM, the DE was associated with higher NYHA classes and prevalence of VT, impaired global LV function and asymmetrical hypertrophy, and conduction disturbance, abnormal Q waves, and giant negative T waves.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19477402",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1482,
					"offsetInEndSection": 1951,
					"text": " In myocardial segments exhibiting DCE, hMBF is reduced. DCE extent is inversely correlated and hMBF directly correlated with systolic thickening. In segments without DCE but contiguous to DCE areas, hMBF is significantly lower than in those remote from DCE and is similar to the value obtained in nontransmural DCE segments. These results suggest that increasing degrees of coronary microvascular dysfunction might play a causative role for myocardial fibrosis in HCM.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18552138",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1334,
					"offsetInEndSection": 1683,
					"text": "In this large HCM cohort with no or only mild symptoms, myocardial fibrosis detected by CMR was associated with greater likelihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulatory Holter ECG. Therefore, contrast-enhanced CMR identifies HCM patients with increased susceptibility to ventricular tachyarrhythmias.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18387438",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which hormone receptor function is altered in patients with Donohue syndrome?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23990696",
				"http://www.ncbi.nlm.nih.gov/pubmed/23824322",
				"http://www.ncbi.nlm.nih.gov/pubmed/23229189",
				"http://www.ncbi.nlm.nih.gov/pubmed/22972224",
				"http://www.ncbi.nlm.nih.gov/pubmed/22768670",
				"http://www.ncbi.nlm.nih.gov/pubmed/21092701",
				"http://www.ncbi.nlm.nih.gov/pubmed/19882513",
				"http://www.ncbi.nlm.nih.gov/pubmed/19774849",
				"http://www.ncbi.nlm.nih.gov/pubmed/18411068",
				"http://www.ncbi.nlm.nih.gov/pubmed/17201797",
				"http://www.ncbi.nlm.nih.gov/pubmed/24498630"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://www.w3.org/2004/02/skos/core#definition",
					"o": "MSH: Rare autosomal recessive syndrome of extreme insulin resistance due to mutations in the binding domain of INSULIN RECEPTOR. Clinical features include severe intrauterine and postnatal growth restriction, characteristic dysmorphic FACIES; HIRSUTISM; VIRILIZATION; multiple endocrine abnormalities, and early death.,NCI: A rare autosomal recessive genetic disorder caused by mutations in the insulin receptor gene. Signs and symptoms include a characteristic facial appearance (protuberant and low-set ears, thick lips, and flaring nostrils), intrauterine growth retardation, insulin resistance, and enlarged genitalia."
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17001090",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Leprechaunisms"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A17001090"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17003896",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Syndrome, Donohue"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18430717"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A17012086"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A13286376",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "LEPRECHAUNISM"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A13288574"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A16995573"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18433068",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Leprechaunism"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18433068"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18430717",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Donohue Syndrome [Disease/Finding]"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A13288574",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "DONOHUE SYNDROME"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A17003896"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A17689250"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18444972"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0265344",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A13286376"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17012086",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Donohue Syndrome"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23990696",
				"http://www.ncbi.nlm.nih.gov/pubmed/23824322",
				"http://www.ncbi.nlm.nih.gov/pubmed/23229189",
				"http://www.ncbi.nlm.nih.gov/pubmed/22972224",
				"http://www.ncbi.nlm.nih.gov/pubmed/22768670",
				"http://www.ncbi.nlm.nih.gov/pubmed/21092701",
				"http://www.ncbi.nlm.nih.gov/pubmed/19882513",
				"http://www.ncbi.nlm.nih.gov/pubmed/19774849",
				"http://www.ncbi.nlm.nih.gov/pubmed/18411068",
				"http://www.ncbi.nlm.nih.gov/pubmed/17201797",
				"http://www.ncbi.nlm.nih.gov/pubmed/24498630"
			],
			"type": "factoid",
			"id": "5314bd7ddae131f847000006",
			"snippets": [
				{
					"offsetInBeginSection": 104,
					"offsetInEndSection": 247,
					"text": "This disease is caused by a defective insulin receptor and features abnormal glucose metabolism and retarded intrauterine and postnatal growth.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23990696",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 180,
					"text": "Biallelic insulin receptor (INSR) gene mutations cause congenital syndromes of severe insulin resistance (SIR) known as Donohue syndrome (DS) and Rabson-Mendenhall syndrome (RMS). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23824322",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 177,
					"text": "Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23229189",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 275,
					"text": "Donohue syndrome (leprechaunism; OMIM *246200) is a rare, recessively inherited disorder of extreme insulin resistance due to mutations in the insulin receptor gene (INSR) causing either defects in insulin binding or receptor autophosphorylation and tyrosine kinase activity.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23229189",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 116,
					"text": "Leprechaunism (Donohue syndrome): a case bearing novel compound heterozygous mutations in the insulin receptor gene.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22972224",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 154,
					"text": "Leprechaunism (Donohue syndrome) is the most severe type of insulin receptor (INSR) gene anomaly with the majority of patients surviving for only 2 years.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22972224",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 106,
					"text": "A novel mutation of the insulin receptor gene in a preterm infant with Donohue syndrome and heart failure.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22768670",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 124,
					"text": "Donohue syndrome (DS) is a rare autosomal recessive condition caused by mutations in the gene encoding the insulin receptor.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22768670",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 318,
					"offsetInEndSection": 578,
					"text": "Any dysfunction of insulin signalling pathway as a result of insulin receptor gene mutations is linked with various forms of insulin resistance, including insulin resistance type A, Donohue or Rabson-Mendenhall syndrome, which differ in the level of severity. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21092701",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 94,
					"text": "Donohue syndrome in a neonate with homozygous deletion of exon 3 of the insulin receptor gene.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19774849",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 114,
					"text": "Donohue syndrome describes the clinical consequences of the most severe genetic loss of insulin receptor function.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19774849",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 378,
					"text": "Homozygous or compound heterozygous mutations within the insulin binding domain of the human insulin receptor (INSR) are usually associated with severe impairment of insulin binding leading to Donohue syndrome (\"Leprechaunism\"), which is characterized by excessive hyperglycemia with hyperinsulinism, pre- and postnatal growth retardation, distinct dysmorphism and early death. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18411068",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1053,
					"offsetInEndSection": 1159,
					"text": "The former mutation has been described in homozygous form in Donohue syndrome, while the latter is novel. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17201797",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 125,
					"offsetInEndSection": 279,
					"text": "This disease is caused by a defective\ninsulin receptor and features abnormal glucose metabolism and retarded intrauterine and\npostnatal growth (1,2,3,4).\n",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23990696",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 126,
					"offsetInEndSection": 220,
					"text": "To our knowledge, she is the longest surviving patient with\nsevere insulin receptor mutation.\n",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23990696",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 516,
					"offsetInEndSection": 696,
					"text": "Molecular\nanalysis of her insulin receptor gene revealed a missense mutation (P87L) in the paternal\nallele and a 1.3-kb deletion between exons 4 and 6 in the maternal allele (14).\n",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23990696",
					"endSection": "sections.1"
				}
			]
		},
		{
			"body": "Are there any specific antidotes for rivaroxaban?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24103671",
				"http://www.ncbi.nlm.nih.gov/pubmed/23821689",
				"http://www.ncbi.nlm.nih.gov/pubmed/23810130",
				"http://www.ncbi.nlm.nih.gov/pubmed/23790307",
				"http://www.ncbi.nlm.nih.gov/pubmed/23657589",
				"http://www.ncbi.nlm.nih.gov/pubmed/23460104",
				"http://www.ncbi.nlm.nih.gov/pubmed/23312927",
				"http://www.ncbi.nlm.nih.gov/pubmed/23117666",
				"http://www.ncbi.nlm.nih.gov/pubmed/22353706",
				"http://www.ncbi.nlm.nih.gov/pubmed/22308807",
				"http://www.ncbi.nlm.nih.gov/pubmed/22177763",
				"http://www.ncbi.nlm.nih.gov/pubmed/20858186",
				"http://www.ncbi.nlm.nih.gov/pubmed/19351313",
				"http://www.ncbi.nlm.nih.gov/pubmed/23634925",
				"http://www.ncbi.nlm.nih.gov/pubmed/23628464",
				"http://www.ncbi.nlm.nih.gov/pubmed/24170233",
				"http://www.ncbi.nlm.nih.gov/pubmed/23953907",
				"http://www.ncbi.nlm.nih.gov/pubmed/23866358",
				"http://www.ncbi.nlm.nih.gov/pubmed/12871541"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24103671",
				"http://www.ncbi.nlm.nih.gov/pubmed/23821689",
				"http://www.ncbi.nlm.nih.gov/pubmed/23810130",
				"http://www.ncbi.nlm.nih.gov/pubmed/23790307",
				"http://www.ncbi.nlm.nih.gov/pubmed/23657589",
				"http://www.ncbi.nlm.nih.gov/pubmed/23460104",
				"http://www.ncbi.nlm.nih.gov/pubmed/23312927",
				"http://www.ncbi.nlm.nih.gov/pubmed/23117666",
				"http://www.ncbi.nlm.nih.gov/pubmed/22353706",
				"http://www.ncbi.nlm.nih.gov/pubmed/22308807",
				"http://www.ncbi.nlm.nih.gov/pubmed/22177763",
				"http://www.ncbi.nlm.nih.gov/pubmed/20858186",
				"http://www.ncbi.nlm.nih.gov/pubmed/19351313",
				"http://www.ncbi.nlm.nih.gov/pubmed/23634925",
				"http://www.ncbi.nlm.nih.gov/pubmed/23628464",
				"http://www.ncbi.nlm.nih.gov/pubmed/24170233",
				"http://www.ncbi.nlm.nih.gov/pubmed/23953907",
				"http://www.ncbi.nlm.nih.gov/pubmed/23866358",
				"http://www.ncbi.nlm.nih.gov/pubmed/12871541"
			],
			"type": "yesno",
			"id": "532f08b8d6d3ac6a34000029",
			"snippets": [
				{
					"offsetInBeginSection": 172,
					"offsetInEndSection": 490,
					"text": "Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24103671",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 414,
					"text": "he new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23821689",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 490,
					"offsetInEndSection": 592,
					"text": "Given the absence of a specific antidote, the action to be taken in these situations must be defined. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23810130",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1018,
					"offsetInEndSection": 1176,
					"text": "The fact that there is no specific antidote to reverse the anticoagulant action of the new anticoagulants can impair management of hemorrhagic complications; ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23790307",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 200,
					"offsetInEndSection": 537,
					"text": "Like any new therapy, the potential benefits must be weighed against the potential challenges and one of the most concerning aspects of the new target-specific oral anticoagulants is the lack of a proven method to reverse their effect. Unlike the vitamin K antagonist, i.e. warfarin, there is no specific antidote for these medications. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23657589",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1442,
					"offsetInEndSection": 1598,
					"text": "Two major drawbacks are on the one hand the risk of drug accumulation in kidney and/or liver disease and, on the other hand, the lack of specific antidotes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23460104",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1518,
					"offsetInEndSection": 1741,
					"text": "NOA also have other unresolved problems: drug interactions are still possible, specific coagulation test to assess them must be developed, and no specific antidote is currently available in case of hemorrhagic complication.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23312927",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1191,
					"offsetInEndSection": 1333,
					"text": "But they have disadvantages also, they depend on renal clearance, they can interact with other medicaments and they lack a specific antidote. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23117666",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 734,
					"offsetInEndSection": 957,
					"text": "While these trial data are extremely encouraging, several practical issues (e.g., lack of specific antidote, safety of long-term treatment or cost-effectiveness in \"real-life\" clinical practice) still need to be elucidated.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22353706",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 505,
					"offsetInEndSection": 661,
					"text": "In case of massive bleeding, management is unclear and none of these newer agents has a specific antidote that completely reverses its anticoagulant effect.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22308807",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1935,
					"offsetInEndSection": 2044,
					"text": "The short half-life of these new agents compensates for the lack of any specific antidote in many instances. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22177763",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 618,
					"offsetInEndSection": 750,
					"text": "Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20858186",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 439,
					"offsetInEndSection": 865,
					"text": "Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor. The drug offers once-daily oral dosing, with no need for injections, dose titration, or frequent blood tests to monitor the international normalised ratio. It has a rapid onset of action and, although there is no specific antidote, it has a short plasma elimination half-life (about 5-9 hours). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19351313",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 508,
					"offsetInEndSection": 731,
					"text": "Increased use of dabigatran, rivaroxaban, and apixaban as oral anticoagulants for the treatment of atrial fibrillation and acute deep venous thrombosis has increased despite the lack of known antidotes to these medications.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23634925",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 686,
					"offsetInEndSection": 812,
					"text": "There is no antidote for reversal and no reliable laboratory monitoring of the anticoagulant effect for emergency situations. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23628464",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1259,
					"offsetInEndSection": 1570,
					"text": "Further concerns about the use of NOAC in the elderly are the high prevalence of renal insufficiency in AF patients >75 years of age, the largely unknown risk of drug-drug and drug-food interactions, the lack of easily available laboratory monitoring tests of anticoagulant activity and the lack of an antidote.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24170233",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 301,
					"offsetInEndSection": 576,
					"text": "Specific antidotes for the reversal of the anticoagulant effect of these drugs, such as monoclonal antibodies against the direct thrombin inhibitor dabigatran or recombinant Xa-analog in the case of factor Xa inhibitors, are still being investigated in early clinical trials.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23953907",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1429,
					"offsetInEndSection": 1596,
					"text": "In early 2013 there is no antidote for dabigatran, rivaroxaban or apixaban, nor any specific treatment with proven efficacy for severe bleeding linked to these drugs. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23866358",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which are the known inhibitors of the TPL2/MAP3K8 protein?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23828905",
				"http://www.ncbi.nlm.nih.gov/pubmed/21862328",
				"http://www.ncbi.nlm.nih.gov/pubmed/21851209",
				"http://www.ncbi.nlm.nih.gov/pubmed/21742493",
				"http://www.ncbi.nlm.nih.gov/pubmed/21705614",
				"http://www.ncbi.nlm.nih.gov/pubmed/20606319",
				"http://www.ncbi.nlm.nih.gov/pubmed/19464884",
				"http://www.ncbi.nlm.nih.gov/pubmed/19217782",
				"http://www.ncbi.nlm.nih.gov/pubmed/17715908",
				"http://www.ncbi.nlm.nih.gov/pubmed/17664070",
				"http://www.ncbi.nlm.nih.gov/pubmed/16165349"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23828905",
				"http://www.ncbi.nlm.nih.gov/pubmed/21862328",
				"http://www.ncbi.nlm.nih.gov/pubmed/21851209",
				"http://www.ncbi.nlm.nih.gov/pubmed/21742493",
				"http://www.ncbi.nlm.nih.gov/pubmed/21705614",
				"http://www.ncbi.nlm.nih.gov/pubmed/20606319",
				"http://www.ncbi.nlm.nih.gov/pubmed/19464884",
				"http://www.ncbi.nlm.nih.gov/pubmed/19217782",
				"http://www.ncbi.nlm.nih.gov/pubmed/17715908",
				"http://www.ncbi.nlm.nih.gov/pubmed/17664070",
				"http://www.ncbi.nlm.nih.gov/pubmed/16165349"
			],
			"type": "list",
			"id": "52fc8b772059c6d71c00006e",
			"snippets": [
				{
					"offsetInBeginSection": 1629,
					"offsetInEndSection": 1821,
					"text": "Taken together, our results suggest that the therapeutic inhibition of Tpl2 by Honokiol thwarts both gastric tumor growth and peritoneal dissemination by inducing ER stress and inhibiting EMT.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23828905",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 124,
					"offsetInEndSection": 337,
					"text": "The article describes the development of a robust pharmacophore model and the investigation of structure-activity relationship analysis of quinoline-3-carbonitrile derivatives reported for Tpl2 kinase inhibition. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21851209",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 443,
					"offsetInEndSection": 613,
					"text": "In the present study, we found that luteolin inhibited TNF-Ξ±-induced COX-2 expression by down-regulating the transactivation of nuclear factor-ΞΊB and activator protein-1.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21705614",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 445,
					"offsetInEndSection": 622,
					"text": "we studied the molecular mechanisms of Tpl2-mediated TNFalpha production using a potent Tpl2 kinase inhibitor, 1,7-naphtyridine-3-carbonitrile, and LPS-stimulated RAW264.7 cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20606319",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 249,
					"offsetInEndSection": 332,
					"text": "a selective and potent inhibitor of Tpl2, 1,7-naphtyridine-3-carbonitrile, was used",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20045951",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 163,
					"offsetInEndSection": 335,
					"text": "We have discovered that 8-halo-4-(3-chloro-4-fluoro-phenylamino)-6-[(1H-[1,2,3]triazol-4-ylmethyl)-amino]-quinoline-3-carbonitriles (4) are potent inhibitors of this enzyme",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19464884",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1236,
					"offsetInEndSection": 1526,
					"text": "urther structure-activity based modifications led to the identification of 8-bromo-4-(3-chloro-4-fluorophenylamino)-6-[(1-methyl-1H-imidazol-4-yl)methylamino]quinoline-3-carbonitrile, which demonstrated in vitro as well as in vivo efficacy in inhibition of LPS-induced TNF-alpha production.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17715908",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 224,
					"text": "nhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17715908",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 42,
					"offsetInEndSection": 92,
					"text": "thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21862328",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 19,
					"offsetInEndSection": 75,
					"text": " selective thieno[2,3-c]pyridine inhibitor of COT kinase",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19217782",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 199,
					"offsetInEndSection": 311,
					"text": "we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitrile",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17664070",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 89,
					"text": "nhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16165349",
					"endSection": "title"
				}
			]
		},
		{
			"body": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18353534"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18353534"
			],
			"type": "summary",
			"id": "52fc94932059c6d71c000072",
			"snippets": [
				{
					"offsetInBeginSection": 380,
					"offsetInEndSection": 519,
					"text": "An incidence peak for aneurysm rupture (28 patients) was seen during the phase of new moon, which was statistically significant (p < 0.001)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18353534",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 607,
					"offsetInEndSection": 763,
					"text": "The lunar cycle seems to affect the incidence of intracranial aneurysm rupture, with the new moon being associated with an increased risk of aneurysmal SAH.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18353534",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Where is the histone variant CENPA preferentially localized?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23439889",
				"http://www.ncbi.nlm.nih.gov/pubmed/21888900",
				"http://www.ncbi.nlm.nih.gov/pubmed/20119530",
				"http://www.ncbi.nlm.nih.gov/pubmed/12217960",
				"http://www.ncbi.nlm.nih.gov/pubmed/12011073",
				"http://www.ncbi.nlm.nih.gov/pubmed/19778997",
				"http://www.ncbi.nlm.nih.gov/pubmed/20940262"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23439889",
				"http://www.ncbi.nlm.nih.gov/pubmed/21888900",
				"http://www.ncbi.nlm.nih.gov/pubmed/20119530",
				"http://www.ncbi.nlm.nih.gov/pubmed/12217960",
				"http://www.ncbi.nlm.nih.gov/pubmed/12011073",
				"http://www.ncbi.nlm.nih.gov/pubmed/19778997",
				"http://www.ncbi.nlm.nih.gov/pubmed/20940262"
			],
			"type": "factoid",
			"id": "52fe52702059c6d71c000078",
			"snippets": [
				{
					"offsetInBeginSection": 745,
					"offsetInEndSection": 774,
					"text": "centromere protein A (CENPA),",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16314512",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 271,
					"offsetInEndSection": 434,
					"text": "Centromere activity of the alphoid YAC was suppressed at ectopic locations on the host chromosome, as indicated by the absent or reduced assembly of CENP-A and -C.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12953060",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 115,
					"offsetInEndSection": 357,
					"text": "Heterozygous and homozygous Cenpa-GFP fusion-protein mouse mutants, generated through targeted insertion of the green fluorescent protein (GFP) gene into the mouse Cenpa gene locus, show specific localized fluorescence at all the centromeres.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12906131",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 634,
					"offsetInEndSection": 884,
					"text": "Co-immunoprecipitation assay demonstrates interaction between PARP-2 and its functional homolog PARP-1, constitutive centromere proteins Cenpa and Cenpb, and spindle checkpoint protein Bub3, but not with a third constitutive centromere protein Cenpc.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12217960",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 631,
					"offsetInEndSection": 824,
					"text": "Here we investigated the interaction of this protein with, and poly(ADP-ribosyl)ation of, three constitutive centromere proteins, Cenpa, Cenpb, and Cenpc, and a spindle checkpoint protein, Bub3",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12011073",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 945,
					"offsetInEndSection": 1091,
					"text": "The evidence is consistent with the proposal of a critical epigenetic function for CENP-A in marking a chromosomal region for centromere formation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10655499",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 94,
					"offsetInEndSection": 319,
					"text": "CENPA is a member of the histone H3-like proteins and is thought to replace histone H3 in centromeric nucleosomes. CENPC is a DNA-binding protein that is located at the inner kinetochore plate of active mammalian centromeres.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9465302",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 57,
					"text": "ENPA/Cse4 assembles centromeric chromatin on diverse DNA",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23439889",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 215,
					"offsetInEndSection": 262,
					"text": "constitutive kinetochore proteins such as CENPA",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21888900",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 407,
					"offsetInEndSection": 579,
					"text": "A specific histone H3 variant, CENPA, replaces conventional histone H3 and together with centromere-specific-DNA-binding factors directs the assembly of active kinetochores",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 381,
					"offsetInEndSection": 466,
					"text": "histone H3-like variant, CENPA, replaces ordinary histone H3 in centromeric chromatin",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1255,
					"offsetInEndSection": 1319,
					"text": "unction of CENPA in kinetochore assembly and centromere activity",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1675,
					"offsetInEndSection": 1729,
					"text": "CENPA is concentrated at the kinetochore in centromere",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2484,
					"offsetInEndSection": 2522,
					"text": "CENPA is a centromere-specific homolog",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2572,
					"offsetInEndSection": 2615,
					"text": "CENPA replaces histone H3 at the centromere",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 18373,
					"offsetInEndSection": 18405,
					"text": "CENPA at centromeric nucleosomes",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 20431,
					"offsetInEndSection": 20463,
					"text": "CENPA loading at the centromere ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 437,
					"offsetInEndSection": 463,
					"text": "CENPA over centromeric DNA",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20119530",
					"endSection": "sections.1"
				}
			]
		},
		{
			"body": "Are there any urine biomarkers for chronic kidney disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24315007",
				"http://www.ncbi.nlm.nih.gov/pubmed/24308223",
				"http://www.ncbi.nlm.nih.gov/pubmed/24281781",
				"http://www.ncbi.nlm.nih.gov/pubmed/24224012",
				"http://www.ncbi.nlm.nih.gov/pubmed/24205707",
				"http://www.ncbi.nlm.nih.gov/pubmed/24152229",
				"http://www.ncbi.nlm.nih.gov/pubmed/24133923",
				"http://www.ncbi.nlm.nih.gov/pubmed/24065527",
				"http://www.ncbi.nlm.nih.gov/pubmed/23061738",
				"http://www.ncbi.nlm.nih.gov/pubmed/22914685",
				"http://www.ncbi.nlm.nih.gov/pubmed/23344473",
				"http://www.ncbi.nlm.nih.gov/pubmed/23758910",
				"http://www.ncbi.nlm.nih.gov/pubmed/23617441",
				"http://www.ncbi.nlm.nih.gov/pubmed/21816077",
				"http://www.ncbi.nlm.nih.gov/pubmed/22189039",
				"http://www.ncbi.nlm.nih.gov/pubmed/23339563"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/pubmed/keyword/CHRONIC+DISEASE%2Furine",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "CHRONIC DISEASE/urine"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24315007",
				"http://www.ncbi.nlm.nih.gov/pubmed/24308223",
				"http://www.ncbi.nlm.nih.gov/pubmed/24281781",
				"http://www.ncbi.nlm.nih.gov/pubmed/24224012",
				"http://www.ncbi.nlm.nih.gov/pubmed/24205707",
				"http://www.ncbi.nlm.nih.gov/pubmed/24152229",
				"http://www.ncbi.nlm.nih.gov/pubmed/24133923",
				"http://www.ncbi.nlm.nih.gov/pubmed/24065527",
				"http://www.ncbi.nlm.nih.gov/pubmed/23061738",
				"http://www.ncbi.nlm.nih.gov/pubmed/22914685",
				"http://www.ncbi.nlm.nih.gov/pubmed/23344473",
				"http://www.ncbi.nlm.nih.gov/pubmed/23758910",
				"http://www.ncbi.nlm.nih.gov/pubmed/23617441",
				"http://www.ncbi.nlm.nih.gov/pubmed/21816077",
				"http://www.ncbi.nlm.nih.gov/pubmed/22189039",
				"http://www.ncbi.nlm.nih.gov/pubmed/23339563"
			],
			"type": "yesno",
			"id": "52ec961098d023950500002a",
			"snippets": [
				{
					"offsetInBeginSection": 465,
					"offsetInEndSection": 666,
					"text": " Neutrophil gelatinase-associated lipocalin (NGAL) is produced in the distal nephron and it is one of the most promising novel biomarkers for acute kidney injury (AKI) and chronic kidney disease (CKD).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24315007",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 79,
					"offsetInEndSection": 607,
					"text": "urinary neutrophil gelatinase-associated lipocalin (uNGAL- a chemiluminescent microparticle immunoassay (CMIA) method became using (Abbott Diagnostics) for the measurement of NGAL in urine samples) and incidence of chronic kidney disease using the Modification of Diet in Renal Disease Study (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations in estimating glomerular filtration rate (eGFR) based on standardised serum creatinine method traceable to isotope dilution mass spectrometry (IDMS) method",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24308223",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 97,
					"text": "Urine albumin is the primary biomarker for detection and monitoring of kidney damage.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24281781",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 909,
					"offsetInEndSection": 1086,
					"text": " In clinical studies of chronic kidney disease (CKD), urinary L-FABP accurately reflected the degree of tubulointerstitial damage and correlated with the rate of CKD progression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24205707",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1462,
					"offsetInEndSection": 1589,
					"text": "These findings suggest that MetS and high CRP were independently associated with increased prevalence of CKD in Chinese adults.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24152229",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 835,
					"offsetInEndSection": 1047,
					"text": "Plasma neutrophil gelatinase-associated lipocalin is a potent tool in the diagnosis of chronic kidney diseases and is shown to have high correlation with serum creatinine and estimated glomerular filtration rate.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24133923",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1454,
					"offsetInEndSection": 1588,
					"text": " Together, these data suggest that urinary AGT might be a potential biomarker of intrarenal RAS and Ang II activities in CKD patients.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24065527",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1624,
					"offsetInEndSection": 1739,
					"text": "Higher circulating GDF-15 is associated with incident renal outcomes and improves risk prediction of incident CKD. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23873716",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 336,
					"offsetInEndSection": 557,
					"text": "RESULTS: Urinary mRNA of CCN2 and CCN3 were distinctively greater in CKDs than healthy controls. Urinary CCN3/CCN2 mRNA ratio correlated to the degree of glomerular histological changes in those who received renal biopsy.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23061738",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 326,
					"offsetInEndSection": 597,
					"text": "Conventional biomarkers (serum creatinine, urine albumin, and clinical variables such as sex, age, and diabetes) have been the cornerstone of most prediction models for CKD progression to end-stage renal disease (ESRD), and adverse cardiovascular outcomes including death",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22914685",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1873,
					"offsetInEndSection": 2092,
					"text": " In the present study, the renal and PBMC levels of KL promoter methylation were estimated and the relationship of KL promoter methylation levels with clinical and histological severity in patients with CKD was analyzed",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24224012",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 124,
					"offsetInEndSection": 350,
					"text": "This study has also provided evidence that PBMC level of KL promoter methylation closely correlates with renal level of KL promoter methylation, and it may be used as a potential biomarker of renal KL promoter hypermethylation",
					"beginSection": "sections.4",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24224012",
					"endSection": "sections.4"
				},
				{
					"offsetInBeginSection": 4411,
					"offsetInEndSection": 4542,
					"text": "it could be speculated these chronic circulating stress factors were involved in PBMC aberrant DNA methylation in patients with CKD",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24224012",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "Are defects in recombination repair involved in carcinogenesis?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24104500",
				"http://www.ncbi.nlm.nih.gov/pubmed/23125219",
				"http://www.ncbi.nlm.nih.gov/pubmed/22276468",
				"http://www.ncbi.nlm.nih.gov/pubmed/16555998",
				"http://www.ncbi.nlm.nih.gov/pubmed/12865926",
				"http://www.ncbi.nlm.nih.gov/pubmed/24051048",
				"http://www.ncbi.nlm.nih.gov/pubmed/23628323",
				"http://www.ncbi.nlm.nih.gov/pubmed/23620081",
				"http://www.ncbi.nlm.nih.gov/pubmed/16258176",
				"http://www.ncbi.nlm.nih.gov/pubmed/23675572",
				"http://www.ncbi.nlm.nih.gov/pubmed/17636314",
				"http://www.ncbi.nlm.nih.gov/pubmed/12488587",
				"http://www.ncbi.nlm.nih.gov/pubmed/22798379",
				"http://www.ncbi.nlm.nih.gov/pubmed/20298636",
				"http://www.ncbi.nlm.nih.gov/pubmed/17363343",
				"http://www.ncbi.nlm.nih.gov/pubmed/17397816"
			],
			"triples": [
				{
					"s": "http://purl.uniprot.org/pubmed/9111189",
					"p": "http://purl.uniprot.org/core/title",
					"o": "Which DNA polymerases are used for DNA-repair in eukaryotes?"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/9111189",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Carcinogenesis"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/9111189",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/9111189"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/11062157",
					"p": "http://purl.uniprot.org/core/title",
					"o": "Identification of single nucleotide polymorphisms in human DNA repair genes."
				},
				{
					"s": "http://purl.uniprot.org/pubmed/11062157",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Carcinogenesis"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/11062157",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/11062157"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/12419828",
					"p": "http://purl.uniprot.org/core/title",
					"o": "Diet, cancer and aging in DNA mismatch repair deficient mice."
				},
				{
					"s": "http://purl.uniprot.org/pubmed/12419828",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/12419828"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/12419828",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Carcinogenesis"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P18887",
					"p": "http://purl.uniprot.org/core/citation",
					"o": "http://purl.uniprot.org/citations/10783319"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10783319",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Carcinogenesis"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10783319",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/medline/20247096"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10783319",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/10783319"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5031383838370036",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "X-ray repair cross-complementing protein 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5031383838370035",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "DNA repair protein XRCC1"
				},
				{
					"s": "http://purl.uniprot.org/citations/10783319",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/10783319"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10590213",
					"p": "http://purl.uniprot.org/core/title",
					"o": "Involvement of p53 in X-ray induced intrachromosomal recombination in mice."
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10590213",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/10590213"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10590213",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Carcinogenesis"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24104500",
				"http://www.ncbi.nlm.nih.gov/pubmed/23125219",
				"http://www.ncbi.nlm.nih.gov/pubmed/22276468",
				"http://www.ncbi.nlm.nih.gov/pubmed/16555998",
				"http://www.ncbi.nlm.nih.gov/pubmed/12865926",
				"http://www.ncbi.nlm.nih.gov/pubmed/24051048",
				"http://www.ncbi.nlm.nih.gov/pubmed/23628323",
				"http://www.ncbi.nlm.nih.gov/pubmed/23620081",
				"http://www.ncbi.nlm.nih.gov/pubmed/16258176",
				"http://www.ncbi.nlm.nih.gov/pubmed/23675572",
				"http://www.ncbi.nlm.nih.gov/pubmed/17636314",
				"http://www.ncbi.nlm.nih.gov/pubmed/12488587",
				"http://www.ncbi.nlm.nih.gov/pubmed/22798379",
				"http://www.ncbi.nlm.nih.gov/pubmed/20298636",
				"http://www.ncbi.nlm.nih.gov/pubmed/17363343",
				"http://www.ncbi.nlm.nih.gov/pubmed/17397816"
			],
			"type": "yesno",
			"id": "52f77f752059c6d71c00002b",
			"snippets": [
				{
					"offsetInBeginSection": 295,
					"offsetInEndSection": 518,
					"text": "Inherited mutations in genes involved in HR are associated with gene rearrangement and may be a prerequisite for tumor development in some cancer-prone hereditary diseases like Bloom, Werner and Rothmund-Thomson syndromes. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22276468",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 175,
					"offsetInEndSection": 312,
					"text": "Variants in the XRCC3 gene might result in altered protein structure or function which may influence DSBR efficiency and lead to cancer. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24104500",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 349,
					"text": "Although alcohol consumption is related to increased cancer risk, its molecular mechanism remains unclear. Here, we demonstrate that an intake of 10% alcohol for 4 weeks in rats is genotoxic due to induction of micronuclei. Acetaldehyde (AA), the first product of ethanol metabolism, is believed to be responsible for DNA damage induced by alcohol. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23125219",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 223,
					"offsetInEndSection": 447,
					"text": "Although efficiency of these repair processes substantially decrease the efficacy of cancer chemotherapies that target DNA, compromised DNA repair contributes to mutagenesis and genomic instability leading to carcinogenesis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16555998",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 82,
					"text": "damage response and repair pathways are important barriers to carcinogenesis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23620081",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 111,
					"offsetInEndSection": 542,
					"text": "olymorphisms in DNA repair genes and differences in repair capacity between individuals have been widely documented. For colorectal cancer, the loss of mismatch repair gene activity is a key genetic determinant. Nucleotide excision repair (NER), recombination repair (RR) and base excision repair (BER) pathways have critical roles in protection against other cancers, and we wished to investigate their role in colorectal cancer. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12865926",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 189,
					"text": "Several complementary DNA repair mechanisms have evolved to protect the genome from DNA damage caused by endogenous or environmental agents, which could lead to mutations and carcinogenesis",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12865926",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 327,
					"offsetInEndSection": 733,
					"text": " An increasing number of DNA repair gene polymorphisms are being described and their involvement in carcinogenesis is being investigated. For colorectal cancer, the importance of mutations in mismatch repair (MMR) genes has been extensively documented. MMR gene defects account for 15% of sporadic colorectal cancer, and germline mutations in MMR genes are the cause of hereditary nonpolyposis colon cancer",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12865926",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 15,
					"offsetInEndSection": 176,
					"text": "we have compared the frequency of polymorphisms in the NER genes (XPD, XPF, XPG, ERCC1), and in XRCC1 and XRCC3 in colorectal cancer patients and a control group",
					"beginSection": "sections.4",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12865926",
					"endSection": "sections.4"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 281,
					"text": "We have investigated the hypothesis that NER gene polymorphisms might predispose to colorectal cancer because some forms of the encoded proteins may be less efficient at repairing DNA damage arising from exposure of the gut epithelium to genotoxic compounds in the lumen",
					"beginSection": "sections.7",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12865926",
					"endSection": "sections.7"
				}
			]
		},
		{
			"body": "List common features of Shapiro syndrome",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24187634",
				"http://www.ncbi.nlm.nih.gov/pubmed/23578790",
				"http://www.ncbi.nlm.nih.gov/pubmed/21041995",
				"http://www.ncbi.nlm.nih.gov/pubmed/19027594",
				"http://www.ncbi.nlm.nih.gov/pubmed/7565067",
				"http://www.ncbi.nlm.nih.gov/pubmed/24339619"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C537594"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C537594"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C537594"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2004/02/skos/core#broader",
					"o": "http://linkedlifedata.com/resource/umls/id/C0796147"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1702570",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "acrocallosal syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1702533",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "acrocallosal syndrome (ACS)"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18440175",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Acrocallosal Syndrome [Disease/Finding]"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A11975298",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "ACROCALLOSAL SYNDROME"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1701640",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Schinzel syndrome 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12032571",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "ACLS"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17700774",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Acrocallosal Syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A11961004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "HALLUX DUPLICATION, POSTAXIAL POLYDACTYLY, AND ABSENCE OF CORPUS CALLOSUM"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0796147",
					"p": "http://www.w3.org/2004/02/skos/core#narrower",
					"o": "http://linkedlifedata.com/resource/umls/id/C2931542"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1702533",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "acrocallosal syndrome (ACS)"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1702570",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "acrocallosal syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18440175",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Acrocallosal Syndrome [Disease/Finding]"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A11975298",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "ACROCALLOSAL SYNDROME"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1701640",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Schinzel syndrome 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12032571",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "ACLS"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17700774",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Acrocallosal Syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A11961004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "HALLUX DUPLICATION, POSTAXIAL POLYDACTYLY, AND ABSENCE OF CORPUS CALLOSUM"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://linkedlifedata.com/resource/relationontology/hasSymptom",
					"o": "http://linkedlifedata.com/resource/umls/id/C0020672"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17699101",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "BODY TEMPERATURE, DECREASED"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18471145",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Recurrent spontaneous hypothermia with hypoplasia of the corpus callosum"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18465004",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18458850",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Shapiro's syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0393370",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "BODY TEMPERATURE LOW"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1144305",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "hypothermia, natural"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17992132",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Hypothermia [Disease/Finding]"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0463819",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TEMPERATURE BODY DECREASE"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18465004"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17678862",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TEMPERATURE, DECREASED BODY"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0419736",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "HYPOPYREXIA"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17822767",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "hypothermia NOS"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10802646",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Decreased Core Body Temperature"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8311249",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Hypothermia"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0419764",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "HYPOTHERMIA"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0393367",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "BODY TEMPERATURE DECREASED"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0481466",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "hypothermia"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0071500",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Hypothermias"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18471145"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2931542",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A18458850"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17699102",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "DECREASED BODY TEMPERATURE"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24187634",
				"http://www.ncbi.nlm.nih.gov/pubmed/23578790",
				"http://www.ncbi.nlm.nih.gov/pubmed/21041995",
				"http://www.ncbi.nlm.nih.gov/pubmed/19027594",
				"http://www.ncbi.nlm.nih.gov/pubmed/7565067",
				"http://www.ncbi.nlm.nih.gov/pubmed/24339619"
			],
			"type": "list",
			"id": "5314c7afdae131f84700000a",
			"snippets": [
				{
					"offsetInBeginSection": 106,
					"offsetInEndSection": 266,
					"text": "Shapiro syndrome is defined as the constellation of periodic hypothermia and hyperhidrosis along with agenesis of the corpus callosum by Shapiro et al. in 1969.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24187634",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 142,
					"text": "Shapiro syndrome is a rare entity, comprising a triad of recurrent hypothermia, hyperhidrosis and congenital agenesis of the corpus callosum. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23578790",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 257,
					"offsetInEndSection": 600,
					"text": "We present a case of an 80 year old woman presenting with recurrent bouts of shivering, sweating and profound malaise, who sought medical attention because the frequency and severity of attacks worsened in her later years. MRI Brain demonstrated agenesis of the corpus callosum; a rigorous work-up excluded other causes for her symptomatology.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23578790",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1002,
					"offsetInEndSection": 1138,
					"text": "These findings imply that aberrant thermoregulation in Shapiro syndrome involves a number of structures remote from the callosal region.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23578790",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 328,
					"offsetInEndSection": 552,
					"text": "A 6-year-old girl previously diagnosed with Shapiro's syndrome was admitted to our hospital on several occasions during a 1-year period with complaints of altered consciousness, syncope, hypothermia and episodes of sweating.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1316,
					"offsetInEndSection": 1470,
					"text": "Hypermelatoninemia should be considered in patients with spontaneous periodic hypothermia and hyperhidrosis, and also in patients with Shapiro's syndrome.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 240,
					"text": "We present a patient diagnosed with Shapiro syndrome without corpus callosum agenesis. A 4-year-old-girl was admitted to the hospital with complaints of sweating, cooling, and drowsiness that continued during the last week of her admission.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19027594",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1519,
					"offsetInEndSection": 1686,
					"text": "Postmortem data regarding the hypothalamic and surrounding areas from future cases of Shapiro syndrome and spontaneous periodic hypothermia would be of great interest.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7565067",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 293,
					"offsetInEndSection": 465,
					"text": "Dr. Shapiro et al. first described a third phenomenon, the association between episodic hypothermia and hyperhidrosis associated with corpus callosum agenesis, in 1969 [2].",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24187634",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 19,
					"offsetInEndSection": 124,
					"text": "Intrinsic, episodic hypothermia associated with corpus callosum agenesis is defined as Shapiro syndrome. ",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24187634",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "Is Tuberous Sclerosis a genetic disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24310804",
				"http://www.ncbi.nlm.nih.gov/pubmed/24092520",
				"http://www.ncbi.nlm.nih.gov/pubmed/19506736",
				"http://www.ncbi.nlm.nih.gov/pubmed/22736301",
				"http://www.ncbi.nlm.nih.gov/pubmed/23438619",
				"http://www.ncbi.nlm.nih.gov/pubmed/24159711",
				"http://www.ncbi.nlm.nih.gov/pubmed/23749404",
				"http://www.ncbi.nlm.nih.gov/pubmed/23661441",
				"http://www.ncbi.nlm.nih.gov/pubmed/23622183",
				"http://www.ncbi.nlm.nih.gov/pubmed/2706800",
				"http://www.ncbi.nlm.nih.gov/pubmed/8825048",
				"http://www.ncbi.nlm.nih.gov/pubmed/9006662"
			],
			"triples": [
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4098",
					"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf",
					"o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://www.dbpedia.org/resource/Tuberous_sclerosis"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155",
					"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
					"o": "Tuberous_sclerosis"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4098",
					"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
					"o": "Tuberous sclerosis-1, 191100"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4099",
					"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf",
					"o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://www.dbpedia.org/resource/Tuberous_sclerosis"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155",
					"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
					"o": "Tuberous_sclerosis"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4099",
					"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
					"o": "Tuberous sclerosis-2, 191100"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q61037",
					"p": "http://purl.uniprot.org/core/citation",
					"o": "http://purl.uniprot.org/citations/10584558"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10584558",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/medline/20051947"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10584558",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Genet. Res."
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5136313033370014",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Tuberin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q61037",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_5136313033370015"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q61037",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_5136313033370014"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5136313033370015",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Tuberous sclerosis 2 protein homolog"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/10584558",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/10584558"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24310804",
				"http://www.ncbi.nlm.nih.gov/pubmed/24092520",
				"http://www.ncbi.nlm.nih.gov/pubmed/19506736",
				"http://www.ncbi.nlm.nih.gov/pubmed/22736301",
				"http://www.ncbi.nlm.nih.gov/pubmed/23438619",
				"http://www.ncbi.nlm.nih.gov/pubmed/24159711",
				"http://www.ncbi.nlm.nih.gov/pubmed/23749404",
				"http://www.ncbi.nlm.nih.gov/pubmed/23661441",
				"http://www.ncbi.nlm.nih.gov/pubmed/23622183",
				"http://www.ncbi.nlm.nih.gov/pubmed/2706800",
				"http://www.ncbi.nlm.nih.gov/pubmed/8825048",
				"http://www.ncbi.nlm.nih.gov/pubmed/9006662"
			],
			"type": "yesno",
			"id": "52f77edb2059c6d71c000028",
			"snippets": [
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 149,
					"text": "Tuberous sclerosis complex (TSC) is a genetic disease in the group known as neurocutaneous syndromes, with dominant autosomal inheritance",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24310804",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 129,
					"text": "Tuberous sclerosis is a rare genetic disease which leads to formation of benign tumours in the brain and other organs of the body",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24092520",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What was the aim of the COSS (Carotid Occlusion Surgery Study) clinical trial?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23909253",
				"http://www.ncbi.nlm.nih.gov/pubmed/23101451",
				"http://www.ncbi.nlm.nih.gov/pubmed/22244016",
				"http://www.ncbi.nlm.nih.gov/pubmed/22068990",
				"http://www.ncbi.nlm.nih.gov/pubmed/21960571",
				"http://www.ncbi.nlm.nih.gov/pubmed/22220280",
				"http://www.ncbi.nlm.nih.gov/pubmed/21772967",
				"http://www.ncbi.nlm.nih.gov/pubmed/24339571",
				"http://www.ncbi.nlm.nih.gov/pubmed/22645702",
				"http://www.ncbi.nlm.nih.gov/pubmed/22682265"
			],
			"triples": [
				{
					"s": "http://data.linkedct.org/resource/trials/NCT00029146",
					"p": "http://data.linkedct.org/resource/linkedct/description",
					"o": "\n      The overall purpose of this research is to determine if a surgical operation called\n      \"Extracranial-Intracranial Bypass\" can reduce the chance of a subsequent stroke in someone\n      who has complete blockage in one main artery in the neck (the carotid artery) that supplies\n      blood to the brain and has already suffered a small stroke. This surgery involves taking an\n      artery from the scalp outside the skull, making a small hole in the skull and then connecting\n      the scalp artery to a brain artery inside the skull. In this way the blockage of the carotid\n      artery in the neck is bypassed and more blood can flow to the brain. In some people natural\n      bypass arteries develop and the brain is already getting plenty of blood. These people have a\n      low risk of stroke if they take medicine. In other people, no natural bypass arteries develop\n      so less blood flows to their brains. This second group has a much higher risk of stroke while\n      taking medicine, as high as 25-50% within the next two years. It is this second group of\n      people who may benefit from having the bypass operation and who are the candidates for this\n      study.\n\n      This bypass surgery is considered experimental because it is not generally performed for this\n      condition and it is unknown whether it leads to a decrease, an increase or no change in the\n      risk of stroke. In order to determine if people fit into this second group of people who may\n      benefit from the bypass operation they need to have a test called a PET scan. The PET scan\n      measures the amount of blood that is getting to the brain and the amount of oxygen that the\n      brain is using. The PET scan uses radioactive oxygen and water and is experimental (not\n      approved by the United States Food and Drug Administration). If the PET scan shows that less\n      blood is getting to the brain, there will be a 50-50 chance (like a coin toss) of receiving\n      the bypass surgery or not. There will then be follow-up visits to the clinic one month later\n      and then every three months for two years to check on the appropriate medical treatment that\n      everyone will receive and to determine who has had a stroke.\n\n      The study hypothesis is that extracranial-intracranial bypass surgery when added to best\n      medical therapy can reduce by 40 percent  subsequent stroke within  two years in participants\n      with recent TIA ('ministroke\") or stroke (</= 120 days) due to blockage of the carotid artery\n      and reduced blood flow to the brain measured by PET.\n    "
				},
				{
					"s": "http://data.linkedct.org/resource/trials/NCT00029146",
					"p": "http://data.linkedct.org/resource/linkedct/summary",
					"o": "\n      The purpose of this study is to determine if extracranial-intracranial bypass surgery when\n      added to best medical therapy can reduce the subsequent risk of ipsilateral stroke in\n      high-risk patients with recently symptomatic carotid occlusion and increased cerebral oxygen\n      extraction fraction measured by PET.\n    "
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23909253",
				"http://www.ncbi.nlm.nih.gov/pubmed/23101451",
				"http://www.ncbi.nlm.nih.gov/pubmed/22244016",
				"http://www.ncbi.nlm.nih.gov/pubmed/22068990",
				"http://www.ncbi.nlm.nih.gov/pubmed/21960571",
				"http://www.ncbi.nlm.nih.gov/pubmed/22220280",
				"http://www.ncbi.nlm.nih.gov/pubmed/21772967",
				"http://www.ncbi.nlm.nih.gov/pubmed/24339571",
				"http://www.ncbi.nlm.nih.gov/pubmed/22645702",
				"http://www.ncbi.nlm.nih.gov/pubmed/22682265"
			],
			"type": "summary",
			"id": "5314c045dae131f847000007",
			"snippets": [
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 399,
					"text": "The Carotid Occlusion Surgery Study (COSS) was conducted to determine if superficial temporal artery-middle cerebral artery (STA-MCA) bypass, when added to the best medical therapy, would reduce subsequent ipsilateral stroke in patients with complete internal carotid artery (ICA) occlusion and an elevated oxygen extraction fraction (OEF) in the cerebral hemisphere distal to the occlusion.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23101451",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 150,
					"text": "Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22068990",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 201,
					"offsetInEndSection": 436,
					"text": "To test the hypothesis that extracranial-intracranial (EC-IC) bypass surgery, added to best medical therapy, reduces subsequent ipsilateral ischemic stroke in patients with recently symptomatic AICAO and hemodynamic cerebral ischemia. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22068990",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 343,
					"text": "The Carotid Occlusion Surgery Study (COSS) was a large, prospective clinical trial that examined whether superficial temporal artery-middle cerebral artery (STA-MCA) bypass, in addition to best medical therapy, reduced the risk of ipsilateral ischemic stroke in patients with carotid artery occlusion and hemodynamic cerebral ischemia.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23909253",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Is the transcriptional regulator BACH1 an activator or a repressor?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24035498",
				"http://www.ncbi.nlm.nih.gov/pubmed/23880309",
				"http://www.ncbi.nlm.nih.gov/pubmed/23738048",
				"http://www.ncbi.nlm.nih.gov/pubmed/23446334",
				"http://www.ncbi.nlm.nih.gov/pubmed/23181164",
				"http://www.ncbi.nlm.nih.gov/pubmed/22847612",
				"http://www.ncbi.nlm.nih.gov/pubmed/22735309",
				"http://www.ncbi.nlm.nih.gov/pubmed/22289179",
				"http://www.ncbi.nlm.nih.gov/pubmed/22127667",
				"http://www.ncbi.nlm.nih.gov/pubmed/21982894",
				"http://www.ncbi.nlm.nih.gov/pubmed/21812759",
				"http://www.ncbi.nlm.nih.gov/pubmed/21473739",
				"http://www.ncbi.nlm.nih.gov/pubmed/21373270",
				"http://www.ncbi.nlm.nih.gov/pubmed/20501657",
				"http://www.ncbi.nlm.nih.gov/pubmed/20388958",
				"http://www.ncbi.nlm.nih.gov/pubmed/20345481",
				"http://www.ncbi.nlm.nih.gov/pubmed/20127796",
				"http://www.ncbi.nlm.nih.gov/pubmed/19591297",
				"http://www.ncbi.nlm.nih.gov/pubmed/19439223",
				"http://www.ncbi.nlm.nih.gov/pubmed/19282658",
				"http://www.ncbi.nlm.nih.gov/pubmed/19119918",
				"http://www.ncbi.nlm.nih.gov/pubmed/19035757",
				"http://www.ncbi.nlm.nih.gov/pubmed/19011633",
				"http://www.ncbi.nlm.nih.gov/pubmed/18948842",
				"http://www.ncbi.nlm.nih.gov/pubmed/18555605",
				"http://www.ncbi.nlm.nih.gov/pubmed/18550526",
				"http://www.ncbi.nlm.nih.gov/pubmed/18426999",
				"http://www.ncbi.nlm.nih.gov/pubmed/18325350",
				"http://www.ncbi.nlm.nih.gov/pubmed/17942419",
				"http://www.ncbi.nlm.nih.gov/pubmed/17901053",
				"http://www.ncbi.nlm.nih.gov/pubmed/17701549",
				"http://www.ncbi.nlm.nih.gov/pubmed/17682061",
				"http://www.ncbi.nlm.nih.gov/pubmed/16824198",
				"http://www.ncbi.nlm.nih.gov/pubmed/16771696",
				"http://www.ncbi.nlm.nih.gov/pubmed/16724942",
				"http://www.ncbi.nlm.nih.gov/pubmed/16487043",
				"http://www.ncbi.nlm.nih.gov/pubmed/15855052",
				"http://www.ncbi.nlm.nih.gov/pubmed/15809329",
				"http://www.ncbi.nlm.nih.gov/pubmed/15743416",
				"http://www.ncbi.nlm.nih.gov/pubmed/15464985",
				"http://www.ncbi.nlm.nih.gov/pubmed/15175654",
				"http://www.ncbi.nlm.nih.gov/pubmed/14660636",
				"http://www.ncbi.nlm.nih.gov/pubmed/14504288",
				"http://www.ncbi.nlm.nih.gov/pubmed/12511571",
				"http://www.ncbi.nlm.nih.gov/pubmed/12356737",
				"http://www.ncbi.nlm.nih.gov/pubmed/11530014",
				"http://www.ncbi.nlm.nih.gov/pubmed/11387216"
			],
			"triples": [
				{
					"s": "http://purl.uniprot.org/uniprot/P97302",
					"p": "http://purl.uniprot.org/core/classifiedWith",
					"o": "http://purl.uniprot.org/keywords/678"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5039373330320012",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "BTB and CNC homolog 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5039373330320011",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transcription regulator protein BACH1"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P97302",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_5039373330320011"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P97302",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_5039373330320012"
				},
				{
					"s": "http://purl.uniprot.org/keywords/678",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Repressor"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/classifiedWith",
					"o": "http://purl.uniprot.org/keywords/678"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001F"
				},
				{
					"s": "http://purl.uniprot.org/intact/EBI-1263541",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "BACH1"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001D"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001D",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transcription regulator protein BACH1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001E",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "BTB and CNC homolog 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001F",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "HA2303"
				},
				{
					"s": "http://purl.uniprot.org/intact/EBI-1263541",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/uniprot/O14867"
				},
				{
					"s": "http://purl.uniprot.org/keywords/678",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Repressor"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001E"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P97302",
					"p": "http://purl.uniprot.org/core/classifiedWith",
					"o": "http://purl.uniprot.org/keywords/10"
				},
				{
					"s": "http://purl.uniprot.org/keywords/10",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Activator"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5039373330320012",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "BTB and CNC homolog 1"
				},
				{
					"s": "http://purl.uniprot.org/keywords/10",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Positive activator"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5039373330320011",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transcription regulator protein BACH1"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P97302",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_5039373330320011"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P97302",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_5039373330320012"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/classifiedWith",
					"o": "http://purl.uniprot.org/go/0003700"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001F"
				},
				{
					"s": "http://purl.uniprot.org/intact/EBI-1263541",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "BACH1"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001D"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001D",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transcription regulator protein BACH1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001E",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "BTB and CNC homolog 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001F",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "HA2303"
				},
				{
					"s": "http://purl.uniprot.org/intact/EBI-1263541",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/uniprot/O14867"
				},
				{
					"s": "http://purl.uniprot.org/go/0003700",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://www.geneontology.org/go#GO:0003700"
				},
				{
					"s": "http://purl.uniprot.org/go/0003700",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "sequence-specific DNA binding transcription factor activity"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001E"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://linkedlifedata.com/resource/relationontology/hasMolecularFunction",
					"o": "http://linkedlifedata.com/resource/geneontology/id/GO:0003700"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001F"
				},
				{
					"s": "http://purl.uniprot.org/intact/EBI-1263541",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "BACH1"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001D"
				},
				{
					"s": "http://linkedlifedata.com/resource/geneontology/id/GO:0003700",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "sequence-specific DNA binding transcription factor activity"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001D",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transcription regulator protein BACH1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001E",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "BTB and CNC homolog 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3134383637001F",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "HA2303"
				},
				{
					"s": "http://purl.uniprot.org/intact/EBI-1263541",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/uniprot/O14867"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O14867",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_4F3134383637001E"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24035498",
				"http://www.ncbi.nlm.nih.gov/pubmed/23880309",
				"http://www.ncbi.nlm.nih.gov/pubmed/23738048",
				"http://www.ncbi.nlm.nih.gov/pubmed/23446334",
				"http://www.ncbi.nlm.nih.gov/pubmed/23181164",
				"http://www.ncbi.nlm.nih.gov/pubmed/22847612",
				"http://www.ncbi.nlm.nih.gov/pubmed/22735309",
				"http://www.ncbi.nlm.nih.gov/pubmed/22289179",
				"http://www.ncbi.nlm.nih.gov/pubmed/22127667",
				"http://www.ncbi.nlm.nih.gov/pubmed/21982894",
				"http://www.ncbi.nlm.nih.gov/pubmed/21812759",
				"http://www.ncbi.nlm.nih.gov/pubmed/21473739",
				"http://www.ncbi.nlm.nih.gov/pubmed/21373270",
				"http://www.ncbi.nlm.nih.gov/pubmed/20501657",
				"http://www.ncbi.nlm.nih.gov/pubmed/20388958",
				"http://www.ncbi.nlm.nih.gov/pubmed/20345481",
				"http://www.ncbi.nlm.nih.gov/pubmed/20127796",
				"http://www.ncbi.nlm.nih.gov/pubmed/19591297",
				"http://www.ncbi.nlm.nih.gov/pubmed/19439223",
				"http://www.ncbi.nlm.nih.gov/pubmed/19282658",
				"http://www.ncbi.nlm.nih.gov/pubmed/19119918",
				"http://www.ncbi.nlm.nih.gov/pubmed/19035757",
				"http://www.ncbi.nlm.nih.gov/pubmed/19011633",
				"http://www.ncbi.nlm.nih.gov/pubmed/18948842",
				"http://www.ncbi.nlm.nih.gov/pubmed/18555605",
				"http://www.ncbi.nlm.nih.gov/pubmed/18550526",
				"http://www.ncbi.nlm.nih.gov/pubmed/18426999",
				"http://www.ncbi.nlm.nih.gov/pubmed/18325350",
				"http://www.ncbi.nlm.nih.gov/pubmed/17942419",
				"http://www.ncbi.nlm.nih.gov/pubmed/17901053",
				"http://www.ncbi.nlm.nih.gov/pubmed/17701549",
				"http://www.ncbi.nlm.nih.gov/pubmed/17682061",
				"http://www.ncbi.nlm.nih.gov/pubmed/16824198",
				"http://www.ncbi.nlm.nih.gov/pubmed/16771696",
				"http://www.ncbi.nlm.nih.gov/pubmed/16724942",
				"http://www.ncbi.nlm.nih.gov/pubmed/16487043",
				"http://www.ncbi.nlm.nih.gov/pubmed/15855052",
				"http://www.ncbi.nlm.nih.gov/pubmed/15809329",
				"http://www.ncbi.nlm.nih.gov/pubmed/15743416",
				"http://www.ncbi.nlm.nih.gov/pubmed/15464985",
				"http://www.ncbi.nlm.nih.gov/pubmed/15175654",
				"http://www.ncbi.nlm.nih.gov/pubmed/14660636",
				"http://www.ncbi.nlm.nih.gov/pubmed/14504288",
				"http://www.ncbi.nlm.nih.gov/pubmed/12511571",
				"http://www.ncbi.nlm.nih.gov/pubmed/12356737",
				"http://www.ncbi.nlm.nih.gov/pubmed/11530014",
				"http://www.ncbi.nlm.nih.gov/pubmed/11387216"
			],
			"type": "factoid",
			"id": "52ed795098d0239505000032",
			"snippets": [
				{
					"offsetInBeginSection": 648,
					"offsetInEndSection": 835,
					"text": "We demonstrate that FBXL17 controls the transcription of the NRF2 target HMOX1 via turnover of the transcriptional repressor BACH1 in the absence or presence of extrinsic oxidative stress",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24035498",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 116,
					"text": "arallel SCF adaptor capture proteomics reveals a role for SCFFBXL17 in NRF2 activation via BACH1 repressor turnover",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24035498",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 119,
					"text": "TB and CNC homology 1 (Bach1) is a transcriptional repressor of antioxidative enzymes, such as heme oxygenase-1 (HO-1)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23880309",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 710,
					"offsetInEndSection": 953,
					"text": "On the other hand, entry and accumulation of Nrf2 protein in the nucleus, while exportting the transcriptional repressor BTB and CNC homology 1 (Bach1) from nucleus to cytoplasm, were also confirmed by western blot and immunofluorescence assay",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738048",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 208,
					"text": "BTB and CNC homolog 1 (Bach1) is a transcriptional repressor of heme oxygenase-1 (HO-1), which plays an important role in the protection of cells and tissues against acute and chronic inflammation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23446334",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 187,
					"text": "ach1 is a transcriptional repressor which modulates several critical transcriptional responses, such as the expression of the heme oxygenase-1 (HO-1) gene in response to oxidative stress",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 189,
					"offsetInEndSection": 301,
					"text": "In our recent study, we found that Bach1 possesses a novel role in mitotic chromosome alignment during metaphase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 750,
					"offsetInEndSection": 869,
					"text": "Our findings suggest that Bach1 might mediate the regulation of mitotic chromosomes under conditions of cellular stress",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 152,
					"offsetInEndSection": 346,
					"text": "Among the genes related to ROS metabolism, Bach1 is a repressor of the oxidative stress response, and a negative regulator of ROS-induced cellular senescence directed by p53 in higher eukaryotes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22847612",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 707,
					"offsetInEndSection": 891,
					"text": "In HaCaT cells, FB and EC (200 ΞΌM) induced nuclear translocation of NRF2 protein after 24 h and reduced nuclear protein levels of BACH1, a repressor of the antioxidant response element",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22735309",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 69,
					"text": "transcriptional repressor Bach1 mediates various stress responses",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22289179",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 226,
					"offsetInEndSection": 327,
					"text": "This study was undertaken to clarify the effects of HO-1 and its repressor Bach1 in osteoclastogenesi",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22127667",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 543,
					"offsetInEndSection": 716,
					"text": "However, the regulation of HMOX1 by the antioxidant-response element is firmly established, with the transcription factor BACH1 serving as a repressor and Nrf2 as an enhance",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21982894",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 110,
					"offsetInEndSection": 166,
					"text": "induction of the transcriptional repressor BACH1 by Nrf2",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 715,
					"offsetInEndSection": 989,
					"text": "Transcription factor BACH1 [BTB (broad-complex, tramtrack and bric-a-brac) and CNC (cap'n'collar protein) homology 1] binds to ARE-like sequences, functioning as a transcriptional repressor in a subset of ARE-regulated genes, thus antagonizing the activator function of Nrf2",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 89,
					"text": "TB and CNC homologue 1 (Bach1) is a transcriptional repressor of heme oxygenase-1 (HO-1)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21473739",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 202,
					"text": "ach1 is a transcriptional repressor of heme oxygenase-1 (HO-1, a.k.a. HSP-32), which is an inducible enzyme and has anti-oxidation/anti-inflammatory properties shown in various models of organ injuries",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21373270",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 207,
					"offsetInEndSection": 353,
					"text": "Because Bach1 is a repressor of the oxidative stress response, we examined the function(s) of Bach1 in keratinocytes subjected to oxidative stress",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20501657",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1351,
					"offsetInEndSection": 1520,
					"text": "Thus, in response to oxidative stress, Bach1 regulates the oxidation state through the negative control of HO-1 expression prior to terminal keratinocyte differentiation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20501657",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1522,
					"offsetInEndSection": 1603,
					"text": "However, Bach1-mediated repression is negated during keratinocyte differentiation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20501657",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 86,
					"text": "TB and CNC homolog 1 (Bach1) is a transcriptional repressor of heme oxygenase-1 (HO-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20388958",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 108,
					"text": "xpression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20345481",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 199,
					"offsetInEndSection": 515,
					"text": "Here we investigated the expression of HO-1 in primary and established AML cells as well as other types of leukemic cells and normal monocytes, and its regulatory mechanism by the transcriptional repressor, BTB and CNC homology 1 (Bach1), and the activator, nuclear factor erythroid-derived 2 related factor 2 (Nrf2)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20345481",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 88,
					"offsetInEndSection": 283,
					"text": "Bach1, a basic leucine zipper mammalian transcriptional repressor, negatively regulates heme oxygenase 1 (HMOX1), a key cytoprotective enzyme that has antioxidant and anti-inflammatory activities",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20127796",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 320,
					"offsetInEndSection": 453,
					"text": "Bach1 inhibits expression of oxidative stress responsive genes by competing with Nrf2, the key activator of oxidative stress response",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19591297",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 455,
					"offsetInEndSection": 636,
					"text": "Bach1 inhibits p53-dependent cellular senescence induced by oxidative stress. Bach1 forms a protein complex with p53, is recruited to p53 target genes, and inhibits their expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19591297",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 70,
					"text": "ach1 is a transcriptional repressor of the heme oxygenase (HO)-1 gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19439223",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 153,
					"text": "ach1 is a basic region-leucine zipper (bZip) protein that forms heterodimers with the small Maf proteins and functions as a repressor of gene expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19282658",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 155,
					"offsetInEndSection": 234,
					"text": "One of the target genes of Bach1 is Hmox-1 that encodes heme oxygenase-1 (HO-1)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19282658",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 109,
					"text": "eme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11387216",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 75,
					"offsetInEndSection": 260,
					"text": "heme. The mammalian transcription factor Bach1 functions as a repressor of the Maf recognition element (MARE) by forming antagonizing hetero-oligomers with the small Maf family proteins",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11387216",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 721,
					"offsetInEndSection": 805,
					"text": "The repressor activity of Bach1 was lost upon addition of hemin in transfected cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11387216",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 807,
					"offsetInEndSection": 943,
					"text": "These results suggest that increased levels of heme inactivate the repressor Bach1, resulting in induction of a host of genes with MARES",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11387216",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 100,
					"text": "promoter of mouse transcription repressor bach1 is regulated by Sp1 and trans-activated by Bach1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11530014",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 83,
					"offsetInEndSection": 189,
					"text": "Bach1 and Bach2 repress MARE-dependent transcription by forming heterodimers with Maf-related oncoproteins",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11530014",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 220,
					"offsetInEndSection": 313,
					"text": "Here we show that a heme-binding factor, Bach1, is a critical physiological repressor of ho-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12356737",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 316,
					"offsetInEndSection": 552,
					"text": "ach1 bound to the multiple Maf recognition elements (MAREs) of ho-1 enhancers with MafK in vitro and repressed their activity in vivo, while heme abrogated this repressor function of Bach1 by inhibiting its binding to the ho-1 enhancers",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12356737",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 982,
					"offsetInEndSection": 1205,
					"text": "Thus, regulation of ho-1 involves a direct sensing of heme levels by Bach1 (by analogy to lac repressor sensitivity to lactose), generating a simple feedback loop whereby the substrate effects repressor-activator antagonism",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12356737",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 470,
					"offsetInEndSection": 635,
					"text": "The hypoxia-mediated repression of HO-1 expression is consistently associated with the induction of Bach1, a heme-regulated transcriptional repressor, in human cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12511571",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1205,
					"offsetInEndSection": 1356,
					"text": "Therefore, Bach1 functions as a hypoxia-inducible repressor for the HO-1 gene, thereby contributing to fine-tuning of oxygen homeostasis in human cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12511571",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 93,
					"text": "admium induces nuclear export of Bach1, a transcriptional repressor of heme oxygenase-1 gene",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14504288",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 435,
					"offsetInEndSection": 597,
					"text": "Although ho-1 is repressed by Bach1/small Maf heterodimers, it is activated by Nrf2/small Maf heterodimers, indicating that Bach1 and Nrf2 compete with each other",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14504288",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1361,
					"offsetInEndSection": 1525,
					"text": "These results indicate that the nuclear export of Bach1 constitutes an important regulatory mechanism to relieve the Bach1-mediated repression of genes such as ho-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14504288",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 140,
					"offsetInEndSection": 214,
					"text": "The repressor activity of Bach1 is inhibited by the direct binding of heme",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14660636",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1791,
					"offsetInEndSection": 1926,
					"text": "We propose that heme positively regulates the beta-globin gene expression by blocking the interaction of Bach1 with the MARE in the LCR",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14660636",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1360,
					"offsetInEndSection": 1488,
					"text": "ransient expression of Bach1 suppressed the microLCR activity, and this repressor activity was cancelled by treatment with hemin",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14660636",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 143,
					"text": "ach1 is a transcriptional repressor of heme oxygenase-1 and beta-globin genes, both of which are known to be transcriptionally induced by heme",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15175654",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 841,
					"offsetInEndSection": 985,
					"text": "These results extend the regulatory roles for heme in protein sorting, and suggest that Bach1 transduces metabolic activity into gene expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15175654",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 150,
					"text": "transcriptional factor Bach1 forms a heterodimer with small Maf family, and functions as a repressor of the Maf recognition element (MARE) in vivo",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15464985",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 119,
					"text": "eme-dependent up-regulation of the alpha-globin gene expression by transcriptional repressor Bach1 in erythroid cells.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15464985",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1101,
					"offsetInEndSection": 1301,
					"text": "The transient expression of Bach1 and mutated Bach1 lacking CP motifs suppressed the HS-40 activity, and cancellation of the repressor activity by hemin was observed when wild-type Bach1 was expressed",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15464985",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1523,
					"offsetInEndSection": 1726,
					"text": "These results indicated that heme plays an important role in the induction of alpha-globin gene expression through disrupting the interaction of Bach1 and the NA site in HS-40 enhancer in erythroid cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15464985",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 89,
					"text": "ach1 is a transcriptional repressor of the cytoprotective enzyme heme oxygenase-1 (HO-1)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15743416",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1202,
					"offsetInEndSection": 1358,
					"text": "hese results indicate that Bach1 plays a critical role in the regulation of HO-1 expression, macrophage function, SMC proliferation and neointimal formation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15743416",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1360,
					"offsetInEndSection": 1447,
					"text": "Bach1 may regulate gene expression in these cells during inflammation and atherogenesis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15743416",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 99,
					"text": "ach1 functions as a transcriptional repressor of heme oxygenase-1 (HO-1) and the beta-globin genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15809329",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1078,
					"offsetInEndSection": 1194,
					"text": "The repression of HO-1 reporter activity by Bach1 was attenuated by co-transfecting IHABP in a dose-dependent manner",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15809329",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 100,
					"text": "ach1 is a transcriptional repressor of heme oxygenase-1, one of the most inducible phase 2 proteins",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15855052",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1053,
					"offsetInEndSection": 1168,
					"text": "These data suggest that redox regulation of Bach1 is an alternative mechanism to induce multiple ARE-governed genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15855052",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 808,
					"offsetInEndSection": 1012,
					"text": "By binding to Bach1, heme induces selective removal of the repressor from the gene enhancers permitting subsequent occupancy of the MAREs by activators that, interestingly, also contain small Maf proteins",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16487043",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 921,
					"offsetInEndSection": 1140,
					"text": "Discovery of Bach1, a transcriptional repressor of HO-1, has greatly contributed to the understanding of the regulation of HO-11 expression, providing a clue to a development of alternative method to enhance HO activity",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16724942",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1142,
					"offsetInEndSection": 1182,
					"text": "Bach1 normally represses HO-1 expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16724942",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 5,
					"offsetInEndSection": 101,
					"text": "Carotene and cigarette smoke condensate regulate heme oxygenase-1 and its repressor factor Bach1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16771696",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 91,
					"text": "ach1 is a transcriptional repressor of heme oxygenase-1 gene (Hmox-1) and beta-globin gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16824198",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1307,
					"offsetInEndSection": 1441,
					"text": "Bach1 inactivation during I/R appears to be a key mechanism controlling the activation level of cytoprotective program involving HO-1.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16824198",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 133,
					"text": "transcription repressor Bach1 is a sensor and effector of heme that regulates the expression of heme oxygenase 1 and globin genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17682061",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 188,
					"text": "mammalian transcription factor Bach1 functions as a repressor of the enhancers of heme oxygenase-1 (HO-1) gene (Hmox-1) by forming heterodimers with the small Maf proteins such as MafK",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17701549",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 434,
					"offsetInEndSection": 662,
					"text": "In addition, overexpression of Bach1 protein in the transfected cells decreased ferritin expression, indicating insufficient endogenous Bach1 for full repression; decreasing Bach1 with antisense RNA increased ferritin expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17901053",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 196,
					"text": "ach1 repression of ferritin and thioredoxin reductase1 is heme-sensitive in cells and in vitro and coordinates expression with heme oxygenase1, beta-globin, and NADP(H) quinone (oxido) reductase1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17901053",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 191,
					"offsetInEndSection": 372,
					"text": "n contrast, the transcriptional repressor BACH1 binds ARE-like enhancers in cells naΓ―ve to oxidative stress and antagonizes NRF2 binding until it becomes inactivated by pro-oxidants",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1116,
					"offsetInEndSection": 1254,
					"text": "Thus, BACH1 confers an additional level of regulation to ARE-dependent genes that reveals a new dimension to the oxidative stress response",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 615,
					"offsetInEndSection": 746,
					"text": "BACH1 repression is dominant over NRF2-mediated HMOX1 transcription and inactivation of BACH1 is a prerequisite for HMOX1 induction",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 86,
					"offsetInEndSection": 141,
					"text": "Bach1 is a mammalian transcriptional repressor of HO-1.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18325350",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 118,
					"text": "yocardial protection against pressure overload in mice lacking Bach1, a transcriptional repressor of heme oxygenase-1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18426999",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 159,
					"text": "ach1 is a stress-responsive transcriptional factor that is thought to control the expression levels of cytoprotective factors, including heme-oxygenase (HO)-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18426999",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1590,
					"offsetInEndSection": 1788,
					"text": "Bach1 repressively controls myocardial HO-1 expression both in basal and stressed conditions, inhibition of Bach1 may be a novel therapeutic strategy to protect the myocardium from pressure overload",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18426999",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1395,
					"offsetInEndSection": 1588,
					"text": "These results suggest that deletion of Bach1 caused upregulation of cytoprotective HO-1, thereby inhibiting TAC-induced LV hypertrophy and remodeling, at least in part, through activation of HO",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18426999",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 70,
					"text": "ACH1 is a specific repressor of HMOX1 that is inactivated by arsenite",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18550526",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 235,
					"offsetInEndSection": 435,
					"text": "In the absence of elevated intracellular heme or oxidative stress, the basic region leucine zipper transcriptional regulator BACH1 binds HMOX1 antioxidant response elements and represses transcription",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18550526",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 374,
					"offsetInEndSection": 537,
					"text": "Bach1 is a transcriptional repressor of the HO-1 gene, and plays a critical role in tissue protection from oxidative stress by reperfusion injury of the myocardium",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18555605",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1183,
					"offsetInEndSection": 1302,
					"text": "Thus, Bach1 plays an important role in regulating the constitutive and inducible expression levels of HO-1 in the brain",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18555605",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 770,
					"offsetInEndSection": 965,
					"text": "Compared with adults, levels of the repressor of HO-1 transcription, Bach1, were higher in the neonatal lung as was nuclear protein-DNA binding to the antioxidant response element (ARE) from HO-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18948842",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 165,
					"offsetInEndSection": 413,
					"text": "Here we show that the transcription factor Bach1 (BTB and CNC homology 1, basic leucine zipper transcription factor 1), which inhibits oxidative stress-inducible genes, is a crucial negative regulator of oxidative stress-induced cellular senescence",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19011633",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 709,
					"offsetInEndSection": 834,
					"text": "Bach1 was recruited to a subset of p53 target genes and contributed to impeding p53 action by promoting histone deacetylation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19011633",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 245,
					"offsetInEndSection": 406,
					"text": "Mice deficient in Bach1 (Bach1-/-), a transcriptional repressor of the HO-1 and beta-globin genes, express high levels of HO-1 mRNA and protein in various organs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19035757",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 143,
					"text": "enetic ablation of transcription repressor Bach1 reduces neural tissue damage and improves locomotor function after spinal cord injury in mice",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19119918",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 228,
					"offsetInEndSection": 290,
					"text": "Bach1 is a transcriptional repressor of the HO-1 gene (Hmox-1)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19119918",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 292,
					"offsetInEndSection": 472,
					"text": "Previous reports have demonstrated that the genetic ablation of Bach1 engenders an increased HO-1 expression and a marked reduction in the degree of oxidative tissue damage in vivo",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19119918",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1207,
					"offsetInEndSection": 1372,
					"text": "These results suggest that Bach1 deficiency engenders a constitutively higher expression of HO-1 and a dramatic increase in cytoprotection against spinal cord injury",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19119918",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3520,
					"offsetInEndSection": 3696,
					"text": "\nOn the other hand, studies on Nrf2 pathway recent years lead to the discovery of Bach1 (BTB and CNC homology 1), a kind of nuclear transcriptional repressor of Nrf2 activation",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738048",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4155,
					"offsetInEndSection": 4286,
					"text": "The relationship between Nrf2 and Bach1, a kind of nuclear transcriptional repressor, was also explored in this experimental study.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738048",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 2510,
					"offsetInEndSection": 2617,
					"text": "\nOn the other hand, a kind of transcriptional repressor, Bach1, has gained close attentions in recent years",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738048",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 2619,
					"offsetInEndSection": 2692,
					"text": "In general, Bach1 serves as a repressor of the oxidative stress responses",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738048",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 2886,
					"offsetInEndSection": 3241,
					"text": "Some researches indicate that activation of Nrf2 requires the inactivation of the transcriptional repressor Bach1 [34], and it is therefore argued that even when Nrf2 enters and accumulates in the nucleus, Nrf2 could not bind to the ARE site to initiate the Nrf2-mediated antioxidant responses unless Bach1 inactivates and probably exits out of the nucleu",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738048",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 3472,
					"offsetInEndSection": 3609,
					"text": " Similarly, it has been demonstrated that knockdown of Bach1 in human keratinocytes specifically upregulated the gene expression of HO-1 ",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738048",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 3805,
					"offsetInEndSection": 3989,
					"text": "It seems that nuclear factor Bach1 might act as a negative regulator of Nrf2 pathway, which gives the Nrf2/ARE system a high range of plasticity to adapt to adverse cellular conditions",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738048",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 1842,
					"offsetInEndSection": 1920,
					"text": "Bach1 occupies MARE enhancers to repress transcription under normal conditions",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1922,
					"offsetInEndSection": 2118,
					"text": "The elimination of the Bach1-mediated transcriptional repression occurs through inhibition of its DNA binding activity and subsequent Crm1-dependent nuclear export in response to oxidative stress.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2995,
					"offsetInEndSection": 3096,
					"text": "A heme-binding factor Bach1 functions as a transcriptional repressor of the gene encoding HO-1 (Hmox1",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21373270",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 381,
					"offsetInEndSection": 603,
					"text": "Consistent with these changes in mRNA expressions, Fig.Β 1B demonstrates 5-fold increase in hepatic HO-1 activity in the absence of Bach1, which was entirely repressed by intraperitoneal injection of ZnPP, an HO-1 inhibitor",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21373270",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 2202,
					"offsetInEndSection": 2437,
					"text": " This arrangement appears to exist between NRF2 and BACH1.\nBACH1 is a transcriptional repressor (12) that is conserved and ubiquitously expressed in tissues (13,14) though its global activity in gene regulation is poorly characterized.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2747,
					"offsetInEndSection": 2852,
					"text": "As a repressive transcription factor, BACH1 allows gene induction upon its release from enhancer elements",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2854,
					"offsetInEndSection": 2956,
					"text": "Originally, BACH1 was described as a heme-regulated repressor of Ξ²-globin genes (12) and HMOX1 (14β€“18)",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3201,
					"offsetInEndSection": 3309,
					"text": "Therefore, it is possible that heme and oxidants trigger gene induction simply by relieving BACH1 repression",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3316,
					"offsetInEndSection": 3487,
					"text": "In this regard, it has been demonstrated that BACH1 plays a role in redox induction of HMOX1 (17) and NQO1 (10), though the exact mechanism of this repression is not clear",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4446,
					"offsetInEndSection": 5037,
					"text": "Here, we have tested whether oxidative stress induced by arsenite exposure can trigger gene induction by simply releasing repressive BACH1 from ARE motifs. We find that NRF2 and BACH1 bind to two distal ARE enhancer sites far upstream of the HMOX1 TSS and that BACH1 removal is necessary for NRF2-mediated HMOX1 gene induction. In contrast to HMOX1, TXNRD1, which has a single ARE motif located 9 bp upstream of the TSS, is regulated by NRF2 but not by BACH1. Comparison of TXNRD1 expression with that of HMOX1 demonstrates that BACH1 repression is dominant over NRF2-mediated transcription.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 17455,
					"offsetInEndSection": 17752,
					"text": "Consistent with whole cell lysate and nuclear extract immunoblots, it is evident that RNA pol II HMOX1 binding precedes NRF2 activation, further supporting the conclusion that loss of BACH1-mediated transcriptional repression is more important than nuclear accumulation of NRF2 for HMOX1 induction",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 22069,
					"offsetInEndSection": 22359,
					"text": "Interestingly, the combination of MG132 plus hemin also shows that, when preceded by CHX treatment, HMOX1 expression remains significantly induced despite the lack of NRF2 and hints at the possible role for BACH1 in repressing the activity of transcriptional activators in addition to NRF2.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 5675,
					"offsetInEndSection": 5894,
					"text": "It is noteworthy that some HMOX1 expression elicited by hemin inactivation of BACH1 persists despite the absence of NRF2 protein, suggesting BACH1 may also play a role in the repression of factor(s) in addition to NRF2.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 6860,
					"offsetInEndSection": 7183,
					"text": "By mass action, NRF2 activation could establish a new equilibrium favoring DNA-bound NRF2/sMAF, thereby increasing the stoichiometric DNA residence of NRF2. Since BACH1 appears to bind at sites containing multiple AREs, NRF2 may not displace a large enough fraction of DNA-bound BACH1 to overcome transcriptional repression",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 7269,
					"offsetInEndSection": 7877,
					"text": "When interpreted in the light of our ChIP enhancer binding data, these findings support the conclusion that inactivation of BACH1 by hemin decreases its DNA-binding affinity resulting in its generalized removal from ARE motifs and concomitant loss of transcriptional repression, leaving the AREs available for binding by NRF2 and possibly other transcription that mediate gene induction.\nBased on the dynamic exchange of BACH1 and NRF2 we propose that in cells naΓ―ve to oxidative stress, BACH1 is bound to the ARE enhancer motifs preventing NRF2 from binding and thereby repressing transcription (Figure 7A).",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 8225,
					"offsetInEndSection": 8378,
					"text": "The vast increase in the presence of nuclear NRF2 permits some increase in NRF2 binding to HMOX1 AREs but the presence of BACH1 maintains gene repression",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 10126,
					"offsetInEndSection": 10232,
					"text": "In this case, genes specifically repressed by BACH1 could be globally induced in response to redox stress.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "Which are the mutational hotspots of the human KRAS oncogene?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23536897",
				"http://www.ncbi.nlm.nih.gov/pubmed/22006429",
				"http://www.ncbi.nlm.nih.gov/pubmed/19430299",
				"http://www.ncbi.nlm.nih.gov/pubmed/12650907",
				"http://www.ncbi.nlm.nih.gov/pubmed/12941809",
				"http://www.ncbi.nlm.nih.gov/pubmed/14534542",
				"http://www.ncbi.nlm.nih.gov/pubmed/21199003"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23536897",
				"http://www.ncbi.nlm.nih.gov/pubmed/22006429",
				"http://www.ncbi.nlm.nih.gov/pubmed/19430299",
				"http://www.ncbi.nlm.nih.gov/pubmed/12650907",
				"http://www.ncbi.nlm.nih.gov/pubmed/12941809",
				"http://www.ncbi.nlm.nih.gov/pubmed/14534542",
				"http://www.ncbi.nlm.nih.gov/pubmed/21199003"
			],
			"type": "summary",
			"id": "52f7d3472059c6d71c00002f",
			"snippets": [
				{
					"offsetInBeginSection": 772,
					"offsetInEndSection": 1217,
					"text": "We verified multiple associations between oncogenic mutations and determined clinicopathological tumor features (1) EGFR A13_deletions are associated with right colon carcinoma (P<0.005), mucinous histotype (P=0.042), G3 grading (P=0.024), and MSI status (P<0.005); (2) PIK3CA mutations are related mucinous histotype (P=0.021); (3) KRAS(G12) and KRAS(G13) mutations are correlated, respectively, with the left and right colon cancer development",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23572025",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 680,
					"offsetInEndSection": 893,
					"text": "To verify the technical characteristics of the microarray system for the correct identification of the KRAS mutational status at the two hotspot codons 12 and 13 and of the BRAF(V600E) mutation in colorectal tumor",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536897",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1453,
					"offsetInEndSection": 1566,
					"text": "In addition, mutations in v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (glycineβ†’serine at codon 12",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22006429",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 307,
					"offsetInEndSection": 399,
					"text": "KRAS mutations are predominantly encoded by nucleotide substitutions within codons 12 and 13",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19430299",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 249,
					"offsetInEndSection": 330,
					"text": "To compare the limit of detection (LOD), mutations in KRAS (codon 12/13 hotspot) ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21199003",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 737,
					"offsetInEndSection": 894,
					"text": "Gain-of-function missense mutations are often somatically acquired in colorectal cancer, prevalently at three hot spots represented by codons 12, 13, and 61.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536897",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1281,
					"offsetInEndSection": 1308,
					"text": "KRAS codon 12/13 mutations ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536897",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3402,
					"offsetInEndSection": 3420,
					"text": "G12R KRAS mutation",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536897",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "Is apixaban effective for treatment of acute venous thromboembolism?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24057162",
				"http://www.ncbi.nlm.nih.gov/pubmed/23808982",
				"http://www.ncbi.nlm.nih.gov/pubmed/23150473",
				"http://www.ncbi.nlm.nih.gov/pubmed/23117646",
				"http://www.ncbi.nlm.nih.gov/pubmed/22795419",
				"http://www.ncbi.nlm.nih.gov/pubmed/18393142"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24057162",
				"http://www.ncbi.nlm.nih.gov/pubmed/23808982",
				"http://www.ncbi.nlm.nih.gov/pubmed/23150473",
				"http://www.ncbi.nlm.nih.gov/pubmed/23117646",
				"http://www.ncbi.nlm.nih.gov/pubmed/22795419",
				"http://www.ncbi.nlm.nih.gov/pubmed/18393142"
			],
			"type": "yesno",
			"id": "52fc94572059c6d71c000070",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 127,
					"text": "Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24057162",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 945,
					"offsetInEndSection": 1132,
					"text": "These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24057162",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1718,
					"offsetInEndSection": 1898,
					"text": "A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23808982",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 186,
					"text": "To critically review the effectiveness of the novel oral anticoagulants (rivaroxaban, dabigatran, ximelagatran, and apixaban) in the treatment of acute venous thromboembolism.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2087,
					"offsetInEndSection": 2308,
					"text": "ompared with vitamin K antagonists, the novel oral anticoagulants had a similar risk of recurrence of acute venous thromboembolism and all cause mortality, though rivaroxaban was associated with a reduced risk of bleeding",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 103,
					"offsetInEndSection": 329,
					"text": "Nowadays, the new anticoagulants, such as dabigatran, rivaroxaban and apixaban, show potential advantages over classical treatments. These agents inhibit specific coagulation factors and are administered orally at fixed doses.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23117646",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1192,
					"offsetInEndSection": 1308,
					"text": "In a recently completed phase III trial, apixaban also demonstrated promising efficacy and safety in that indication",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22795419",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 318,
					"offsetInEndSection": 419,
					"text": "the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18393142",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 8496,
					"offsetInEndSection": 8666,
					"text": "ConclusionsIn conclusion, the novel oral anticoagulants had similar efficacy and mortality profiles compared with conventional anticoagulation with vitamin K antagonists.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24311722",
				"http://www.ncbi.nlm.nih.gov/pubmed/24157582",
				"http://www.ncbi.nlm.nih.gov/pubmed/24085367",
				"http://www.ncbi.nlm.nih.gov/pubmed/24009233",
				"http://www.ncbi.nlm.nih.gov/pubmed/23782158",
				"http://www.ncbi.nlm.nih.gov/pubmed/23656200",
				"http://www.ncbi.nlm.nih.gov/pubmed/23619564",
				"http://www.ncbi.nlm.nih.gov/pubmed/23617325",
				"http://www.ncbi.nlm.nih.gov/pubmed/23617253",
				"http://www.ncbi.nlm.nih.gov/pubmed/23359016",
				"http://www.ncbi.nlm.nih.gov/pubmed/22960555",
				"http://www.ncbi.nlm.nih.gov/pubmed/22830347",
				"http://www.ncbi.nlm.nih.gov/pubmed/22300471"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24311722",
				"http://www.ncbi.nlm.nih.gov/pubmed/24157582",
				"http://www.ncbi.nlm.nih.gov/pubmed/24085367",
				"http://www.ncbi.nlm.nih.gov/pubmed/24009233",
				"http://www.ncbi.nlm.nih.gov/pubmed/23782158",
				"http://www.ncbi.nlm.nih.gov/pubmed/23656200",
				"http://www.ncbi.nlm.nih.gov/pubmed/23619564",
				"http://www.ncbi.nlm.nih.gov/pubmed/23617325",
				"http://www.ncbi.nlm.nih.gov/pubmed/23617253",
				"http://www.ncbi.nlm.nih.gov/pubmed/23359016",
				"http://www.ncbi.nlm.nih.gov/pubmed/22960555",
				"http://www.ncbi.nlm.nih.gov/pubmed/22830347",
				"http://www.ncbi.nlm.nih.gov/pubmed/22300471"
			],
			"type": "factoid",
			"id": "530cf4c54a5037880c000008",
			"snippets": [
				{
					"offsetInBeginSection": 187,
					"offsetInEndSection": 620,
					"text": "Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL. Early clinical results in CLL with other reversible and irreversible BTK inhibitors have been less promising, however, raising the question of whether BTK kinase activity is an important target of ibrutinib and also in CLL. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24311722",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 876,
					"offsetInEndSection": 1152,
					"text": "Inhibition of BTK kinase activity through either targeted genetic inactivation or ibrutinib in the TCL1 mouse significantly delays the development of CLL, demonstrating that BTK is a critical kinase for CLL development and expansion and thus an important target of ibrutinib. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24311722",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 292,
					"offsetInEndSection": 473,
					"text": "Ibrutinib, an inhibitor of Bruton's tyrosine kinase is showing impressive responses in heavily pre-treated high-risk CLL, whether alone or in combination with MoAbs or chemotherapy.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24157582",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 931,
					"offsetInEndSection": 1113,
					"text": "Ibrutinib acts by inhibiting the Bruton's tyrosine kinase (BTK) while idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24085367",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1096,
					"offsetInEndSection": 1261,
					"text": "Furthermore, we demonstrate that the Bruton's tyrosine kinase inhibitor ibrutinib or the PI3K inhibitor idelalisib block B-cell receptor induced activation of LCP1. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24009233",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 70,
					"text": "Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23782158",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 319,
					"offsetInEndSection": 625,
					"text": "We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23782158",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 315,
					"text": "Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23656200",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 890,
					"offsetInEndSection": 997,
					"text": "Next, we used this model to study ibrutinib, a Bruton's tyrosine kinase inhibitor in clinical development. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23619564",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 127,
					"text": "Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23617325",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 368,
					"offsetInEndSection": 607,
					"text": "Ibrutinib, a Bruton's tyrosine kinase inhibitor, has shown highly encouraging results in phase I/II trials in patients with treatment-naive, relapsed and refractory CLL even in the presence of high risk disease or poor prognostic markers. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23617325",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 869,
					"offsetInEndSection": 1078,
					"text": "The compounds that are currently investigated in patients with CLL include ibrutinib -inhibitor of Btk, fostamatinib-inhibitor of Syk and idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23617253",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 354,
					"offsetInEndSection": 600,
					"text": "Ibrutinib (PCI-32765), demonstrated that Btk inhibition sensitizes CLL cells to apoptosis and alters their migratory behavior, these studies however did not address whether Btk-mediated signaling is involved in the process of CLL leukemogenesis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23359016",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1087,
					"offsetInEndSection": 1315,
					"text": "Small molecule inhibitors of BCR signaling kinases, Bruton's tyrosine kinase (Btk) inhibitor ibrutinib and the phosphoinositide 3'-kinase delta (PI3KΞ΄) inhibitor GS-1101, are currently transforming the landscape of CLL therapy. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22960555",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 708,
					"offsetInEndSection": 938,
					"text": "More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22830347",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which enzyme is inhibited by a drug fostamatinib?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/21438742",
				"http://www.ncbi.nlm.nih.gov/pubmed/21304505",
				"http://www.ncbi.nlm.nih.gov/pubmed/21279990",
				"http://www.ncbi.nlm.nih.gov/pubmed/21239804",
				"http://www.ncbi.nlm.nih.gov/pubmed/21209239",
				"http://www.ncbi.nlm.nih.gov/pubmed/20879879",
				"http://www.ncbi.nlm.nih.gov/pubmed/20716772",
				"http://www.ncbi.nlm.nih.gov/pubmed/20601600",
				"http://www.ncbi.nlm.nih.gov/pubmed/20522642",
				"http://www.ncbi.nlm.nih.gov/pubmed/20415544",
				"http://www.ncbi.nlm.nih.gov/pubmed/19965662",
				"http://www.ncbi.nlm.nih.gov/pubmed/19959716",
				"http://www.ncbi.nlm.nih.gov/pubmed/19333898",
				"http://www.ncbi.nlm.nih.gov/pubmed/19107952",
				"http://www.ncbi.nlm.nih.gov/pubmed/18975322",
				"http://www.ncbi.nlm.nih.gov/pubmed/17537677",
				"http://www.ncbi.nlm.nih.gov/pubmed/23861534",
				"http://www.ncbi.nlm.nih.gov/pubmed/23617253",
				"http://www.ncbi.nlm.nih.gov/pubmed/23574525",
				"http://www.ncbi.nlm.nih.gov/pubmed/23523202",
				"http://www.ncbi.nlm.nih.gov/pubmed/23398911",
				"http://www.ncbi.nlm.nih.gov/pubmed/23378467",
				"http://www.ncbi.nlm.nih.gov/pubmed/23233565",
				"http://www.ncbi.nlm.nih.gov/pubmed/23190017",
				"http://www.ncbi.nlm.nih.gov/pubmed/23151054",
				"http://www.ncbi.nlm.nih.gov/pubmed/23078058",
				"http://www.ncbi.nlm.nih.gov/pubmed/23055694",
				"http://www.ncbi.nlm.nih.gov/pubmed/22875912",
				"http://www.ncbi.nlm.nih.gov/pubmed/22830347",
				"http://www.ncbi.nlm.nih.gov/pubmed/22776094",
				"http://www.ncbi.nlm.nih.gov/pubmed/22612424",
				"http://www.ncbi.nlm.nih.gov/pubmed/22492694",
				"http://www.ncbi.nlm.nih.gov/pubmed/22421457",
				"http://www.ncbi.nlm.nih.gov/pubmed/22374444",
				"http://www.ncbi.nlm.nih.gov/pubmed/22362000",
				"http://www.ncbi.nlm.nih.gov/pubmed/22357358",
				"http://www.ncbi.nlm.nih.gov/pubmed/22301676",
				"http://www.ncbi.nlm.nih.gov/pubmed/22284392",
				"http://www.ncbi.nlm.nih.gov/pubmed/22035435",
				"http://www.ncbi.nlm.nih.gov/pubmed/21711059",
				"http://www.ncbi.nlm.nih.gov/pubmed/21700926",
				"http://www.ncbi.nlm.nih.gov/pubmed/23642011",
				"http://www.ncbi.nlm.nih.gov/pubmed/23431463",
				"http://www.ncbi.nlm.nih.gov/pubmed/24376763",
				"http://www.ncbi.nlm.nih.gov/pubmed/21211067",
				"http://www.ncbi.nlm.nih.gov/pubmed/23094030",
				"http://www.ncbi.nlm.nih.gov/pubmed/23281837",
				"http://www.ncbi.nlm.nih.gov/pubmed/21394647",
				"http://www.ncbi.nlm.nih.gov/pubmed/24072968",
				"http://www.ncbi.nlm.nih.gov/pubmed/23170196",
				"http://www.ncbi.nlm.nih.gov/pubmed/23455231",
				"http://www.ncbi.nlm.nih.gov/pubmed/22166799",
				"http://www.ncbi.nlm.nih.gov/pubmed/23717217",
				"http://www.ncbi.nlm.nih.gov/pubmed/21878134",
				"http://www.ncbi.nlm.nih.gov/pubmed/23133664",
				"http://www.ncbi.nlm.nih.gov/pubmed/24455520"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/21438742",
				"http://www.ncbi.nlm.nih.gov/pubmed/21304505",
				"http://www.ncbi.nlm.nih.gov/pubmed/21279990",
				"http://www.ncbi.nlm.nih.gov/pubmed/21239804",
				"http://www.ncbi.nlm.nih.gov/pubmed/21209239",
				"http://www.ncbi.nlm.nih.gov/pubmed/20879879",
				"http://www.ncbi.nlm.nih.gov/pubmed/20716772",
				"http://www.ncbi.nlm.nih.gov/pubmed/20601600",
				"http://www.ncbi.nlm.nih.gov/pubmed/20522642",
				"http://www.ncbi.nlm.nih.gov/pubmed/20415544",
				"http://www.ncbi.nlm.nih.gov/pubmed/19965662",
				"http://www.ncbi.nlm.nih.gov/pubmed/19959716",
				"http://www.ncbi.nlm.nih.gov/pubmed/19333898",
				"http://www.ncbi.nlm.nih.gov/pubmed/19107952",
				"http://www.ncbi.nlm.nih.gov/pubmed/18975322",
				"http://www.ncbi.nlm.nih.gov/pubmed/17537677",
				"http://www.ncbi.nlm.nih.gov/pubmed/23861534",
				"http://www.ncbi.nlm.nih.gov/pubmed/23617253",
				"http://www.ncbi.nlm.nih.gov/pubmed/23574525",
				"http://www.ncbi.nlm.nih.gov/pubmed/23523202",
				"http://www.ncbi.nlm.nih.gov/pubmed/23398911",
				"http://www.ncbi.nlm.nih.gov/pubmed/23378467",
				"http://www.ncbi.nlm.nih.gov/pubmed/23233565",
				"http://www.ncbi.nlm.nih.gov/pubmed/23190017",
				"http://www.ncbi.nlm.nih.gov/pubmed/23151054",
				"http://www.ncbi.nlm.nih.gov/pubmed/23078058",
				"http://www.ncbi.nlm.nih.gov/pubmed/23055694",
				"http://www.ncbi.nlm.nih.gov/pubmed/22875912",
				"http://www.ncbi.nlm.nih.gov/pubmed/22830347",
				"http://www.ncbi.nlm.nih.gov/pubmed/22776094",
				"http://www.ncbi.nlm.nih.gov/pubmed/22612424",
				"http://www.ncbi.nlm.nih.gov/pubmed/22492694",
				"http://www.ncbi.nlm.nih.gov/pubmed/22421457",
				"http://www.ncbi.nlm.nih.gov/pubmed/22374444",
				"http://www.ncbi.nlm.nih.gov/pubmed/22362000",
				"http://www.ncbi.nlm.nih.gov/pubmed/22357358",
				"http://www.ncbi.nlm.nih.gov/pubmed/22301676",
				"http://www.ncbi.nlm.nih.gov/pubmed/22284392",
				"http://www.ncbi.nlm.nih.gov/pubmed/22035435",
				"http://www.ncbi.nlm.nih.gov/pubmed/21711059",
				"http://www.ncbi.nlm.nih.gov/pubmed/21700926",
				"http://www.ncbi.nlm.nih.gov/pubmed/23642011",
				"http://www.ncbi.nlm.nih.gov/pubmed/23431463",
				"http://www.ncbi.nlm.nih.gov/pubmed/24376763",
				"http://www.ncbi.nlm.nih.gov/pubmed/21211067",
				"http://www.ncbi.nlm.nih.gov/pubmed/23094030",
				"http://www.ncbi.nlm.nih.gov/pubmed/23281837",
				"http://www.ncbi.nlm.nih.gov/pubmed/21394647",
				"http://www.ncbi.nlm.nih.gov/pubmed/24072968",
				"http://www.ncbi.nlm.nih.gov/pubmed/23170196",
				"http://www.ncbi.nlm.nih.gov/pubmed/23455231",
				"http://www.ncbi.nlm.nih.gov/pubmed/22166799",
				"http://www.ncbi.nlm.nih.gov/pubmed/23717217",
				"http://www.ncbi.nlm.nih.gov/pubmed/21878134",
				"http://www.ncbi.nlm.nih.gov/pubmed/23133664",
				"http://www.ncbi.nlm.nih.gov/pubmed/24455520"
			],
			"type": "factoid",
			"id": "53357ca0d6d3ac6a3400004b",
			"snippets": [
				{
					"offsetInBeginSection": 618,
					"offsetInEndSection": 806,
					"text": "It outlines preclinical and early clinical experiences with the Syk inhibitor fostamatinib disodium (R788) and discusses various options for further clinical development of this compound. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21438742",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 218,
					"text": "To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21279990",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 519,
					"offsetInEndSection": 866,
					"text": "The mTOR inhibitors temsirolimus and everolimus have demonstrated antitumor activity in all types of lymphoma, the Syk inhibitor fostamatinib has activity in diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and the PKC-Ξ² inhibitor enzastaurin is being used as consolidation therapy after remission in diffuse large B-cell lymphoma. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21239804",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 122,
					"text": "Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21209239",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 88,
					"offsetInEndSection": 273,
					"text": "The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20879879",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 171,
					"text": "The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the EΞΌ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20716772",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 223,
					"offsetInEndSection": 444,
					"text": "We have now investigated whether inhibition of BCR signaling with the selective Syk inhibitor fostamatinib disodium (R788) will affect the growth of the leukemias that develop in the EΞΌ-TCL1 transgenic mouse model of CLL.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20716772",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 122,
					"offsetInEndSection": 378,
					"text": "We show that conditional ablation of the syk gene in dendritic cells (DCs) abrogates FcgammaR-mediated cross priming of diabetogenic T cells in RIP-mOVA mice, a situation phenocopied in wild-type RIP-mOVA mice treated with the selective Syk inhibitor R788.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20601600",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 502,
					"offsetInEndSection": 678,
					"text": "We investigated the ability of a small drug Syk inhibitor, R788, to protect mice against mesenteric ischemia-reperfusion (I/R)-induced local (intestine) and remote lung injury.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20522642",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 92,
					"text": "The spleen tyrosine kinase (Syk) inhibitor R406 is orally administered as the prodrug R788. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20415544",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 136,
					"text": "Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19965662",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 256,
					"offsetInEndSection": 444,
					"text": "These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19965662",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 385,
					"offsetInEndSection": 540,
					"text": "We examined the effect of R788 (fostamatinib disodium), an oral prodrug of the selective Syk inhibitor R406, in nephrotoxic nephritis in Wistar-Kyoto rats.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19959716",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 81,
					"text": "Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19333898",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 266,
					"text": "Rigel Pharmaceuticals Inc is developing fostamatinib, a prodrug of the spleen tyrosine kinase (Syk) inhibitor R-406, for the potential treatment of autoimmune diseases such as rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and B-cell lymphomas.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19333898",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 91,
					"offsetInEndSection": 225,
					"text": "In developmental toxicity studies with the Syk kinase inhibitor R788, a spectrum of findings, including renal agenesis, were observed.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19107952",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 165,
					"offsetInEndSection": 386,
					"text": "R788, a prodrug of active metabolite R406, has been shown to be an inhibitor of Syk kinase, active in a variety of in vitro and in vivo models, suggesting potential activity in the treatment of rheumatoid arthritis (RA). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18975322",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 212,
					"offsetInEndSection": 381,
					"text": "In collagen-induced arthritis, R788/R406, a novel and potent small molecule Syk inhibitor suppressed clinical arthritis, bone erosions, pannus formation, and synovitis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17537677",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 444,
					"offsetInEndSection": 621,
					"text": "Fostamatinib (R788) inhibits spleen tyrosine kinase (Syk) and has been in clinical trials involving both MTX inadequate responders (MTX-IRs) and biologic inadequate responders. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23861534",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 869,
					"offsetInEndSection": 1078,
					"text": "The compounds that are currently investigated in patients with CLL include ibrutinib -inhibitor of Btk, fostamatinib-inhibitor of Syk and idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23617253",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 458,
					"offsetInEndSection": 807,
					"text": "TK inhibitors including spleen TK (fostamatinib) and Janus kinases (tofacitinib) inhibitors are two novel oral therapies that have demonstrated short-term good clinical responses in active rheumatoid arthritis patients with and inadequate responses to methotrexate or other traditional (non-biologic) disease-modifying antirheumatic drugs (DMARDs). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23574525",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 470,
					"offsetInEndSection": 656,
					"text": "Progress is also being made with orally active Syk inhibitors. One such inhibitor (fostamatinib) is currently in large-scale phase 3 trials, and there are others in clinical development.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23523202",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 418,
					"offsetInEndSection": 664,
					"text": "We have shown that R406, the active metabolite of the Syk inhibitor fostamatinib, induces apoptosis and cell cycle arrest while decreasing downstream phosphatidylinositol-3'-kinase (PI3K)/Akt signaling in EBV+ B cell lymphoma PTLD lines in vitro.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23398911",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 250,
					"text": "Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23378467",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 169,
					"text": "Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23190017",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 5,
					"offsetInEndSection": 194,
					"text": "Fostamatinib (R788) is an orally dosed prodrug designed to deliver the active metabolite R940406 (R406), a spleen tyrosine kinase (SYK) inhibitor, for the treatment of rheumatoid arthritis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23190017",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1318,
					"offsetInEndSection": 1404,
					"text": "Fostamatinib demonstrates rapid and extensive conversion to R406, an inhibitor of SYK.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23190017",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 260,
					"offsetInEndSection": 388,
					"text": "Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23151054",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 240,
					"text": "Fostamatinib (R788) is a prodrug rapidly converted to its active metabolite on oral administration. This (known as R406) is a potent inhibitor of spleen tyrosine kinase, required for the expression of a number of proinflammatory cytokines. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23078058",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 737,
					"offsetInEndSection": 865,
					"text": "The Syk inhibitor, fostamatinib, proved superior to placebo in Phase II trials and is currently under Phase III investigation. T",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23055694",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 708,
					"offsetInEndSection": 938,
					"text": "More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22830347",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1379,
					"offsetInEndSection": 1606,
					"text": "Because inhibitors of SYK activity, such as fostamatinib, are in advanced clinical trials for rheumatoid arthritis and other autoimmune diseases, understanding the role of SYK in signalling via TLR4 is of immediate importance. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22776094",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 578,
					"offsetInEndSection": 999,
					"text": "The search terms used were Bruton's tyrosine kinase (Btk) inhibitors, PCI-32765, GDC-0834, LFM-A13, AVL-101, AVL-292, spleen tyrosine kinase (Syk) inhibitors, R343, R406, R112, R788, fostamatinib, BAY-61-3606, C-61, piceatannol, Lyn, imatinib, nilotinib, bafetinib, dasatinib, GDC-0834, PP2, SU6656 in conjunction with lymphoid malignancy, NHL, CLL, autoimmune disease, allergic disease, asthma, and rheumatoid arthritis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22612424",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 128,
					"text": "Inhibition of Syk activity by R788 in platelets prevents remote lung tissue damage after mesenteric ischemia-reperfusion injury.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22492694",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 744,
					"offsetInEndSection": 949,
					"text": "Recently, Syk inhibitor fostamatinib has exerted potent therapeutic efficacy against autoimmune and allergic diseases such as rheumatoid arthritis (RA), bronchial asthma and thrombocytopenic purpura (ITP).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22374444",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 253,
					"offsetInEndSection": 476,
					"text": "In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22362000",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 533,
					"offsetInEndSection": 747,
					"text": "In vivo expansion of luciferase(+) donor Tcs in mice developing GvHD was reduced by treatment with the Syk inhibitor Fostamatinib, which led to increased survival and reduced histologically confirmed GvHD severity.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22301676",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 78,
					"text": "Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22284392",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 225,
					"offsetInEndSection": 401,
					"text": "No oral biologic agents are available at this time but promising data is emerging for two drugs, tofacitinib and fostamatinib, inhibitors of JAK and Syk kinases, respectively. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22035435",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 321,
					"offsetInEndSection": 444,
					"text": "Fostamatinib (R-788) is an orally bioavailable small molecule. It is the prodrug of R406, which is a potent Syk inhibitor. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21711059",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 148,
					"text": "The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21700926",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 465,
					"offsetInEndSection": 756,
					"text": "Low-density lipoprotein receptor-deficient mice consuming a high-cholesterol diet supplemented with 2 doses of the orally available SYK inhibitor fostamatinib for 16 weeks showed a dose-dependent reduction in atherosclerotic lesion size by up to 59Β±6% compared with the respective controls. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21700926",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3082,
					"offsetInEndSection": 3580,
					"text": "Pharmacological inhibition of Syk by the Syk inhibitor fostamatininb (R788) or its active metabolite (R406) reduced the severity of autoantibody-induced arthritis in experimental mice [32] as well as in collagen-induced arthritis in experimental rats [33]. It should be noted that R406/fostamatinib is known to inhibit a number of kinases and non-kinase targets other than Syk [32,34,35], raising the possibility that the effect of the inhibitors were caused by targeting molecules other than Syk. ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23574525",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "Which JAK (Janus kinase) inhibitor is approved for treatment of rheumatoid arthritis?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24285764",
				"http://www.ncbi.nlm.nih.gov/pubmed/24218541",
				"http://www.ncbi.nlm.nih.gov/pubmed/24193189",
				"http://www.ncbi.nlm.nih.gov/pubmed/24013646",
				"http://www.ncbi.nlm.nih.gov/pubmed/23961674",
				"http://www.ncbi.nlm.nih.gov/pubmed/23627915",
				"http://www.ncbi.nlm.nih.gov/pubmed/23599436",
				"http://www.ncbi.nlm.nih.gov/pubmed/23523202",
				"http://www.ncbi.nlm.nih.gov/pubmed/23384668",
				"http://www.ncbi.nlm.nih.gov/pubmed/23212593",
				"http://www.ncbi.nlm.nih.gov/pubmed/22971156",
				"http://www.ncbi.nlm.nih.gov/pubmed/22899318",
				"http://www.ncbi.nlm.nih.gov/pubmed/22777068",
				"http://www.ncbi.nlm.nih.gov/pubmed/22460142",
				"http://www.ncbi.nlm.nih.gov/pubmed/22374445",
				"http://www.ncbi.nlm.nih.gov/pubmed/22252297",
				"http://www.ncbi.nlm.nih.gov/pubmed/22209716",
				"http://www.ncbi.nlm.nih.gov/pubmed/22147632",
				"http://www.ncbi.nlm.nih.gov/pubmed/22121136",
				"http://www.ncbi.nlm.nih.gov/pubmed/22006202",
				"http://www.ncbi.nlm.nih.gov/pubmed/21952978",
				"http://www.ncbi.nlm.nih.gov/pubmed/21884580",
				"http://www.ncbi.nlm.nih.gov/pubmed/21548952",
				"http://www.ncbi.nlm.nih.gov/pubmed/21105711",
				"http://www.ncbi.nlm.nih.gov/pubmed/20732649",
				"http://www.ncbi.nlm.nih.gov/pubmed/20701804",
				"http://www.ncbi.nlm.nih.gov/pubmed/20233177",
				"http://www.ncbi.nlm.nih.gov/pubmed/19587388",
				"http://www.ncbi.nlm.nih.gov/pubmed/19565475",
				"http://www.ncbi.nlm.nih.gov/pubmed/19404006",
				"http://www.ncbi.nlm.nih.gov/pubmed/23642011"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24285764",
				"http://www.ncbi.nlm.nih.gov/pubmed/24218541",
				"http://www.ncbi.nlm.nih.gov/pubmed/24193189",
				"http://www.ncbi.nlm.nih.gov/pubmed/24013646",
				"http://www.ncbi.nlm.nih.gov/pubmed/23961674",
				"http://www.ncbi.nlm.nih.gov/pubmed/23627915",
				"http://www.ncbi.nlm.nih.gov/pubmed/23599436",
				"http://www.ncbi.nlm.nih.gov/pubmed/23523202",
				"http://www.ncbi.nlm.nih.gov/pubmed/23384668",
				"http://www.ncbi.nlm.nih.gov/pubmed/23212593",
				"http://www.ncbi.nlm.nih.gov/pubmed/22971156",
				"http://www.ncbi.nlm.nih.gov/pubmed/22899318",
				"http://www.ncbi.nlm.nih.gov/pubmed/22777068",
				"http://www.ncbi.nlm.nih.gov/pubmed/22460142",
				"http://www.ncbi.nlm.nih.gov/pubmed/22374445",
				"http://www.ncbi.nlm.nih.gov/pubmed/22252297",
				"http://www.ncbi.nlm.nih.gov/pubmed/22209716",
				"http://www.ncbi.nlm.nih.gov/pubmed/22147632",
				"http://www.ncbi.nlm.nih.gov/pubmed/22121136",
				"http://www.ncbi.nlm.nih.gov/pubmed/22006202",
				"http://www.ncbi.nlm.nih.gov/pubmed/21952978",
				"http://www.ncbi.nlm.nih.gov/pubmed/21884580",
				"http://www.ncbi.nlm.nih.gov/pubmed/21548952",
				"http://www.ncbi.nlm.nih.gov/pubmed/21105711",
				"http://www.ncbi.nlm.nih.gov/pubmed/20732649",
				"http://www.ncbi.nlm.nih.gov/pubmed/20701804",
				"http://www.ncbi.nlm.nih.gov/pubmed/20233177",
				"http://www.ncbi.nlm.nih.gov/pubmed/19587388",
				"http://www.ncbi.nlm.nih.gov/pubmed/19565475",
				"http://www.ncbi.nlm.nih.gov/pubmed/19404006",
				"http://www.ncbi.nlm.nih.gov/pubmed/23642011"
			],
			"type": "factoid",
			"id": "53357193d6d3ac6a34000047",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 94,
					"text": "Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24285764",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 774,
					"offsetInEndSection": 876,
					"text": "Tofacitinib is the first oral Janus kinase inhibitor indicated for treatment of moderate to severe RA.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24285764",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 102,
					"text": "Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24218541",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 180,
					"offsetInEndSection": 434,
					"text": "The preclinical pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clinical PK/PD data from patients with rheumatoid arthritis (RA).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24218541",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 296,
					"offsetInEndSection": 430,
					"text": "With tofacitinib, the first Janus kinase (JAK) inhibitor has been approved in the USA, as well as in Switzerland and other countries. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24193189",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 134,
					"text": "Tofacitinib, which is a Janus kinase (JAK) inhibitor, has shown clinical effects in the treatment of rheumatoid arthritis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24013646",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 257,
					"offsetInEndSection": 625,
					"text": "Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved by the FDA for rheumatoid arthritis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23627915",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1139,
					"offsetInEndSection": 1272,
					"text": " In patients treated with the JAK inhibitor tofacitinib, RR for hypercholesterolaemia was 1.70 (1.10 to 2.63) that was dose related. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23599436",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 250,
					"text": "After two decades of research and development activity focussed on orally active kinase inhibitors, the first such drug (the JAK inhibitor Xeljanz, tofacitinib) was approved by the FDA in November 2012 for the treatment of rheumatoid arthritis (RA). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23523202",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 84,
					"text": "JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23212593",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 317,
					"offsetInEndSection": 474,
					"text": "An orally available JAK3 inhibitor, tofacitinib, has been applied for RA, with satisfactory effects and acceptable safety in multiple clinical examinations. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23212593",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 588,
					"offsetInEndSection": 935,
					"text": "Subsequently, multiple phase 3 studies were carried out, and tofacitinib with or without methotrexate (MTX) is efficacious and has a manageable safety profile in active RA patients who are MTX naΓ―ve or show inadequate response to methotrexate (MTX-IR), disease-modifying antirheumatic drugs (DMARD)-IR, or tumor necrosis factor (TNF)-inhibitor-IR.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23212593",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1369,
					"offsetInEndSection": 1519,
					"text": "Taken together, an orally available kinase inhibitor tofacitinib targeting JAK-mediated signals would be expected to be a new option for RA treatment.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23212593",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 187,
					"offsetInEndSection": 355,
					"text": "A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22971156",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 885,
					"offsetInEndSection": 1138,
					"text": "The recent disclosure of the clinical efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22971156",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1632,
					"offsetInEndSection": 1818,
					"text": "These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast-mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22899318",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1139,
					"offsetInEndSection": 1285,
					"text": "More recently, the Janus kinase (JAK) inhibitor tofacitinib has been evaluated as a potential new treatment option in RA and is awaiting approval.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22777068",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1300,
					"offsetInEndSection": 1794,
					"text": "A total of 140 patients were randomised to tofacitinib 1, 3, 5, 10 mg or placebo twice daily and the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12, a primary end point, was significant for all tofacitinib treatment groups. Thus, an orally available tofacitinib in combination with MTX was efficacious and had a manageable safety profile. Tofacitinib at 5 and 10 mg twice a day appears suitable for further evaluation to optimise the treatment of RA.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22460142",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1244,
					"offsetInEndSection": 1440,
					"text": "Moreover, induction of IL-10 production by DCs can be one mechanism of action of the JAK inhibitor (tofacitinib) which have shown high efficiency on active rheumatoid arthritis in clinical trials.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22374445",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 230,
					"offsetInEndSection": 539,
					"text": "Recently, CP-690,550 (tofacitinib), originally developed as a JAK3 inhibitor, has been shown to be effective in phase III clinical trials of rheumatoid arthritis and collagen-induced arthritis (CIA) models, but the precise mechanism of the effect, especially with respect to Th17 cells, is poorly understood. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22252297",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 10,
					"offsetInEndSection": 146,
					"text": " Tofacitinib (CP-690,550) is a novel JAK inhibitor that is currently in clinical trials for the treatment of rheumatoid arthritis (RA). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22147632",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 298,
					"text": "To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22006202",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1724,
					"offsetInEndSection": 1930,
					"text": "In patients with active RA in whom the response to MTX has been inadequate, the addition of tofacitinib at a dosage β‰¥3 mg twice daily showed sustained efficacy and a manageable safety profile over 24 weeks.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22006202",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 279,
					"text": "OBJECTIVE: To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21952978",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1749,
					"offsetInEndSection": 1913,
					"text": "Tofacitinib monotherapy at β‰¥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 weeks and demonstrated a manageable safety profile.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21952978",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 107,
					"text": "The new JAK3 inhibitor, CP690,550, has shown efficacy in the treatment of rheumatoid arthritis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21884580",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 175,
					"offsetInEndSection": 326,
					"text": "CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20701804",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 156,
					"text": "Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20233177",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 6,
					"offsetInEndSection": 369,
					"text": "To investigate the effects of methotrexate (MTX) on the pharmacokinetics (PK) of CP-690,550, a novel Janus kinase (JAK) inhibitor in development as a therapy for rheumatoid arthritis (RA), to determine the effects of multiple doses of CP-690,550 on the PK of MTX, and to evaluate the short-term safety and tolerability of co-administration of CP-690,550 and MTX. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20233177",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 230,
					"text": "Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19587388",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 981,
					"offsetInEndSection": 1101,
					"text": "CP-690,550 was efficacious in improving the pain, function and health status of patients with RA, from week 1 to week 6.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19587388",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1537,
					"offsetInEndSection": 1730,
					"text": "Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clinically meaningful reductions in the signs and symptoms of RA.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19565475",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 458,
					"offsetInEndSection": 578,
					"text": "INCB18424 targeting Jak1/2 and CP690,550 targeting Jak3 has been developed and is now on phase II clinical study for RA.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19404006",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 574,
					"text": "CP-690,550, a selective inhibitor of the JAK family of protein tyrosine kinases, is being developed as an immunosuppressive and anti-inflammatory agent for the treatment and prevention of acute allograft rejection, RA, psoriasis and other immune mediated diseases [1-6].\nIn clinical trials, CP-690,550 administration resulted in a dose-related decrease in PBNCs in active RA patients [7,8] within 2 weeks of treatment, but not in psoriasis patients [9], renal allograft patients [10] or normal volunteers [11] for up to 14 and 28 days of treatment, respectively. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20701804",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1071,
					"offsetInEndSection": 1230,
					"text": "CP690,550, a JAK3 inhibitor that is currently in clinical trials, has been shown to significantly reduce joint inflammation in rheumatoid arthritis (RA) [8,9].",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21884580",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 343,
					"offsetInEndSection": 469,
					"text": "CP690,550, a JAK inhibitor that is currently in clinical trials, has shown significant efficacy in the treatment of RA [8,9]. ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21884580",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "Which enzyme is targeted by the drug Imetelstat?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23545855",
				"http://www.ncbi.nlm.nih.gov/pubmed/23516479",
				"http://www.ncbi.nlm.nih.gov/pubmed/22906540",
				"http://www.ncbi.nlm.nih.gov/pubmed/21549308",
				"http://www.ncbi.nlm.nih.gov/pubmed/21332640",
				"http://www.ncbi.nlm.nih.gov/pubmed/21208905",
				"http://www.ncbi.nlm.nih.gov/pubmed/21062983",
				"http://www.ncbi.nlm.nih.gov/pubmed/20824134",
				"http://www.ncbi.nlm.nih.gov/pubmed/20232321",
				"http://www.ncbi.nlm.nih.gov/pubmed/20072842",
				"http://www.ncbi.nlm.nih.gov/pubmed/20048334",
				"http://www.ncbi.nlm.nih.gov/pubmed/19908230",
				"http://www.ncbi.nlm.nih.gov/pubmed/23326372",
				"http://www.ncbi.nlm.nih.gov/pubmed/21845093",
				"http://www.ncbi.nlm.nih.gov/pubmed/23386830",
				"http://www.ncbi.nlm.nih.gov/pubmed/23272238",
				"http://www.ncbi.nlm.nih.gov/pubmed/24327604",
				"http://www.ncbi.nlm.nih.gov/pubmed/23727752",
				"http://www.ncbi.nlm.nih.gov/pubmed/23521791",
				"http://www.ncbi.nlm.nih.gov/pubmed/22382179",
				"http://www.ncbi.nlm.nih.gov/pubmed/23467584",
				"http://www.ncbi.nlm.nih.gov/pubmed/23558965",
				"http://www.ncbi.nlm.nih.gov/pubmed/22870217"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2746063",
					"p": "http://www.w3.org/2004/02/skos/core#definition",
					"o": "NCI: A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, telomerase inhibitor GRN163L as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by telomerase inhibitor GRN163L results in telomere shortening, which leads to cell cycle arrest or apoptosis."
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17693237",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "IMETELSTAT"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17693235",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Imetelstat"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2746063",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A17693237"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2746063",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A17693236"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2746063",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A17693235"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17693236",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "DNA, d(3'-amino-3'-deoxy-P-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-[O-[2-hydroxy-3- [(1-oxohexadecyl)amino]propyl] hydrogen phosphorothioate]"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23545855",
				"http://www.ncbi.nlm.nih.gov/pubmed/23516479",
				"http://www.ncbi.nlm.nih.gov/pubmed/22906540",
				"http://www.ncbi.nlm.nih.gov/pubmed/21549308",
				"http://www.ncbi.nlm.nih.gov/pubmed/21332640",
				"http://www.ncbi.nlm.nih.gov/pubmed/21208905",
				"http://www.ncbi.nlm.nih.gov/pubmed/21062983",
				"http://www.ncbi.nlm.nih.gov/pubmed/20824134",
				"http://www.ncbi.nlm.nih.gov/pubmed/20232321",
				"http://www.ncbi.nlm.nih.gov/pubmed/20072842",
				"http://www.ncbi.nlm.nih.gov/pubmed/20048334",
				"http://www.ncbi.nlm.nih.gov/pubmed/19908230",
				"http://www.ncbi.nlm.nih.gov/pubmed/23326372",
				"http://www.ncbi.nlm.nih.gov/pubmed/21845093",
				"http://www.ncbi.nlm.nih.gov/pubmed/23386830",
				"http://www.ncbi.nlm.nih.gov/pubmed/23272238",
				"http://www.ncbi.nlm.nih.gov/pubmed/24327604",
				"http://www.ncbi.nlm.nih.gov/pubmed/23727752",
				"http://www.ncbi.nlm.nih.gov/pubmed/23521791",
				"http://www.ncbi.nlm.nih.gov/pubmed/22382179",
				"http://www.ncbi.nlm.nih.gov/pubmed/23467584",
				"http://www.ncbi.nlm.nih.gov/pubmed/23558965",
				"http://www.ncbi.nlm.nih.gov/pubmed/22870217"
			],
			"type": "factoid",
			"id": "532498959b2d7acc7e000017",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 83,
					"text": "Imetelstat (a telomerase antagonist) exerts offβ€‘target effects on the cytoskeleton.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23545855",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 228,
					"offsetInEndSection": 636,
					"text": "imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'β†’P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23545855",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 841,
					"offsetInEndSection": 1017,
					"text": "In addition to the inhibition of telomerase activity in cancer cell lines, GRN163L causes morphological cell rounding changes, independent of hTR expression or telomere length.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23545855",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 130,
					"offsetInEndSection": 421,
					"text": "We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer. Our results showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22906540",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 547,
					"offsetInEndSection": 695,
					"text": "Furthermore, long-term treatment with imetelstat decreased cell growth of esophageal cancer cells with different kinetics regarding telomere lengths",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22906540",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 456,
					"offsetInEndSection": 691,
					"text": " Telomerase extension is less processive during the first few weeks following the reversal of long-term treatment with the telomerase inhibitor Imetelstat (GRN163L), a time when Cajal bodies fail to deliver telomerase RNA to telomeres.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21549308",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 683,
					"offsetInEndSection": 883,
					"text": "The role of telomerase as an immunotherapy, as a gene therapy approach using telomerase promoter driven oncolytic viruses and as a small oligonucleotide targeted therapy (Imetelstat) will be discussed",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21332640",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 651,
					"offsetInEndSection": 811,
					"text": "We then tested the efficacy of the telomerase inhibitor Imetelstat on propagation and self-renewal capacity of TIC and normal stem cells in vitro and in vivo. R",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21208905",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2,
					"offsetInEndSection": 105,
					"text": "e telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21062983",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 455,
					"offsetInEndSection": 769,
					"text": "In this study, we investigated the effects of imetelstat (GRN163L), a potent telomerase inhibitor, on both the bulk cancer cells and putative CSCs. When breast and pancreatic cancer cell lines were treated with imetelstat in vitro, telomerase activity in the bulk tumor cells and CSC subpopulations were inhibited.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21062983",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 537,
					"offsetInEndSection": 700,
					"text": "Telomerase activity is required for the maintenance of normal adult stem cells, and we examined the activity of the telomerase inhibitor imetelstat against MM CSC.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20824134",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 867,
					"offsetInEndSection": 1205,
					"text": "Human MM CSC were isolated from cell lines and primary clinical specimens and treated with imetelstat, a specific inhibitor of the reverse transcriptase activity of telomerase. Two weeks of exposure to imetelstat resulted in a significant reduction in telomere length and the inhibition of clonogenic MM growth both in vitro and in vivo. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20824134",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1666,
					"offsetInEndSection": 1851,
					"text": "Short oligonucleotide N3'-->P5' thio-phosphoramidate conjugated to 5'-palmitoyl group, designated as GRN163L (Imetelstat), was recently introduced as a potent human telomerase inhibitor",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20232321",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2,
					"offsetInEndSection": 54,
					"text": "etelstat (GRN163L)--telomerase-based cancer therapy.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20072842",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 579,
					"offsetInEndSection": 703,
					"text": "Imetelstat (GRN163L) is a potent and specific telomerase inhibitor and so far the only drug of its class in clinical trials.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20072842",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2,
					"offsetInEndSection": 147,
					"text": "e telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20048334",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 108,
					"offsetInEndSection": 271,
					"text": "The effects of a novel human telomerase antagonist, imetelstat, on primary human glioblastoma (GBM) tumor-initiating cells were investigated in vitro and in vivo. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20048334",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 704,
					"offsetInEndSection": 961,
					"text": "Imetelstat treatment produced a dose-dependent inhibition of telomerase (IC(50) 0.45 micromol/L). Long-term imetelstat treatment led to progressive telomere shortening, reduced rates of proliferation, and eventually cell death in GBM tumor-initiating cells.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20048334",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 579,
					"offsetInEndSection": 1040,
					"text": " We have found that prostate TICs have significant telomerase activity which is inhibited by imetelstat sodium (GRN163L), a new telomerase antagonist that is currently in Phase I/II clinical trials for several hematological and solid tumor malignancies. Prostate TICs telomeres were of similar average length to the telomeres of the main population of cells and significant telomere shortening was detected in prostate TICs as a result of imetelstat treatment. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19908230",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2497,
					"offsetInEndSection": 2674,
					"text": "Thus, we studied the role of telomerase in MM CSC by examining the effects of imetelstat, a specific competitive inhibitor of the telomerase reverse transcriptase activity [26].",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20824134",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 269,
					"text": "Imetelstat inhibits TA in MM plasma cells and CSCMM plasma cells express the characteristic surface antigen CD138, but the self-renewing cells responsible for tumor initiation in immunodeficient mice phenotypically resemble memory B cells and are CD138neg [2]. ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20824134",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 2403,
					"offsetInEndSection": 2680,
					"text": "We studied the ability of imetelstat to inhibit TA in MM and treated RPMI8226, NCI-H929, and U266 cells for 48 hours. Using the TRAP assay, we detected at least a 60% reduction in TA in cells treated with imetelstat compared to a mismatched control oligonucleotide (Figure 1C).",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20824134",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 3452,
					"offsetInEndSection": 3648,
					"text": "By two weeks, cells treated with imetelstat displayed a significantly increased proportion (p<0.01, Figure 2A) of shortened telomeres (<1.4 kb) using the single telomere length assay (STELA)[35]. ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20824134",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 6582,
					"offsetInEndSection": 6749,
					"text": "Therefore, telomerase inhibition by imetelstat significantly reduces MM clonogenic potential both in vitro and in vivo in parallel with its effects on telomere length.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20824134",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 2096,
					"offsetInEndSection": 2250,
					"text": "The efficacy of long-term telomerase inhibition suggests that imetelstat modulates MM CSC growth and self-renewal primarily by modulating telomere length.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20824134",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 568,
					"offsetInEndSection": 677,
					"text": "Telomerase activation was countered by co-treatment with Imetelstat (GRN163L), a potent telomerase inhibitor.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23516479",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1216,
					"offsetInEndSection": 1646,
					"text": "Since co-treatment of mice with both GRN510 and a potent telomerase inhibitor imetelstat (GRN163L) largely suppressed both the GRN510-mediated activation of telomerase in lung tissue (Fig. 1B) and its protective effect against induced fibrosis (Figure 4), we believe that the principle mechanism of action of GRN510 is mediated through the telomerase and telomere lengthening pathways, as suggested by previous studies [31], [32].",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23516479",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "What is the mode of inheritance of Marchesani syndrome?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20301293",
				"http://www.ncbi.nlm.nih.gov/pubmed/19836009",
				"http://www.ncbi.nlm.nih.gov/pubmed/19396027",
				"http://www.ncbi.nlm.nih.gov/pubmed/14598350",
				"http://www.ncbi.nlm.nih.gov/pubmed/12525539",
				"http://www.ncbi.nlm.nih.gov/pubmed/11941487",
				"http://www.ncbi.nlm.nih.gov/pubmed/10707143",
				"http://www.ncbi.nlm.nih.gov/pubmed/8914744",
				"http://www.ncbi.nlm.nih.gov/pubmed/6739588"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20301293",
				"http://www.ncbi.nlm.nih.gov/pubmed/19836009",
				"http://www.ncbi.nlm.nih.gov/pubmed/19396027",
				"http://www.ncbi.nlm.nih.gov/pubmed/14598350",
				"http://www.ncbi.nlm.nih.gov/pubmed/12525539",
				"http://www.ncbi.nlm.nih.gov/pubmed/11941487",
				"http://www.ncbi.nlm.nih.gov/pubmed/10707143",
				"http://www.ncbi.nlm.nih.gov/pubmed/8914744",
				"http://www.ncbi.nlm.nih.gov/pubmed/6739588"
			],
			"type": "factoid",
			"id": "532f0bd6d6d3ac6a3400002d",
			"snippets": [
				{
					"offsetInBeginSection": 534,
					"offsetInEndSection": 633,
					"text": "Autosomal recessive and autosomal dominant WMS cannot be distinguished by clinical findings alone. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20301293",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 245,
					"text": "Weill-Marchesani syndrome (WMS) is a well-characterized disorder in which patients develop eye and skeletal abnormalities. Autosomal-recessive and autosomal-dominant forms of WMS are caused by mutations in ADAMTS10 and FBN1 genes, respectively. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19836009",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 616,
					"offsetInEndSection": 830,
					"text": "Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19396027",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 335,
					"text": "Weill-Marchesani syndrome (WMS) is a rare condition characterized by short stature, brachydactyly, joint stiffness, and characteristic eye abnormalities including microspherophakia, ectopia of lens, severe myopia, and glaucoma. Both autosomal recessive (AR) and autosomal dominant (AD) modes of inheritance have been described for WMS.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14598350",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 416,
					"text": "Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterised by short stature, brachydactyly, joint stiffness, and characteristic eye anomalies including microspherophakia, ectopia of the lenses, severe myopia, and glaucoma. Both autosomal recessive (AR) and autosomal dominant (AD) modes of inheritance have been described and a gene for AR WMS has recently been mapped to chromosome 19p13.3-p13.2.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12525539",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 211,
					"offsetInEndSection": 325,
					"text": "Both autosomal recessive and autosomal dominant modes of inheritance have been described in association with WMS. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11941487",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 179,
					"offsetInEndSection": 440,
					"text": "We report 6 patients with Weill-Marchesani syndrome (with or without ocular involvement) in three generations, identified by screening 26 members of two families. This is the largest family in the literature showing an autosomal dominant pattern of inheritance.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10707143",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 157,
					"text": "Weill-Marchesani syndrome comprises short stature, brachydactyly, microspherophakia, glaucoma, and ectopia lentis is regarded as an autosomal recessive trait",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8914744",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 177,
					"offsetInEndSection": 323,
					"text": "We present two families each with affected individuals in 3 generations demonstrating autosomal dominant inheritance of Weill-Marchesani syndrome.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8914744",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 176,
					"text": "Weill-Marchesani syndrome is a rare, generalized disorder of connective tissue manifested by short stature, brachymorphia, and spherophakia. Inheritance is autosomal recessive.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/6739588",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the frequency of mutations induced spontaneously through Ethylnitrosourea (ENU) mutagenesis?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18504270",
				"http://www.ncbi.nlm.nih.gov/pubmed/15450411",
				"http://www.ncbi.nlm.nih.gov/pubmed/12410959",
				"http://www.ncbi.nlm.nih.gov/pubmed/10886029",
				"http://www.ncbi.nlm.nih.gov/pubmed/10700191",
				"http://www.ncbi.nlm.nih.gov/pubmed/3863118",
				"http://www.ncbi.nlm.nih.gov/pubmed/509687"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18504270",
				"http://www.ncbi.nlm.nih.gov/pubmed/15450411",
				"http://www.ncbi.nlm.nih.gov/pubmed/12410959",
				"http://www.ncbi.nlm.nih.gov/pubmed/10886029",
				"http://www.ncbi.nlm.nih.gov/pubmed/10700191",
				"http://www.ncbi.nlm.nih.gov/pubmed/3863118",
				"http://www.ncbi.nlm.nih.gov/pubmed/509687"
			],
			"type": "factoid",
			"id": "533ba85ffd9a95ea0d000008",
			"snippets": [
				{
					"offsetInBeginSection": 820,
					"offsetInEndSection": 991,
					"text": "The mutation frequency increased linearly with MNU or ENU concentration (0.01--2.0 mM); mean values were 2800 and 840 mutants per 10(6) clonable cells per mM, respectively",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/509687",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 609,
					"offsetInEndSection": 900,
					"text": "The mutation frequency induced by a 400 mg/kg dosage of ethylnitrosourea is 12 times the maximal mutation frequency achievable with a single exposure to x-rays and 36 times that reported for procarbazine, the most effective chemical mutagen previously known for mouse stem-cell spermatogonia",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/3863118",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 523,
					"offsetInEndSection": 694,
					"text": "Specific locus tests designed to detect recessive mutations showed that ENU is the most efficient mutagen in mouse with an approximate mutation rate of 1 in 1,000 gametes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10700191",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 966,
					"offsetInEndSection": 1153,
					"text": "Theoretical considerations and empirical analysis suggest that the per-base mutation frequency for a fractionated-dose treatment protocol is on the order of 1 sequence change per 10(5) bp",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10886029",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1285,
					"offsetInEndSection": 1504,
					"text": "Unlike spontaneous chromosome damage, spontaneous mutant frequencies did not differ significantly among homozygous, heterozygous, and wild-type mice (3.2 x 10(-5), 3.1 x 10(-5), and 3.1 x 10(-5), respectively; P > 0.05)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15450411",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1667,
					"offsetInEndSection": 1831,
					"text": "The ENU-induced mutation frequency in Blmtm3Brd homozygous, heterozygous, and wild mice were 54 x 10(-5), 35 x 10(-5), and 25 x 10(-5) mutants/plaques, respectively",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15450411",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 888,
					"offsetInEndSection": 1130,
					"text": "mutation frequencies per nucleotide based on mutant spectra from this study and published literature. We found this frequency in control spleen to be similar for lacI (3.8 +/- 0.7 x 10(-8)) and PhiX174 (3.1 +/- 1.2 x 10(-8)) at 6 weeks of age",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18504270",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "In which genomic positions is the histone variant macroH2A enriched?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20937776",
				"http://www.ncbi.nlm.nih.gov/pubmed/20670405",
				"http://www.ncbi.nlm.nih.gov/pubmed/18936163",
				"http://www.ncbi.nlm.nih.gov/pubmed/18195046",
				"http://www.ncbi.nlm.nih.gov/pubmed/17570398",
				"http://www.ncbi.nlm.nih.gov/pubmed/16738309",
				"http://www.ncbi.nlm.nih.gov/pubmed/16213499",
				"http://www.ncbi.nlm.nih.gov/pubmed/14608463",
				"http://www.ncbi.nlm.nih.gov/pubmed/12082075"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20937776",
				"http://www.ncbi.nlm.nih.gov/pubmed/20670405",
				"http://www.ncbi.nlm.nih.gov/pubmed/18936163",
				"http://www.ncbi.nlm.nih.gov/pubmed/18195046",
				"http://www.ncbi.nlm.nih.gov/pubmed/17570398",
				"http://www.ncbi.nlm.nih.gov/pubmed/16738309",
				"http://www.ncbi.nlm.nih.gov/pubmed/16213499",
				"http://www.ncbi.nlm.nih.gov/pubmed/14608463",
				"http://www.ncbi.nlm.nih.gov/pubmed/12082075"
			],
			"type": "list",
			"id": "533c384dc45e133714000006",
			"snippets": [
				{
					"offsetInBeginSection": 291,
					"offsetInEndSection": 429,
					"text": "Although macroH2A1 nucleosomes are widely distributed across the genome, their local concentration varies over a range of 100-fold or more",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20937776",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 431,
					"offsetInEndSection": 614,
					"text": "The transcribed regions of most active genes are depleted of macroH2A1, often in sharply localized domains that show depletion of 4-fold or more relative to bulk mouse liver chromatin",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20937776",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 957,
					"offsetInEndSection": 1119,
					"text": "This repressor activity is further supported by the substantial and relatively uniform macroH2A1 enrichment along the inactive X chromosome, which averages 4-fold",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20937776",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1121,
					"offsetInEndSection": 1315,
					"text": "mH2A1 consistently colocalizes with a heterochromatin marker (H3K27me2; histone H3 trimethylated at lysine 27) and mH2A2 with a euchromatin marker (H3K4me3; histone H3 trimethylated at lysine 4)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1317,
					"offsetInEndSection": 1408,
					"text": "Similar results were found for the L41gene, with enrichment of mH2A in the promoter region.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 117,
					"offsetInEndSection": 358,
					"text": "By using highly specific antibodies against mH2A1 and stable HEK 293 cell lines expressing either green fluorescent protein (GFP)-mH2A1 or GFP-H2A, we found that the Xi chromosome contains approximately 1.5-fold more mH2A1 than the autosomes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18936163",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 693,
					"offsetInEndSection": 775,
					"text": "The data show that mH2A1 is uniformly distributed across the entire Xi chromosome.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18936163",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 776,
					"offsetInEndSection": 892,
					"text": "Interestingly, a stronger mH2A1 enrichment along the pseudoautosomal X chromosome region was observed in both sexes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18936163",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 478,
					"offsetInEndSection": 596,
					"text": "macroH2A1 nucleosomes were enriched on endogenous MLVs, with the highest enrichment occurring on the 5' end of pro-pol",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18195046",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 440,
					"offsetInEndSection": 564,
					"text": "macroH2A1 is enriched on the inactive X chromosome in female mammalian cells, where it functions to maintain gene silencing.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17570398",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 190,
					"offsetInEndSection": 269,
					"text": "We found that macroH2A1 was depleted on the transcribed regions of active genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16738309",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 402,
					"offsetInEndSection": 528,
					"text": "In contrast, macroH2A1 was concentrated on the inactive X chromosome, consistent with our previous immunofluorescence studies.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16738309",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 722,
					"offsetInEndSection": 812,
					"text": "These results support the hypothesis that macroH2As function as transcriptional repressors",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16738309",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 785,
					"offsetInEndSection": 1198,
					"text": "Taking into account the properties of macroH2A toward chromatin structure and dynamics and its role in gene repression our data suggest that the increased expression of macroH2A and the hypermethylation of DNA which occurs upon winter-acclimatization plays a major role for the reorganization of chromatin structure and the regulation of gene expression during the physiological adaptation to a colder environment",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16213499",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 153,
					"offsetInEndSection": 380,
					"text": "Inactivation is a multistep process that involves a large non-coding RNA termed XIST, a variety of epigenetic modifications of chromatin, and alterations in protein composition such as enrichment of the histone variant macroH2A",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14608463",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 214,
					"text": "One of several features acquired by chromatin of the inactive X chromosome (Xi) is enrichment for the core histone H2A variant macroH2A within a distinct nuclear structure referred to as a macrochromatin body (MCB)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 216,
					"offsetInEndSection": 328,
					"text": "In addition to localizing to the MCB, macroH2A accumulates at a perinuclear structure centered at the centrosome",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1010,
					"offsetInEndSection": 1110,
					"text": "The centrosomal pool of macroH2A1 accumulates in the presence of an inhibitor of the 20S proteasome.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 650,
					"offsetInEndSection": 849,
					"text": "Although the MCB dissipates during late S phase and G2 before reforming in late G1, macroH2A1 remains associated during mitosis with specific regions of the Xi, including at the X inactivation center",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 19226,
					"offsetInEndSection": 19444,
					"text": " To evaluate the potential association of macroH2A1 with the proteasome, cells were synchronized at the G1β€“S boundary and in mitosis before releasing in the presence of lactacystin, an irreversible proteasome inhibitor",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 19707,
					"offsetInEndSection": 19931,
					"text": "The dramatic accumulation of macroH2A1 at the centrosome after inhibition of the proteasome is consistent with the inability to degrade the protein, suggesting that macroH2A1 may be targeted to the centrosome for degradation",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 19470,
					"offsetInEndSection": 19622,
					"text": "Centrosomal accumulation of macroH2A1 significantly increased after incubation for 12 h in lactacystin and colocalized with an enlarged ubiquitin domain",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 1506,
					"offsetInEndSection": 1599,
					"text": "Two separate genes encode macroH2A1 and macroH2A2, both of which are enriched in Xi chromatin",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1665,
					"offsetInEndSection": 1800,
					"text": "The enrichment of macroH2A at the Xi forms a characteristic structure in the female nucleus, referred to as a macrochromatin body (MCB)",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2616,
					"offsetInEndSection": 2749,
					"text": "Prior to the onset of X inactivation in ES cells, a cytoplasmic concentration of macroH2A1 is evident, coincident with the centrosome",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4152,
					"offsetInEndSection": 4368,
					"text": "We found that mH2A associates with ribosomal genes during acclimatization, and more importantly, that there is differential enrichment of the mH2A variant subtypes, depending on the seasonal transcriptional activity.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3245,
					"offsetInEndSection": 3370,
					"text": "Evaluation of mH2A1 and mH2A2 enrichment in the promoter regions of the L41 and prolactin genes om seasonal acclimatized carp",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 3743,
					"offsetInEndSection": 4277,
					"text": "To investigate whether the differential seasonal enrichment observed for mH2A subtypes during carp acclimatization correlated with either the activated or the repressed transcriptional state, we carried out sequential ChIP assays to assess the colocalization of mH2A1 and mH2A2 with histone post-translational modifications such as H3K4me3 (histone H3 trimethylated at lysine 4) and H3K27me2 (histone H3 dimethylated at lysine 27), which are classic epigenetic markers for activated and repressed transcriptional regions, respectively",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 4095,
					"offsetInEndSection": 4462,
					"text": "Thus, when mH2A1 was enriched in the carp ribosomal cistron, it colocalized with a heterochromatin marker (H3K27me2), which coincides with the transcriptional repression previously reported in winter during carp acclimatization, whereas the mH2A2 enrichment in summer colocalized with a euchromatin marker (H3K4me3), correlating with an increase in rRNA transcription",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20670405",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 165,
					"text": "MacroH2A1 and macroH2A2 associate with centrosomes in male and female somatic cellsA centrosomal association of macroH2A1 was observed in human somatic cells",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 519,
					"offsetInEndSection": 657,
					"text": "Using independent antisera specific to either the macroH2A1 or the macroH2A2 protein, we detected both forms of macroH2A at the centrosome",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 5197,
					"offsetInEndSection": 5350,
					"text": " We have investigated the relationship of macroH2A with the human and mouse Xi and consistently observed a distinct banding pattern on the Xi chromosome ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 5360,
					"offsetInEndSection": 5543,
					"text": "As previously observed, macroH2A associates with the autosomes and active X chromosome (Xa) in human metaphase spreads as well, but at a significantly lower level than that for the Xi",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 2144,
					"offsetInEndSection": 2351,
					"text": "Although a smaller macroH2A2 band is not detected in centrosome preparations (Fig. 2 a, lane 2), a considerably weaker smaller band can be detected in nucleosome fractions with antisera specific to macroH2A2",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 3399,
					"offsetInEndSection": 3492,
					"text": "Detection of macroH2A1 and macroH2A2 in fractions from nucleosome and centrosome preparations",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 11055,
					"offsetInEndSection": 11125,
					"text": "whereas macroH2A1 was observed at the centrosome shortly after release",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 11375,
					"offsetInEndSection": 11476,
					"text": "Distribution of macroH2A1 in relation to the centrosome and XIST RNA through the somatic cell cycle. ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 21316,
					"offsetInEndSection": 21465,
					"text": "To determine how specific macroH2A1 association with the centrosome is, we looked at a number of other chromatin proteins for centrosome association ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 323,
					"text": "MacroH2A1 associates with the centrosome in a manner characteristic of a degradation pathwayThe association of macroH2A at the centrosome is not restricted to undifferentiated mouse ES cells (Rasmussen et al., 2000), but is a common feature of male and female mouse (Mermoud et al., 2001) and human somatic cells",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 336,
					"offsetInEndSection": 505,
					"text": "Centrosomal macroH2A is composed of both macroH2A1 and macroH2A2 (Fig. 1 b and Fig. 2 a), indicating that both proteins are spatially indistinguishable at the centrosome",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1367,
					"offsetInEndSection": 1553,
					"text": "The accumulation of macroH2A1 at the centrosome in the presence of lactacystin (Fig. 7) suggests that macroH2A1 is targeted to the centrosomeβ€“proteasome as part of a degradation pathway.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1554,
					"offsetInEndSection": 1713,
					"text": "In contrast, despite the association of macroH2A2 with the centrosome (Fig. 1 b and Fig. 2 a), an accumulation was not detected in the presence of lactacystin ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 3761,
					"offsetInEndSection": 3854,
					"text": "In addition to macroH2A1, a number of other chromatin proteins associate with the centrosome ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 5344,
					"offsetInEndSection": 5502,
					"text": "As cells proceed through S phase and G2 toward mitosis, the concentration of macroH2A1 at the centrosome increases to a level detectable by immunofluorescence",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 5628,
					"offsetInEndSection": 5777,
					"text": "The accumulation of macroH2A1 at the centrosome in the presence of lactacystin is most prominent in cells as they pass through S phase toward mitosis",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 5981,
					"offsetInEndSection": 6146,
					"text": "The association of macroH2A1 with the Xi chromatin is most prominent at S phaseA prerequisite for the formation of an MCB is the association of XIST RNA with the Xi ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 6198,
					"offsetInEndSection": 6348,
					"text": "Whereas XIST RNA coats the Xi through early G1 to late G2, the stable presence of XIST does not immediately direct macroH2A1 to the Xi to form an MCB ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 6458,
					"offsetInEndSection": 6594,
					"text": "MacroH2A1 is unlikely to be marking chromatin for late replication, as not all sites of late replication overlap with macroH2A1 staining",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 4955,
					"offsetInEndSection": 5145,
					"text": "Both macroH2A1 and macroH2A2 concentrate in distinct bands on the human and mouse XiPrevious observations have indicated that macroH2A1 is uniformly associated with the mouse Xi at metaphase",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 5732,
					"offsetInEndSection": 5806,
					"text": "MacroH2A displays distinct banding patterns on the metaphase Xi chromosome",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 8360,
					"offsetInEndSection": 8434,
					"text": "Up to four macroH2A bands were observed on the Xi in a variety of human 46",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 9235,
					"offsetInEndSection": 9319,
					"text": "As seen in humans, macroH2A1 formed a characteristic banding pattern on the mouse Xi",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 9583,
					"offsetInEndSection": 9827,
					"text": "The macroH2A band at Xq22-24 overlaps with the site of histone H3 lysine-4 methylationIn addition to a reproducible banding pattern of macroH2A on the Xi, a distinct banding pattern of histone H3 lysine-4 methylation (DimH3K4) has been observed",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 6759,
					"offsetInEndSection": 6930,
					"text": "he cell cycleβ€“influenced appearance of an MCB suggests that macroH2A1 (and perhaps macroH2A2) may be substituting the H2A position in Xi nucleosomes at and around S phase.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 7331,
					"offsetInEndSection": 7553,
					"text": " Preparations of nucleosomes from cells blocked at the beginning of S phase or in mitosis have comparable levels of macroH2A1 (unpublished data), despite the significant decrease in macroH2A at the Xi as the MCB disappears",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 7564,
					"offsetInEndSection": 7768,
					"text": "Put into a genomic perspective, fluctuations in the local concentrations of macroH2A1 at the Xi visualized as an MCB in females may be masked by the total concentrations of nucleosomal macroH2A1 in a cell",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 8109,
					"offsetInEndSection": 8314,
					"text": "More speculatively, it is conceivable that macroH2A1 at the MCB is not all nucleosomal, but functioning with other components of the dosage compensation complex at the Xi outside of the nucleosome context.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 8785,
					"offsetInEndSection": 9844,
					"text": "MacroH2A is enriched at specific bands on the metaphase Xi overlapping a site of histone H3 methylationAlthough the MCB is not evident before the onset of mitosis (Fig. 5; Tables I and II), macroH2A1 does remain associated with both the human and mouse Xi during mitosis as distinct bands (Figs. 3 and 4). Intriguingly, these bands appear to mimic the banding seen with Xist RNA on the mouse Xi during mitosis (Duthie et al., 1999), suggesting that macroH2A may be functioning to anchor Xist RNA in cis with the Xi. However, in humans, XIST RNA does not remain associated with the Xi during mitosis (Clemson et al., 1996). Bands enriched for macroH2A may function as reentry sites for XIST RNA and the dosage compensation complex, assisting in the rapid spread along the Xi in a manner analogous to reentry sites of the Drosophila dosage compensation complex (Meller et al., 2000). The band of macroH2A at the site of the XIST locus (Fig. 3 b) is perhaps analogous to reentry of the Drosophila dosage compensation complex at the site of the roX1 and roX2 loci",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 10840,
					"offsetInEndSection": 11064,
					"text": " Identification of genomic sequences and chromatin modifications at the boundary of each of the macroH2A bands will provide invaluable insight into the functional significance and influence of the histone code used by the Xi",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082075",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "Which histone modification is primarily linked to elongating transcription?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23209427",
				"http://www.ncbi.nlm.nih.gov/pubmed/22184065",
				"http://www.ncbi.nlm.nih.gov/pubmed/21423663",
				"http://www.ncbi.nlm.nih.gov/pubmed/17510366",
				"http://www.ncbi.nlm.nih.gov/pubmed/17346757",
				"http://www.ncbi.nlm.nih.gov/pubmed/17046836",
				"http://www.ncbi.nlm.nih.gov/pubmed/16503129",
				"http://www.ncbi.nlm.nih.gov/pubmed/12667453"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23209427",
				"http://www.ncbi.nlm.nih.gov/pubmed/22184065",
				"http://www.ncbi.nlm.nih.gov/pubmed/21423663",
				"http://www.ncbi.nlm.nih.gov/pubmed/17510366",
				"http://www.ncbi.nlm.nih.gov/pubmed/17346757",
				"http://www.ncbi.nlm.nih.gov/pubmed/17046836",
				"http://www.ncbi.nlm.nih.gov/pubmed/16503129",
				"http://www.ncbi.nlm.nih.gov/pubmed/12667453"
			],
			"type": "factoid",
			"id": "53372ba3d6d3ac6a34000058",
			"snippets": [
				{
					"offsetInBeginSection": 1492,
					"offsetInEndSection": 1659,
					"text": "Similarly, H3K36 trimethylation, a mark associated with transcription elongation, was specifically increased at the HD locus in the striatum and not in the cerebellum.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23209427",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 368,
					"offsetInEndSection": 649,
					"text": "y expressing Myc protein fused with the estrogen receptor (Myc-ER) in fibroblasts, we observed that Myc, binding to the regulatory elements of Suz12, Ezh2, and Eed, induces the acetylation of histones H3 and H4 and the recruitment of elongating RNA polymerase II at their promoters",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22184065",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 752,
					"offsetInEndSection": 910,
					"text": "A basal level of JIL-1 binding can be defined that correlates best with the methylation of histone H3 at lysine 36, a mark that is placed co-transcriptionally",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423663",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 142,
					"offsetInEndSection": 329,
					"text": "RNA polymerase II signals for deacetylation through the methylation of histone H3 lysine 36 (H3K36), which provides the recruitment signal for the Rpd3S histone deacetylase complex (HDAC)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17510366",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 706,
					"offsetInEndSection": 868,
					"text": "Recent studies reviewed here demonstrate that histone deacetylation on the body of a transcribed gene is regulated via Set2-mediated methylation of histone H3-K36",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17346757",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 30,
					"offsetInEndSection": 114,
					"text": "H3K56 acetylation: a chromatin mark associated with the elongating RNA polymerase II",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17046836",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1006,
					"offsetInEndSection": 1164,
					"text": "Furthermore, Rtt109 and H3K56 acetylation appear to correlate with actively transcribed genes and associate with the elongating form of polymerase II in yeast",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17046836",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 136,
					"offsetInEndSection": 371,
					"text": "In addition to coordinating the processing of the nascent transcript, elongating RNA polymerase II recruits histone methyltransferases to methylate lysines 4 and 36 of histone H3 in nucleosomes in the body of actively transcribed genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16503129",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 180,
					"text": "Set1, the yeast histone H3-lysine 4 (H3-K4) methylase, is recruited by the Pol II elongation machinery to a highly localized domain at the 5' portion of active mRNA coding regions.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12667453",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 5961,
					"offsetInEndSection": 6095,
					"text": "Strikingly, H3K36 trimethylation and elongating RNA Pol II were increased at the HD locus in the striatum of both R6/1 and R6/2 mice. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23209427",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 20189,
					"offsetInEndSection": 20406,
					"text": "We further examined the correlation between transcription elongation and somatic CAG instability by performing ChIP with an antibody to Me3H3K36, a histone mark associated with transcription elongation and termination",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23209427",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 20419,
					"offsetInEndSection": 20542,
					"text": "Me3H3K36 is particularly elevated at the 3β€² ends of transcribed genes, and, accordingly, was elevated at the last Hdh exon ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23209427",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 815,
					"offsetInEndSection": 1063,
					"text": "Remarkably however, the level of a histone mark and RNA Pol II form associated with transcription elongation (e.g. Me3H3K36 and phosphorylated Ser2 RNA Pol II, respectively) correlated strongly with CAG instability in tissues of R6/1 and R6/2 mice ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23209427",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1002,
					"offsetInEndSection": 1149,
					"text": "A basal level of JIL-1 binding correlates strongly with H3K36me3, an elongation marker that is placed co-transcriptionally by ePol-associated dSet2",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423663",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1156,
					"offsetInEndSection": 1300,
					"text": "The turnover time of this modification is not known and hence it is possible that H3K36me3 remains on chromatin between pulses of transcription.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423663",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1847,
					"offsetInEndSection": 2084,
					"text": "The profiles resemble the distribution of histone H3 methylated at lysine 36 (H3K36me3), a modification that is placed co-transcriptionally by the CTD-associated methylase Set2 and therefore serves as a hallmark of transcribed chromatin ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423663",
					"endSection": "sections.1"
				}
			]
		},
		{
			"body": "Does splicing occur co-transcriptionally?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23638305",
				"http://www.ncbi.nlm.nih.gov/pubmed/22955974",
				"http://www.ncbi.nlm.nih.gov/pubmed/22326677",
				"http://www.ncbi.nlm.nih.gov/pubmed/22056773",
				"http://www.ncbi.nlm.nih.gov/pubmed/22022255",
				"http://www.ncbi.nlm.nih.gov/pubmed/21264352",
				"http://www.ncbi.nlm.nih.gov/pubmed/20631007",
				"http://www.ncbi.nlm.nih.gov/pubmed/19710184",
				"http://www.ncbi.nlm.nih.gov/pubmed/19656867",
				"http://www.ncbi.nlm.nih.gov/pubmed/19185575",
				"http://www.ncbi.nlm.nih.gov/pubmed/16440002",
				"http://www.ncbi.nlm.nih.gov/pubmed/11602343"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23638305",
				"http://www.ncbi.nlm.nih.gov/pubmed/22955974",
				"http://www.ncbi.nlm.nih.gov/pubmed/22326677",
				"http://www.ncbi.nlm.nih.gov/pubmed/22056773",
				"http://www.ncbi.nlm.nih.gov/pubmed/22022255",
				"http://www.ncbi.nlm.nih.gov/pubmed/21264352",
				"http://www.ncbi.nlm.nih.gov/pubmed/20631007",
				"http://www.ncbi.nlm.nih.gov/pubmed/19710184",
				"http://www.ncbi.nlm.nih.gov/pubmed/19656867",
				"http://www.ncbi.nlm.nih.gov/pubmed/19185575",
				"http://www.ncbi.nlm.nih.gov/pubmed/16440002",
				"http://www.ncbi.nlm.nih.gov/pubmed/11602343"
			],
			"type": "yesno",
			"id": "533c3871c45e133714000007",
			"snippets": [
				{
					"offsetInBeginSection": 78,
					"offsetInEndSection": 350,
					"text": "Researchers working in multiple model organisms - notably yeast, insects and mammalian cells - have shown that pre-mRNA can be spliced during the process of transcription (i.e. co-transcriptionally), as well as after transcription termination (i.e. post-transcriptionally)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 752,
					"offsetInEndSection": 895,
					"text": "The consensus view, based on four organisms, is that the majority of splicing events take place co-transcriptionally in most cells and tissues.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 98,
					"text": "Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22955974",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 234,
					"offsetInEndSection": 319,
					"text": "We show that in the human genome, splicing occurs predominantly during transcription.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22955974",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 993,
					"offsetInEndSection": 1228,
					"text": "Consistent with co-transcriptional spliceosome assembly and splicing, we have found significant enrichment of spliceosomal snRNAs in chromatin-associated RNA compared with other cellular RNA fractions and other nonspliceosomal snRNAs. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22955974",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 303,
					"offsetInEndSection": 449,
					"text": "The majority of introns in higher eukaryotes are excised prior to transcript release in a manner that is dependent on transcription through pol II",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22326677",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 452,
					"offsetInEndSection": 681,
					"text": "s a result of co-transcriptional splicing, variations in pol II elongation influence alternative splicing patterns, wherein a slower elongation rate is associated with increased inclusion of alternative exons within mature mRNA. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22326677",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 516,
					"offsetInEndSection": 661,
					"text": "We show that the pattern of intronic sequence read coverage is explained by nascent transcription in combination with co-transcriptional splicing",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22056773",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 573,
					"offsetInEndSection": 797,
					"text": "Modelling reveals co-transcriptional splicing to be the most probable and most efficient splicing pathway for the reporter transcripts, due in part to a positive feedback mechanism for co-transcriptional second step splicing",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 67,
					"text": "Modelling reveals kinetic advantages of co-transcriptional splicing",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 87,
					"text": "The in vivo kinetics of RNA polymerase II elongation during co-transcriptional splicing",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21264352",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 273,
					"text": "RNA processing events that take place on the transcribed pre-mRNA include capping, splicing, editing, 3' processing, and polyadenylation. Most of these processes occur co-transcriptionally while the RNA polymerase II (Pol II) enzyme is engaged in transcriptional elongation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21264352",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 55,
					"text": "A model in vitro system for co-transcriptional splicing",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20631007",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 122,
					"offsetInEndSection": 266,
					"text": "Abundant evidence indicates that splicing to excise introns occurs co-transcriptionally, prior to release of the nascent transcript from RNAP II",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20631007",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 912,
					"offsetInEndSection": 1087,
					"text": "Together, our work establishes a system for co-transcriptional splicing in vitro, in which the spliceosome containing the 5' and 3' exons are tethered to RNAP II for splicing.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20631007",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 65,
					"text": "Co-transcriptional splicing of constitutive and alternative exons",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19656867",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 184,
					"offsetInEndSection": 351,
					"text": "Current evidence supports co-transcriptional spliceosomal assembly, but there is little quantitative information on how much splicing is completed during RNA synthesis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19656867",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1215,
					"offsetInEndSection": 1352,
					"text": "Thus, we demonstrate that the decision to include or skip an alternative exon is made during transcription and not post-transcriptionally",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19656867",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 115,
					"offsetInEndSection": 284,
					"text": "Here, we demonstrated that the co-transcriptional splicing of the intron in vitro was blocked by antisense oligonucleotides (AONs) targeting the P3-P7 core of the intron",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19185575",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 87,
					"text": "RNA editing and alternative splicing: the importance of co-transcriptional coordination",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16440002",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 107,
					"text": "Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11602343",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 226,
					"offsetInEndSection": 321,
					"text": "The realization that splicing occurs co-transcriptionally requires two important considerations",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11602343",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 525,
					"offsetInEndSection": 723,
					"text": "Subsequently, a number of key studies in several model systems supported the notion that splicing at least begins co-transcriptionally, i.e. on nascent RNA tethered to chromatin by elongating Pol II",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 732,
					"offsetInEndSection": 962,
					"text": "Co-transcriptional splicing is not surprising: nucleoplasm is filled with spliceosomal components that should be able to associate with nascent RNA, much as ribosomes are capable of translating RNA co-transcriptionally in bacteria",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1227,
					"offsetInEndSection": 1596,
					"text": "Nevertheless, some dramatic examples of post-transcriptional splicing β€“ for example, in anucleate platelets upon activation and in developing fern gametes β€“ remind us of the potential importance of not splicing co-transcriptionally in certain biological contexts [17,18].\nThe regulatory potential of co-transcriptional splicing is what the field has found so exciting. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1838,
					"offsetInEndSection": 1927,
					"text": "We asked ourselves: how frequent is co-transcriptional splicing among genes and introns? ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 47,
					"offsetInEndSection": 272,
					"text": "he first global study on co-transcriptional splicing was undertaken in budding yeast, where it became clear that most introns are spliced co-transcriptionally; 50% of introns are >74% spliced before transcription termination ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 1044,
					"offsetInEndSection": 1252,
					"text": "That said, not all intron removal is co-transcriptional. In particular, terminal introns are least well removed co-transcriptionally, and 20% of activated spliceosomes in the cell are not chromatin-associated",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 3594,
					"offsetInEndSection": 3870,
					"text": "Windhager et al. 2012 [25] calculated the co-transcriptional splicing frequency as the ratio of observed reads in the set of analyzed genes to the number of reads calculated when expecting a uniform read distribution without splicing and weighted for the transcript expression",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 4350,
					"offsetInEndSection": 4491,
					"text": "Determination of co-transcriptional splicing frequency around a given exon, by subtracting the read coverage over 2kb of the upstream intron ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 4497,
					"offsetInEndSection": 4564,
					"text": "from read coverage over 2kb of the 5β€™ end of the downstream intron ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 4575,
					"offsetInEndSection": 5241,
					"text": "Determination of co-transcriptional splicing frequency for each intron, by calculating the ratio of reads around the 3β€™ splice site: read coverage over the last 25 bp of a given intron, a, is divided by read coverage over the first 25 bp of the downstream exon, b. (d) Determination of co-transcriptional splicing frequency for each gene, by dividing the read coverage over exons by the read coverage over the whole locus. (e) Determination of co-transcriptional splicing frequency (completed splicing index, coSI) around a given exon, using exon-intron and exon-exon junction reads; c, d, and e represent exon-exon junctions; f and g represent exon-intron junctions",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 5808,
					"offsetInEndSection": 6049,
					"text": "Though Ameur et al. could not calculate co-transcriptional splicing frequencies for short introns genome-wide, their RT-PCR results suggest that high co-transcriptional splicing observed for long introns can also be inferred for shorter ones",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 7637,
					"offsetInEndSection": 7926,
					"text": "The average co-transcriptional splicing frequencies obtained for each gene will likely be influenced by gene length and the total number of introns within the gene; terminal exons are long and generally full of reads, and terminal introns tend to be least well spliced co-transcriptionally",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 8268,
					"offsetInEndSection": 8448,
					"text": "The relatively low co-transcriptional splicing frequencies from both mouse studies contrast sharply with the high co-transcriptional splicing frequencies from yeast, fly, and human",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 8992,
					"offsetInEndSection": 9163,
					"text": "For example, chromatin preparations can be contaminated with mRNA, which is highly abundant and could lead to an over-estimate in the degree of co-transcriptional splicing",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 30,
					"offsetInEndSection": 186,
					"text": "Taken together, this array of high quality global studies enables us to reach a consensus on co-transcriptional splicing: it is widespread, albeit not 100%.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 9801,
					"offsetInEndSection": 10017,
					"text": "Nevertheless, an independent, small-scale study focusing on 22 human genes was able to validate the high frequencies of co-transcriptional splicing seen in the global data, even among terminal and alternative introns",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 394,
					"offsetInEndSection": 601,
					"text": "For example, histone modifications, which would have a bearing on co-transcriptional but not post-transcriptional splicing, can directly or indirectly recruit splicing factors and modify alternative splicing",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 779,
					"offsetInEndSection": 1111,
					"text": "Co-transcriptional splicing may also have long-lasting effects on the RNA's lifetime, by ensuring proper assembly of export-competent mRNPs [19]. These examples show that co-transcriptional splicing is important for mRNA biogenesis. Co-transcriptional splicing has also emerged as an important regulator of transcriptional activity.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1744,
					"offsetInEndSection": 2138,
					"text": "In this sense, it is important to recognize that no study claims 100% of introns are 100% co-transcriptionally removed. Advances in high-throughput sequencing that enable sequencing of longer DNA molecules (in the kilobase range) will provide clarity and facilitate analysis, as well as providing insight into the order of intron removal and co-transcriptional dynamics of alternative splicing.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23638305",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 575,
					"offsetInEndSection": 712,
					"text": "A large body of work in vivo indicates that splicing occurs co-transcriptionally, prior to release of the nascent transcript from RNAP II",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20631007",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 743,
					"offsetInEndSection": 902,
					"text": "ndeed, recent qPCR data showed that most constitutive exons are removed co-transcriptionally and that alternative exon choice also occurs during transcription ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20631007",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1387,
					"offsetInEndSection": 1670,
					"text": "In previous work in vivo, Dye and co-workers (13) obtained support for the RNAP II exon-tethering model by showing that a nascent RNAP II transcript that is co-transcriptionally cleaved within the intron is spliced as efficiently as the nascent transcript containing an intact intron",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20631007",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2832,
					"offsetInEndSection": 2985,
					"text": "Together, our data indicate that the spliceosome and the 5β€² and 3β€² exons associate (indirectly or directly) with RNAP II for co-transcriptional splicing.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20631007",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1470,
					"offsetInEndSection": 1773,
					"text": "Co-transcriptional splicing implies that splicing, at least in part, should occur at the site of transcription. This is supported by kinetic studies showing that splicing is completed within a short β�Ό5β€“10 min time-frame from the time of transcription, and these times are not influenced by intron length",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21264352",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 8421,
					"offsetInEndSection": 8686,
					"text": "We conclude that co-transcriptional splicing is occurring on the pre-mRNAs associated with the active transcription sites, and that the mRNA processing factors are recruited either via association with the transcribing polymerase or directly with the nascent mRNAs.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21264352",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 8727,
					"offsetInEndSection": 8790,
					"text": "Co-transcriptional splicing occurs at the site of transcription",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21264352",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 16141,
					"offsetInEndSection": 16346,
					"text": "We compared a polymerase passing through the MS2 region of an intronless E1 gene to a polymerase moving through the MS2 region of the intron-containing E3/E4 genes that undergo co-transcriptional splicing ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21264352",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 9231,
					"offsetInEndSection": 9619,
					"text": "The plausibility of a co-transcriptional splicing mechanism can be imagined just by the fact that human gene exons tend to be short compared to extremely larger intronic sequences [67], and genes contain an average of 5β€“12 exons [68]. This means that if co-transcriptional splicing did not take place, then the splicing machinery would have to hold back until transcription has completed.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21264352",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 2755,
					"offsetInEndSection": 2846,
					"text": "Splicing can occur during transcript elongation on the co-transcriptional splicing pathway.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3581,
					"offsetInEndSection": 3739,
					"text": "The characteristics of post-transcriptional splicing steps one and two ( and ), and co-transcriptional splicing step two () are determined by model comparison",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1932,
					"offsetInEndSection": 2148,
					"text": "In these sections, the occurrence of the first step of splicing of an RNA is represented in the model by a change of state of the associated Pol II, which can make a transition to the co-transcriptional splicing path",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 23301,
					"offsetInEndSection": 23528,
					"text": "Values for  in pathways III, V and VII imply the same proportion of co-transcriptional splicing, as do the values of  and  in the four remaining pathways where the proportion of co-transcriptional splicing is approximately 85%.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 20548,
					"offsetInEndSection": 20721,
					"text": "Pathways I-IV incorporate the feedback mechanism for co-transcriptional splicing step two and this feature correlates with a good fit (low AIC) for all lariat-exon2 species.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 11753,
					"offsetInEndSection": 11920,
					"text": "The proportion of co-transcriptional splicing can be calculated from these reaction rates and this proportion can be compared with that predicted for the 40 step model",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 10120,
					"offsetInEndSection": 10536,
					"text": "However, the rapid accumulation of uncleaved mRNA between 540 and 600 s prior to detection of polyadenylated spliced mRNA at 600 s, clearly shows that co-transcriptional splicing occurs before post-transcriptional splicing. By formally modelling the splicing pathway, we aim to quantify the extent to which mature mRNA is derived from co-transcriptional splicing, and from post-transcriptional splicing respectively.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 4341,
					"offsetInEndSection": 4517,
					"text": "The probability of co-transcriptional splicing is not known, and this, along with precise values for all other parameters, will be inferred from fitting the pathway to the data",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 4926,
					"offsetInEndSection": 5047,
					"text": " Co-transcriptional splicing is evident in the data, and modelling shows that this pathway may be activated after a delay",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 4626,
					"offsetInEndSection": 4743,
					"text": "Therefore co-transcriptional splicing is the more efficient pathway under the high induction conditions studied here.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 3052,
					"offsetInEndSection": 3221,
					"text": "Cooperativity in the interaction of splicing factors with the spliceosome or with the nascent pre-mRNA may also contribute to the kinetics of co-transcriptional splicing",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022255",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 4315,
					"offsetInEndSection": 4470,
					"text": "The in vitro co-transcriptional splicing system described here provides a new model for elucidating the mechanisms involved in co-transcriptional splicing.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20631007",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "Are there any specific antidotes for dabigatran?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24103671",
				"http://www.ncbi.nlm.nih.gov/pubmed/23821689",
				"http://www.ncbi.nlm.nih.gov/pubmed/23810130",
				"http://www.ncbi.nlm.nih.gov/pubmed/23790307",
				"http://www.ncbi.nlm.nih.gov/pubmed/23657589",
				"http://www.ncbi.nlm.nih.gov/pubmed/23634730",
				"http://www.ncbi.nlm.nih.gov/pubmed/23460104",
				"http://www.ncbi.nlm.nih.gov/pubmed/23312927",
				"http://www.ncbi.nlm.nih.gov/pubmed/22669799",
				"http://www.ncbi.nlm.nih.gov/pubmed/22615265",
				"http://www.ncbi.nlm.nih.gov/pubmed/22353706",
				"http://www.ncbi.nlm.nih.gov/pubmed/22308807",
				"http://www.ncbi.nlm.nih.gov/pubmed/22177763",
				"http://www.ncbi.nlm.nih.gov/pubmed/21748501",
				"http://www.ncbi.nlm.nih.gov/pubmed/20858186",
				"http://www.ncbi.nlm.nih.gov/pubmed/20352166",
				"http://www.ncbi.nlm.nih.gov/pubmed/23389753",
				"http://www.ncbi.nlm.nih.gov/pubmed/22008738",
				"http://www.ncbi.nlm.nih.gov/pubmed/23953907"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24103671",
				"http://www.ncbi.nlm.nih.gov/pubmed/23821689",
				"http://www.ncbi.nlm.nih.gov/pubmed/23810130",
				"http://www.ncbi.nlm.nih.gov/pubmed/23790307",
				"http://www.ncbi.nlm.nih.gov/pubmed/23657589",
				"http://www.ncbi.nlm.nih.gov/pubmed/23634730",
				"http://www.ncbi.nlm.nih.gov/pubmed/23460104",
				"http://www.ncbi.nlm.nih.gov/pubmed/23312927",
				"http://www.ncbi.nlm.nih.gov/pubmed/22669799",
				"http://www.ncbi.nlm.nih.gov/pubmed/22615265",
				"http://www.ncbi.nlm.nih.gov/pubmed/22353706",
				"http://www.ncbi.nlm.nih.gov/pubmed/22308807",
				"http://www.ncbi.nlm.nih.gov/pubmed/22177763",
				"http://www.ncbi.nlm.nih.gov/pubmed/21748501",
				"http://www.ncbi.nlm.nih.gov/pubmed/20858186",
				"http://www.ncbi.nlm.nih.gov/pubmed/20352166",
				"http://www.ncbi.nlm.nih.gov/pubmed/23389753",
				"http://www.ncbi.nlm.nih.gov/pubmed/22008738",
				"http://www.ncbi.nlm.nih.gov/pubmed/23953907"
			],
			"type": "yesno",
			"id": "532f08dcd6d3ac6a3400002a",
			"snippets": [
				{
					"offsetInBeginSection": 172,
					"offsetInEndSection": 491,
					"text": "Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24103671",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 202,
					"offsetInEndSection": 413,
					"text": "However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23821689",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 490,
					"offsetInEndSection": 592,
					"text": "Given the absence of a specific antidote, the action to be taken in these situations must be defined. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23810130",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1018,
					"offsetInEndSection": 1175,
					"text": "The fact that there is no specific antidote to reverse the anticoagulant action of the new anticoagulants can impair management of hemorrhagic complications;",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23790307",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 436,
					"offsetInEndSection": 537,
					"text": "Unlike the vitamin K antagonist, i.e. warfarin, there is no specific antidote for these medications. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23657589",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 117,
					"offsetInEndSection": 342,
					"text": "The lack of guidelines, protocols, and an established specific antidote to reverse the anticoagulation effect of dabigatran potentially increases the rates of morbidity and mortality in patients with closed head injury (CHI).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23634730",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 921,
					"offsetInEndSection": 1599,
					"text": "The novel oral anticoagulants (NOAC) dabigatran etexilat (PradaxaΒ®), rivaroxaban (XareltoΒ®) and apixaban (EliquisΒ®), also known as \"direct\" anticoagulants, act independently from antithrombin by inhibiting thrombin, as in the case of dabigatran, or by inhibiting factor Xa, as in the case of rivaroxaban and apixaban. It is assumed that they are suitable for long-term use and do not require laboratory monitoring. Nevertheless, clinical experience is very limited and caution rather than quick conclusions is necessary. Two major drawbacks are on the one hand the risk of drug accumulation in kidney and/or liver disease and, on the other hand, the lack of specific antidotes. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23460104",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1518,
					"offsetInEndSection": 1741,
					"text": "NOA also have other unresolved problems: drug interactions are still possible, specific coagulation test to assess them must be developed, and no specific antidote is currently available in case of hemorrhagic complication.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23312927",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1648,
					"offsetInEndSection": 1812,
					"text": " It is critical to identify and subsequently manage dabigatran etexilate toxicity because there is no specific antidote to reverse the drug's anticoagulant effects.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22669799",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 256,
					"offsetInEndSection": 473,
					"text": "In the absence of a specific antidote for this novel oral anticoagulant medication, even in an emergency situation, successful surgical treatment was possible with an aggressive use of available prohaemostatic agents.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22615265",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 734,
					"offsetInEndSection": 957,
					"text": "While these trial data are extremely encouraging, several practical issues (e.g., lack of specific antidote, safety of long-term treatment or cost-effectiveness in \"real-life\" clinical practice) still need to be elucidated.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22353706",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 505,
					"offsetInEndSection": 661,
					"text": "In case of massive bleeding, management is unclear and none of these newer agents has a specific antidote that completely reverses its anticoagulant effect.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22308807",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1935,
					"offsetInEndSection": 2044,
					"text": "The short half-life of these new agents compensates for the lack of any specific antidote in many instances. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22177763",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1237,
					"offsetInEndSection": 1354,
					"text": "As there is no specific antidote, the only treatment option is discontinuation of the drug and supportive management.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21748501",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 618,
					"offsetInEndSection": 750,
					"text": "Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20858186",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1388,
					"offsetInEndSection": 1609,
					"text": "Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticoagulant activity. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20352166",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the mode of inheritance of Acromicric dysplasia?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22791552",
				"http://www.ncbi.nlm.nih.gov/pubmed/19396027",
				"http://www.ncbi.nlm.nih.gov/pubmed/11694546"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22791552",
				"http://www.ncbi.nlm.nih.gov/pubmed/19396027",
				"http://www.ncbi.nlm.nih.gov/pubmed/11694546"
			],
			"type": "factoid",
			"id": "53318685d6d3ac6a3400003d",
			"snippets": [
				{
					"offsetInBeginSection": 696,
					"offsetInEndSection": 840,
					"text": "AD has an autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22791552",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 616,
					"offsetInEndSection": 830,
					"text": "Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19396027",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1332,
					"offsetInEndSection": 1507,
					"text": "The condition appeared to be sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant mode of inheritance.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11694546",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the clinical indication of cardiac T1 mapping magnetic resonance?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22903654",
				"http://www.ncbi.nlm.nih.gov/pubmed/24058912",
				"http://www.ncbi.nlm.nih.gov/pubmed/23845576",
				"http://www.ncbi.nlm.nih.gov/pubmed/23498672",
				"http://www.ncbi.nlm.nih.gov/pubmed/23498674",
				"http://www.ncbi.nlm.nih.gov/pubmed/23349348",
				"http://www.ncbi.nlm.nih.gov/pubmed/23272704",
				"http://www.ncbi.nlm.nih.gov/pubmed/23071146"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22903654",
				"http://www.ncbi.nlm.nih.gov/pubmed/24058912",
				"http://www.ncbi.nlm.nih.gov/pubmed/23845576",
				"http://www.ncbi.nlm.nih.gov/pubmed/23498672",
				"http://www.ncbi.nlm.nih.gov/pubmed/23498674",
				"http://www.ncbi.nlm.nih.gov/pubmed/23349348",
				"http://www.ncbi.nlm.nih.gov/pubmed/23272704",
				"http://www.ncbi.nlm.nih.gov/pubmed/23071146"
			],
			"type": "factoid",
			"id": "533ba218fd9a95ea0d000007",
			"snippets": [
				{
					"offsetInBeginSection": 504,
					"offsetInEndSection": 671,
					"text": "More diverse patterns of late enhancement including patchy, mid-wall, subepicardial, or diffuse enhancement are of interest in diagnosing nonischemic cardiomyopathies.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22903654",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1102,
					"offsetInEndSection": 1339,
					"text": "Methods for quantification of T1 and extracellular volume fraction are emerging to tackle the issue of discriminating globally diffuse fibrosis from normal healthy tissue which is challenging using conventional late enhancement methods. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22903654",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 474,
					"offsetInEndSection": 593,
					"text": "Recent T1 mapping techniques aim to overcome the limitations of late gadolinium enhancement to assess diffuse fibrosis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24058912",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1282,
					"offsetInEndSection": 1432,
					"text": "T1 mapping techniques performed both with and without contrast are enabling quantification of diffuse myocardial fibrosis and myocardial infiltration.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23845576",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1857,
					"offsetInEndSection": 2094,
					"text": "Noncontrast T1 mapping has high diagnostic accuracy for detecting cardiac AL amyloidosis, correlates well with markers of systolic and diastolic dysfunction, and is potentially more sensitive for detecting early disease than LGE imaging.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23498672",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 277,
					"offsetInEndSection": 544,
					"text": "T1 mapping has been proposed as potentially valuable in the quantitative assessment of diffuse myocardial fibrosis, but no studies to date have systematically evaluated its role in the differentiation of healthy myocardium from diffuse disease in a clinical setting. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23498674",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2141,
					"offsetInEndSection": 2318,
					"text": "This study demonstrates that native and post-contrast T1 values provide indexes with high diagnostic accuracy for the discrimination of normal and diffusely diseased myocardium.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23498674",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1454,
					"offsetInEndSection": 1646,
					"text": "T1 values lengthened with greater LVMI and correlated with the degree of biopsy-quantified fibrosis. This may provide a useful clinical assessment of diffuse myocardial fibrosis in the future.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23349348",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 115,
					"text": "Cardiac magnetic resonance (CMR) T1 mapping has been used to characterize myocardial diffuse fibrosis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23272704",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1846,
					"offsetInEndSection": 1986,
					"text": "In HCM and DCM, noncontrast T1 mapping detects underlying disease processes beyond those assessed by LGE in relatively low-risk individuals.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23071146",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 288,
					"offsetInEndSection": 473,
					"text": "Although still not widely available in clinical practice, T1 mapping offers the possibility of overcoming the limitations of late gadolinium enhancement by visualizing diffuse fibrosis.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24058912",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 343,
					"text": "We have shown that non-contrast T1 values measured using the ShMOLLI CMR sequence correlate with DMF burden measured by histology in patients with AS. The application of this technique is feasible in a clinical setting and it has the potential to be used as a simple, non-invasive, non-contrast assessment of DFM in cardiac disease.",
					"beginSection": "sections.4",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23349348",
					"endSection": "sections.4"
				},
				{
					"offsetInBeginSection": 632,
					"offsetInEndSection": 1123,
					"text": "DMF results in increased collagen content with expansion of the extracellular space to a greater extent than that of normal myocardium [8,9], resulting in accumulation of gadolinium-based contrast agents (GBCA). This, in turn, lowers the T1 time of the myocardium. Altered myocardial T1 times have been demonstrated in a range of nonischemic cardiomyopathies [10], including chronic aortic regurgitation [11], heart failure [7], aortic stenosis [12], and adult congenital heart disease [13].",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23272704",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Do thyroid hormone receptors change after brain injury?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/14761671",
				"http://www.ncbi.nlm.nih.gov/pubmed/24174657",
				"http://www.ncbi.nlm.nih.gov/pubmed/6329444"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/14761671",
				"http://www.ncbi.nlm.nih.gov/pubmed/24174657",
				"http://www.ncbi.nlm.nih.gov/pubmed/6329444"
			],
			"type": "yesno",
			"id": "533e50fdc45e13371400000f",
			"snippets": [
				{
					"offsetInBeginSection": 786,
					"offsetInEndSection": 984,
					"text": "For example, the T3 receptor alpha was predominantly expressed in stroke-tissue, indicating that regeneration of nerves in stroke tissue may be facilitated by increased T3 receptor alpha expression.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14761671",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 983,
					"offsetInEndSection": 1044,
					"text": "TRΞ± expression was also increased in human infants with IVH. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24174657",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1422,
					"offsetInEndSection": 1595,
					"text": "Thus, in infants with IVH the combined elevation in deiodinase-3 and reduction in deiodinase-2 decreases TH signaling that can be worsened by an increase in unliganded TRΞ±. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24174657",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 360,
					"offsetInEndSection": 758,
					"text": "A rapid increase of the total number of binding sites for T3 appeared within 30 min of ischemia and reached over 40% by 3 h. During the same 3-h period, the relative binding affinity was reduced by 25%. Upon recirculation after 30 min or 3 h of ischemia, a rapid reversal of measured T3 binding sites occurred, which progressed to 20-30% below the control value by the recirculation period of 3 h. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/6329444",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is Prudent Diet?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23885043",
				"http://www.ncbi.nlm.nih.gov/pubmed/23398686",
				"http://www.ncbi.nlm.nih.gov/pubmed/21676220",
				"http://www.ncbi.nlm.nih.gov/pubmed/20624672",
				"http://www.ncbi.nlm.nih.gov/pubmed/11493127",
				"http://www.ncbi.nlm.nih.gov/pubmed/23741179",
				"http://www.ncbi.nlm.nih.gov/pubmed/18796495",
				"http://www.ncbi.nlm.nih.gov/pubmed/17076904",
				"http://www.ncbi.nlm.nih.gov/pubmed/22914994",
				"http://www.ncbi.nlm.nih.gov/pubmed/23953031",
				"http://www.ncbi.nlm.nih.gov/pubmed/23933622",
				"http://www.ncbi.nlm.nih.gov/pubmed/23639938",
				"http://www.ncbi.nlm.nih.gov/pubmed/23530637",
				"http://www.ncbi.nlm.nih.gov/pubmed/23524862",
				"http://www.ncbi.nlm.nih.gov/pubmed/22835136",
				"http://www.ncbi.nlm.nih.gov/pubmed/22717188",
				"http://www.ncbi.nlm.nih.gov/pubmed/22034645",
				"http://www.ncbi.nlm.nih.gov/pubmed/7870637",
				"http://www.ncbi.nlm.nih.gov/pubmed/1852180",
				"http://www.ncbi.nlm.nih.gov/pubmed/1511475",
				"http://www.ncbi.nlm.nih.gov/pubmed/3886611",
				"http://www.ncbi.nlm.nih.gov/pubmed/15853117",
				"http://www.ncbi.nlm.nih.gov/pubmed/4072955",
				"http://www.ncbi.nlm.nih.gov/pubmed/15539255",
				"http://www.ncbi.nlm.nih.gov/pubmed/6622440",
				"http://www.ncbi.nlm.nih.gov/pubmed/3819235",
				"http://www.ncbi.nlm.nih.gov/pubmed/207959",
				"http://www.ncbi.nlm.nih.gov/pubmed/2173390",
				"http://www.ncbi.nlm.nih.gov/pubmed/216895",
				"http://www.ncbi.nlm.nih.gov/pubmed/16580586",
				"http://www.ncbi.nlm.nih.gov/pubmed/422845"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23885043",
				"http://www.ncbi.nlm.nih.gov/pubmed/23398686",
				"http://www.ncbi.nlm.nih.gov/pubmed/21676220",
				"http://www.ncbi.nlm.nih.gov/pubmed/20624672",
				"http://www.ncbi.nlm.nih.gov/pubmed/11493127",
				"http://www.ncbi.nlm.nih.gov/pubmed/23741179",
				"http://www.ncbi.nlm.nih.gov/pubmed/18796495",
				"http://www.ncbi.nlm.nih.gov/pubmed/17076904",
				"http://www.ncbi.nlm.nih.gov/pubmed/22914994",
				"http://www.ncbi.nlm.nih.gov/pubmed/23953031",
				"http://www.ncbi.nlm.nih.gov/pubmed/23933622",
				"http://www.ncbi.nlm.nih.gov/pubmed/23639938",
				"http://www.ncbi.nlm.nih.gov/pubmed/23530637",
				"http://www.ncbi.nlm.nih.gov/pubmed/23524862",
				"http://www.ncbi.nlm.nih.gov/pubmed/22835136",
				"http://www.ncbi.nlm.nih.gov/pubmed/22717188",
				"http://www.ncbi.nlm.nih.gov/pubmed/22034645",
				"http://www.ncbi.nlm.nih.gov/pubmed/7870637",
				"http://www.ncbi.nlm.nih.gov/pubmed/1852180",
				"http://www.ncbi.nlm.nih.gov/pubmed/1511475",
				"http://www.ncbi.nlm.nih.gov/pubmed/3886611",
				"http://www.ncbi.nlm.nih.gov/pubmed/15853117",
				"http://www.ncbi.nlm.nih.gov/pubmed/4072955",
				"http://www.ncbi.nlm.nih.gov/pubmed/15539255",
				"http://www.ncbi.nlm.nih.gov/pubmed/6622440",
				"http://www.ncbi.nlm.nih.gov/pubmed/3819235",
				"http://www.ncbi.nlm.nih.gov/pubmed/207959",
				"http://www.ncbi.nlm.nih.gov/pubmed/2173390",
				"http://www.ncbi.nlm.nih.gov/pubmed/216895",
				"http://www.ncbi.nlm.nih.gov/pubmed/16580586",
				"http://www.ncbi.nlm.nih.gov/pubmed/422845"
			],
			"type": "summary",
			"id": "533175add6d3ac6a3400003c",
			"snippets": [
				{
					"offsetInBeginSection": 518,
					"offsetInEndSection": 704,
					"text": "Long-term diet was assessed by using FFQs every 4 y since 1986. Prudent (high in vegetables) and Western (high in meats) patterns were identified by using a principal component analysis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23885043",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 815,
					"offsetInEndSection": 1076,
					"text": "The Prudent dietary pattern was characterised by high intakes of vegetables, fruits, whole grain products and low intakes of refined grain products and the Western dietary pattern, by high intakes of refined grain products, desserts, sweets and processed meats.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23398686",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 547,
					"offsetInEndSection": 765,
					"text": "aerobic exercise combined with diet recommendations (saturated/trans fat intake less than 10% of total calories and cholesterol less than 300 mg/day and/or fiber intake β‰¥ 25 g/day in women and β‰¥ 35 grams per day in men",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21676220",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 862,
					"offsetInEndSection": 1039,
					"text": " a prudent pattern (high in fish, peas, honey, nuts, juice, dry fruits, vegetable oil, liver and organic meat, and coconuts and low in hydrogenated fat and non-leafy vegetables)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20624672",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 676,
					"offsetInEndSection": 942,
					"text": " The prudent pattern was characterized by higher intakes of fruits, vegetables, legumes, fish, poultry, and whole grains, while the Western pattern was characterized by higher intakes of red and processed meats, sweets and desserts, french fries, and refined grains.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11493127",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Is indicated the use of antioxidant supplements in patients at risk for coronary artery disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18377792",
				"http://www.ncbi.nlm.nih.gov/pubmed/18277182",
				"http://www.ncbi.nlm.nih.gov/pubmed/23877741",
				"http://www.ncbi.nlm.nih.gov/pubmed/22342390",
				"http://www.ncbi.nlm.nih.gov/pubmed/21996047",
				"http://www.ncbi.nlm.nih.gov/pubmed/20350251",
				"http://www.ncbi.nlm.nih.gov/pubmed/19033020",
				"http://www.ncbi.nlm.nih.gov/pubmed/18460663",
				"http://www.ncbi.nlm.nih.gov/pubmed/17275460",
				"http://www.ncbi.nlm.nih.gov/pubmed/12090883",
				"http://www.ncbi.nlm.nih.gov/pubmed/11702901",
				"http://www.ncbi.nlm.nih.gov/pubmed/10498115",
				"http://www.ncbi.nlm.nih.gov/pubmed/10639540",
				"http://www.ncbi.nlm.nih.gov/pubmed/21115589",
				"http://www.ncbi.nlm.nih.gov/pubmed/22254063",
				"http://www.ncbi.nlm.nih.gov/pubmed/24489984",
				"http://www.ncbi.nlm.nih.gov/pubmed/22645453",
				"http://www.ncbi.nlm.nih.gov/pubmed/19774218",
				"http://www.ncbi.nlm.nih.gov/pubmed/23055813",
				"http://www.ncbi.nlm.nih.gov/pubmed/19859067",
				"http://www.ncbi.nlm.nih.gov/pubmed/10812586",
				"http://www.ncbi.nlm.nih.gov/pubmed/20400494",
				"http://www.ncbi.nlm.nih.gov/pubmed/16603825",
				"http://www.ncbi.nlm.nih.gov/pubmed/15693087",
				"http://www.ncbi.nlm.nih.gov/pubmed/15117174",
				"http://www.ncbi.nlm.nih.gov/pubmed/12968298",
				"http://www.ncbi.nlm.nih.gov/pubmed/12741415",
				"http://www.ncbi.nlm.nih.gov/pubmed/12675072",
				"http://www.ncbi.nlm.nih.gov/pubmed/12069675",
				"http://www.ncbi.nlm.nih.gov/pubmed/11192356",
				"http://www.ncbi.nlm.nih.gov/pubmed/10696633",
				"http://www.ncbi.nlm.nih.gov/pubmed/10600089",
				"http://www.ncbi.nlm.nih.gov/pubmed/10575394",
				"http://www.ncbi.nlm.nih.gov/pubmed/10329064",
				"http://www.ncbi.nlm.nih.gov/pubmed/9849356",
				"http://www.ncbi.nlm.nih.gov/pubmed/9659191",
				"http://www.ncbi.nlm.nih.gov/pubmed/9193380",
				"http://www.ncbi.nlm.nih.gov/pubmed/7977015",
				"http://www.ncbi.nlm.nih.gov/pubmed/23335472",
				"http://www.ncbi.nlm.nih.gov/pubmed/15153272",
				"http://www.ncbi.nlm.nih.gov/pubmed/10656300",
				"http://www.ncbi.nlm.nih.gov/pubmed/12204790",
				"http://www.ncbi.nlm.nih.gov/pubmed/18548846",
				"http://www.ncbi.nlm.nih.gov/pubmed/8164066",
				"http://www.ncbi.nlm.nih.gov/pubmed/15531665",
				"http://www.ncbi.nlm.nih.gov/pubmed/10386507",
				"http://www.ncbi.nlm.nih.gov/pubmed/8570438",
				"http://www.ncbi.nlm.nih.gov/pubmed/10987596",
				"http://www.ncbi.nlm.nih.gov/pubmed/11944023",
				"http://www.ncbi.nlm.nih.gov/pubmed/8602181",
				"http://www.ncbi.nlm.nih.gov/pubmed/10711786",
				"http://www.ncbi.nlm.nih.gov/pubmed/22293859",
				"http://www.ncbi.nlm.nih.gov/pubmed/11089430",
				"http://www.ncbi.nlm.nih.gov/pubmed/12732794",
				"http://www.ncbi.nlm.nih.gov/pubmed/8650957",
				"http://www.ncbi.nlm.nih.gov/pubmed/15567903",
				"http://www.ncbi.nlm.nih.gov/pubmed/9723625",
				"http://www.ncbi.nlm.nih.gov/pubmed/7695869",
				"http://www.ncbi.nlm.nih.gov/pubmed/8479463",
				"http://www.ncbi.nlm.nih.gov/pubmed/8479464",
				"http://www.ncbi.nlm.nih.gov/pubmed/23022248",
				"http://www.ncbi.nlm.nih.gov/pubmed/10077397",
				"http://www.ncbi.nlm.nih.gov/pubmed/15585762",
				"http://www.ncbi.nlm.nih.gov/pubmed/15302616",
				"http://www.ncbi.nlm.nih.gov/pubmed/23833580",
				"http://www.ncbi.nlm.nih.gov/pubmed/8472392",
				"http://www.ncbi.nlm.nih.gov/pubmed/12492632",
				"http://www.ncbi.nlm.nih.gov/pubmed/9430400",
				"http://www.ncbi.nlm.nih.gov/pubmed/9164706",
				"http://www.ncbi.nlm.nih.gov/pubmed/8946266",
				"http://www.ncbi.nlm.nih.gov/pubmed/9877124",
				"http://www.ncbi.nlm.nih.gov/pubmed/9746269"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18377792",
				"http://www.ncbi.nlm.nih.gov/pubmed/18277182",
				"http://www.ncbi.nlm.nih.gov/pubmed/23877741",
				"http://www.ncbi.nlm.nih.gov/pubmed/22342390",
				"http://www.ncbi.nlm.nih.gov/pubmed/21996047",
				"http://www.ncbi.nlm.nih.gov/pubmed/20350251",
				"http://www.ncbi.nlm.nih.gov/pubmed/19033020",
				"http://www.ncbi.nlm.nih.gov/pubmed/18460663",
				"http://www.ncbi.nlm.nih.gov/pubmed/17275460",
				"http://www.ncbi.nlm.nih.gov/pubmed/12090883",
				"http://www.ncbi.nlm.nih.gov/pubmed/11702901",
				"http://www.ncbi.nlm.nih.gov/pubmed/10498115",
				"http://www.ncbi.nlm.nih.gov/pubmed/10639540",
				"http://www.ncbi.nlm.nih.gov/pubmed/21115589",
				"http://www.ncbi.nlm.nih.gov/pubmed/22254063",
				"http://www.ncbi.nlm.nih.gov/pubmed/24489984",
				"http://www.ncbi.nlm.nih.gov/pubmed/22645453",
				"http://www.ncbi.nlm.nih.gov/pubmed/19774218",
				"http://www.ncbi.nlm.nih.gov/pubmed/23055813",
				"http://www.ncbi.nlm.nih.gov/pubmed/19859067",
				"http://www.ncbi.nlm.nih.gov/pubmed/10812586",
				"http://www.ncbi.nlm.nih.gov/pubmed/20400494",
				"http://www.ncbi.nlm.nih.gov/pubmed/16603825",
				"http://www.ncbi.nlm.nih.gov/pubmed/15693087",
				"http://www.ncbi.nlm.nih.gov/pubmed/15117174",
				"http://www.ncbi.nlm.nih.gov/pubmed/12968298",
				"http://www.ncbi.nlm.nih.gov/pubmed/12741415",
				"http://www.ncbi.nlm.nih.gov/pubmed/12675072",
				"http://www.ncbi.nlm.nih.gov/pubmed/12069675",
				"http://www.ncbi.nlm.nih.gov/pubmed/11192356",
				"http://www.ncbi.nlm.nih.gov/pubmed/10696633",
				"http://www.ncbi.nlm.nih.gov/pubmed/10600089",
				"http://www.ncbi.nlm.nih.gov/pubmed/10575394",
				"http://www.ncbi.nlm.nih.gov/pubmed/10329064",
				"http://www.ncbi.nlm.nih.gov/pubmed/9849356",
				"http://www.ncbi.nlm.nih.gov/pubmed/9659191",
				"http://www.ncbi.nlm.nih.gov/pubmed/9193380",
				"http://www.ncbi.nlm.nih.gov/pubmed/7977015",
				"http://www.ncbi.nlm.nih.gov/pubmed/23335472",
				"http://www.ncbi.nlm.nih.gov/pubmed/15153272",
				"http://www.ncbi.nlm.nih.gov/pubmed/10656300",
				"http://www.ncbi.nlm.nih.gov/pubmed/12204790",
				"http://www.ncbi.nlm.nih.gov/pubmed/18548846",
				"http://www.ncbi.nlm.nih.gov/pubmed/8164066",
				"http://www.ncbi.nlm.nih.gov/pubmed/15531665",
				"http://www.ncbi.nlm.nih.gov/pubmed/10386507",
				"http://www.ncbi.nlm.nih.gov/pubmed/8570438",
				"http://www.ncbi.nlm.nih.gov/pubmed/10987596",
				"http://www.ncbi.nlm.nih.gov/pubmed/11944023",
				"http://www.ncbi.nlm.nih.gov/pubmed/8602181",
				"http://www.ncbi.nlm.nih.gov/pubmed/10711786",
				"http://www.ncbi.nlm.nih.gov/pubmed/22293859",
				"http://www.ncbi.nlm.nih.gov/pubmed/11089430",
				"http://www.ncbi.nlm.nih.gov/pubmed/12732794",
				"http://www.ncbi.nlm.nih.gov/pubmed/8650957",
				"http://www.ncbi.nlm.nih.gov/pubmed/15567903",
				"http://www.ncbi.nlm.nih.gov/pubmed/9723625",
				"http://www.ncbi.nlm.nih.gov/pubmed/7695869",
				"http://www.ncbi.nlm.nih.gov/pubmed/8479463",
				"http://www.ncbi.nlm.nih.gov/pubmed/8479464",
				"http://www.ncbi.nlm.nih.gov/pubmed/23022248",
				"http://www.ncbi.nlm.nih.gov/pubmed/10077397",
				"http://www.ncbi.nlm.nih.gov/pubmed/15585762",
				"http://www.ncbi.nlm.nih.gov/pubmed/15302616",
				"http://www.ncbi.nlm.nih.gov/pubmed/23833580",
				"http://www.ncbi.nlm.nih.gov/pubmed/8472392",
				"http://www.ncbi.nlm.nih.gov/pubmed/12492632",
				"http://www.ncbi.nlm.nih.gov/pubmed/9430400",
				"http://www.ncbi.nlm.nih.gov/pubmed/9164706",
				"http://www.ncbi.nlm.nih.gov/pubmed/8946266",
				"http://www.ncbi.nlm.nih.gov/pubmed/9877124",
				"http://www.ncbi.nlm.nih.gov/pubmed/9746269"
			],
			"type": "yesno",
			"id": "53329c84d6d3ac6a34000040",
			"snippets": [
				{
					"offsetInBeginSection": 157,
					"offsetInEndSection": 331,
					"text": "We and others have published observational epidemiologic studies in support of vitamins in the primary prevention of CVD, but the results from intervention studies are mixed.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18377792",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 529,
					"offsetInEndSection": 1053,
					"text": "For vitamin E, observational data suggest benefit at doses of 100 to 400 IU/d. Results from recent large-scale trials are mixed, with some showing modest benefit but others suggesting no benefit, especially for secondary prevention. Results for B vitamins are also mixed and further complicated by the recent folate fortification of the flour supply. If greater B vitamin intake does reduce CVD, the benefits are likely to be greatest for primary prevention and in populations with intake below dietary reference standards. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18377792",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1445,
					"offsetInEndSection": 1911,
					"text": "In the dose-response meta-analysis, each 30 mg/day increase in vitamin C, 30 IU/day increase in vitamin E, and 1 mg/day increase in beta-carotene yielded the estimated overall relative risk for CHD of 1.01 (95% CI, 0.99-1.02), 0.96 (95% CI, 0.94-0.99), and 1.00 (95% CI, 0.88-1.14), respectively. CONCLUSIONS: Our findings in this meta-analysis suggest that an increase in dietary intake of antioxidant vitamins has encouraging prospects for possible CHD prevention.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18277182",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1183,
					"offsetInEndSection": 1514,
					"text": "High levels of Ξ±-tocopherol in serum were associated with 30% lower CAD risk in another study (HR 0.71; 95%CI 0.53-0.94). Among minerals (zinc, selenium, and chromium), an inverse association between zinc and CAD was observed; levels lower than 14.1 Βµmol/L were associated with an increased risk for CAD (RR 1.70; 95%CI 1.21-2.38).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23877741",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1527,
					"offsetInEndSection": 1711,
					"text": "The information available on this issue is scarce. Further prospective studies are needed to elucidate the role of these nutrients in the cardiovascular risk of patients with diabetes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23877741",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1523,
					"offsetInEndSection": 1644,
					"text": "Coenzyme Q10 supplementation at a dosage of 150 mg appears to decrease the inflammatory marker IL-6 in patients with CAD.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22342390",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1973,
					"offsetInEndSection": 2237,
					"text": " Coenzyme Q10 supplements at a dose of 150 mg can decrease oxidative stress and increase antioxidant enzyme activity in patients with CAD. A higher dose of coenzyme Q10 supplements (>150 mg/d) might promote rapid and sustainable antioxidation in patients with CAD.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21996047",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1267,
					"offsetInEndSection": 1412,
					"text": "Alpha-tocopherol or beta-carotene supplementation has no protective effect on macrovascular outcomes or total mortality of diabetic male smokers.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20350251",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1589,
					"offsetInEndSection": 1769,
					"text": "Sodium selenite supplementation increases GPx-1 activity in endothelial cells and in CAD patients. Future studies have to demonstrate whether long-term CAD outcome can be improved.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19033020",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2236,
					"offsetInEndSection": 2474,
					"text": "After 7.3 years of treatment and follow-up, a combination pill of folic acid, vitamin B6, and vitamin B12 did not reduce a combined end point of total cardiovascular events among high-risk women, despite significant homocysteine lowering.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18460663",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1627,
					"offsetInEndSection": 1885,
					"text": " In this population-based study, vitamin E use was unrelated to mortality, but this apparently null finding seems to represent a combination of increased mortality in those with severe cardiovascular disease and a possible protective effect in those without.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17275460",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1356,
					"offsetInEndSection": 1572,
					"text": " In this large cohort of apparently healthy US male physicians, self-selected supplementation with vitamin E, vitamin C, or multivitamins was not associated with a significant decrease in total CVD or CHD mortality. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12090883",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1278,
					"offsetInEndSection": 1712,
					"text": "The American Heart Association has recommended consumption of a balanced diet with emphasis on antioxidant-rich fruits and vegetables but has made no recommendations regarding vitamin E supplementation for the general population. Although vitamin E supplementation seems to be safe for most people, recommendations from health care professionals should reflect the uncertainty of established benefit as demonstrated in clinical trials",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11702901",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 369,
					"offsetInEndSection": 961,
					"text": "Recent studies show that supplementation with antioxidant vitamins E and C have benefits in CHD prevention; however, supplementation with beta-carotene may have deleterious effects and is not recommended. Current evidence suggests that patients with CHD would probably benefit from taking vitamin E in a dosage of 400 IU per day and vitamin C in a dosage of 500 to 1,000 mg per day. Clinicians may also want to consider vitamin supplementation for CHD prevention in high-risk patients. Folate lowers elevated homocysteine levels, but evidence for routine supplemental use does not yet exist. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10498115",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1931,
					"offsetInEndSection": 2082,
					"text": "In patients at high risk for cardiovascular events, treatment with vitamin E for a mean of 4.5 years had no apparent effect on cardiovascular outcomes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10639540",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Is delayed enhancement documented in patients with non-ischemic dilated cardiomyopathy?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/21234292",
				"http://www.ncbi.nlm.nih.gov/pubmed/21176853",
				"http://www.ncbi.nlm.nih.gov/pubmed/19317068",
				"http://www.ncbi.nlm.nih.gov/pubmed/17885521",
				"http://www.ncbi.nlm.nih.gov/pubmed/24315973",
				"http://www.ncbi.nlm.nih.gov/pubmed/23021326",
				"http://www.ncbi.nlm.nih.gov/pubmed/22875171",
				"http://www.ncbi.nlm.nih.gov/pubmed/22552168",
				"http://www.ncbi.nlm.nih.gov/pubmed/20149594",
				"http://www.ncbi.nlm.nih.gov/pubmed/23422782",
				"http://www.ncbi.nlm.nih.gov/pubmed/19185371",
				"http://www.ncbi.nlm.nih.gov/pubmed/17602984",
				"http://www.ncbi.nlm.nih.gov/pubmed/17131077",
				"http://www.ncbi.nlm.nih.gov/pubmed/20118568"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/21234292",
				"http://www.ncbi.nlm.nih.gov/pubmed/21176853",
				"http://www.ncbi.nlm.nih.gov/pubmed/19317068",
				"http://www.ncbi.nlm.nih.gov/pubmed/17885521",
				"http://www.ncbi.nlm.nih.gov/pubmed/24315973",
				"http://www.ncbi.nlm.nih.gov/pubmed/23021326",
				"http://www.ncbi.nlm.nih.gov/pubmed/22875171",
				"http://www.ncbi.nlm.nih.gov/pubmed/22552168",
				"http://www.ncbi.nlm.nih.gov/pubmed/20149594",
				"http://www.ncbi.nlm.nih.gov/pubmed/23422782",
				"http://www.ncbi.nlm.nih.gov/pubmed/19185371",
				"http://www.ncbi.nlm.nih.gov/pubmed/17602984",
				"http://www.ncbi.nlm.nih.gov/pubmed/17131077",
				"http://www.ncbi.nlm.nih.gov/pubmed/20118568"
			],
			"type": "yesno",
			"id": "5339ed7bd6d3ac6a34000060",
			"snippets": [
				{
					"offsetInBeginSection": 714,
					"offsetInEndSection": 814,
					"text": "Myocardial fibrosis was present in 30% of patients, the majority of which was mid-myocardial (63%). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21234292",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1290,
					"offsetInEndSection": 1400,
					"text": " DCM patients frequently have myocardial fibrosis detected on CE-CMR, the majority of which is mid-myocardial.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21234292",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 616,
					"offsetInEndSection": 689,
					"text": "Fifty (40%) patients showed myocardial DE, representing 12Β±7% of LV mass.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21176853",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 573,
					"offsetInEndSection": 675,
					"text": "one case was dilated cardiomyopathy, in which the delayed enhancement was diffuse small midwall spots ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19317068",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 849,
					"offsetInEndSection": 1013,
					"text": "In the dilated cardiomyopathy group, only seven (29%) patients showed delayed enhancement and its pattern was characterized by mid-wall, patchy or diffuse location.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17885521",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1388,
					"offsetInEndSection": 1838,
					"text": "Patterns of delayed enhancement are different in dilated cardiomyopathy and ischemic cardiomyopathy, reflecting the presence of scarring or various degrees of fibrosis in left ventricular myocardium. The presence of subendocardial or transmural delayed enhancement at contrast-enhanced cardiovascular magnetic resonance allowed distinction between dilated cardiomyopathy and ischemic cardiomyopathy with high sensitivity (88%) and specificity (100%).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17885521",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Does prudent diet reduce cardiovascular risk?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23953031",
				"http://www.ncbi.nlm.nih.gov/pubmed/22739999",
				"http://www.ncbi.nlm.nih.gov/pubmed/19656644",
				"http://www.ncbi.nlm.nih.gov/pubmed/19303267",
				"http://www.ncbi.nlm.nih.gov/pubmed/18936332",
				"http://www.ncbi.nlm.nih.gov/pubmed/18574045",
				"http://www.ncbi.nlm.nih.gov/pubmed/14972059",
				"http://www.ncbi.nlm.nih.gov/pubmed/10597981",
				"http://www.ncbi.nlm.nih.gov/pubmed/16401383",
				"http://www.ncbi.nlm.nih.gov/pubmed/9430390",
				"http://www.ncbi.nlm.nih.gov/pubmed/22012753",
				"http://www.ncbi.nlm.nih.gov/pubmed/11493127"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23953031",
				"http://www.ncbi.nlm.nih.gov/pubmed/22739999",
				"http://www.ncbi.nlm.nih.gov/pubmed/19656644",
				"http://www.ncbi.nlm.nih.gov/pubmed/19303267",
				"http://www.ncbi.nlm.nih.gov/pubmed/18936332",
				"http://www.ncbi.nlm.nih.gov/pubmed/18574045",
				"http://www.ncbi.nlm.nih.gov/pubmed/14972059",
				"http://www.ncbi.nlm.nih.gov/pubmed/10597981",
				"http://www.ncbi.nlm.nih.gov/pubmed/16401383",
				"http://www.ncbi.nlm.nih.gov/pubmed/9430390",
				"http://www.ncbi.nlm.nih.gov/pubmed/22012753",
				"http://www.ncbi.nlm.nih.gov/pubmed/11493127"
			],
			"type": "yesno",
			"id": "53319653d6d3ac6a3400003e",
			"snippets": [
				{
					"offsetInBeginSection": 685,
					"offsetInEndSection": 902,
					"text": "Using this approach, large prospective studies have reported reductions in CVD risk ranging from 10 to 60% in groups whose diets can be variously classified as β€�Healthyβ€™, β€�Prudentβ€™, Mediterraneanβ€™ or β€�DASH compliantβ€™.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23953031",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1456,
					"offsetInEndSection": 1595,
					"text": "Our findings suggest that a heart healthy dietary pattern is associated with moderately reduced risk of MI, but not related to risk of VTE.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22739999",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 965,
					"offsetInEndSection": 1165,
					"text": "The systematically reviewed studies reveal that a high adherence to a Mediterranean type of diet or \"prudent diet\" is associated with reduced risk of CVD and some types of cancer, even in the elderly.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19656644",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1399,
					"offsetInEndSection": 1693,
					"text": "In a large healthy Italian population, non-predefined dietary patterns including foods considered to be rather unhealthy, were associated with higher levels of cardiovascular risk factors, CRP and individual global CVD risk, whereas a \"prudent-healthy\" pattern was associated with lower levels.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19303267",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 682,
					"offsetInEndSection": 790,
					"text": "We observed an inverse association between the prudent pattern and AMI, with higher levels being protective.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18936332",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1031,
					"offsetInEndSection": 1314,
					"text": "After multivariable adjustment, the prudent diet was associated with a 28% lower risk of cardiovascular mortality (95% confidence interval [CI], 13 to 40) and a 17% lower risk of all-cause mortality (95% CI, 10 to 24) when the highest quintile was compared with the lowest quintile. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18574045",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1530,
					"offsetInEndSection": 1731,
					"text": "Greater adherence to the prudent pattern may reduce the risk of cardiovascular and total mortality, whereas greater adherence to the Western pattern may increase the risk among initially healthy women.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18574045",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1317,
					"offsetInEndSection": 1456,
					"text": "Composite diets (such as DASH diets, Mediterranean diet, 'prudent' diet) have been demonstrated to reduce the risk of hypertension and CHD.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14972059",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Is exome sequencing efficient for the detection of germline mutations?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24102379",
				"http://www.ncbi.nlm.nih.gov/pubmed/23832012",
				"http://www.ncbi.nlm.nih.gov/pubmed/23341325",
				"http://www.ncbi.nlm.nih.gov/pubmed/22468815"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24102379",
				"http://www.ncbi.nlm.nih.gov/pubmed/23832012",
				"http://www.ncbi.nlm.nih.gov/pubmed/23341325",
				"http://www.ncbi.nlm.nih.gov/pubmed/22468815"
			],
			"type": "yesno",
			"id": "5318b452b166e2b806000021",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 149,
					"text": "Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24102379",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1711,
					"offsetInEndSection": 1812,
					"text": "Whole exome sequencing is sensitive, rapid and efficient for detection of PCC/PGL germline mutations.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24102379",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 512,
					"offsetInEndSection": 649,
					"text": "These results from deep sequencing demonstrate a higher mutational detection rate than reported with conventional sequencing methodology.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23832012",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 534,
					"offsetInEndSection": 743,
					"text": "We performed exome sequencing of germline DNA from members of the affected family. Exome-wide analysis identified a novel loss-of-function mutation in the BAP1 gene, previously suggested as a tumor suppressor.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23341325",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 362,
					"offsetInEndSection": 576,
					"text": "whole-exome sequencing has been widely applied in the identification of germline mutations underlying Mendelian disorders, somatic mutations in various cancers and de novo mutations in neurodevelopmental disorders.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22468815",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 205,
					"text": "ere we report whole exome sequencing of patients with various myeloid malignancies, and identify recurrent somatic mutations in SETBP1, consistent with a recent report on atypical chronic myeloid leukemia",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23832012",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 500,
					"offsetInEndSection": 638,
					"text": "These results by deep sequencing demonstrated the higher mutational detection rate than reported using conventional sequencing methodology",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23832012",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3658,
					"offsetInEndSection": 4172,
					"text": "Among all the candidates for somatic mutations, the accuracy of prediction of such SNVs and indels by whole exome sequencing was tested by validation of 65 genes (80 events) by Sanger sequencing and targeted deep sequencing as described in Methods. The prediction had true positive rate of 47% (39% for missense mutation, 75% for nonsense mutations and 75% for indels). Of note is that prediction of known somatic mutations (for example, TET2 (N=9), CBL (N=2), SETBP1 (N=2) and ASXL1 (N=2)) showed accuracy of 100%",
					"beginSection": "sections.12",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23832012",
					"endSection": "sections.12"
				}
			]
		},
		{
			"body": "What is the mechanism of action of geldanamycin?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23986774",
				"http://www.ncbi.nlm.nih.gov/pubmed/23701727",
				"http://www.ncbi.nlm.nih.gov/pubmed/21525416",
				"http://www.ncbi.nlm.nih.gov/pubmed/20534344",
				"http://www.ncbi.nlm.nih.gov/pubmed/18001136",
				"http://www.ncbi.nlm.nih.gov/pubmed/15971989",
				"http://www.ncbi.nlm.nih.gov/pubmed/9817749"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23986774",
				"http://www.ncbi.nlm.nih.gov/pubmed/23701727",
				"http://www.ncbi.nlm.nih.gov/pubmed/21525416",
				"http://www.ncbi.nlm.nih.gov/pubmed/20534344",
				"http://www.ncbi.nlm.nih.gov/pubmed/18001136",
				"http://www.ncbi.nlm.nih.gov/pubmed/15971989",
				"http://www.ncbi.nlm.nih.gov/pubmed/9817749"
			],
			"type": "summary",
			"id": "5319a73cb166e2b806000026",
			"snippets": [
				{
					"offsetInBeginSection": 932,
					"offsetInEndSection": 962,
					"text": "Geldanamycin (HSP90 inhibitor)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23986774",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 187,
					"offsetInEndSection": 575,
					"text": "Geldanamycin is an antibiotic originally discovered based on its ability to bind heat-shock protein 90. This interaction can lead to the disruption of heat-shock protein 90-containing multimolecular complexes. It can also induce the inhibition or even degradation of partner proteins dissociated from the 90 kDa chaperone and, eventually, can cause apoptosis, for instance, in PC12 cells.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23701727",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 656,
					"offsetInEndSection": 849,
					"text": "An Hsp90 ATPase inhibitor, geldanamycin, inhibits luciferase reactivation demonstrating the importance of the ATP-dependent chaperone activity of E. coli Hsp90 during client protein remodeling.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21525416",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 372,
					"offsetInEndSection": 568,
					"text": "Unique proteome patterns were observed in HeLa cells treated with the HSP90 inhibitor geldanamycin, and were similar to the patterns induced by radicicol, a structurally different HSP90 inhibitor.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20534344",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 414,
					"offsetInEndSection": 446,
					"text": "the Hsp90 inhibitor geldanamycin",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18001136",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 572,
					"offsetInEndSection": 1342,
					"text": "The molecular chaperone heat-shock protein (Hsp) 90 is an important anticancer drug target because it maintains the conformation, stability, and function of many important oncogenic client proteins, including those involved with signal transduction, cell proliferation, survival, differentiation, motility angiogenesis, and metastasis. Using the standard inhibitors of the adenosine triphosphatase (ATPase) activity of Hsp90, geldanamycin (GA) and 17-allylamino-17- demethoxygeldanamycin (17AAG), novel solid-phase immunoassays have been validated using a time-resolved fluorescence (TRF) end point. Their utility for confirming the mechanism of action of Hsp90 inhibition in secondary cell-based assays has been shown and applied to the novel Hsp90 inhibitor CCT018159.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15971989",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 348,
					"offsetInEndSection": 568,
					"text": "A recent crystal structure of the NH2-terminal domain of yeast Hsp90 established the presence of a conserved nucleotide binding site that is identical with the binding site of geldanamycin, a specific inhibitor of Hsp90.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 569,
					"offsetInEndSection": 743,
					"text": "The functional significance of nucleotide binding by Hsp90 has remained unclear. Here we present evidence for a slow but clearly detectable ATPase activity in purified Hsp90.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2150,
					"offsetInEndSection": 2180,
					"text": "a HSP90 inhibitor Geldanamycin",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23986774",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 2439,
					"offsetInEndSection": 2470,
					"text": "Geldanamycin, a HSP90 inhibitor",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23986774",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 438,
					"offsetInEndSection": 599,
					"text": "Inhibition of  Hsp90 function by the ansamycin antibiotics (geldanamycin [GA], herbimycin A, macbecin) causes the misfolding  and degradation of these substrates",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 573,
					"offsetInEndSection": 859,
					"text": "The recent crystal structures of the NH2-terminal 25-kD domain of human and yeast Hsp90 revealed  that this domain binds not only the ansamycin antibiotic  GA but also, in the same site, adenine nucleotide, thus  suggesting that GA acts by inhibiting an ATP-dependent  function of Hsp90",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 8078,
					"offsetInEndSection": 8140,
					"text": "an authentic Hsp90 ATPase activity should be inhibited by  GA.",
					"beginSection": "sections.5",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.5"
				},
				{
					"offsetInBeginSection": 1746,
					"offsetInEndSection": 1865,
					"text": "ATP binding to Hsp90 is inhibited by the ansamycin antibiotic GA that occupies the ATP binding site with high  affinity",
					"beginSection": "sections.6",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.6"
				},
				{
					"offsetInBeginSection": 89,
					"offsetInEndSection": 180,
					"text": "We have previously reported the structure of the NH2-terminal domain of Hsp90 with bound GA",
					"beginSection": "sections.5",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.5"
				},
				{
					"offsetInBeginSection": 736,
					"offsetInEndSection": 898,
					"text": "As was observed with the structure of the NH2-terminal  domain of yeast Hsp90 (Prodromou et al., 1997a), ADP-Mg binds to a site in human Hsp90 where GA also binds",
					"beginSection": "sections.5",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.5"
				},
				{
					"offsetInBeginSection": 14291,
					"offsetInEndSection": 14423,
					"text": "As GA inhibits complex formation in the presence of  ATP, the ansamycin antibiotic mimics the ADP state of  Hsp90, not the ATP state",
					"beginSection": "sections.5",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.5"
				},
				{
					"offsetInBeginSection": 2022,
					"offsetInEndSection": 2133,
					"text": "the cellular effects of GA must be interpreted as the consequence of the interruption of the Hsp90 ATPase cycle",
					"beginSection": "sections.6",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.6"
				},
				{
					"offsetInBeginSection": 2135,
					"offsetInEndSection": 2427,
					"text": "GA blocks the maturation of specific Hsp90 substrates  (for example Whitesell et al., 1994; Smith et al., 1995;  Schneider et al., 1996; Whitesell and Cook, 1996; Dittmar  and Pratt, 1997; Stancato et al., 1997) and the re-folding of  certain stress-denatured polypeptides by the Hsp90 system",
					"beginSection": "sections.6",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.6"
				},
				{
					"offsetInBeginSection": 2451,
					"offsetInEndSection": 3019,
					"text": "Whereas in some cases treatment  with GA has been reported to result in the dissociation of  Hsp90β€“substrate complexes (for example Whitesell et al.,  1994), substrate polypeptides often accumulate on GA-bound Hsp90 in an unfolded conformation that is subject  to degradation by the proteasome system (Smith et al.,  1995; Schneider et al., 1996; Dittmar and Pratt, 1997). This  effect forms the basis for the potential therapeutic application of GA derivatives in depleting the cellular levels of  steroid receptors and Hsp90-dependent protooncogenic  protein kinases",
					"beginSection": "sections.6",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.6"
				},
				{
					"offsetInBeginSection": 6484,
					"offsetInEndSection": 6530,
					"text": "GA binding mimics the  ADP-bound form of Hsp90",
					"beginSection": "sections.6",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9817749",
					"endSection": "sections.6"
				}
			]
		},
		{
			"body": "What is the role played by mTOR in hypertrophic response and heart failure?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20644257"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20644257"
			],
			"type": "summary",
			"id": "5319a80fb166e2b80600002b",
			"snippets": [
				{
					"offsetInBeginSection": 212,
					"offsetInEndSection": 287,
					"text": "Myocardial MTOR activity changes during hypertrophy and heart failure (HF).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20644257",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 794,
					"offsetInEndSection": 927,
					"text": "When subjected to pressure overload, Mtor-ablated mice demonstrated an impaired hypertrophic response and accelerated HF progression.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20644257",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1068,
					"offsetInEndSection": 1486,
					"text": "Our results demonstrate a role for the MTORC1 signaling network in the myocardial response to stress. In particular, they highlight the role of 4E-BP1 in regulating cardiomyocyte viability and in HF. Because the effects of reduced MTOR activity were mediated through increased 4E-BP1 inhibitory activity, blunting this mechanism may represent a novel therapeutic strategy for improving cardiac function in clinical HF.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20644257",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the Arnold-Chiari syndrome?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/19287845",
				"http://www.ncbi.nlm.nih.gov/pubmed/18546951",
				"http://www.ncbi.nlm.nih.gov/pubmed/17874345",
				"http://www.ncbi.nlm.nih.gov/pubmed/15785984"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/19287845",
				"http://www.ncbi.nlm.nih.gov/pubmed/18546951",
				"http://www.ncbi.nlm.nih.gov/pubmed/17874345",
				"http://www.ncbi.nlm.nih.gov/pubmed/15785984"
			],
			"type": "summary",
			"id": "5318985eb166e2b80600001d",
			"snippets": [
				{
					"offsetInBeginSection": 137,
					"offsetInEndSection": 256,
					"text": "Arnold Chiari syndrome is a condition characterized by herniation of the cerebellar tonsils through the foramen magnum.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19287845",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 140,
					"text": "The Arnold-Chiari malformation is very rare hindbrain abnormalities characterized by herniation of the hindbrain through the foramen magnum.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18546951",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 691,
					"offsetInEndSection": 833,
					"text": "The origin of Arnold-Chiari syndrome is connected with narrowness in the posterior fossa, particularly with narrowing of the arachnoid spaces.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17874345",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 193,
					"text": "Arnold-Chiari Syndrome I is a malformation of the cervicomedullary junction, manifesting usually with downbeat nystagmus, palsy of the caudal cerebral nerves, headache, and vertigo.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15785984",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What clinical use aptamers may have?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24198064",
				"http://www.ncbi.nlm.nih.gov/pubmed/23738000",
				"http://www.ncbi.nlm.nih.gov/pubmed/22352726",
				"http://www.ncbi.nlm.nih.gov/pubmed/21838685",
				"http://www.ncbi.nlm.nih.gov/pubmed/20463739",
				"http://www.ncbi.nlm.nih.gov/pubmed/20161621",
				"http://www.ncbi.nlm.nih.gov/pubmed/18708826",
				"http://www.ncbi.nlm.nih.gov/pubmed/18025536",
				"http://www.ncbi.nlm.nih.gov/pubmed/17951900",
				"http://www.ncbi.nlm.nih.gov/pubmed/16842232",
				"http://www.ncbi.nlm.nih.gov/pubmed/16631118",
				"http://www.ncbi.nlm.nih.gov/pubmed/15968382",
				"http://www.ncbi.nlm.nih.gov/pubmed/15926872",
				"http://www.ncbi.nlm.nih.gov/pubmed/15461575",
				"http://www.ncbi.nlm.nih.gov/pubmed/12828856",
				"http://www.ncbi.nlm.nih.gov/pubmed/9704089",
				"http://www.ncbi.nlm.nih.gov/pubmed/20855639"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24198064",
				"http://www.ncbi.nlm.nih.gov/pubmed/23738000",
				"http://www.ncbi.nlm.nih.gov/pubmed/22352726",
				"http://www.ncbi.nlm.nih.gov/pubmed/21838685",
				"http://www.ncbi.nlm.nih.gov/pubmed/20463739",
				"http://www.ncbi.nlm.nih.gov/pubmed/20161621",
				"http://www.ncbi.nlm.nih.gov/pubmed/18708826",
				"http://www.ncbi.nlm.nih.gov/pubmed/18025536",
				"http://www.ncbi.nlm.nih.gov/pubmed/17951900",
				"http://www.ncbi.nlm.nih.gov/pubmed/16842232",
				"http://www.ncbi.nlm.nih.gov/pubmed/16631118",
				"http://www.ncbi.nlm.nih.gov/pubmed/15968382",
				"http://www.ncbi.nlm.nih.gov/pubmed/15926872",
				"http://www.ncbi.nlm.nih.gov/pubmed/15461575",
				"http://www.ncbi.nlm.nih.gov/pubmed/12828856",
				"http://www.ncbi.nlm.nih.gov/pubmed/9704089",
				"http://www.ncbi.nlm.nih.gov/pubmed/20855639"
			],
			"type": "summary",
			"id": "5318a6b2b166e2b80600001f",
			"snippets": [
				{
					"offsetInBeginSection": 1215,
					"offsetInEndSection": 1642,
					"text": "In murine tumor models, the aptamer-targeted siRNA-mediated NMD inhibition in tumor cells led to significant inhibition of tumor growth, which was superior to best-in-class \"conventional\" cancer vaccination protocols. Tumor-targeted NMD inhibition forms the basis of a simple, broadly useful, and clinically feasible approach to enhance the antigenicity of disseminated tumors leading to their immune recognition and rejection.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24198064",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 109,
					"text": "An RNA aptamer provides a novel approach for the induction of apoptosis by targeting the HPV16 E7 oncoprotein",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 568,
					"offsetInEndSection": 876,
					"text": "This study is focused on one aptamer (termed A2). Transfection of this molecule into HPV16-transformed cells resulted in inhibition of cell proliferation (shown using real-time cell electronic sensing and MTT assays) due to the induction of apoptosis (as demonstrated by Annexin V/propidium iodide staining).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1483,
					"offsetInEndSection": 1579,
					"text": "Transfection of cells with A2 was correlated with the loss of E7 and the induction of apoptosis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1580,
					"offsetInEndSection": 1768,
					"text": "Aptamers specific for a number of cellular and viral proteins have been documented previously; one aptamer (Macugen) is approved for clinical use and several others are in clinical trials.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 203,
					"offsetInEndSection": 355,
					"text": "The high binding affinity and specificity of aptamers allows for isolation of an artificial ligand for theoretically any therapeutic target of interest.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22352726",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 410,
					"text": "Aptamers are a special class of nucleic acid molecules that are beginning to be investigated for clinical use. These small RNA/DNA molecules can form secondary and tertiary structures capable of specifically binding proteins or other cellular targets; they are essentially a chemical equivalent of antibodies. Aptamers have the advantage of being highly specific, relatively small in size, and non-immunogenic.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21838685",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 582,
					"offsetInEndSection": 741,
					"text": "In the last two decades, many aptamers have been clinically developed as inhibitors for targets such as vascular endothelial growth factor (VEGF) and thrombin.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21838685",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 742,
					"offsetInEndSection": 933,
					"text": "The first aptamer based therapeutic was FDA approved in 2004 for the treatment of age-related macular degeneration and several other aptamers are currently being evaluated in clinical trials.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21838685",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1139,
					"offsetInEndSection": 1295,
					"text": "Preclinical studies using aptamer-siRNA chimeras and aptamer targeted nanoparticle therapeutics have been very successful in mouse models of cancer and HIV.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21838685",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1296,
					"offsetInEndSection": 1437,
					"text": "In summary aptamers are in several stages of development, from pre-clinical studies to clinical trials and even as FDA approved therapeutics.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21838685",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 851,
					"offsetInEndSection": 1233,
					"text": "In subcutaneous and metastatic tumour models, tumour-targeted delivery of NMD factor-specific siRNAs conjugated to oligonucleotide aptamer ligands led to significant inhibition of tumour growth that was superior to that of vaccination with granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing irradiated tumour cells, and could be further enhanced by co-stimulation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20463739",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 545,
					"offsetInEndSection": 764,
					"text": "An assortment of non-viral carriers including liposomes, peptides, polymers, and aptamers are being evaluated for their ability to shepherd siRNA to the target tissue and cross the plasma membrane barrier into the cell.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20161621",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 635,
					"offsetInEndSection": 951,
					"text": "In addition, a new thromboxane receptor antagonist, NCX-4016, a newly discovered protease-activated receptor antagonist that targets thrombin-induced platelet aggregation, and anti-von Willebrand factor aptamers show tremendous promise in refining antiplatelet therapy by targeting different receptors and molecules.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18708826",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 105,
					"text": "First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18025536",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 268,
					"text": "ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coronary syndromes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18025536",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1527,
					"offsetInEndSection": 1794,
					"text": "This is the first-in-human evaluation of a novel aptamer antagonist of vWF. ARC1779 produced dose- and concentration-dependent inhibition of vWF activity and platelet function with duration of effect suitable for the intended clinical use in acute coronary syndromes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18025536",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 160,
					"text": "A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17951900",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 218,
					"text": "Wet age-related macular degeneration and diabetic retinopathy are pathological consequences of vascular endothelial growth factor (VEGF) release as a reaction to deficiency of oxygen and nutrients in the macular cells.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17951900",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 663,
					"offsetInEndSection": 848,
					"text": "FDA recently approved two drugs specifically aimed at VEGF, bevacizumab, a humanized monoclonal antibody, and pegaptinib, a pegylated aptamer with application in ophthalmic pathologies.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16842232",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 93,
					"text": "Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16631118",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 401,
					"offsetInEndSection": 550,
					"text": "Our lead thioaptamer, R12-2, targets the RNase H domain of the HIV-1 reverse transcriptase (RT) and inhibits viral infection in U373-MAGI-CCR5 cells.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16631118",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1073,
					"offsetInEndSection": 1263,
					"text": "In this report, we demonstrate that monothioate-modified DNA duplex oligonucleotides can be efficiently delivered into cells by liposome-based transfection agents to inhibit HIV replication.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16631118",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 52,
					"text": "Nucleic acid aptamers in therapeutic anticoagulation",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15968382",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 83,
					"text": "Pegaptanib sodium for the treatment of neovascular age-related macular degeneration",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15926872",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 617,
					"offsetInEndSection": 722,
					"text": "Pegaptanib sodium is one of the first therapeutics belonging to the class of compounds known as aptamers.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15926872",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 837,
					"offsetInEndSection": 1075,
					"text": "The article highlights and summarises the results of the multi-centre, randomised, sham-controlled clinical trials with pegaptanib sodium to treat subfoveal choroidal neovascularisation in AMD. In addition, the safety profile is reviewed.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15926872",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 68,
					"text": "Regulatable aptamers in medicine: focus on antithrombotic strategies",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15461575",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 397,
					"offsetInEndSection": 692,
					"text": "After a decade of intensive research, technology development and initial clinical evaluation, aptamers have now demonstrated broad potential as direct protein ligands and inhibitors, and thus represent an exciting class of compounds for the development of new therapeutic and diagnostic agents. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15461575",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 604,
					"offsetInEndSection": 840,
					"text": "Two R-aptamers (R10-60 and D-R15-8) with the predominant shared characteristics were selected for further study on primary human chronic lymphocytic leukemia (CLL) B cells, which are well known to be difficult to transfect and activate.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12828856",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1401,
					"offsetInEndSection": 1633,
					"text": "Together, these findings suggest that the sequence compositions in R-aptamers that promote multimerization and contain optimal ISS CpG motifs facilitate the delivery of ISS-ODN to CLL cells and enhance the activation of these cells.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12828856",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 414,
					"offsetInEndSection": 528,
					"text": "In particular, the use of aptamers for the alleviation of blood clotting and the treatment of AIDS are considered.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9704089",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 224,
					"offsetInEndSection": 674,
					"text": "We synthesized an RNA aptamer probe specific for human CD4 using a reported sequence and investigated the potential use of this probe in cell phenotyping. Studies in cultured cells demonstrated that the synthetic CD4 aptamer had a nearly identical cell-binding specificity as the standard CD4 antibody. Fluorescent microscopy confirmed that the aptamer and antibody generated the same CD4 staining pattern in cells without competing with one another.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20855639",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1184,
					"offsetInEndSection": 1291,
					"text": "transfection of HPV16-transformed cells with A2 appeared to result in the loss of E7 and rise in pRb levels",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4032,
					"offsetInEndSection": 4205,
					"text": "We also demonstrate that this aptamer binds to the region of E7 required for interaction with pRb and is capable of blocking the interaction of E7 with cellular pRb in vitro",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4220,
					"offsetInEndSection": 4399,
					"text": "transfection of the HPV16-positive cervical cancer cell line, CaSki [30], with this aptamer appeared to result in a loss of the E7 oncoprotein and in a rise in cellular pRb levels",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 10186,
					"offsetInEndSection": 10393,
					"text": "the changes seen in A2-E7 binding as a result of point mutations/deletions in E7, provides support for the interaction between E7 and A2 being specific, rather than E7 acting as a general RNA-binding protein",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 11938,
					"offsetInEndSection": 12111,
					"text": "In the absence of A2 (lane 2), pRb was precipitated by GST-E7, however, with increasing concentrations of A2 (lanes 3β€“5) the amount of pRb precipitated by GST-E7 was reduced",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 12220,
					"offsetInEndSection": 12374,
					"text": "These data confirm that A2 is able to disrupt the E7-pRb interaction in vitro in a dose-dependent manner, by up to 96% at the highest concentration tested",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 14682,
					"offsetInEndSection": 14858,
					"text": "A2 transfection reduced the level of E7 in these cells by 75% (comparing lanes 1 and 2), whilst in cells which received the SF1 control, the level of E7 was reduced by only 18%",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 12443,
					"offsetInEndSection": 12520,
					"text": "Disruption of the interaction between HPV16 E7 and pRb by aptamer A2 in vitro",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 14251,
					"offsetInEndSection": 14529,
					"text": "In both mock-transfected and SF1-transfected samples, efficient co-immunoprecipitation of E7 was observed using anti-pRb (Figure 5A, lanes 4 and 6, respectively). However, when 100 nM A2 was transfected into the cells, co-immunoprecipitation of E7 by anti-pRb was reduced by 80%",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 15882,
					"offsetInEndSection": 16235,
					"text": "Densitometry analysis of 4 independent experiments (Figure 5C) showed that in CaSki cells transfected with A2, the level of E7 was reduced by 62.7Β±10.5% (lane 2), while in SF1-transfected cells the level was reduced by only 15.0Β±15.7% (lane 3). Together, these results indicate that during the 24 hour incubation with A2, E7 had been lost from the cells",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 16725,
					"offsetInEndSection": 16813,
					"text": "Reduction of HPV16 E7 protein levels in CaSki cells following transfection of aptamer A2",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 194,
					"offsetInEndSection": 707,
					"text": "We have characterised an RNA aptamer (termed A2) selected against the HPV16 oncoprotein E7. Transfection of A2 into an HPV16-transformed cell line (SiHa) resulted in decreased cell viability by the induction of apoptosis. This aptamer was able to inhibit the interaction between HPV16 E7 and pRb in vitro. Upon further investigation, it appeared that transfection of CaSki cells with this molecule resulted in a reduction in E7 levels and that this loss appeared to correlate with an increase in the levels of pRb",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 2000,
					"offsetInEndSection": 2155,
					"text": "We suggest that the loss of E7 that was detected upon transfection of A2 resulted in a release of active pRb, ultimately resulting in an apoptotic response",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738000",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 931,
					"offsetInEndSection": 1224,
					"text": "Following is a brief comparative debate on the various anti-VGEF drugs commonly in use today, such as pegaptanib sodium (Macugen, Pfizer United States, Eyetech Pharmaceuticals Inc.; Pfizer, Inc.), ranibizumab (Lucentis, Genentech, Switzerland) and bevacizumab (Avastin, Genentech, Switzerland)",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17951900",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 31,
					"offsetInEndSection": 255,
					"text": "The US Food and Drug Administration (FDA) announced the approval of pegaptanib sodium injection in December 2004, which at that time was a \"new therapy to slow vision loss in people with the eye disease neovascular (wet) AMD",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17951900",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 411,
					"offsetInEndSection": 569,
					"text": "More than 50,000 patients with wet AMD were treated with pegaptanib sodium in the United States last year. Pegaptanibβ€²s approval represented a major milestone",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17951900",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 860,
					"offsetInEndSection": 1034,
					"text": "Pegaptanib sodium is an aptamer binding VEGF165, the isoform most frequently identified with pathological angiogenesis in the retina and thus has a selective anti-VEGF action",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17951900",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 5898,
					"offsetInEndSection": 6289,
					"text": "Recently, Genentech the founder company for ranibizumab and bevacizumab has given a warning about a potential stroke risk with 0.5 mg ranibizumab injections in predisposed patients - having preexisting history of myocardial infarction or stroke and thus pegaptanib sodium is being recommended for this category of patients because of its specificity in targeting the pathologic VEGF molecule",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17951900",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "Is c-met involved in the activation of the Akt pathway?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23345546",
				"http://www.ncbi.nlm.nih.gov/pubmed/23229794",
				"http://www.ncbi.nlm.nih.gov/pubmed/22820099",
				"http://www.ncbi.nlm.nih.gov/pubmed/22789825",
				"http://www.ncbi.nlm.nih.gov/pubmed/21687953",
				"http://www.ncbi.nlm.nih.gov/pubmed/21536148",
				"http://www.ncbi.nlm.nih.gov/pubmed/20233866",
				"http://www.ncbi.nlm.nih.gov/pubmed/19850646",
				"http://www.ncbi.nlm.nih.gov/pubmed/18262389",
				"http://www.ncbi.nlm.nih.gov/pubmed/18234991",
				"http://www.ncbi.nlm.nih.gov/pubmed/17942284",
				"http://www.ncbi.nlm.nih.gov/pubmed/17464994",
				"http://www.ncbi.nlm.nih.gov/pubmed/17258200",
				"http://www.ncbi.nlm.nih.gov/pubmed/16278380",
				"http://www.ncbi.nlm.nih.gov/pubmed/15522281",
				"http://www.ncbi.nlm.nih.gov/pubmed/14570904",
				"http://www.ncbi.nlm.nih.gov/pubmed/11821397",
				"http://www.ncbi.nlm.nih.gov/pubmed/10714768"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23345546",
				"http://www.ncbi.nlm.nih.gov/pubmed/23229794",
				"http://www.ncbi.nlm.nih.gov/pubmed/22820099",
				"http://www.ncbi.nlm.nih.gov/pubmed/22789825",
				"http://www.ncbi.nlm.nih.gov/pubmed/21687953",
				"http://www.ncbi.nlm.nih.gov/pubmed/21536148",
				"http://www.ncbi.nlm.nih.gov/pubmed/20233866",
				"http://www.ncbi.nlm.nih.gov/pubmed/19850646",
				"http://www.ncbi.nlm.nih.gov/pubmed/18262389",
				"http://www.ncbi.nlm.nih.gov/pubmed/18234991",
				"http://www.ncbi.nlm.nih.gov/pubmed/17942284",
				"http://www.ncbi.nlm.nih.gov/pubmed/17464994",
				"http://www.ncbi.nlm.nih.gov/pubmed/17258200",
				"http://www.ncbi.nlm.nih.gov/pubmed/16278380",
				"http://www.ncbi.nlm.nih.gov/pubmed/15522281",
				"http://www.ncbi.nlm.nih.gov/pubmed/14570904",
				"http://www.ncbi.nlm.nih.gov/pubmed/11821397",
				"http://www.ncbi.nlm.nih.gov/pubmed/10714768"
			],
			"type": "yesno",
			"id": "5318a955b166e2b806000020",
			"snippets": [
				{
					"offsetInBeginSection": 421,
					"offsetInEndSection": 726,
					"text": "Amplification of MET has been reported in approximately 5%-22% of lung tumors with acquired resistance to small-molecule inhibitors of the epidermal growth factor receptor (EGFR). Resistance to EGFR inhibitors is likely mediated through downstream activation of the phosphoinositide 3-kinase /AKT pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23345546",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 727,
					"offsetInEndSection": 965,
					"text": "Simultaneous treatment of resistant tumors with a MET inhibitor plus an EGFR inhibitor can abrogate activation of downstream effectors of cell growth, proliferation, and survival, thereby overcoming acquired resistance to EGFR inhibitors.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23345546",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 839,
					"offsetInEndSection": 885,
					"text": "HGF mediated both ERK and Akt phosphorylation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23229794",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1263,
					"offsetInEndSection": 1360,
					"text": "ERK/Akt signaling, but not the Smad pathway, may be one of the main processes in HGF-induced EMT,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23229794",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1442,
					"offsetInEndSection": 1503,
					"text": "The MAPK/Akt pathway is indispensable in HGF/c-Met signaling.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23229794",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 115,
					"text": "Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22820099",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 933,
					"offsetInEndSection": 1083,
					"text": "Specifically, we demonstrated that inhibition of c-Met activity led to suppression of the PI3K-Akt pathway, thus enhancing cisplatin chemosensitivity.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22820099",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1084,
					"offsetInEndSection": 1245,
					"text": "Our study clearly suggests that inhibition of c-Met activity can effectively sensitize osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22820099",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 604,
					"offsetInEndSection": 806,
					"text": "We found that a dual Met/VEGF receptor 2 kinase inhibitor, E7050, circumvented HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer cell lines by inhibiting the Met/Gab1/PI3K/Akt pathway in vitro.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22789825",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 514,
					"offsetInEndSection": 728,
					"text": "Here, we report that i) treatment of RL95-2 cells with HGF resulted in phosphorylation of the HGF receptor c-Met, activation of Akt and IΞΊB, translocation of NF-ΞΊB into the nucleus, and up-regulation of COX-2 mRNA;",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21687953",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1062,
					"offsetInEndSection": 1205,
					"text": "Our data suggest that HGF possesses chemotactic ability, has anti-apoptosis action, and induces cellular infiltration via the PI3K/Akt pathway;",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21687953",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 177,
					"text": "Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking IΞΊB kinase activity",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21536148",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 715,
					"offsetInEndSection": 938,
					"text": "Activation of c-Src in turn establishes a complex consisting of phosphatidylinositol 3-kinase and c-MET, and promotes downstream activation of the phosphatidylinositol 3-kinase/AKT pathway and mammalian target of rapamycin.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21536148",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1150,
					"offsetInEndSection": 1443,
					"text": "Notably, hepatocyte growth factor-stimulated c-Src activation results in induction of phosphatidylinositol 3-kinase complexes p85Ξ±/p110Ξ± and p85Ξ±/p110Ξ΄, which is required for activation of mammalian target of rapamycin, and consequent inhibition of IΞΊB kinase and nuclear factor-ΞΊB activation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21536148",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1444,
					"offsetInEndSection": 1735,
					"text": "Our findings, for the first time, have identified the c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway that plays a pivotal role in mediating the inhibitory effects of hepatocyte growth factor on dendritic cell activation by blocking nuclear factor-ΞΊB signaling.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21536148",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1280,
					"offsetInEndSection": 1487,
					"text": "Cyr61 siRNA inhibited a second phase of Akt phosphorylation measured 12 hours after cell stimulation with HGF and also inhibited HGF-induced phosphorylation of the Akt target glycogen synthase kinase 3alpha.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20233866",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1342,
					"offsetInEndSection": 1594,
					"text": "HGF+EGF treatment increased the duration of ERK1/2 and AKT activation compared to HGF or EGF alone. All these data indicate that a crosstalk between the EGF and HGF pathways in mammary epithelial cells may modulate the development of the mammary gland.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19850646",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 125,
					"text": "Hepatocyte growth factor and c-Met promote dendritic maturation during hippocampal neuron differentiation via the Akt pathway",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18262389",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 758,
					"offsetInEndSection": 1053,
					"text": "Consistent with these results, HGF activated Akt, which phosphorylates glycogen synthase kinase-3beta (GSK-3beta) to inactivate it, and reduced phosphorylation of microtubule-associated protein 2 (MAP2), which can promote microtubule polymerization and dendrite elongation when dephosphorylated.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18262389",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1054,
					"offsetInEndSection": 1374,
					"text": "Conversely, pharmacological inhibition of c-Met with its specific inhibitor, PHA-665752, or genetic knock-down of c-Met with short hairpin RNAs (shRNAs) suppressed HGF-induced phosphorylation of Akt and GSK-3beta, increased phosphorylation of MAP2, and reduced dendrite number and length in cultured hippocampal neurons.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18262389",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1458,
					"offsetInEndSection": 1699,
					"text": "Inhibiting Akt activity with the phosphoinositide-3-kinase inhibitor LY294002 or Akt inhibitor X suppressed HGF-induced phosphorylation of GSK-3beta, increased MAP2 phosphorylation, and blocked the ability of HGF to enhance dendritic length.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18262389",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1700,
					"offsetInEndSection": 1844,
					"text": "These observations indicate that HGF and c-Met can regulate the early stages of dendrite maturation via activation of the Akt/GSK-3beta pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18262389",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 111,
					"text": "Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18234991",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1031,
					"offsetInEndSection": 1415,
					"text": "HGF was found to enhance cell migration, and that HGF-induced migration depends on PI3K/Akt pathway. The activation of PI3K/Akt pathway induced by the HGF/c-Met axis is involved in the downregulation of cell adhesion molecules E-cadherin and beta-catenin, contributing to the attenuation of cell-cell adhesion and promoting the enhanced motility and migration of uveal melanoma cells.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18234991",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 122,
					"text": "HGF protects cultured cortical neurons against hypoxia/reoxygenation induced cell injury via ERK1/2 and PI-3K/Akt pathways",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942284",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 462,
					"offsetInEndSection": 528,
					"text": "HGF stimulated both ERK1/2 and Akt activities in cortical neurons.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942284",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 529,
					"offsetInEndSection": 718,
					"text": "Inhibition of ERK activation completely abolished the protective effects of HGF, and inhibition of Akt activation reduced, but did not completely eliminate the HGF mediated neuroprotection.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942284",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 719,
					"offsetInEndSection": 837,
					"text": "It is suggested that the neuroprotection of HGF depend on ERK1/2 pathway, and, to a lesser extent, PI-3K/Akt pathway. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942284",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 107,
					"text": "Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17464994",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1318,
					"offsetInEndSection": 1488,
					"text": "Thus, Met acting on PI3K and Akt ensures high levels of FLIPL, and disruption of this pathway contributes to hepatic apoptosis and possibly to Fas-related liver diseases.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17464994",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 744,
					"offsetInEndSection": 990,
					"text": "The HGF-induced increase in Nkx 2.5 expression was inhibited by co-treatment with the PI3 kinase inhibitors Wortmannin and LY294002, but not by its inactive homolog LY303511, suggesting an involvement of the PI3 kinase/Akt pathway in this effect.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17258200",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 150,
					"text": "X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16278380",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1263,
					"offsetInEndSection": 1347,
					"text": "Activation of XIAP expression by HGF was inhibited by siRNA targeting Akt1 and Akt2.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16278380",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1361,
					"offsetInEndSection": 1419,
					"text": "Activation of C-MET enhances XIAP through the Akt pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16278380",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 113,
					"text": "Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15522281",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1167,
					"offsetInEndSection": 1331,
					"text": "A significant reduction in apoptosis in the HGF-treated hearts was observed compared with control hearts, and was strongly associated with increased Akt activation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15522281",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1461,
					"offsetInEndSection": 1546,
					"text": "The antiapoptotic effect of HGF was mediated by activation of PI3-kinase/Akt pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15522281",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 508,
					"offsetInEndSection": 874,
					"text": "The protective effect of HGF/SF against the ADR-induced apoptosis was abolished in the presence of either LY294002, an inhibitor of phosphatidylinositol-3'-OH kinase (PI3-K) or 1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate, an inhibitor of Akt, thus implicating the activation of PI3-K-Akt signaling in the antiapoptotic action of HGF/SF.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14570904",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 875,
					"offsetInEndSection": 985,
					"text": "Immunoblotting analysis revealed that HGF/SF stimulated the sustained phosphorylation of Akt for several hours",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14570904",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1048,
					"offsetInEndSection": 1185,
					"text": "Furthermore, ADR-induced activation of caspase-9, a downstream molecule of Akt, was inhibited for at least 24 h after HGF/SF stimulation,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14570904",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1479,
					"offsetInEndSection": 1656,
					"text": "These results indicate that HGF/SF, but not EGF, transmitted protective signals against ADR-induced apoptosis by causing sustained activation of the PI3-K-Akt signaling pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14570904",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 186,
					"text": "Hepatocyte growth factor/scatter factor inhibits UVB-induced apoptosis of human keratinocytes but not of keratinocyte-derived cell lines via the phosphatidylinositol 3-kinase/AKT pathway",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11821397",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 349,
					"offsetInEndSection": 575,
					"text": "When we analyzed the signaling pathways initiated by the HGF/SF receptor c-met, we found that the phosphatidylinositol (PI) 3-kinase and its downstream-element AKT and the mitogen-activated protein (MAP) kinase were activated.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11821397",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 576,
					"offsetInEndSection": 728,
					"text": "Inhibition of PI 3-kinase led to a complete abrogation of the anti-apoptotic effect of HGF/SF, whereas blockade of the MAP kinase pathway had no effect.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11821397",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1261,
					"offsetInEndSection": 1411,
					"text": "We now show in detached cells a cooperative effect of HGF and FN in the activation of PI 3-kinase and on the phosphorylation of PKB/Akt at serine 473.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10714768",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1412,
					"offsetInEndSection": 1554,
					"text": "PI 3-kinase activity is also required for the HGF- and fibronectin-induced survival responses, as well as anchorage-independent colony growth.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10714768",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1645,
					"offsetInEndSection": 1964,
					"text": "Together, these results demonstrate that the PI 3-kinase/Akt pathway is a key effector of the HGF- and fibronectin-induced survival response of breast carcinoma cells under detached conditions and corroborate an interaction between integrin and HGF/ Met signalling pathways in the development of invasive breast cancer.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10714768",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22370907",
				"http://www.ncbi.nlm.nih.gov/pubmed/19272424",
				"http://www.ncbi.nlm.nih.gov/pubmed/16691119",
				"http://www.ncbi.nlm.nih.gov/pubmed/15854770",
				"http://www.ncbi.nlm.nih.gov/pubmed/12722831",
				"http://www.ncbi.nlm.nih.gov/pubmed/12536227",
				"http://www.ncbi.nlm.nih.gov/pubmed/11207422",
				"http://www.ncbi.nlm.nih.gov/pubmed/11005264",
				"http://www.ncbi.nlm.nih.gov/pubmed/10967182",
				"http://www.ncbi.nlm.nih.gov/pubmed/10867800",
				"http://www.ncbi.nlm.nih.gov/pubmed/10822429",
				"http://www.ncbi.nlm.nih.gov/pubmed/10787032",
				"http://www.ncbi.nlm.nih.gov/pubmed/9759660",
				"http://www.ncbi.nlm.nih.gov/pubmed/9600226"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22370907",
				"http://www.ncbi.nlm.nih.gov/pubmed/19272424",
				"http://www.ncbi.nlm.nih.gov/pubmed/16691119",
				"http://www.ncbi.nlm.nih.gov/pubmed/15854770",
				"http://www.ncbi.nlm.nih.gov/pubmed/12722831",
				"http://www.ncbi.nlm.nih.gov/pubmed/12536227",
				"http://www.ncbi.nlm.nih.gov/pubmed/11207422",
				"http://www.ncbi.nlm.nih.gov/pubmed/11005264",
				"http://www.ncbi.nlm.nih.gov/pubmed/10967182",
				"http://www.ncbi.nlm.nih.gov/pubmed/10867800",
				"http://www.ncbi.nlm.nih.gov/pubmed/10822429",
				"http://www.ncbi.nlm.nih.gov/pubmed/10787032",
				"http://www.ncbi.nlm.nih.gov/pubmed/9759660",
				"http://www.ncbi.nlm.nih.gov/pubmed/9600226"
			],
			"type": "factoid",
			"id": "53189656b166e2b80600001c",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 117,
					"text": "Ξ±-Synuclein is the major protein associated with Lewy body dementia, Parkinson's disease and multiple system atrophy.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22370907",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 310,
					"offsetInEndSection": 518,
					"text": "With the aim to develop antibodies showing high specificity and sensitivity for disease-associated Ξ±-synuclein, synthetic peptides containing different amino acid sequences were used for immunization of mice.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22370907",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 387,
					"text": "Parkinson's disease and dementia with Lewy bodies are very frequent neurological disorders of the elderly. Mutations in the alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia. Neuropathologically these diseases are characterized by the presence of Lewy bodies and Lewy neurites, intraneuronal inclusions mostly composed of alphaSYN protein fibrils.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19272424",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 594,
					"offsetInEndSection": 677,
					"text": "Immunohistochemistry for alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16691119",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 294,
					"text": "We immunohistochemically investigated the degeneration processes of the nigro-striatal and nigro-amygdaloid pathways and the relationship between the loss of dopaminergic neurons and Lewy bodies (LB) formation in the substantia nigra using 15 autopsied cases of dementia with Lewy bodies (DLB).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15854770",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 459,
					"offsetInEndSection": 650,
					"text": "The substantia nigra possessed alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15854770",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 166,
					"text": "The major protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12722831",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 167,
					"offsetInEndSection": 251,
					"text": "Recently, alpha-synuclein (alphaS) has been found to be a central constituent of LB.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12536227",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 456,
					"offsetInEndSection": 824,
					"text": "By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11207422",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 680,
					"offsetInEndSection": 880,
					"text": "Notably, carboxy-terminal alpha-syn epitopes were immunodominant in GCIs, but the entire panel of antibodies immunostained cortical Lewy bodies (LBs) in dementia with LBs brain with similar intensity.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11005264",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 994,
					"offsetInEndSection": 1165,
					"text": "Discrete immunostaining was demonstrated in NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10967182",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 223,
					"text": "The identification of the alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and of alpha-synuclein as a component of Lewy bodies has heralded a new era in the study of Parkinson's disease.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10867800",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 83,
					"text": "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10822429",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 358,
					"offsetInEndSection": 524,
					"text": "recent advances in immunostaining of alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10822429",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1012,
					"offsetInEndSection": 1133,
					"text": "CLBs positive for alpha-synuclein are highly sensitive (91%) and specific (90%) neuropathologic markers of dementia in PD",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10822429",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1314,
					"offsetInEndSection": 1433,
					"text": "CLBs detected by alpha-synuclein antibodies in patients with PD are a more sensitive and specific correlate of dementia",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10822429",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 61,
					"text": "alpha-Synuclein immunoreactivity in dementia with Lewy bodies",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10787032",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 123,
					"text": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10787032",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 609,
					"offsetInEndSection": 738,
					"text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10787032",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 325,
					"text": "The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD) and in the Lewy bodies (LBs) of Lewy body variant of AD, diffuse Lewy body disease, and Parkinson's disease.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9759660",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 326,
					"offsetInEndSection": 725,
					"text": "To better understand the distribution of NACP/alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify the patterns of NACP/alpha-synuclein compartmentalization, we studied NACP/alpha-synuclein immunoreactivity using antibodies against the C-terminal, N-terminal, and NAC regions after Proteinase K and formic acid treatment in the cortex of patients with LBs.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9759660",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1656,
					"offsetInEndSection": 1872,
					"text": "Ultrastructural analysis revealed that NACP/alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters in the filaments of LBs and neurites.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9759660",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1873,
					"offsetInEndSection": 2023,
					"text": "These results support the view that aggregated NACP/alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9759660",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 157,
					"text": "Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9600226",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 341,
					"offsetInEndSection": 453,
					"text": "PD brain demonstrated alpha-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9600226",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 526,
					"offsetInEndSection": 651,
					"text": "DLB cases demonstrated these findings as well as alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9600226",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 652,
					"offsetInEndSection": 833,
					"text": "These results suggest that, even in sporadic cases, there is an early and direct role for alpha-synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9600226",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which is the genetic lesion associated with Huntingtonβ€™s disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/7620118"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/7620118"
			],
			"type": "factoid",
			"id": "5319a6e9b166e2b806000023",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 360,
					"text": "Early in 1993, an unstable, expanded trinucleotide repeat in a novel gene of unknown function was identified on HD chromosomes. This discovery unleased a flurry of experimentation that has established the expanded CAG repeat the almost universal cause of the characteristic neurologic symptoms and pathology of this neurodegenerative disorder of midlife onset.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7620118",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which multiple kinase inhibitors are used in cancer therapy?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/16159418"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/16159418"
			],
			"type": "list",
			"id": "5319a6c9b166e2b806000022",
			"snippets": [
				{
					"offsetInBeginSection": 660,
					"offsetInEndSection": 973,
					"text": "These inhibitors generally hinder the phosphorylation of several protein kinases of membrane receptors, such as vascular endothelial growth factor receptors, platelet-derived growth factor receptors, the human epidermal growth factor receptor family, and cytoplasmic receptors such as c-Kit, Raf kinase, and FLT3.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16159418",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 974,
					"offsetInEndSection": 1061,
					"text": "These inhibitors include ZD6474, SU11248, AEE 788, sorafenib, vatalanib, and AG-013736.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16159418",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which trinucleotide repeat disorders are affecting the nervous system?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/17417937",
				"http://www.ncbi.nlm.nih.gov/pubmed/7998766"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/17417937",
				"http://www.ncbi.nlm.nih.gov/pubmed/7998766"
			],
			"type": "list",
			"id": "5319a724b166e2b806000025",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 253,
					"text": "The discovery that expansion of unstable repeats can cause a variety of neurological disorders has changed the landscape of disease-oriented research for several forms of mental retardation, Huntington disease, inherited ataxias, and muscular dystrophy.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17417937",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 410,
					"text": "Expansion of trinucleotide repeats is now recognized as a major cause of neurological disease. At least seven disorders result from trinucleotide repeat expansion: X-linked spinal and bulbar muscular atrophy (SBMA), two fragile X syndromes of mental retardation (FRAXA and FRAXE), myotonic dystrophy, Huntington's disease, spinocerebellar ataxia type 1 (SCA1), and dentatorubral-pallidoluysian atrophy (DRPLA).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7998766",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 746,
					"offsetInEndSection": 1054,
					"text": "Fragile X and myotonic dystrophy are multisystem disorders usually associated with large expansions of untranslated repeats, while the four neurodegenerative disorders, SBMA, Huntington's disease, SCA1, and DRPLA, are caused by smaller expansions of CAG repeats within the protein coding portion of the gene.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7998766",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which is the target of bortezomib used in cancer therapy?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23822887",
				"http://www.ncbi.nlm.nih.gov/pubmed/23055533",
				"http://www.ncbi.nlm.nih.gov/pubmed/22204764",
				"http://www.ncbi.nlm.nih.gov/pubmed/22057347",
				"http://www.ncbi.nlm.nih.gov/pubmed/22819849",
				"http://www.ncbi.nlm.nih.gov/pubmed/22037302",
				"http://www.ncbi.nlm.nih.gov/pubmed/21862633",
				"http://www.ncbi.nlm.nih.gov/pubmed/21824109",
				"http://www.ncbi.nlm.nih.gov/pubmed/21242725",
				"http://www.ncbi.nlm.nih.gov/pubmed/19164757",
				"http://www.ncbi.nlm.nih.gov/pubmed/20616904",
				"http://www.ncbi.nlm.nih.gov/pubmed/19037995",
				"http://www.ncbi.nlm.nih.gov/pubmed/18491989",
				"http://www.ncbi.nlm.nih.gov/pubmed/18347166",
				"http://www.ncbi.nlm.nih.gov/pubmed/18205878",
				"http://www.ncbi.nlm.nih.gov/pubmed/17591945",
				"http://www.ncbi.nlm.nih.gov/pubmed/17504161",
				"http://www.ncbi.nlm.nih.gov/pubmed/17197231",
				"http://www.ncbi.nlm.nih.gov/pubmed/16258456",
				"http://www.ncbi.nlm.nih.gov/pubmed/16034054",
				"http://www.ncbi.nlm.nih.gov/pubmed/15846112",
				"http://www.ncbi.nlm.nih.gov/pubmed/15687646",
				"http://www.ncbi.nlm.nih.gov/pubmed/14695130",
				"http://www.ncbi.nlm.nih.gov/pubmed/14688465"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23822887",
				"http://www.ncbi.nlm.nih.gov/pubmed/23055533",
				"http://www.ncbi.nlm.nih.gov/pubmed/22204764",
				"http://www.ncbi.nlm.nih.gov/pubmed/22057347",
				"http://www.ncbi.nlm.nih.gov/pubmed/22819849",
				"http://www.ncbi.nlm.nih.gov/pubmed/22037302",
				"http://www.ncbi.nlm.nih.gov/pubmed/21862633",
				"http://www.ncbi.nlm.nih.gov/pubmed/21824109",
				"http://www.ncbi.nlm.nih.gov/pubmed/21242725",
				"http://www.ncbi.nlm.nih.gov/pubmed/19164757",
				"http://www.ncbi.nlm.nih.gov/pubmed/20616904",
				"http://www.ncbi.nlm.nih.gov/pubmed/19037995",
				"http://www.ncbi.nlm.nih.gov/pubmed/18491989",
				"http://www.ncbi.nlm.nih.gov/pubmed/18347166",
				"http://www.ncbi.nlm.nih.gov/pubmed/18205878",
				"http://www.ncbi.nlm.nih.gov/pubmed/17591945",
				"http://www.ncbi.nlm.nih.gov/pubmed/17504161",
				"http://www.ncbi.nlm.nih.gov/pubmed/17197231",
				"http://www.ncbi.nlm.nih.gov/pubmed/16258456",
				"http://www.ncbi.nlm.nih.gov/pubmed/16034054",
				"http://www.ncbi.nlm.nih.gov/pubmed/15846112",
				"http://www.ncbi.nlm.nih.gov/pubmed/15687646",
				"http://www.ncbi.nlm.nih.gov/pubmed/14695130",
				"http://www.ncbi.nlm.nih.gov/pubmed/14688465"
			],
			"type": "factoid",
			"id": "5319a708b166e2b806000024",
			"snippets": [
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 543,
					"text": "The ubiquitin-proteasome system (UPS) degrades 80 - 90% of intracellular proteins. Cancer cells take advantage of the UPS for their increased growth and decreased apoptotic cell death. Thus, the components that make up the UPS represent a diverse group of potential anti-cancer targets. The success of the first-in-class proteasome inhibitor bortezomib not only proved that the proteasome is a feasible and valuable anti-cancer target, but also inspired researchers to extensively explore other potential targets of this pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23822887",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 314,
					"text": "The ubiquitin-proteasome pathway has been identified as a potential molecular target for cancer therapy. In this study, we investigated the effect of the proteasome inhibitor bortezomib on anaplastic thyroid carcinoma (ATC) characterized by complete refractoriness to multimodal therapeutic approaches.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23055533",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 354,
					"text": "The ubiquitin-proteasome pathway regulates many basic cellular processes and has been proven to be a promising target for cancer therapy. Bortezomib is the first U.S. Food and Drug Administration (FDA) approved proteasome inhibitor used in the treatment of newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and mantle cell lymphoma.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22204764",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1618,
					"offsetInEndSection": 1785,
					"text": "This review summarizes the current status of bortezomib as well as several other proteasome inhibitors that are currently under clinical and preclinical investigation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22204764",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 301,
					"text": "Ubiquitin-tagged substrates are degraded by the 26S proteasome, which is a multisubunit complex comprising a proteolytic 20S core particle capped by 19S regulatory particles. The approval of bortezomib for the treatment of multiple myeloma validated the 20S core particle as an anticancer drug target.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22057347",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 172,
					"text": "The ubiquitin-proteasome system (UPS) is a conserved pathway regulating numerous biological processes including protein turnover, DNA repair, and intracellular trafficking.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22819849",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 299,
					"offsetInEndSection": 531,
					"text": "The development of bortezomib (Velcade(Β®)) as a treatment for multiple myeloma and mantle cell lymphoma has verified this and suggests that targeting other components of the UPS may be a viable strategy for the treatment for cancer.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22819849",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1560,
					"offsetInEndSection": 1668,
					"text": "The proteasome inhibitor bortezomib is now in the clinic to treat multiple myeloma and mantle cell lymphoma.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22037302",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 459,
					"offsetInEndSection": 727,
					"text": "In this study, we investigated the transcriptome-wide effects of the proteasome inhibitor bortezomib on estrogen-regulated transcription in MCF7 human breast cancer cells and showed that bortezomib caused a specific global decrease in estrogen-induced gene expression.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21862633",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 975,
					"offsetInEndSection": 1202,
					"text": "The clinical efficacy of the proteasome inhibitor bortezomib toward multiple myeloma and other hematologic malignancies provides the \"proof of concept\" that targeting the proteasome is a promising strategy for cancer treatment.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21824109",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 809,
					"offsetInEndSection": 1231,
					"text": "It has previously been suggested that the excess proteins not targeted to the proteasome, or that accumulate when the proteasome is inhibited through the use of chemically active agents such as bortezomib, are linked to impaired cell survival, and that their packaging in the form of an aggresome somehow minimizes their 'proteotoxicity' allowing these toxic proteins to be sequestered away from normal cellular machinery.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21242725",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 111,
					"offsetInEndSection": 214,
					"text": "The proteasome inhibitor bortezomib has clinical activity in multiple myeloma and mantle cell lymphoma.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19164757",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 234,
					"offsetInEndSection": 485,
					"text": "Bortezomib (PS-341) is a potent and specific reversible proteasome inhibitor, which has shown strong in vitro antitumor activity as single agent and in combination with other cytotoxic drugs in a broad spectrum of hematological and solid malignancies.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20616904",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 823,
					"offsetInEndSection": 1067,
					"text": "In addition to the development and clinical validation of proteasome inhibitor, bortezomib, in myeloma therapy, recent studies have demonstrated that it is possible to develop inhibitors for specific ubiquitination and deubiquitination enzymes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19037995",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 558,
					"offsetInEndSection": 931,
					"text": "Bortezomib as first-in-class proteasome inhibitor has proven to be highly effective in some hematological malignancies, overcomes conventional chemoresistance, directly induces cell cycle arrest and apoptosis, and also targets the tumor microenvironment. It has been granted approval by the FDA for relapsed multiple myeloma, and recently for relapsed mantle cell lymphoma.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18491989",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 632,
					"offsetInEndSection": 903,
					"text": "Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a standard of care.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18347166",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 701,
					"offsetInEndSection": 853,
					"text": "Cells were cultured, exposed to proteasome inhibitors (bortezomib, ALLN, MG-132 and epoxomicin) and then assayed for cell cycle and cell death analyses.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18205878",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 199,
					"text": "The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17591945",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 178,
					"offsetInEndSection": 437,
					"text": "Bortezomib is the first proteasome inhibitor to enter clinical use, and received approval by the Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma, therefore validating inhibition of the proteasome as an anticancer target.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17504161",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 399,
					"offsetInEndSection": 573,
					"text": "Bortezomib (Velcade, PS-341) was the first proteasome inhibitor to receive regulatory approval from the US Food and Drug Administration for the treatment of multiple myeloma.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17197231",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 841,
					"offsetInEndSection": 1213,
					"text": "Preclinical evidence using bortezomib, the only proteasome inhibitor to enter clinical trials, suggests that proteasome inhibition may be effective in the treatment of hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, and inhibiting tumor cell adhesion and production of growth factors by acting on molecules such as nuclear factor-kappaB.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16258456",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1380,
					"offsetInEndSection": 1584,
					"text": "Bortezomib was recently approved for the treatment of multiple myeloma. It is currently being investigated, both as a single agent and in combination, in phase I and II trials in a variety of tumor types.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16258456",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1065,
					"offsetInEndSection": 1221,
					"text": "Protein degradation pathways are also targets for cancer therapy, as shown by the successful introduction of bortezomib, an inhibitor of the 26S proteasome.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16034054",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1077,
					"offsetInEndSection": 1467,
					"text": "Bortezomib is the first proteasome inhibitor that has entered clinical trials. In multiple myeloma, both the US Food and Drug Administration and European Medicine Evaluation Agency granted approval for the use of bortezomib (Velcade) for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15846112",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 684,
					"offsetInEndSection": 835,
					"text": "The potent and selective proteasome inhibitor bortezomib (VELCADE; formerly known as PS-341) is particularly promising as a potential anticancer agent.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15687646",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 649,
					"offsetInEndSection": 1097,
					"text": "Inhibitors of the proteasome impact on cells in part through down-regulation of nuclear factor kappaB, but also through modulation of cell cycle proteins and other pro- and antiapoptotic pathways. Bortezomib (VELCADE; formerly PS-341), the first such inhibitor to undergo clinical testing, has demonstrated impressive antitumor activity and manageable toxicities in Phase I and II trials both as a single agent, and in combination with other drugs.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14695130",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1444,
					"offsetInEndSection": 1726,
					"text": "Although targeting E3 ubiquitin ligases is still in its infancy, speedy approval of the general proteasome inhibitor, Velcade (bortezomib) by the FDA for the treatment of relapsed and refractory multiple myeloma suggests the promise of specific E3 inhibitors in anti-cancer therapy.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14688465",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 662,
					"offsetInEndSection": 907,
					"text": "The first-in-class proteasome inhibitor, bortezomib (PS-341; VelcadeΒ®; Millennium Pharmaceuticals), a boronic acid dipeptide derivative, received approval in the United States (2003) and Europe (2004) for relapsed and refractory multiple myeloma",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20616904",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Is there any cross-talk between the Wnt and the Akt pathways?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23776620",
				"http://www.ncbi.nlm.nih.gov/pubmed/23646150",
				"http://www.ncbi.nlm.nih.gov/pubmed/22337886",
				"http://www.ncbi.nlm.nih.gov/pubmed/20888802",
				"http://www.ncbi.nlm.nih.gov/pubmed/20028853",
				"http://www.ncbi.nlm.nih.gov/pubmed/19887570",
				"http://www.ncbi.nlm.nih.gov/pubmed/19850932",
				"http://www.ncbi.nlm.nih.gov/pubmed/19158508",
				"http://www.ncbi.nlm.nih.gov/pubmed/18687666",
				"http://www.ncbi.nlm.nih.gov/pubmed/17896924",
				"http://www.ncbi.nlm.nih.gov/pubmed/16940750",
				"http://www.ncbi.nlm.nih.gov/pubmed/15655376",
				"http://www.ncbi.nlm.nih.gov/pubmed/15537647",
				"http://www.ncbi.nlm.nih.gov/pubmed/11782444",
				"http://www.ncbi.nlm.nih.gov/pubmed/23657601"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23776620",
				"http://www.ncbi.nlm.nih.gov/pubmed/23646150",
				"http://www.ncbi.nlm.nih.gov/pubmed/22337886",
				"http://www.ncbi.nlm.nih.gov/pubmed/20888802",
				"http://www.ncbi.nlm.nih.gov/pubmed/20028853",
				"http://www.ncbi.nlm.nih.gov/pubmed/19887570",
				"http://www.ncbi.nlm.nih.gov/pubmed/19850932",
				"http://www.ncbi.nlm.nih.gov/pubmed/19158508",
				"http://www.ncbi.nlm.nih.gov/pubmed/18687666",
				"http://www.ncbi.nlm.nih.gov/pubmed/17896924",
				"http://www.ncbi.nlm.nih.gov/pubmed/16940750",
				"http://www.ncbi.nlm.nih.gov/pubmed/15655376",
				"http://www.ncbi.nlm.nih.gov/pubmed/15537647",
				"http://www.ncbi.nlm.nih.gov/pubmed/11782444",
				"http://www.ncbi.nlm.nih.gov/pubmed/23657601"
			],
			"type": "yesno",
			"id": "5319a7b2b166e2b806000028",
			"snippets": [
				{
					"offsetInBeginSection": 1593,
					"offsetInEndSection": 1926,
					"text": "Our data demonstrate that engaging Wnt signaling at the receptor level by this method leads to necessary crosstalk between multiple signaling pathways including activation of Akt, mTOR, Wnt/Ξ²-catenin, PKA/CREB, and inhibition of RhoA/ROCK that substantially increase human Ξ²-cell proliferation while maintaining the Ξ²-cell phenotype.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23776620",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1665,
					"offsetInEndSection": 1862,
					"text": "The cross-talk role of Wnt/Ξ²-catenin and PI3K/Akt signaling pathway, with GSK-3Ξ² as the key enzyme bridging these pathways, may contribute to the inhibition of cholangiocarcinoma cells by hUC-MSCs.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23646150",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 365,
					"offsetInEndSection": 577,
					"text": "We find that Wnt stimulation leads to phosphorylation of insulin signaling key mediators, including Akt, GSK3Ξ², and ERK1/2, although with a lower fold stimulation and slower time course than observed for insulin.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22337886",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1129,
					"offsetInEndSection": 1233,
					"text": "Wnt induces phosphorylation of Akt, ERK1/2, and GSK3Ξ², and this is dependent on insulin/IGF-1 receptors.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22337886",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 475,
					"offsetInEndSection": 622,
					"text": "Pharmacologic inhibition of PI3K resulted in the downregulation of several members of the Ξ²-catenin pathway, including Fra-1, c-Myc, and cyclin D1.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20888802",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 777,
					"offsetInEndSection": 1004,
					"text": "Similar results were observed in vivo, as intratumoral injection of LY294002 downregulated the expression of the components of the Ξ²-catenin pathway and delayed tumor growth in nude mice harboring subcutaneous LN229 xenografts.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20888802",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1005,
					"offsetInEndSection": 1152,
					"text": "These results suggest that the PI3K/AKT signaling pathway regulates glioma cell proliferation, in part via repression of the Wnt/Ξ²-catenin pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20888802",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 152,
					"text": "Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20028853",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 585,
					"offsetInEndSection": 850,
					"text": "Small-molecule inhibitors targeting the PI3K/Akt signaling pathway affected beta-catenin signaling by activation [corrected] of GSK-3beta, [corrected] resulting in cytoplasmic retention of beta-catenin and reduced expression of its target genes cyclin D1 and c-Myc.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20028853",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1246,
					"offsetInEndSection": 1468,
					"text": "These findings demonstrate the importance of cross-talk between the PI3K/Akt and beta-catenin pathways in medulloblastoma and rationalize the PI3K/Akt signaling pathway as a therapeutic target in treatment of this disease.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20028853",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 628,
					"offsetInEndSection": 853,
					"text": "Western blot analyses revealed that the recombinant Wnt ligand Wnt-3A increased phosphorylation of AKT and the downstream kinase glycogen synthase kinase (GSK)-3beta as well as accumulation of activated, nuclear beta-catenin.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19887570",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1024,
					"offsetInEndSection": 1223,
					"text": "Chemical inhibition of PI3K abolished Wnt-dependent phosphorylation of AKT and GSK-3beta and trophoblast motility but did not affect appearance of activated beta-catenin or Wnt/TCF reporter activity.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19887570",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1574,
					"offsetInEndSection": 1680,
					"text": "The data suggest that Wnt-3A may activate canonical Wnt signaling and PI3K/AKT through distinct receptors.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19887570",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 381,
					"text": "Mutational activation of the phosphatidylinositol 3-kinase (PI3K) pathway occurs in a wide variety of tumors, whereas activating Wnt pathway mutants are predominantly found in colon cancer. Because GSK3 is a key component of both pathways, it is widely assumed that active PI3K signaling feeds positively into the Wnt pathway by protein kinase B (PKB)-mediatefd inhibition of GSK3.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19850932",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 383,
					"offsetInEndSection": 527,
					"text": "n addition, PKB has been proposed to modulate the canonical Wnt signaling through direct stabilization and nuclear localization of beta-catenin.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19850932",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 528,
					"offsetInEndSection": 741,
					"text": "Here, we show that compartmentalization by Axin of GSK3 prohibits cross-talk between the PI3K and Wnt pathways and that Wnt-mediated transcriptional activity is not modulated by activation of the PI3K/PKB pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19850932",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 373,
					"offsetInEndSection": 605,
					"text": "Our recent study revealed a second mechanism for Cby-mediated beta-catenin inhibition in which Cby cooperates with 14-3-3 adaptor proteins to facilitate nuclear export of beta-catenin, following phosphorylation of Cby by Akt kinase.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19158508",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 606,
					"offsetInEndSection": 824,
					"text": "Therefore, our findings unravel a novel molecular mechanism regulating the dynamic nucleo-cytoplasmic trafficking of beta-catenin and provide new insights into the cross-talk between the Wnt and Akt signaling pathways.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19158508",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 825,
					"offsetInEndSection": 971,
					"text": "Here, we review recent literature concerning Cby function and discuss our current understanding of the relationship between Wnt and Akt signaling.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19158508",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1134,
					"offsetInEndSection": 1355,
					"text": "As inappropriate activation of WNT/CTNNB1 signaling causes late-onset GCT development and cross talk between the PI3K/AKT and WNT/CTNNB1 pathways has been reported, we tested whether these pathways could synergize in GCT.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18687666",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 907,
					"offsetInEndSection": 1354,
					"text": "This explains why prostate tumors subjected to androgen ablation experience an increase in Akt phosphorylation, and suggest that the tumor compensates for the loss of one pathway with another. Different modes of interaction between the two pathways, including direct interaction, or regulation via downstream intermediates, such as the wnt/GSK-3beta/beta-catenin pathway, NF-kappaB, and the FOXO family of transcription factors, will be discussed.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17896924",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 459,
					"offsetInEndSection": 870,
					"text": "FGF signals are transduced through FGF receptor to the FRS2-GRB2-GAB1-PI3K-AKT signaling cascade to downregulate GSK3beta activity depending on Ser 9 phosphorylation. Because GSK3beta-dependent phosphorylation of beta-catenin and SNAIL leads to FBXW1 (betaTRCP)-mediated ubiquitination and degradation, GSK3beta downregulation results in the stabilization and the nuclear accumulation of beta-catenin and SNAIL.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16940750",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 66,
					"text": "Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15655376",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 633,
					"offsetInEndSection": 858,
					"text": "Concurrently, PTEN, an inhibitor of PI3K/Akt pathway, is also primarily inactivated in the ISCs, leading to activation of Akt. Thus, Akt may contribute to activation of beta-catenin in ISCs in coordination with Wnt signaling.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15655376",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1091,
					"offsetInEndSection": 1346,
					"text": "Thus, we propose that BMP signaling plays a role in inhibition of ISC self-renewal through suppression of Wnt/beta-catenin signaling in ISC, and this cross-talk is bridged, at least in part, through the PTEN/Akt pathway and further enforced by 14-3-3zeta.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15655376",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 101,
					"offsetInEndSection": 324,
					"text": "In MC3T3-E1 osteoblast-like cultures, dexamethasone (DEX) activates glycogen synthase kinase-3beta (GSK3beta) and inhibits a differentiation-related cell cycle that occurs at a commitment stage immediately after confluence.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15537647",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 325,
					"offsetInEndSection": 502,
					"text": "Here we show that DEX inhibition of the differentiation-related cell cycle is associated with a decrease in beta-catenin levels and inhibition of LEF/TCF-mediated transcription.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15537647",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 503,
					"offsetInEndSection": 603,
					"text": "These inhibitory activities are no longer observed in the presence of lithium, a GSK3beta inhibitor.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15537647",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 604,
					"offsetInEndSection": 885,
					"text": "DEX decreased the serum-responsive phosphorylation of protein kinase B/Akt-Ser(473) within minutes, and this inhibition was also observed after 12 h. When the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was inhibited by wortmannin, DEX no longer inhibited beta-catenin levels.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15537647",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 886,
					"offsetInEndSection": 1138,
					"text": "Furthermore, DEX-mediated inhibition of LEF/TCF transcriptional activity was attenuated in the presence of dominant negative forms of either PI3K or protein kinase B/Akt. These results suggest cross-talk between the PI3K/Akt and Wnt signaling pathways.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15537647",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1805,
					"offsetInEndSection": 2034,
					"text": "These results suggest that inhibition of a PI3K/Akt/GSK3beta/beta-catenin/LEF axis and stimulation of HDAC1 cooperate to mediate the inhibitory effect of DEX on Wnt signaling and the osteoblast differentiation-related cell cycle.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15537647",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 114,
					"text": "WISP-1 (Wnt-1-induced secreted protein) was identified as an oncogene regulated by the Wnt-1-beta-catenin pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11782444",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 391,
					"offsetInEndSection": 478,
					"text": "Here it is shown that WISP-1 can activate the antiapoptotic Akt/PKB signaling pathway. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11782444",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 995,
					"offsetInEndSection": 1122,
					"text": "Our results show that both TGFΞ²1 and Wnt3a lead to increased accumulation of Ξ²-catenin, phosphorylation of AKT and p44/42 MAPK.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23657601",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 7198,
					"offsetInEndSection": 7508,
					"text": "This novel strategy engages both canonical and non-canonical Wnt signaling, and in combination with RhoA/ROCK inhibition removes insulin signaling pathway resistance and allows necessary crosstalk between Wnt/GSK-3/Ξ²-catenin, Akt/mTOR, and PKA/CREB pathways associated with human Ξ²-cell regenerative processes.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23776620",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 14122,
					"offsetInEndSection": 14394,
					"text": "activation of Wnt signaling at the level of GSK-3 inhibition by LiCl had no effect on enhancing Akt phosphorylation (lanes 1 vs 2), whereas engaging Wnt signaling at the receptor level with L-WRN or L-WRN+ resulted in significant increases in Akt phosphorylation at Ser473",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23776620",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 14923,
					"offsetInEndSection": 15071,
					"text": "these results suggest that L-WRN+ promotes crosstalk between PKA, Wnt/Ξ²-catenin and Akt signaling in human islets to enhance proliferative processes",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23776620",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 15113,
					"offsetInEndSection": 15197,
					"text": "L-WRN+ promotes crosstalk between Wnt and PKA/CREB and Akt signaling in human islets",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23776620",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 4889,
					"offsetInEndSection": 5036,
					"text": "Non-canonical Wnt pathway activation increases RhoA/ROCK signaling that results in degradation of IRS1/2 and negatively affects Akt phosphorylation",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23776620",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 14008,
					"offsetInEndSection": 14131,
					"text": "It has been shown that activated Akt can effectively suppress the role of GSK-3Ξ² in regulating the degradation of Ξ²-catenin",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23646150",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 2418,
					"offsetInEndSection": 2596,
					"text": "GSK-3Ξ² is a key molecule in the PI3K/Akt signaling pathway, and activated Akt has been shown to effectively suppress the role of GSK-3Ξ² in regulating the degradation of Ξ²-catenin",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23646150",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 2887,
					"offsetInEndSection": 3095,
					"text": "It has been shown that in response to certain growth stimuli, PI3K-activated AKT can phosphorylate GSK-3Ξ² at Ser9, leading to inactivation of GSK-3Ξ² and augmentation of Ξ²-catenin-TCF4 transcriptional activity",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23646150",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 3181,
					"offsetInEndSection": 3876,
					"text": "We found that conditioned media from hUC-MSCs can affect PI3K/Akt signal transduction through inhibition of PDK1 phosphorylation and inhibit Akt activity resulting in activation of GSK-3Ξ². This may lead to inhibition of nuclear Ξ²-catenin translocation, which down-regulates the expression of target genes c-Myc and cyclin D1, and induces the apoptosis of HCCC-9810 cells.\nInhibition of nuclear Ξ²-catenin translocation is likely to be due to the observed inhibition of Akt activity by hUC-MSC conditioned media. This, in turn, could have triggered activation of GSK-3Ξ² function because activated Akt has been shown to effectively suppress GSK-3Ξ² levels which regulate the degradation of Ξ²-catenin",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23646150",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 4596,
					"offsetInEndSection": 5305,
					"text": "Based on our findings, we propose a schematic model of how the hUC-MSC cultures could have affected various molecular events by the cross-talk between the PI3K/Akt and the Wnt/Ξ²-catenin signaling pathways, leading to apoptosis in human HCCC-9810 cells (Fig. 8). In this scheme, inhibitory molecules in hUC-MSC conditioned media mediate Akt phosphorylation in HCCC-9810 cells, thereby decreasing phosphorylation of GSK-3Ξ² and increasing its activity. Activation of GSK-3Ξ²leads to increased degradation of Ξ²-catenin, and decreased cellular Ξ²-catenin levels. A reduction in Ξ²-catenin translocation to the nucleus to bind TCF4, leads to decreased transcription of its specific target genes resulting in apoptosis.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23646150",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 5347,
					"offsetInEndSection": 5844,
					"text": "Proposed model by which hUC-MSC cultures mediates cross-talk between Wnt and Akt signaling in HCCC-9810 cells.Inhibitory molecules in hUC-MSC conditioned media mediate Akt phosphorylation in HCCC-9810 cells, thereby decreasing phosphorylation of GSK-3Ξ²and increasing its activity. Activation of GSK-3Ξ²leads to decreased cellularΞ²-catenin levels. A decrease in Ξ²-catenin translocation to the nucleus to bind TCF4, and decreases the transcription of its specific target genes resulting in apoptosis.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23646150",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 5996,
					"offsetInEndSection": 6176,
					"text": "The molecular cross-talk between the PI3K/Akt and the Wnt/Ξ²-catenin signaling pathways is involved in this inhibitory effect, with GSK-3Ξ² as the key enzyme bridging these pathways.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23646150",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "Are DNA helicases involved in progeroid syndromes?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/17131053",
				"http://www.ncbi.nlm.nih.gov/pubmed/16987878",
				"http://www.ncbi.nlm.nih.gov/pubmed/15743670",
				"http://www.ncbi.nlm.nih.gov/pubmed/15734684",
				"http://www.ncbi.nlm.nih.gov/pubmed/10984715"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/17131053",
				"http://www.ncbi.nlm.nih.gov/pubmed/16987878",
				"http://www.ncbi.nlm.nih.gov/pubmed/15743670",
				"http://www.ncbi.nlm.nih.gov/pubmed/15734684",
				"http://www.ncbi.nlm.nih.gov/pubmed/10984715"
			],
			"type": "yesno",
			"id": "5319a752b166e2b806000027",
			"snippets": [
				{
					"offsetInBeginSection": 349,
					"offsetInEndSection": 510,
					"text": "Among these syndromes, relevant advances have recently been made in Werner syndrome, one of several progeroid syndromes characterized by defective DNA helicases,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17131053",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 139,
					"text": "Progeroid syndromes (PSs) constitute a group of disorders characterized by clinical features mimicking physiological aging at an early age.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16987878",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 560,
					"offsetInEndSection": 928,
					"text": "However, all the characterized PSs enter in the field of rare monogenic disorders and several causative genes have been identified. These can be separated in subcategories corresponding to (i) genes encoding DNA repair factors, in particular, DNA helicases, and (ii) genes affecting the structure or post-translational maturation of lamin A, a major nuclear component.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16987878",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 239,
					"offsetInEndSection": 710,
					"text": "None of the known progerias represents true precocious ageing. Some of them, including Werner (WS), Bloom (BS), and Rothmund-Thomson syndromes (RTS) as well as combined xeroderma pigmentosa-Cockayne syndrome (XP-CS) are characterised by features resembling precocious ageing and the increased risk of malignant disease. Such phenotypes result from the mutations of the genes encoding proteins involved in the maintenance of genomic integrity, in most cases DNA helicases.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15743670",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 110,
					"text": "Single-gene mutations can produce human progeroid syndromes--phenotypes that mimic usual or \"normative\" aging.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15734684",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 347,
					"offsetInEndSection": 476,
					"text": "The prototypic example of the former is the Werner syndrome, a condition caused by mutations of the RecQ family of DNA helicases.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15734684",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 294,
					"text": "Progeria and progeroid syndromes are characterized by the earlier onset of complex senescent phenotypes. WRN was originally identified as a gene responsible for Werner syndrome (WS; \"Progeria of Adults\"). The WRN gene product has RecQ-type helicase domains in the central region of the protein.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10984715",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the result of the interaction between TSC1 and PLK1?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/16339216"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/16339216"
			],
			"type": "summary",
			"id": "5319a7f2b166e2b80600002a",
			"snippets": [
				{
					"offsetInBeginSection": 663,
					"offsetInEndSection": 775,
					"text": "Phosphorylated hamartin interacts with Plk1 independent of tuberin with all three proteins present in a complex.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16339216",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1089,
					"offsetInEndSection": 1146,
					"text": "Hamartin negatively regulates the protein levels of Plk1.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16339216",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1147,
					"offsetInEndSection": 1293,
					"text": "Finally, Tsc1(-/-) mouse embryonic fibroblasts (MEFs) have increased number of centrosomes and increased DNA content, compared to Tsc1(+/+) cells.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16339216",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1294,
					"offsetInEndSection": 1684,
					"text": "Both phenotypes are rescued after pre-treatment with the mTOR inhibitor rapamycin. RNAi inhibition of Plk1 in Tsc1(-/-) MEFs failed to rescue the increased centrosome number phenotype. These data reveal a novel subcellular localization for hamartin and a novel interaction partner for the hamartin/tuberin complex and implicate hamartin and mTOR in the regulation of centrosome duplication.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16339216",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which is the E3 ubiquitin ligase of Hsp90?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23429937",
				"http://www.ncbi.nlm.nih.gov/pubmed/23344957",
				"http://www.ncbi.nlm.nih.gov/pubmed/20618441",
				"http://www.ncbi.nlm.nih.gov/pubmed/17209571"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23429937",
				"http://www.ncbi.nlm.nih.gov/pubmed/23344957",
				"http://www.ncbi.nlm.nih.gov/pubmed/20618441",
				"http://www.ncbi.nlm.nih.gov/pubmed/17209571"
			],
			"type": "factoid",
			"id": "5319a7d2b166e2b806000029",
			"snippets": [
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 232,
					"text": "C-terminal Hsp-interacting protein (CHIP) is an HSP70 and HSP90 interacting co-chaperone and an E3 ubiquitin ligase. Previous studies have reported the role of CHIP in cancer progression by targeting protein degradation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23429937",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 209,
					"text": "The U-box E3 ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein) binds Hsp90 and/or Hsp70 via its tetratricopeptide repeat (TPR), facilitating ubiquitination of the chaperone-bound client proteins.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23344957",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 882,
					"offsetInEndSection": 1055,
					"text": "In vitro ubiquitination assays indicated that Ca(2+)/S100A2 and S100P are efficient and specific inhibitors of CHIP-mediated ubiquitination of Hsp70, Hsp90, HSF1, and Smad1.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23344957",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 247,
					"text": "The E3 ubiquitin ligase CHIP (C-terminus of Hsc70-interacting protein) is believed to be a central player in the cellular triage decision, as it links the molecular chaperones Hsp70/Hsc70 and Hsp90 to the ubiquitin proteasomal degradation pathway.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20618441",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 596,
					"offsetInEndSection": 675,
					"text": "We found that CHIP has a sixfold higher affinity for Hsp90 compared with Hsc70.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20618441",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 208,
					"text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90) in vitro",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17209571",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 619,
					"offsetInEndSection": 864,
					"text": "The analysis of the sucrose-gradient-fractionated in vitro translated AhR complexes revealed that CHIP can mediate hsp90 ubiquitination while cooperating with unidentified factors to promote the ubiquitination of mature unliganded AhR complexes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17209571",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the use of emulsion PCR in Next Generation Sequencing?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23900195",
				"http://www.ncbi.nlm.nih.gov/pubmed/23744319",
				"http://www.ncbi.nlm.nih.gov/pubmed/23665194",
				"http://www.ncbi.nlm.nih.gov/pubmed/23546785",
				"http://www.ncbi.nlm.nih.gov/pubmed/23398507",
				"http://www.ncbi.nlm.nih.gov/pubmed/23148498",
				"http://www.ncbi.nlm.nih.gov/pubmed/22668416",
				"http://www.ncbi.nlm.nih.gov/pubmed/22355625",
				"http://www.ncbi.nlm.nih.gov/pubmed/21543404",
				"http://www.ncbi.nlm.nih.gov/pubmed/21513157"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23900195",
				"http://www.ncbi.nlm.nih.gov/pubmed/23744319",
				"http://www.ncbi.nlm.nih.gov/pubmed/23665194",
				"http://www.ncbi.nlm.nih.gov/pubmed/23546785",
				"http://www.ncbi.nlm.nih.gov/pubmed/23398507",
				"http://www.ncbi.nlm.nih.gov/pubmed/23148498",
				"http://www.ncbi.nlm.nih.gov/pubmed/22668416",
				"http://www.ncbi.nlm.nih.gov/pubmed/22355625",
				"http://www.ncbi.nlm.nih.gov/pubmed/21543404",
				"http://www.ncbi.nlm.nih.gov/pubmed/21513157"
			],
			"type": "summary",
			"id": "5319a83bb166e2b80600002c",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 130,
					"text": "Emulsion PCR-coupled target enrichment: an effective fishing method for high-throughput sequencing of poorly preserved ancient DNA",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23900195",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 325,
					"offsetInEndSection": 680,
					"text": "We present a unified strategy in which emulsion PCR is coupled with target enrichment followed by next-generation sequencing. The method made it possible to obtain efficiently non-duplicated reads mapped to target sequences of interest, and this can achieve deep and reliable sequencing of ancient DNA from typical materials, even though poorly preserved.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23900195",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 492,
					"offsetInEndSection": 900,
					"text": "Three multiplex PCR reactions were carried out to amplify the coding exons of 328 genes including FBN1, TGFBR1 and TGFBR2. DNA fragments from different samples were ligated with barcoded sequencing adaptors. Template preparation and emulsion PCR, and Ion Sphere Particles enrichment were carried out using an Ion One Touch system. The ion sphere particles were sequenced on a 318 chip using the PGM platform.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23744319",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 802,
					"offsetInEndSection": 1156,
					"text": "In our NGS approach, the 16,569-bp mtDNA is enriched by long-range PCR and the 108 nuclear genes (which represent 1301 amplicons and 680 kb) are enriched by RainDance emulsion PCR. Sequencing is performed on Illumina HiSeq 2000 or MiSeq platforms, and bioinformatics analysis is performed using commercial and in-house developed bioinformatics pipelines.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23665194",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 461,
					"offsetInEndSection": 684,
					"text": "However, pyrosequencing of emulsion PCR reactions, amplifying from only one molecule at a time, can generate megabases of clonally amplified loci at high coverage, thereby greatly simplifying allelic sequence determination.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23546785",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 861,
					"offsetInEndSection": 1319,
					"text": "During genomic PCR, in this 4-primer system, the outer set of primers containing the MID and the 454 adaptor sequences are incorporated into an amplicon generated by the inner HLA target-specific primers each containing a common sequence tag at the 5' end of the forward and reverse primers. Pools of the resulting amplicons are used for emulsion PCR and clonal sequencing on the 454 Life Sciences GS FLX System, followed by genotyping with Conexio software.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23398507",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 428,
					"offsetInEndSection": 724,
					"text": "The purpose of our study was to compare NGS enrichment methods for a clinical assay targeting the nine genes known to be associated with aortopathy. RainDance emulsion PCR and SureSelect RNA-bait hybridization capture enrichment methods were directly compared by enriching DNA from eight samples.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23148498",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 872,
					"offsetInEndSection": 1073,
					"text": "We show the efficacy by comparing the method to a commercial kit and further demonstrate that emulsion PCR can be used for bias free amplification and virtual immortalization of DNA template libraries.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22668416",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 281,
					"offsetInEndSection": 403,
					"text": "Here, we describe a novel approach for normalization of multiplex next generation sequencing libraries after emulsion PCR.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22355625",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 404,
					"offsetInEndSection": 607,
					"text": "Briefly, amplified libraries carrying unique barcodes are prepared by fluorescent tagging of complementary sequences and then resolved by high-speed flow cytometric sorting of labeled emulsion PCR beads.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22355625",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 608,
					"offsetInEndSection": 959,
					"text": "The protocol is simple and provides an even sequence distribution of multiplex libraries when sequencing the flow-sorted beads. Moreover, since many empty and mixed emulsion PCR beads are removed, the approach gives rise to a substantial increase in sequence quality and mean read length, as compared to that obtained by standard enrichment protocols.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22355625",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 156,
					"offsetInEndSection": 307,
					"text": "Based on the mechanism of emulsion PCR, a unique DNA template would only generate a unique sequence read after being amplified and sequenced on GS FLX.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21543404",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 763,
					"offsetInEndSection": 1015,
					"text": "Prior to SOLiD sequencing reaction, the libraries were amplified with emulsion PCR and enriched with the P2 enrichment beads. The library samples were loaded to sequencing Chip for Work Flow Analysis (WFA) or sequencing running with default parameters.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21513157",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2486,
					"offsetInEndSection": 3017,
					"text": "Genomic DNA (1.5-3 ΞΌg) was sheared to 2β€“4 kb fragments using a Covaris S2 instrument (Covaris, Woburn, MA) and added to a mixture that included all the components of the PCR reaction excluding the primers. This mixture and the primer library were loaded separately onto the RDT1000 instrument, and PCR droplets containing one primer pair per droplet were generated. After amplification, emulsion PCR droplets were broken releasing the amplicons which were then purified and concatenated according to the manufacturerβ€™s instructions",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23148498",
					"endSection": "sections.1"
				}
			]
		},
		{
			"body": "What is the characteristic domain of histone methyltransferases?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23652029",
				"http://www.ncbi.nlm.nih.gov/pubmed/23453808",
				"http://www.ncbi.nlm.nih.gov/pubmed/21564555",
				"http://www.ncbi.nlm.nih.gov/pubmed/21196496",
				"http://www.ncbi.nlm.nih.gov/pubmed/21124902",
				"http://www.ncbi.nlm.nih.gov/pubmed/20599755",
				"http://www.ncbi.nlm.nih.gov/pubmed/20084102",
				"http://www.ncbi.nlm.nih.gov/pubmed/19187761",
				"http://www.ncbi.nlm.nih.gov/pubmed/18693240",
				"http://www.ncbi.nlm.nih.gov/pubmed/17517655",
				"http://www.ncbi.nlm.nih.gov/pubmed/17355966",
				"http://www.ncbi.nlm.nih.gov/pubmed/17338551",
				"http://www.ncbi.nlm.nih.gov/pubmed/17259630",
				"http://www.ncbi.nlm.nih.gov/pubmed/16519522",
				"http://www.ncbi.nlm.nih.gov/pubmed/16292313",
				"http://www.ncbi.nlm.nih.gov/pubmed/16055700",
				"http://www.ncbi.nlm.nih.gov/pubmed/15939934",
				"http://www.ncbi.nlm.nih.gov/pubmed/15933069",
				"http://www.ncbi.nlm.nih.gov/pubmed/15659850",
				"http://www.ncbi.nlm.nih.gov/pubmed/14633678",
				"http://www.ncbi.nlm.nih.gov/pubmed/14522075",
				"http://www.ncbi.nlm.nih.gov/pubmed/12887887",
				"http://www.ncbi.nlm.nih.gov/pubmed/12628190",
				"http://www.ncbi.nlm.nih.gov/pubmed/12514135",
				"http://www.ncbi.nlm.nih.gov/pubmed/12398767",
				"http://www.ncbi.nlm.nih.gov/pubmed/12389038",
				"http://www.ncbi.nlm.nih.gov/pubmed/12372304",
				"http://www.ncbi.nlm.nih.gov/pubmed/10949293"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23652029",
				"http://www.ncbi.nlm.nih.gov/pubmed/23453808",
				"http://www.ncbi.nlm.nih.gov/pubmed/21564555",
				"http://www.ncbi.nlm.nih.gov/pubmed/21196496",
				"http://www.ncbi.nlm.nih.gov/pubmed/21124902",
				"http://www.ncbi.nlm.nih.gov/pubmed/20599755",
				"http://www.ncbi.nlm.nih.gov/pubmed/20084102",
				"http://www.ncbi.nlm.nih.gov/pubmed/19187761",
				"http://www.ncbi.nlm.nih.gov/pubmed/18693240",
				"http://www.ncbi.nlm.nih.gov/pubmed/17517655",
				"http://www.ncbi.nlm.nih.gov/pubmed/17355966",
				"http://www.ncbi.nlm.nih.gov/pubmed/17338551",
				"http://www.ncbi.nlm.nih.gov/pubmed/17259630",
				"http://www.ncbi.nlm.nih.gov/pubmed/16519522",
				"http://www.ncbi.nlm.nih.gov/pubmed/16292313",
				"http://www.ncbi.nlm.nih.gov/pubmed/16055700",
				"http://www.ncbi.nlm.nih.gov/pubmed/15939934",
				"http://www.ncbi.nlm.nih.gov/pubmed/15933069",
				"http://www.ncbi.nlm.nih.gov/pubmed/15659850",
				"http://www.ncbi.nlm.nih.gov/pubmed/14633678",
				"http://www.ncbi.nlm.nih.gov/pubmed/14522075",
				"http://www.ncbi.nlm.nih.gov/pubmed/12887887",
				"http://www.ncbi.nlm.nih.gov/pubmed/12628190",
				"http://www.ncbi.nlm.nih.gov/pubmed/12514135",
				"http://www.ncbi.nlm.nih.gov/pubmed/12398767",
				"http://www.ncbi.nlm.nih.gov/pubmed/12389038",
				"http://www.ncbi.nlm.nih.gov/pubmed/12372304",
				"http://www.ncbi.nlm.nih.gov/pubmed/10949293"
			],
			"type": "factoid",
			"id": "532dcfc9d6d3ac6a34000021",
			"snippets": [
				{
					"offsetInBeginSection": 123,
					"offsetInEndSection": 185,
					"text": "C-terminal SET domain that catalyzes methylation of histone H3",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23652029",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 809,
					"offsetInEndSection": 883,
					"text": "not all members of the H3K4 methyltransferase family contain n-SET domains",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23453808",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 77,
					"offsetInEndSection": 377,
					"text": "protein methyltransferases (both protein arginine and lysine methyltransferases) and the relatedness of their catalytic domains. We identified 51 protein lysine methyltransferase proteins based on similarity to the canonical Drosophila Su(var)3-9, enhancer of zeste (E(z)), and trithorax (trx) domain",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21564555",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 41,
					"offsetInEndSection": 81,
					"text": " a SET domain histone methyltransferase ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21196496",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 173,
					"offsetInEndSection": 338,
					"text": "A common feature of the mammalian MLL/SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET domain",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21124902",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 262,
					"offsetInEndSection": 308,
					"text": "catalytic histone methyltransferase SET-domain",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20599755",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 103,
					"text": "SET domain methyltransferases deposit methyl marks on specific histone tail lysine residues",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20084102",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 134,
					"offsetInEndSection": 261,
					"text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19187761",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 71,
					"offsetInEndSection": 336,
					"text": "Polycomb repressive complex 2 (PRC2), which methylates lysine 27 of histone H3. Information on how PRC2 works is limited by lack of structural data on the catalytic subunit, Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18693240",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 198,
					"offsetInEndSection": 314,
					"text": "histone modification is catalyzed by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17517655",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 37,
					"offsetInEndSection": 129,
					"text": "Set1A complex analogous to the yeast Set1/COMPASS histone H3-Lys4 methyltransferase complex ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17355966",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 242,
					"offsetInEndSection": 318,
					"text": "Set1A protein shares 39% identity with an uncharacterized SET domain protein",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17355966",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 45,
					"offsetInEndSection": 117,
					"text": "multiple methylations catalyzed by SET domain protein methyltransferases",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17338551",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1190,
					"offsetInEndSection": 1261,
					"text": "methyl group transfers by SET domain protein lysine methyltransferases.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17338551",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 70,
					"text": "SET domain protein functions as a histone methyltransferase",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17259630",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1780,
					"offsetInEndSection": 1867,
					"text": "SUV39H1 impaired enzyme activity despite the presence of an intact catalytic SET domain",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16519522",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 105,
					"offsetInEndSection": 217,
					"text": "Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16292313",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 273,
					"offsetInEndSection": 327,
					"text": "The fly complex contains a catalytic SET domain subuni",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16055700",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 122,
					"text": "ESC-E(Z) complex of Drosophila melanogaster Polycomb group (PcG) repressors is a histone H3 methyltransferase (HMTase)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16055700",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 183,
					"offsetInEndSection": 295,
					"text": "Murine G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain and ANK repeats",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15939934",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 531,
					"offsetInEndSection": 665,
					"text": "domains of SET proteins becoming ordered upon addition of AdoMet cofactor and develop a model for the catalytic cycle of these enzymes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15933069",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 200,
					"text": "SET domain, first identified within and named after proteins encoded by three Drosophila genes [Su(var)3-9, E(z), and Trithorax], is recognized as a signature motif for histone methyltransferases ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15659850",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 160,
					"text": "(HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14633678",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 6,
					"offsetInEndSection": 162,
					"text": "ERG-associated protein with a SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (H3-K9)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14522075",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 100,
					"offsetInEndSection": 136,
					"text": "SET domain histone methyltransferase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12887887",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 121,
					"offsetInEndSection": 198,
					"text": " Unlike other histone methyltransferases, Dot1 does not contain a SET domain,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12628190",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 937,
					"offsetInEndSection": 966,
					"text": "SET domain-containing HMTase ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12514135",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 175,
					"offsetInEndSection": 331,
					"text": "SET (suppressor of variegation, enhancer of zest and trithorax) domain (ESET) that was found to have the activity of a histone H3-specific methyltransferase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12398767",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 150,
					"text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and regulate chromatin function",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12389038",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 166,
					"offsetInEndSection": 289,
					"text": " The evolutionarily conserved SET domain occurs in most proteins known to possess histone lysine methyltransferase activity",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12372304",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 615,
					"offsetInEndSection": 746,
					"text": "the evolutionarily conserved SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10949293",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Is poly (ADP- ribosylation) involved in transcriptional control?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18851700",
				"http://www.ncbi.nlm.nih.gov/pubmed/18396434",
				"http://www.ncbi.nlm.nih.gov/pubmed/17286852",
				"http://www.ncbi.nlm.nih.gov/pubmed/17158748",
				"http://www.ncbi.nlm.nih.gov/pubmed/9790974",
				"http://www.ncbi.nlm.nih.gov/pubmed/1828533"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18851700",
				"http://www.ncbi.nlm.nih.gov/pubmed/18396434",
				"http://www.ncbi.nlm.nih.gov/pubmed/17286852",
				"http://www.ncbi.nlm.nih.gov/pubmed/17158748",
				"http://www.ncbi.nlm.nih.gov/pubmed/9790974",
				"http://www.ncbi.nlm.nih.gov/pubmed/1828533"
			],
			"type": "yesno",
			"id": "53380000d6d3ac6a34000059",
			"snippets": [
				{
					"offsetInBeginSection": 336,
					"offsetInEndSection": 547,
					"text": "Histone phosphorylation, ubiquitylation, SUMOylation and poly-ADP-ribosylation, as well as ATP-dependent nucleosome remodeling complexes, play equally pivotal roles in the maintenance of transcriptional fidelity",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18851700",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 188,
					"text": "oly(ADP-ribose) polymerase-1 (PARP-1; EC 2.4.2.30) is an abundant nuclear protein that is involved in DNA repair, cell cycle control, programmed cell death and transcriptional regulation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18396434",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 213,
					"text": "Many lines of evidence suggest that poly(ADP-ribose) polymerase-1 (Parp-1) is involved in transcriptional regulation of various genes as a coactivator or a corepressor by modulating chromatin structure",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1631,
					"offsetInEndSection": 1765,
					"text": "These results suggest that Parp-1 is required to maintain transcriptional regulation of a wide variety of genes on a genome-wide scale",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 480,
					"offsetInEndSection": 602,
					"text": "PARP-1 was identified as a part of the mH2A1.1 nucleosome complex and was found to be associated with the Hsp70.1 promoter",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17158748",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1020,
					"offsetInEndSection": 1174,
					"text": "Upon heat shock, the Hsp70.1 promoter-bound PARP-1 is released to activate transcription through ADP-ribosylation of other Hsp70.1 promoter-bound proteins",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17158748",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1028,
					"offsetInEndSection": 1409,
					"text": "Cycloheximide-induced cells were treated with two chemical inhibitors of poly(ADP-ribose) polymerase. 3-Aminobenzamide inhibited 75% of PAP gene induction and 4-hydroxyquinazolone, the highly specific inhibitor of the enzyme, blocked almost completely PAP expression, suggesting that ADP-ribosylation was indeed required for the upregulation of PAP gene expression by cycloheximide",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9790974",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 471,
					"offsetInEndSection": 589,
					"text": " inhibitors of poly(ADP-ribose) polymerase suppressed UV-induced HIV-1 gene expression but not tat-mediated expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/1828533",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 110,
					"text": "oly(ADP-ribose) polymerase inhibitors suppress UV-induced human immunodeficiency virus type 1 gene expression",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/1828533",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 571,
					"offsetInEndSection": 726,
					"text": "Accumulating evidence suggests that under Parp-1 deficiency, transcriptional regulation, cell differentiation, and tumorigenesis are substantially affected",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 841,
					"offsetInEndSection": 993,
					"text": "Parp-1 plays a role in the regulation of ligand-induced transactivation of ecdysone receptor [4], and in the transcriptional control of the target genes",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1924,
					"offsetInEndSection": 1995,
					"text": "Parp-1 is associated with transcriptionally repressed chromatin domains",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 8463,
					"offsetInEndSection": 8533,
					"text": "Parp-1 regulates gene expression by modulating transcriptional factors",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 38,
					"offsetInEndSection": 123,
					"text": "Parp-1 is required to maintain transcriptional regulation of a wide variety of genes ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "Are CD44 variants (CD44v) associated with poor prognosis of metastasis?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/12842543",
				"http://www.ncbi.nlm.nih.gov/pubmed/12747468",
				"http://www.ncbi.nlm.nih.gov/pubmed/11751503",
				"http://www.ncbi.nlm.nih.gov/pubmed/10601048",
				"http://www.ncbi.nlm.nih.gov/pubmed/9949626",
				"http://www.ncbi.nlm.nih.gov/pubmed/9849582",
				"http://www.ncbi.nlm.nih.gov/pubmed/9742519",
				"http://www.ncbi.nlm.nih.gov/pubmed/9732216",
				"http://www.ncbi.nlm.nih.gov/pubmed/9413216",
				"http://www.ncbi.nlm.nih.gov/pubmed/9815811",
				"http://www.ncbi.nlm.nih.gov/pubmed/9224749",
				"http://www.ncbi.nlm.nih.gov/pubmed/8869105",
				"http://www.ncbi.nlm.nih.gov/pubmed/7585612",
				"http://www.ncbi.nlm.nih.gov/pubmed/7587629",
				"http://www.ncbi.nlm.nih.gov/pubmed/7544777"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/12842543",
				"http://www.ncbi.nlm.nih.gov/pubmed/12747468",
				"http://www.ncbi.nlm.nih.gov/pubmed/11751503",
				"http://www.ncbi.nlm.nih.gov/pubmed/10601048",
				"http://www.ncbi.nlm.nih.gov/pubmed/9949626",
				"http://www.ncbi.nlm.nih.gov/pubmed/9849582",
				"http://www.ncbi.nlm.nih.gov/pubmed/9742519",
				"http://www.ncbi.nlm.nih.gov/pubmed/9732216",
				"http://www.ncbi.nlm.nih.gov/pubmed/9413216",
				"http://www.ncbi.nlm.nih.gov/pubmed/9815811",
				"http://www.ncbi.nlm.nih.gov/pubmed/9224749",
				"http://www.ncbi.nlm.nih.gov/pubmed/8869105",
				"http://www.ncbi.nlm.nih.gov/pubmed/7585612",
				"http://www.ncbi.nlm.nih.gov/pubmed/7587629",
				"http://www.ncbi.nlm.nih.gov/pubmed/7544777"
			],
			"type": "yesno",
			"id": "533bf29cc45e133714000001",
			"snippets": [
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 41,
					"text": "CD44 variants and prognosis",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10601048",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 136,
					"text": "The CD44 variant (CD44v) isoforms have been noted as markers for tumour metastasis and prognosis in several adenocarcinomas.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10601048",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1285,
					"offsetInEndSection": 1417,
					"text": "Positive CD44v3 expression was associated with more advanced pathological stage and poorer prognosis than negative CD44v3 expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11751503",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1393,
					"offsetInEndSection": 1518,
					"text": "CD44v6 expression in the adenocarcinoma component may directly affect the behavior of carcinoma and the prognosis of patients",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12747468",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 138,
					"text": "D44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12747468",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1661,
					"offsetInEndSection": 1852,
					"text": "CD44v5 expression is independently positively correlated with the aggressiveness of thymic epithelial tumors. The expression of CD44v5 may be a potential trigger of tumor invasion in thymomas",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12842543",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2363,
					"offsetInEndSection": 2497,
					"text": "analysis of CD44v expression provides indications of biological and clinical relevance also in low grade lymphoproliferative disorders",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9949626",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 15,
					"offsetInEndSection": 107,
					"text": "clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9949626",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 82,
					"text": "CD44 variants and its association with survival in pancreatic cancer",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9849582",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 10,
					"offsetInEndSection": 117,
					"text": "CD44 variant 6(v6) molecule has been noted as a marker for tumor metastasis and prognosis in several tumors",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9849582",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1530,
					"offsetInEndSection": 1637,
					"text": "CD44v2 and CD44v6 may be useful markers for poor prognosis in curatively resected primary pancreatic cancer",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9849582",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1272,
					"offsetInEndSection": 1508,
					"text": "CD44v8-10 may play an important role in the adhesion of tumor cells to the capillaries of distant organs in the metastatic process, and that immunohistochemical detection of CD44v8-10 may be a biologic marker of prognostic significance.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9742519",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 899,
					"offsetInEndSection": 991,
					"text": "combined expression of CD44v8-10 and SLX may be a biologic marker of prognostic significance",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9732216",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 195,
					"text": "variant isoforms (CD44v) are expressed on different malignant cells and tissues. Their upregulation has been implicated, in the progression and metastasis of malignomas.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9413216",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 112,
					"text": "expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9815811",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1409,
					"offsetInEndSection": 1639,
					"text": "a number of variant forms of CD44 are frequently expressed, although these variants are infrequently expressed in normal lung tissue, and that the expression of CD44v6 is particularly associated with lymph node metastasis in NSCLC",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9815811",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1305,
					"offsetInEndSection": 1397,
					"text": "Expression of CD44v6 may suggest an increased risk for local lymph node metastasis in NSCLCs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9224749",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 831,
					"offsetInEndSection": 926,
					"text": "different CD44 isoforms are found in human skin cancers and are modulated during carcinogenesis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8869105",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 99,
					"text": "D44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7585612",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 683,
					"offsetInEndSection": 851,
					"text": "Correlations between prognosis and expression of CD44v have been reported for gastric and colon carcinoma, for non-Hodgkin's lymphoma, and recently for breast carcinoma",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7585612",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 236,
					"offsetInEndSection": 459,
					"text": "Certain splice variants (CD44v) can promote the metastatic behaviour of cancer cells. In human colon and breast cancer the presence of epitopes encoded by exon v6 on primary resected tumour material indicates poor prognosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7587629",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 296,
					"offsetInEndSection": 434,
					"text": "In human mammary carcinomas and colorectal carcinomas, the expression of CD44v has also been correlated with more progressed tumor stages.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7544777",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23942795",
				"http://www.ncbi.nlm.nih.gov/pubmed/23666688",
				"http://www.ncbi.nlm.nih.gov/pubmed/23285088",
				"http://www.ncbi.nlm.nih.gov/pubmed/23233201",
				"http://www.ncbi.nlm.nih.gov/pubmed/23174189",
				"http://www.ncbi.nlm.nih.gov/pubmed/23090888",
				"http://www.ncbi.nlm.nih.gov/pubmed/23032801",
				"http://www.ncbi.nlm.nih.gov/pubmed/22985168",
				"http://www.ncbi.nlm.nih.gov/pubmed/22895079",
				"http://www.ncbi.nlm.nih.gov/pubmed/22893108",
				"http://www.ncbi.nlm.nih.gov/pubmed/22761178",
				"http://www.ncbi.nlm.nih.gov/pubmed/22519766",
				"http://www.ncbi.nlm.nih.gov/pubmed/22506320",
				"http://www.ncbi.nlm.nih.gov/pubmed/22461032",
				"http://www.ncbi.nlm.nih.gov/pubmed/22460758",
				"http://www.ncbi.nlm.nih.gov/pubmed/22349810",
				"http://www.ncbi.nlm.nih.gov/pubmed/22191306",
				"http://www.ncbi.nlm.nih.gov/pubmed/22160058",
				"http://www.ncbi.nlm.nih.gov/pubmed/22151181",
				"http://www.ncbi.nlm.nih.gov/pubmed/22087818",
				"http://www.ncbi.nlm.nih.gov/pubmed/22052279",
				"http://www.ncbi.nlm.nih.gov/pubmed/22037271",
				"http://www.ncbi.nlm.nih.gov/pubmed/21903771",
				"http://www.ncbi.nlm.nih.gov/pubmed/21892537",
				"http://www.ncbi.nlm.nih.gov/pubmed/21672900",
				"http://www.ncbi.nlm.nih.gov/pubmed/21672337",
				"http://www.ncbi.nlm.nih.gov/pubmed/21279819",
				"http://www.ncbi.nlm.nih.gov/pubmed/21203982",
				"http://www.ncbi.nlm.nih.gov/pubmed/17382013",
				"http://www.ncbi.nlm.nih.gov/pubmed/17379100",
				"http://www.ncbi.nlm.nih.gov/pubmed/17364993",
				"http://www.ncbi.nlm.nih.gov/pubmed/17292736",
				"http://www.ncbi.nlm.nih.gov/pubmed/16988930",
				"http://www.ncbi.nlm.nih.gov/pubmed/16850123",
				"http://www.ncbi.nlm.nih.gov/pubmed/16843101",
				"http://www.ncbi.nlm.nih.gov/pubmed/16757427",
				"http://www.ncbi.nlm.nih.gov/pubmed/16689455",
				"http://www.ncbi.nlm.nih.gov/pubmed/16475128",
				"http://www.ncbi.nlm.nih.gov/pubmed/16146726",
				"http://www.ncbi.nlm.nih.gov/pubmed/21061842",
				"http://www.ncbi.nlm.nih.gov/pubmed/20945321",
				"http://www.ncbi.nlm.nih.gov/pubmed/20875546",
				"http://www.ncbi.nlm.nih.gov/pubmed/20607973",
				"http://www.ncbi.nlm.nih.gov/pubmed/20529808",
				"http://www.ncbi.nlm.nih.gov/pubmed/20425400",
				"http://www.ncbi.nlm.nih.gov/pubmed/19860186",
				"http://www.ncbi.nlm.nih.gov/pubmed/19641300",
				"http://www.ncbi.nlm.nih.gov/pubmed/19254884",
				"http://www.ncbi.nlm.nih.gov/pubmed/19075651",
				"http://www.ncbi.nlm.nih.gov/pubmed/19064740",
				"http://www.ncbi.nlm.nih.gov/pubmed/18974832",
				"http://www.ncbi.nlm.nih.gov/pubmed/18533795",
				"http://www.ncbi.nlm.nih.gov/pubmed/18205699",
				"http://www.ncbi.nlm.nih.gov/pubmed/17970609",
				"http://www.ncbi.nlm.nih.gov/pubmed/17956348",
				"http://www.ncbi.nlm.nih.gov/pubmed/17929114",
				"http://www.ncbi.nlm.nih.gov/pubmed/17671641",
				"http://www.ncbi.nlm.nih.gov/pubmed/20425355",
				"http://www.ncbi.nlm.nih.gov/pubmed/17382020",
				"http://www.ncbi.nlm.nih.gov/pubmed/15899391",
				"http://www.ncbi.nlm.nih.gov/pubmed/15791812",
				"http://www.ncbi.nlm.nih.gov/pubmed/15739279",
				"http://www.ncbi.nlm.nih.gov/pubmed/15027317",
				"http://www.ncbi.nlm.nih.gov/pubmed/14744784",
				"http://www.ncbi.nlm.nih.gov/pubmed/14639002",
				"http://www.ncbi.nlm.nih.gov/pubmed/12869662",
				"http://www.ncbi.nlm.nih.gov/pubmed/12796373",
				"http://www.ncbi.nlm.nih.gov/pubmed/12783369",
				"http://www.ncbi.nlm.nih.gov/pubmed/12755554",
				"http://www.ncbi.nlm.nih.gov/pubmed/12750692",
				"http://www.ncbi.nlm.nih.gov/pubmed/12454739",
				"http://www.ncbi.nlm.nih.gov/pubmed/12411298",
				"http://www.ncbi.nlm.nih.gov/pubmed/12200353",
				"http://www.ncbi.nlm.nih.gov/pubmed/12176881",
				"http://www.ncbi.nlm.nih.gov/pubmed/12173333",
				"http://www.ncbi.nlm.nih.gov/pubmed/12082821",
				"http://www.ncbi.nlm.nih.gov/pubmed/11986206",
				"http://www.ncbi.nlm.nih.gov/pubmed/11870241",
				"http://www.ncbi.nlm.nih.gov/pubmed/11808344"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23942795",
				"http://www.ncbi.nlm.nih.gov/pubmed/23666688",
				"http://www.ncbi.nlm.nih.gov/pubmed/23285088",
				"http://www.ncbi.nlm.nih.gov/pubmed/23233201",
				"http://www.ncbi.nlm.nih.gov/pubmed/23174189",
				"http://www.ncbi.nlm.nih.gov/pubmed/23090888",
				"http://www.ncbi.nlm.nih.gov/pubmed/23032801",
				"http://www.ncbi.nlm.nih.gov/pubmed/22985168",
				"http://www.ncbi.nlm.nih.gov/pubmed/22895079",
				"http://www.ncbi.nlm.nih.gov/pubmed/22893108",
				"http://www.ncbi.nlm.nih.gov/pubmed/22761178",
				"http://www.ncbi.nlm.nih.gov/pubmed/22519766",
				"http://www.ncbi.nlm.nih.gov/pubmed/22506320",
				"http://www.ncbi.nlm.nih.gov/pubmed/22461032",
				"http://www.ncbi.nlm.nih.gov/pubmed/22460758",
				"http://www.ncbi.nlm.nih.gov/pubmed/22349810",
				"http://www.ncbi.nlm.nih.gov/pubmed/22191306",
				"http://www.ncbi.nlm.nih.gov/pubmed/22160058",
				"http://www.ncbi.nlm.nih.gov/pubmed/22151181",
				"http://www.ncbi.nlm.nih.gov/pubmed/22087818",
				"http://www.ncbi.nlm.nih.gov/pubmed/22052279",
				"http://www.ncbi.nlm.nih.gov/pubmed/22037271",
				"http://www.ncbi.nlm.nih.gov/pubmed/21903771",
				"http://www.ncbi.nlm.nih.gov/pubmed/21892537",
				"http://www.ncbi.nlm.nih.gov/pubmed/21672900",
				"http://www.ncbi.nlm.nih.gov/pubmed/21672337",
				"http://www.ncbi.nlm.nih.gov/pubmed/21279819",
				"http://www.ncbi.nlm.nih.gov/pubmed/21203982",
				"http://www.ncbi.nlm.nih.gov/pubmed/17382013",
				"http://www.ncbi.nlm.nih.gov/pubmed/17379100",
				"http://www.ncbi.nlm.nih.gov/pubmed/17364993",
				"http://www.ncbi.nlm.nih.gov/pubmed/17292736",
				"http://www.ncbi.nlm.nih.gov/pubmed/16988930",
				"http://www.ncbi.nlm.nih.gov/pubmed/16850123",
				"http://www.ncbi.nlm.nih.gov/pubmed/16843101",
				"http://www.ncbi.nlm.nih.gov/pubmed/16757427",
				"http://www.ncbi.nlm.nih.gov/pubmed/16689455",
				"http://www.ncbi.nlm.nih.gov/pubmed/16475128",
				"http://www.ncbi.nlm.nih.gov/pubmed/16146726",
				"http://www.ncbi.nlm.nih.gov/pubmed/21061842",
				"http://www.ncbi.nlm.nih.gov/pubmed/20945321",
				"http://www.ncbi.nlm.nih.gov/pubmed/20875546",
				"http://www.ncbi.nlm.nih.gov/pubmed/20607973",
				"http://www.ncbi.nlm.nih.gov/pubmed/20529808",
				"http://www.ncbi.nlm.nih.gov/pubmed/20425400",
				"http://www.ncbi.nlm.nih.gov/pubmed/19860186",
				"http://www.ncbi.nlm.nih.gov/pubmed/19641300",
				"http://www.ncbi.nlm.nih.gov/pubmed/19254884",
				"http://www.ncbi.nlm.nih.gov/pubmed/19075651",
				"http://www.ncbi.nlm.nih.gov/pubmed/19064740",
				"http://www.ncbi.nlm.nih.gov/pubmed/18974832",
				"http://www.ncbi.nlm.nih.gov/pubmed/18533795",
				"http://www.ncbi.nlm.nih.gov/pubmed/18205699",
				"http://www.ncbi.nlm.nih.gov/pubmed/17970609",
				"http://www.ncbi.nlm.nih.gov/pubmed/17956348",
				"http://www.ncbi.nlm.nih.gov/pubmed/17929114",
				"http://www.ncbi.nlm.nih.gov/pubmed/17671641",
				"http://www.ncbi.nlm.nih.gov/pubmed/20425355",
				"http://www.ncbi.nlm.nih.gov/pubmed/17382020",
				"http://www.ncbi.nlm.nih.gov/pubmed/15899391",
				"http://www.ncbi.nlm.nih.gov/pubmed/15791812",
				"http://www.ncbi.nlm.nih.gov/pubmed/15739279",
				"http://www.ncbi.nlm.nih.gov/pubmed/15027317",
				"http://www.ncbi.nlm.nih.gov/pubmed/14744784",
				"http://www.ncbi.nlm.nih.gov/pubmed/14639002",
				"http://www.ncbi.nlm.nih.gov/pubmed/12869662",
				"http://www.ncbi.nlm.nih.gov/pubmed/12796373",
				"http://www.ncbi.nlm.nih.gov/pubmed/12783369",
				"http://www.ncbi.nlm.nih.gov/pubmed/12755554",
				"http://www.ncbi.nlm.nih.gov/pubmed/12750692",
				"http://www.ncbi.nlm.nih.gov/pubmed/12454739",
				"http://www.ncbi.nlm.nih.gov/pubmed/12411298",
				"http://www.ncbi.nlm.nih.gov/pubmed/12200353",
				"http://www.ncbi.nlm.nih.gov/pubmed/12176881",
				"http://www.ncbi.nlm.nih.gov/pubmed/12173333",
				"http://www.ncbi.nlm.nih.gov/pubmed/12082821",
				"http://www.ncbi.nlm.nih.gov/pubmed/11986206",
				"http://www.ncbi.nlm.nih.gov/pubmed/11870241",
				"http://www.ncbi.nlm.nih.gov/pubmed/11808344"
			],
			"type": "factoid",
			"id": "5324a8ac9b2d7acc7e000018",
			"snippets": [
				{
					"offsetInBeginSection": 108,
					"offsetInEndSection": 193,
					"text": "CR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23942795",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 135,
					"text": "reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11), Philadelphia chromosome] creates a BCR-ABL1 fusion protein",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23666688",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 655,
					"offsetInEndSection": 780,
					"text": "A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted treatment in most CML patients",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23666688",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 184,
					"text": "The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib i",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23285088",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 270,
					"offsetInEndSection": 492,
					"text": "The BCR/ABL fusion tyrosine kinase is expressed in chronic myeloid leukemia and Philadelphia-positive (Ph+) acute lymphoblastic leukemia cells, and its inhibition by the clinically used tyrosine kinase inhibitors imatinib ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23233201",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 183,
					"text": "Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative disorder characterized by the expansion of hematopoietic cells carrying the Philadelphia chromosome",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23174189",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 437,
					"offsetInEndSection": 556,
					"text": "Patients received imatinib after diagnosis and underwent regular laboratory monitoring (quantification of BCR-ABL ratio",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23174189",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 217,
					"offsetInEndSection": 494,
					"text": "CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23090888",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 668,
					"offsetInEndSection": 711,
					"text": "tyrosine kinase inhibitors (TKIs), imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23090888",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 143,
					"offsetInEndSection": 346,
					"text": "Characterized by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, small-molecule tyrosine kinase inhibitors (TKIs) targeted against the oncogenic BCR-ABL fusion protein",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23032801",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 176,
					"text": "Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22985168",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 361,
					"offsetInEndSection": 398,
					"text": "ABL-kinase inhibitors (AKIs) Imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22985168",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 120,
					"text": "hiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22895079",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 280,
					"offsetInEndSection": 324,
					"text": " BCR-ABL tyrosine kinase inhibitor imatinib ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22895079",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 56,
					"text": "matinib was the first BCR-ABL tyrosine kinase inhibitor",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22893108",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 185,
					"text": "CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR-ABL, ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22761178",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 322,
					"offsetInEndSection": 385,
					"text": "Imatinib mesylate, an orally available BCR-ABL kinase inhibitor",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22761178",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 193,
					"text": "Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22519766",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 202,
					"text": "CML) originates from a hematopoietic stem cell carrying the Philadelphia (Ph) chromosome and oncogenic BCR-ABL1 fusion gene. The first tyrosine-kinase inhibitor (TKI) imatinib ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22506320",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 131,
					"offsetInEndSection": 171,
					"text": "chronic myeloid leukemia (CML) patients ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22461032",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 363,
					"offsetInEndSection": 455,
					"text": "Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22461032",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 152,
					"text": "matinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22460758",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 9,
					"offsetInEndSection": 64,
					"text": "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22349810",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 160,
					"text": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22191306",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 309,
					"offsetInEndSection": 575,
					"text": "The development of first-generation (imatinib) and second-generation (dasatinib and nilotinib) tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 fusion protein produced by the Ph chromosome revolutionized the treatment of chronic myelogenous leukemia (CML).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22160058",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 219,
					"text": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22151181",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 137,
					"text": "chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be successfully targeted with the BCRABL- inhibitors imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22087818",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 195,
					"text": "matinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22052279",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 380,
					"offsetInEndSection": 448,
					"text": "Philadelphia chromosome positive chronic myelogenous leukemia (CML) ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22052279",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 263,
					"text": "CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22037271",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 343,
					"offsetInEndSection": 357,
					"text": "BCR-ABL levels",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21903771",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 9,
					"offsetInEndSection": 125,
					"text": "Imatinib induces a durable response in most patients with Philadelphia chromosome-positive chronic myeloid leukemia,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21903771",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 167,
					"offsetInEndSection": 295,
					"text": "CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21892537",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 357,
					"offsetInEndSection": 373,
					"text": "imatinib therapy",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21892537",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 971,
					"offsetInEndSection": 1186,
					"text": "The discovery of targeted tyrosine kinase inhibition of BCR-ABL kinase dramatically changed the treatment of CML. Imatinib, the first TKI approved for treatment of patients with Philadelphia chromosome--positive CML",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21672900",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 27,
					"offsetInEndSection": 299,
					"text": "CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21672337",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 492,
					"offsetInEndSection": 603,
					"text": "imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21279819",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 651,
					"offsetInEndSection": 848,
					"text": "CML is induced by the BCR-ABL oncogene, whose gene product is a BCR-ABL tyrosine kinase. Currently, inhibition of BCR-ABL kinase activity by its kinase inhibitor such as imatinib mesylate (Gleevec)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21203982",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 414,
					"offsetInEndSection": 518,
					"text": "The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17382013",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 231,
					"offsetInEndSection": 352,
					"text": "Imatinib (Glivec, Gleevec), a specific small molecule inhibitor of Bcr-Abl, has become the standard drug therapy for CML,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17379100",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 336,
					"offsetInEndSection": 416,
					"text": "Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 191,
					"offsetInEndSection": 429,
					"text": "CML is the presence of a balanced translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11.2), which is known as the Philadelphia (Ph) chromosome. This translocation results in the formation of the bcr-abl fusion gene,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17292736",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 984,
					"offsetInEndSection": 1005,
					"text": "emergence of imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17292736",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 210,
					"text": "matinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16988930",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 312,
					"text": "Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. This fusion protein constitutively activate ABL tyrosine kinase and causes CML. Imatinib mesylate is a selective tyrosine kinase inhibitor on ABL",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16850123",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 244,
					"text": "CML) is characterized by the presence of a BCR-ABL fusion gene, which is the result of a reciprocal translocation between chromosomes 9 and 22, and is cytogenetically visible as a shortened chromosome 22 (Philadelphia)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16843101",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 528,
					"offsetInEndSection": 595,
					"text": "imatinib mesylate was introduced into the treatment regimen for CML",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16843101",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 179,
					"text": "matinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16757427",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 218,
					"text": "hronic myelogenous leukemia is characterized by the Philadelphia-chromosome, a shortened chromosome 22 which is the result of a reciprocal translocation between chromosome 9 and 22. The fusion gene is called BCR-ABL. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16689455",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 594,
					"offsetInEndSection": 621,
					"text": "Imatinib mesylate (Glivec) ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16689455",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 487,
					"offsetInEndSection": 611,
					"text": " BCR-ABL transcripts in the peripheral blood of patients with CML who were treated with imatinib mesylate (Glivec, Novartis)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16475128",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 367,
					"offsetInEndSection": 450,
					"text": "Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16146726",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 60,
					"text": "hronic myeloid leukemia cells contain a BCR-ABL oncoprotein",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16146726",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 246,
					"text": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21061842",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 93,
					"offsetInEndSection": 489,
					"text": "The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20945321",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1135,
					"offsetInEndSection": 1157,
					"text": "original TKI, imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20875546",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 518,
					"offsetInEndSection": 759,
					"text": "CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CM",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20875546",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 186,
					"text": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20607973",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 93,
					"offsetInEndSection": 415,
					"text": "The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph) that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase (TK). The introduction of imatinib, a TK inhibitor (TKI) specific for BCR-ABL, was a major breakthrough in CML therapy",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20529808",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 338,
					"offsetInEndSection": 439,
					"text": "CML has enabled the development of Abl-specific tyrosine kinase inhibitors, such as imatinib mesylate",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20425400",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 150,
					"text": "CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20425400",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 133,
					"text": "CML) is a paradigm for neoplasias that are defined by a unique genetic aberration, the BCR-ABL1 fusion gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19860186",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 213,
					"offsetInEndSection": 257,
					"text": "protein tyrosine kinase inhibitor, imatinib,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19860186",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 150,
					"text": "BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19641300",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 370,
					"offsetInEndSection": 406,
					"text": "CML patients with imatinib treatment",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19641300",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 244,
					"text": "CML) is characterized by the presence of the Philadelphia chromosome (Ph), a genetic aberration that codes for bcrabl, which plays a key role in disease pathophysiology. The first oral inhibitor of Brc-Abl was imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19254884",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 328,
					"text": "CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t(9;22)(q34;q11). This translocation creates two new genes, BCR-ABL on the 22q- (Ph chromosome) and the reciprocal ABL-BCR on 9q-. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19075651",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 704,
					"offsetInEndSection": 801,
					"text": "tyrosine kinase inhibitor (TKI), introduced into clinical practice in 1998, was imatinib mesylate",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19075651",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 465,
					"offsetInEndSection": 613,
					"text": "BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19064740",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 290,
					"text": "CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective inhibitor of the Bcr-Abl tyrosine kinase, ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18974832",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 279,
					"text": "CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18533795",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 545,
					"offsetInEndSection": 631,
					"text": "Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18533795",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 173,
					"text": "CR-ABL tyrosine kinase inhibitors, such as imatinib (Gleevec) are highly effective in treating human Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18205699",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 174,
					"text": "Chronic myeloid leukemia (CML) is a hematopoietic stem cell cancer driven by the BCR-ABL fusion protein that arises from the translocation of chromosomes 9 and 22",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17970609",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 969,
					"offsetInEndSection": 1005,
					"text": "BCR-ABL inhibitors, such as imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17970609",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 509,
					"offsetInEndSection": 577,
					"text": "TKIs (tyrosine kinase inhibitors), including IM (imatinib mesylate),",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17956348",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 5,
					"offsetInEndSection": 228,
					"text": "chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome) and bcr-abl oncoprotein",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17956348",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 310,
					"text": "CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and its pivotal role in the pathogenesis of CML provided new opportunities to develop molecular-targeted therapies. Imatinib mesylate",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17929114",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 297,
					"text": " identification of the Philadelphia chromosome in cells from individuals with chronic myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase causes CML. This in turn led to the development of imatinib mesylate, a clinically successful inhibitor of the BCR-ABL kinase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17671641",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 441,
					"text": "CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR break-points. Imatinib mesylate is a highly selective inhibitor of this kinase,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20425355",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 358,
					"text": "CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17382020",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 163,
					"text": "matinib mesylate was designed as an inhibitor targeting the BCR-ABL tyrosine kinase, the molecular counterpart of the Philadelphia translocation t(9;22)(q34;q11).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15899391",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 30,
					"offsetInEndSection": 431,
					"text": "CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15791812",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 187,
					"offsetInEndSection": 458,
					"text": "CML was the first human cancer demonstrated to be strongly associated to the presence of a recurrent chromosomal translocation (the t(9;22)(q34;q11) that creates the Philadelphia (Ph)-chromosome) and to a specific molecular defect, the formation of a hybrid BCR-ABL gene ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15739279",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 651,
					"offsetInEndSection": 747,
					"text": "imatinib, (Glivec, Gleevec, Novartis), a potent tyrosine kinase inhibitor of the Bcr-Abl protein",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15739279",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 391,
					"text": "matinib mesylate is a new drug that can inhibit the tyrosine kinase activity of Bcr-Abl, the receptors for platelet-derived growth factor receptor(PDGF) and stem cell factor, or c-kit. Chronic myeloid leukemia (CML) is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22 that results in a shortened chromosome 22, termed the Philadelphia(Ph) chromosome.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15027317",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 19,
					"offsetInEndSection": 51,
					"text": "IM) binds to the BCR-ABL protein",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14744784",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 224,
					"text": "Philadelphia chromosome found in leukemia cells of chronic myelogenous leukemia (CML) patients is produced by translocation between chromosomes 9 and 22, resulting in expression of a chimera protein of Bcr and Abl kinase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14639002",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 351,
					"offsetInEndSection": 416,
					"text": "Abl kinase inhibitors were synthesized. STI571 (imatinib mesylate",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14639002",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 167,
					"text": "CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12869662",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 321,
					"offsetInEndSection": 380,
					"text": "Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12869662",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 9,
					"offsetInEndSection": 183,
					"text": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12796373",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 319,
					"offsetInEndSection": 414,
					"text": "BCR/ABL, encodes an activated tyrosine kinase that can act alone to induce a CML-like syndrome ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12783369",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 545,
					"offsetInEndSection": 593,
					"text": "The kinase inhibitor imatinib mesylate (Gleevec)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12783369",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 5,
					"offsetInEndSection": 240,
					"text": "hiladelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12755554",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 634,
					"offsetInEndSection": 661,
					"text": "imatinib mesylate (Gleevec,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12755554",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 180,
					"text": "matinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12750692",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 174,
					"text": "matinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12454739",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 30,
					"offsetInEndSection": 238,
					"text": "CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype. Imatinib, a selective inhibitor of Bcr-Abl",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12411298",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 314,
					"offsetInEndSection": 398,
					"text": "Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12200353",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 211,
					"offsetInEndSection": 328,
					"text": "Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12176881",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 320,
					"text": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12173333",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 27,
					"offsetInEndSection": 497,
					"text": "CML) is characterised by the occurrence of the Philadelphia (Ph) chromosome (9/22 translocation) and the formation of a fusion protein--the BCR-ABL transcript with constitutive activation of the BCR-ABL tyrosine kinase and consequent changes in the intracellular signal transduction, which is responsible for the deregulated myeloid cell proliferation. STI571 (signal transduction inhibition number 571) is a potent and selective inhibitor of the BCR-ABL tyrosine kinase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 199,
					"offsetInEndSection": 356,
					"text": "Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11986206",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 209,
					"text": "Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11870241",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 265,
					"text": "CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Is the Prostate- Specific Antigen (PSA) test relevant only for prostate cancer?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24223021",
				"http://www.ncbi.nlm.nih.gov/pubmed/23588999",
				"http://www.ncbi.nlm.nih.gov/pubmed/23400279",
				"http://www.ncbi.nlm.nih.gov/pubmed/20065953",
				"http://www.ncbi.nlm.nih.gov/pubmed/19579539",
				"http://www.ncbi.nlm.nih.gov/pubmed/18808732",
				"http://www.ncbi.nlm.nih.gov/pubmed/18569246",
				"http://www.ncbi.nlm.nih.gov/pubmed/18355899",
				"http://www.ncbi.nlm.nih.gov/pubmed/17559560",
				"http://www.ncbi.nlm.nih.gov/pubmed/17489318",
				"http://www.ncbi.nlm.nih.gov/pubmed/17233806",
				"http://www.ncbi.nlm.nih.gov/pubmed/15925651",
				"http://www.ncbi.nlm.nih.gov/pubmed/15530599",
				"http://www.ncbi.nlm.nih.gov/pubmed/12088291",
				"http://www.ncbi.nlm.nih.gov/pubmed/11583357",
				"http://www.ncbi.nlm.nih.gov/pubmed/10697616",
				"http://www.ncbi.nlm.nih.gov/pubmed/9494604",
				"http://www.ncbi.nlm.nih.gov/pubmed/9494603",
				"http://www.ncbi.nlm.nih.gov/pubmed/9329582",
				"http://www.ncbi.nlm.nih.gov/pubmed/7544735",
				"http://www.ncbi.nlm.nih.gov/pubmed/7687205"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24223021",
				"http://www.ncbi.nlm.nih.gov/pubmed/23588999",
				"http://www.ncbi.nlm.nih.gov/pubmed/23400279",
				"http://www.ncbi.nlm.nih.gov/pubmed/20065953",
				"http://www.ncbi.nlm.nih.gov/pubmed/19579539",
				"http://www.ncbi.nlm.nih.gov/pubmed/18808732",
				"http://www.ncbi.nlm.nih.gov/pubmed/18569246",
				"http://www.ncbi.nlm.nih.gov/pubmed/18355899",
				"http://www.ncbi.nlm.nih.gov/pubmed/17559560",
				"http://www.ncbi.nlm.nih.gov/pubmed/17489318",
				"http://www.ncbi.nlm.nih.gov/pubmed/17233806",
				"http://www.ncbi.nlm.nih.gov/pubmed/15925651",
				"http://www.ncbi.nlm.nih.gov/pubmed/15530599",
				"http://www.ncbi.nlm.nih.gov/pubmed/12088291",
				"http://www.ncbi.nlm.nih.gov/pubmed/11583357",
				"http://www.ncbi.nlm.nih.gov/pubmed/10697616",
				"http://www.ncbi.nlm.nih.gov/pubmed/9494604",
				"http://www.ncbi.nlm.nih.gov/pubmed/9494603",
				"http://www.ncbi.nlm.nih.gov/pubmed/9329582",
				"http://www.ncbi.nlm.nih.gov/pubmed/7544735",
				"http://www.ncbi.nlm.nih.gov/pubmed/7687205"
			],
			"type": "yesno",
			"id": "5327139ad6d3ac6a3400000d",
			"snippets": [
				{
					"offsetInBeginSection": 13,
					"offsetInEndSection": 129,
					"text": "rostate cancer (PCa) is the most frequently diagnosed malignancy and the second leading cause of cancer death in men",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24223021",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 378,
					"offsetInEndSection": 436,
					"text": "PSA is known to be prostate specific, but not PCa specific",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24223021",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 96,
					"text": "deficiencies of serum PSA as a prostate-cancer-specific diagnostic test are well recognized.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20065953",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 98,
					"offsetInEndSection": 206,
					"text": "medical debate surrounding the use of the prostate-specific antigen (PSA) test for prostate cancer screening",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19579539",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2712,
					"offsetInEndSection": 2834,
					"text": "The clinical relevance of this surprisingly high rate of prostate cancer in men with a normal PSA is yet to be determined ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15925651",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 159,
					"text": "Rapid uptake of prostate-specific antigen (PSA) testing has occurred in the United States despite inconclusive evidence regarding mortality benefit",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15530599",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 9,
					"offsetInEndSection": 173,
					"text": "Routine cancer screening with prostate-specific antigen (PSA) is controversial, and practice guidelines recommend that men be counseled about its risks and benefits",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12088291",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 895,
					"offsetInEndSection": 1135,
					"text": "Prostate carcinoma was histologically confirmed in 14 (0.66%) of the men, nine times in the early stage (T2) and five times in the clinical stage (T3), corresponding to an incidence of circa 650 cases per 100,000 men in the target age group",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11583357",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1150,
					"offsetInEndSection": 1278,
					"text": "This newly developed PSA test system can enhance the acceptance rate and effectiveness of medical check-ups for prostate cancer,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11583357",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1484,
					"offsetInEndSection": 1601,
					"text": "PSA can be used reliably as a unique tool in the follow-up of patients for the early detection of progressive disease",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7544735",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 727,
					"offsetInEndSection": 831,
					"text": "PSA showed negative predictive values of 82 and 77%, respectively, using 4 and 10 ng/ml as cutoff points",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7544735",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 200,
					"text": "have assessed the feasibility of using fixed-limit criteria based on medical relevance and biological variation for evaluating the analytical performance of the prostate-specific antigen (PSA) test",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7687205",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the gene mutated in the Gaucher disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23936319",
				"http://www.ncbi.nlm.nih.gov/pubmed/22230121",
				"http://www.ncbi.nlm.nih.gov/pubmed/21704274",
				"http://www.ncbi.nlm.nih.gov/pubmed/21223590",
				"http://www.ncbi.nlm.nih.gov/pubmed/20004604",
				"http://www.ncbi.nlm.nih.gov/pubmed/17427031",
				"http://www.ncbi.nlm.nih.gov/pubmed/16039881",
				"http://www.ncbi.nlm.nih.gov/pubmed/14757438",
				"http://www.ncbi.nlm.nih.gov/pubmed/11479729",
				"http://www.ncbi.nlm.nih.gov/pubmed/10882637",
				"http://www.ncbi.nlm.nih.gov/pubmed/9733040",
				"http://www.ncbi.nlm.nih.gov/pubmed/9295080",
				"http://www.ncbi.nlm.nih.gov/pubmed/9187679",
				"http://www.ncbi.nlm.nih.gov/pubmed/9175735",
				"http://www.ncbi.nlm.nih.gov/pubmed/8986634",
				"http://www.ncbi.nlm.nih.gov/pubmed/8556817",
				"http://www.ncbi.nlm.nih.gov/pubmed/7857677",
				"http://www.ncbi.nlm.nih.gov/pubmed/7923859",
				"http://www.ncbi.nlm.nih.gov/pubmed/8051940",
				"http://www.ncbi.nlm.nih.gov/pubmed/8213821",
				"http://www.ncbi.nlm.nih.gov/pubmed/1899336",
				"http://www.ncbi.nlm.nih.gov/pubmed/2117855",
				"http://www.ncbi.nlm.nih.gov/pubmed/2349952",
				"http://www.ncbi.nlm.nih.gov/pubmed/2464926"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23936319",
				"http://www.ncbi.nlm.nih.gov/pubmed/22230121",
				"http://www.ncbi.nlm.nih.gov/pubmed/21704274",
				"http://www.ncbi.nlm.nih.gov/pubmed/21223590",
				"http://www.ncbi.nlm.nih.gov/pubmed/20004604",
				"http://www.ncbi.nlm.nih.gov/pubmed/17427031",
				"http://www.ncbi.nlm.nih.gov/pubmed/16039881",
				"http://www.ncbi.nlm.nih.gov/pubmed/14757438",
				"http://www.ncbi.nlm.nih.gov/pubmed/11479729",
				"http://www.ncbi.nlm.nih.gov/pubmed/10882637",
				"http://www.ncbi.nlm.nih.gov/pubmed/9733040",
				"http://www.ncbi.nlm.nih.gov/pubmed/9295080",
				"http://www.ncbi.nlm.nih.gov/pubmed/9187679",
				"http://www.ncbi.nlm.nih.gov/pubmed/9175735",
				"http://www.ncbi.nlm.nih.gov/pubmed/8986634",
				"http://www.ncbi.nlm.nih.gov/pubmed/8556817",
				"http://www.ncbi.nlm.nih.gov/pubmed/7857677",
				"http://www.ncbi.nlm.nih.gov/pubmed/7923859",
				"http://www.ncbi.nlm.nih.gov/pubmed/8051940",
				"http://www.ncbi.nlm.nih.gov/pubmed/8213821",
				"http://www.ncbi.nlm.nih.gov/pubmed/1899336",
				"http://www.ncbi.nlm.nih.gov/pubmed/2117855",
				"http://www.ncbi.nlm.nih.gov/pubmed/2349952",
				"http://www.ncbi.nlm.nih.gov/pubmed/2464926"
			],
			"type": "factoid",
			"id": "532f55fed6d3ac6a34000036",
			"snippets": [
				{
					"offsetInBeginSection": 127,
					"offsetInEndSection": 242,
					"text": "The glucocerebrosidase gene (GBA), located in a gene-rich region on chromosome 1q 21, is mutated in Gaucher disease",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21704274",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 143,
					"text": "(GD) is the most common of the lysosomal storage disorders and is caused by defects in the GBA gene encoding glucocerebrosidase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23936319",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 18,
					"offsetInEndSection": 91,
					"text": "(GD) results from a deficiency of the lysosomal enzyme glucocerebrosidase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22230121",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 78,
					"text": "Gaucher disease is caused by defective glucocerebrosidase activity",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21223590",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 71,
					"text": "Gaucher disease (GD), the inherited deficiency of glucocerebrosidase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20004604",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 73,
					"text": "utations in the glucocerebrosidase (GBA) gene cause Gaucher disease (GD)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17427031",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 554,
					"offsetInEndSection": 596,
					"text": "mutations in glucocerebrosidase (GBA) gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16039881",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 17,
					"offsetInEndSection": 122,
					"text": "GD) is a disorder of glycosphinglipid metabolism caused by deficiency of lysosomal acid beta-glucosidase ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16039881",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 134,
					"text": "Gaucher disease (GD) is a heterogeneous disease characterized by an impaired activity of the lysosomal glucocerebrosidase.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14757438",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 232,
					"offsetInEndSection": 276,
					"text": "Mutations in GBA may lead to Gaucher disease",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11479729",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 20,
					"offsetInEndSection": 129,
					"text": "Gaucher's disease (GD) is an autosomal recessive disease produced by mutations of the Glucocerebrosidase gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10882637",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 97,
					"text": "aucher disease results, in most patients, from mutations in the gene encoding glucocerebrosidase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9733040",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 293,
					"offsetInEndSection": 333,
					"text": "mutations in the glucocerebrosidase gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9295080",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 107,
					"offsetInEndSection": 129,
					"text": "type I Gaucher disease",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9295080",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 264,
					"offsetInEndSection": 394,
					"text": "complete deletion of the beta-glucocerebrosidase gene was investigated in 25 unrelated non-Jewish patients with Gaucher's disease ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9187679",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 120,
					"text": "aucher disease is a heterogeneous disease characterized by impaired activity of the lysosomal enzyme glucocerebrosidase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9175735",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 97,
					"text": "aucher disease, resulting from the decreased activity of the lysosomal enzyme glucocerebrosidase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8986634",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 9,
					"offsetInEndSection": 148,
					"text": "screening of the glucocerebrosidase gene by SSCP analysis revealed an abnormal pattern of exon 10 in two unrelated Italian Gaucher patients",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8556817",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 17,
					"offsetInEndSection": 74,
					"text": "GD) is an inherited deficiency of beta-glucocerebrosidase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7857677",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 55,
					"offsetInEndSection": 160,
					"text": "Gaucher disease is type 1. The N370S glucocerebrosidase gene mutation accounts for 63% of mutated alleles",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7923859",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 43,
					"offsetInEndSection": 115,
					"text": "mutated glucocerebrosidase alleles of Portuguese type 1 Gaucher patients",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8051940",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 32,
					"offsetInEndSection": 132,
					"text": "mutated alleles known to occur in the glucocerebrosidase gene was determined in 247 Gaucher patients",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8213821",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 115,
					"offsetInEndSection": 264,
					"text": "Gaucher disease has marked phenotypic variation and molecular heterogeneity, and several simple and complex alleles of the acid beta-glucosidase gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/1899336",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 49,
					"offsetInEndSection": 193,
					"text": "Gaucher disease in 3 successive generations were tested for the presence of the 2 common mutations known to occur in the glucocerebrosidase gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/2117855",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 115,
					"offsetInEndSection": 262,
					"text": "Gaucher disease has marked phenotypic variation and molecular heterogeneity, and seven point mutations in the acid beta-glucosidase (beta-Glc) gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/2349952",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 147,
					"text": "cDNA clones containing the entire coding sequence of human glucocerebrosidase were isolated from libraries originated from Gaucher patients",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/2464926",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Is nucleosome eviction ATP-dependent?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24068556",
				"http://www.ncbi.nlm.nih.gov/pubmed/24008565",
				"http://www.ncbi.nlm.nih.gov/pubmed/23460895",
				"http://www.ncbi.nlm.nih.gov/pubmed/22177115",
				"http://www.ncbi.nlm.nih.gov/pubmed/20513433",
				"http://www.ncbi.nlm.nih.gov/pubmed/19933844",
				"http://www.ncbi.nlm.nih.gov/pubmed/19470761",
				"http://www.ncbi.nlm.nih.gov/pubmed/19029894",
				"http://www.ncbi.nlm.nih.gov/pubmed/17235287"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24068556",
				"http://www.ncbi.nlm.nih.gov/pubmed/24008565",
				"http://www.ncbi.nlm.nih.gov/pubmed/23460895",
				"http://www.ncbi.nlm.nih.gov/pubmed/22177115",
				"http://www.ncbi.nlm.nih.gov/pubmed/20513433",
				"http://www.ncbi.nlm.nih.gov/pubmed/19933844",
				"http://www.ncbi.nlm.nih.gov/pubmed/19470761",
				"http://www.ncbi.nlm.nih.gov/pubmed/19029894",
				"http://www.ncbi.nlm.nih.gov/pubmed/17235287"
			],
			"type": "yesno",
			"id": "532ff558d6d3ac6a34000037",
			"snippets": [
				{
					"offsetInBeginSection": 33,
					"offsetInEndSection": 166,
					"text": "ATP-dependent chromatin remodeling and nucleosome-depleted 'barriers' co-operate to determine the kinetics of nucleosome organization",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 99,
					"offsetInEndSection": 275,
					"text": "ATP-dependent nucleosome-remodeling factors endow chromatin with structural flexibility by promoting assembly or disruption of nucleosomes and the exchange of histone variants.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24008565",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 948,
					"offsetInEndSection": 1164,
					"text": "remodeling takes place in an ATP-independent manner. Binding of distamycin to the linker and nucleosomal DNA culminates in eviction of the linker histone and the formation of a population of off-centered nucleosomes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23460895",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 574,
					"offsetInEndSection": 735,
					"text": "which promotes histone deposition onto DNA, and a novel activity, which prevents nucleosome eviction but not remodeling mediated by the ATP-dependent RSC complex",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22177115",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 134,
					"text": "ATP-dependent chromatin remodeling complex SWI/SNF regulates transcription and has been implicated in promoter nucleosome eviction",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20513433",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 122,
					"text": "ATP-dependent nucleosome-remodeling enzyme involved in transcription, replication, and the DNA damage response",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19933844",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1361,
					"offsetInEndSection": 1430,
					"text": "Iec1-Ino80 complex promotes transcription through nucleosome eviction",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19933844",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 237,
					"offsetInEndSection": 323,
					"text": "Ino80 complex from fission yeast mediates ATP-dependent nucleosome remodeling in vitro",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19933844",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 969,
					"offsetInEndSection": 1153,
					"text": "reconstitution of nucleosome disassembly using the ATP-dependent chromatin remodeler Rsc and Vps75 revealed that these proteins can cooperate to remove H2A/H2B dimers from nucleosomes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19470761",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 106,
					"text": "TP-dependent chromatin-remodeling complexes, such as RSC, can reposition, evict or restructure nucleosome",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19029894",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 87,
					"text": "TP-dependent chromatin remodeling complexes play a critical role in chromatin dynamics",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17235287",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 348,
					"offsetInEndSection": 418,
					"text": " activity of SWI/SNF to histone eviction in trans from gene promoters.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17235287",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3654,
					"offsetInEndSection": 3816,
					"text": "owing to ATP-driven remodeling, nucleosome organization is highly dynamic, with kinetics and time-averaged properties which are far from thermodynamic equilibrium",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 9302,
					"offsetInEndSection": 9382,
					"text": "The sliding of nucleosomes in our model is facilitated by ATP-dependent enzymes.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4048,
					"offsetInEndSection": 4124,
					"text": "sequence-dependent nucleosomeβ€“DNA interactions and ATP-dependent remodeling ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 5686,
					"offsetInEndSection": 5900,
					"text": "we take into account four major factors that influence nucleosome assembly: DNAβ€“histone interactions, nucleosomeβ€“nucleosome interactions, ATP-dependent nucleosome reorganization and the effect of barriers near TSSs",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 113,
					"offsetInEndSection": 210,
					"text": "DNA sequence and ATP-dependent molecular machines work together to control nucleosome positioning",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 248,
					"offsetInEndSection": 390,
					"text": "ATP-dependent remodeling is absolutely necessary to obtain the oscillatory statistical positioning observed near nucleosome-depleting barriers",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 517,
					"offsetInEndSection": 628,
					"text": " Our results suggest that ATP-dependent nucleosome eviction is crucial in obtaining the statistical positioning",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "What histone trimethylation has been associated to RNA splicing?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23740743",
				"http://www.ncbi.nlm.nih.gov/pubmed/23676078",
				"http://www.ncbi.nlm.nih.gov/pubmed/22308494",
				"http://www.ncbi.nlm.nih.gov/pubmed/22188810",
				"http://www.ncbi.nlm.nih.gov/pubmed/21807997",
				"http://www.ncbi.nlm.nih.gov/pubmed/21792193",
				"http://www.ncbi.nlm.nih.gov/pubmed/19823040",
				"http://www.ncbi.nlm.nih.gov/pubmed/18042460"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23740743",
				"http://www.ncbi.nlm.nih.gov/pubmed/23676078",
				"http://www.ncbi.nlm.nih.gov/pubmed/22308494",
				"http://www.ncbi.nlm.nih.gov/pubmed/22188810",
				"http://www.ncbi.nlm.nih.gov/pubmed/21807997",
				"http://www.ncbi.nlm.nih.gov/pubmed/21792193",
				"http://www.ncbi.nlm.nih.gov/pubmed/19823040",
				"http://www.ncbi.nlm.nih.gov/pubmed/18042460"
			],
			"type": "factoid",
			"id": "532ff917d6d3ac6a34000038",
			"snippets": [
				{
					"offsetInBeginSection": 1031,
					"offsetInEndSection": 1236,
					"text": "histone H3 lysine 36 tri-methylation (H3K36Me3), exhibits different patterns around the cleavage sites of genes using multiple polyadenylation sites from those of genes using a single polyadenylation site.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23740743",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1229,
					"offsetInEndSection": 1439,
					"text": "ChIP-sequencing data mapped onto skipped exon events reveal a correlation between histone H3K36 trimethylation peaks and skipped exons, suggesting epigenetic marks being part of alternative splicing regulation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23676078",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1128,
					"offsetInEndSection": 1290,
					"text": "Vezf1 interacts with Mrg15/Mrgbp, a protein that recognizes H3K36 trimethylation, consistent with the role of histone modifications at alternatively spliced sites",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22308494",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 931,
					"offsetInEndSection": 1182,
					"text": "H2BK123ub1 is also a feature of introns in the yeast genome, and the disruption of this modification alters the intragenic distribution of H3 trimethylation on lysine 36 (H3K36me3), which functionally correlates with alternative RNA splicing in humans",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22188810",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 124,
					"offsetInEndSection": 300,
					"text": "We investigated whether a causal relationship exists between splicing and chromatin modification by asking whether splice-site mutations affect the methylation of histone H3K36",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21807997",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 104,
					"offsetInEndSection": 158,
					"text": " splicing can also contribute to histone modification,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21792193",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 251,
					"offsetInEndSection": 452,
					"text": "Genome-wide analysis of histone methylation in human cell lines and mouse primary T cells reveals that intron-containing genes are preferentially marked with histone H3 Lys36 trimethylation (H3K36me3) ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21792193",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 188,
					"offsetInEndSection": 442,
					"text": " transcription and splicing are functionally intertwined, and that modified nucleosomes with trimethylation of lysine 36 in histone subunit 3 (H3K36me3) are enriched at internal exons and the downstream flanking intronic regions of highly expressed genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19823040",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 987,
					"offsetInEndSection": 1062,
					"text": "methylated H3K4 serves to facilitate the competency of pre-mRNA maturation ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18042460",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3954,
					"offsetInEndSection": 3992,
					"text": "Skipped exons are\nenriched in H3K36me3",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23676078",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 25453,
					"offsetInEndSection": 25558,
					"text": "we find that both the\nupstream intron and the skipped exon display higher levels of H3K36me3 than average",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23676078",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 26030,
					"offsetInEndSection": 26140,
					"text": "Isoforms with the exon\nincluded can thus be more prevalent and account for the observed enrichment in\nH3K36me3",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23676078",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 3834,
					"offsetInEndSection": 3913,
					"text": "H3K36me3 has been functionally linked to pre-mRNA splicing in worms and humans ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22188810",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4874,
					"offsetInEndSection": 5009,
					"text": "These observations suggest two possible roles for H3K36me3 in pre-mRNA splicing, and specifically in the regulation of pre-RNA splicing",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22188810",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "Has the protein TIEG1 been associated with apoptosis?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18930345",
				"http://www.ncbi.nlm.nih.gov/pubmed/17951258",
				"http://www.ncbi.nlm.nih.gov/pubmed/17729309",
				"http://www.ncbi.nlm.nih.gov/pubmed/17659279",
				"http://www.ncbi.nlm.nih.gov/pubmed/12788480",
				"http://www.ncbi.nlm.nih.gov/pubmed/12771931",
				"http://www.ncbi.nlm.nih.gov/pubmed/12065093",
				"http://www.ncbi.nlm.nih.gov/pubmed/23815903",
				"http://www.ncbi.nlm.nih.gov/pubmed/23244828",
				"http://www.ncbi.nlm.nih.gov/pubmed/22563190",
				"http://www.ncbi.nlm.nih.gov/pubmed/22349513",
				"http://www.ncbi.nlm.nih.gov/pubmed/22025675",
				"http://www.ncbi.nlm.nih.gov/pubmed/21524276",
				"http://www.ncbi.nlm.nih.gov/pubmed/21423731",
				"http://www.ncbi.nlm.nih.gov/pubmed/20945337",
				"http://www.ncbi.nlm.nih.gov/pubmed/20691807",
				"http://www.ncbi.nlm.nih.gov/pubmed/20201061",
				"http://www.ncbi.nlm.nih.gov/pubmed/17308981",
				"http://www.ncbi.nlm.nih.gov/pubmed/14743447",
				"http://www.ncbi.nlm.nih.gov/pubmed/10573529",
				"http://www.ncbi.nlm.nih.gov/pubmed/10471833"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C491384"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C491384"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C491384"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C491384"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C491384"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q13118",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_513133313138001D"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513133313138001D",
					"p": "http://www.w3.org/2004/02/skos/core#altLabel",
					"o": "TIEG"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5131333131380019",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transforming growth factor-beta-inducible early growth response protein 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5131333131380018",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "EGR-alpha"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5131333131380019",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "TGFB-inducible early growth response protein 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513133313138001D",
					"p": "http://www.w3.org/2004/02/skos/core#altLabel",
					"o": "TIEG1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5131333131380017",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Krueppel-like factor 10"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513133313138001D",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "KLF10"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5131333131380019",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "TIEG-1"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C098111"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C098111"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C098111"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C098111"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C098111"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C098111"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C098111"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C098111"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O08876",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_4F303838373600E"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600E",
					"p": "http://www.w3.org/2004/02/skos/core#altLabel",
					"o": "Tieg"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600E",
					"p": "http://www.w3.org/2004/02/skos/core#altLabel",
					"o": "Cpg20"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600B",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "TIEG-1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600B",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "TGFB-inducible early growth response protein 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600E",
					"p": "http://www.w3.org/2004/02/skos/core#altLabel",
					"o": "Tieg1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600E",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "Klf10"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600C",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Zinc finger transcription factor homolog CPG20"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Krueppel-like factor 10"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F303838373600B",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transforming growth factor-beta-inducible early growth response protein 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12983919"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8423440",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG1 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414282"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12983919",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TIEG protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8428062",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "early growth response alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410040",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGR alpha protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12986334",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8414547"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410044"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8410044",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "EGRA protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8428062"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414282",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "KLF10 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8423440"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A12986334"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0386762",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8410040"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8414547",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Kruppel-like factor 10, human"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O89091",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_4F38393039310010"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F383930393100E",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "TGFB-inducible early growth response protein 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F38393039310010",
					"p": "http://www.w3.org/2004/02/skos/core#altLabel",
					"o": "Tieg"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F383930393100C",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "GDNF-inducible factor"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F383930393100D",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transcription factor GIF"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F38393039310010",
					"p": "http://www.w3.org/2004/02/skos/core#altLabel",
					"o": "Gdnfif"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F383930393100E",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Transforming growth factor-beta-inducible early growth response protein 1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F383930393100D",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "mGIF"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F383930393100B",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Krueppel-like factor 10"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F38393039310010",
					"p": "http://www.w3.org/2004/02/skos/core#altLabel",
					"o": "Tieg1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F38393039310010",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "Klf10"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F383930393100E",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "TIEG-1"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2004/02/skos/core#broader",
					"o": "http://linkedlifedata.com/resource/umls/id/C0012940"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0050767",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "DNA Binding Protein"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0404940",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "DNA binding protein"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17877761",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "DNA-Binding Proteins [Chemical/Ingredient]"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17974184",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Binding Protein, DNA"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0050901",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "DNA-Binding Proteins"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0050769",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "DNA Binding Proteins"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2004/02/skos/core#broader",
					"o": "http://linkedlifedata.com/resource/umls/id/C0040648"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828631",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNF inducible factor protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0057942",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Factors, Transcription"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15583787",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7829067",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Tieg1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17904335",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Transcription Factors [Chemical/Ingredient]"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7835462",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TGFB inducible early growth response 1 protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18024172",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Factor, Transcription"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7835462"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828632"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0127530",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Transcription Factors"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7828631"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7828632",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "GDNFIF protein, mouse"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1811857",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "transcription factors"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A18048422",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Transcription Factor"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1959548",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "TRANSCRIPTION FACTOR"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15583787"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1308314",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7829067"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0490726",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "transcription factor"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18930345",
				"http://www.ncbi.nlm.nih.gov/pubmed/17951258",
				"http://www.ncbi.nlm.nih.gov/pubmed/17729309",
				"http://www.ncbi.nlm.nih.gov/pubmed/17659279",
				"http://www.ncbi.nlm.nih.gov/pubmed/12788480",
				"http://www.ncbi.nlm.nih.gov/pubmed/12771931",
				"http://www.ncbi.nlm.nih.gov/pubmed/12065093",
				"http://www.ncbi.nlm.nih.gov/pubmed/23815903",
				"http://www.ncbi.nlm.nih.gov/pubmed/23244828",
				"http://www.ncbi.nlm.nih.gov/pubmed/22563190",
				"http://www.ncbi.nlm.nih.gov/pubmed/22349513",
				"http://www.ncbi.nlm.nih.gov/pubmed/22025675",
				"http://www.ncbi.nlm.nih.gov/pubmed/21524276",
				"http://www.ncbi.nlm.nih.gov/pubmed/21423731",
				"http://www.ncbi.nlm.nih.gov/pubmed/20945337",
				"http://www.ncbi.nlm.nih.gov/pubmed/20691807",
				"http://www.ncbi.nlm.nih.gov/pubmed/20201061",
				"http://www.ncbi.nlm.nih.gov/pubmed/17308981",
				"http://www.ncbi.nlm.nih.gov/pubmed/14743447",
				"http://www.ncbi.nlm.nih.gov/pubmed/10573529",
				"http://www.ncbi.nlm.nih.gov/pubmed/10471833"
			],
			"type": "yesno",
			"id": "53386282d6d3ac6a3400005a",
			"snippets": [
				{
					"offsetInBeginSection": 33,
					"offsetInEndSection": 215,
					"text": "TGF-beta) inducible early gene 1 (TIEG1) is known to induce apoptosis in TGF-beta sensitive pancreatic cancer cells, yet its effect on TGF-beta resistant cancer cells remains unclear",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18930345",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1032,
					"offsetInEndSection": 1116,
					"text": "overexpression of TIEG1, protected ALL cells against chemotherapy-induced cell death",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18798273",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1267,
					"offsetInEndSection": 1366,
					"text": " TIEG1 might be involved in mediating this effect from the microenvironment onto the leukemia cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18798273",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 664,
					"offsetInEndSection": 813,
					"text": "We also demonstrate that TIEG-1 ectopic expression in CGNPs induces cell cycle arrest that can lead to apoptosis but fails to promote differentiation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17951258",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 633,
					"offsetInEndSection": 830,
					"text": "TIEG1 acts as an inducer or repressor of gene transcription to enhance the TGFbeta/Smad pathway, as well at other signaling pathways, to regulate cell proliferation, differentiation, and apoptosis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17729309",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 18,
					"offsetInEndSection": 98,
					"text": "TGFbeta inducible early gene (TIEG1) mimics TGFbeta action and induces apoptosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17659279",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 342,
					"offsetInEndSection": 514,
					"text": "the transforming growth factor-beta- (TGF-beta-) inducible early response 1 gene (TIEG1), which plays a pivotal role in TGF-beta-regulated cell growth control and apoptosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12788480",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1240,
					"offsetInEndSection": 1430,
					"text": "Induction of mRNA for Smad4 and the TGF-beta1-regulated apoptosis-inducing transcription factor TGF-beta1-inducible early gene (TIEG1) was detected within the first 6 h of doxazosin treatmen",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12771931",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 126,
					"offsetInEndSection": 316,
					"text": "TIEG1 (TGF-beta inducible early gene) is a recently characterized transcription factor regulated by TGF-beta that induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12065093",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 32,
					"text": "Influence of TIEG1 on apoptosis",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23815903",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 36,
					"offsetInEndSection": 118,
					"text": "the influence of TIEG1 on apoptosis of HL-60 cells and the expression of Bcl-2/Bax",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23815903",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 835,
					"offsetInEndSection": 1030,
					"text": "The expression of genes involved in insulin resistance (PDK4, AHSG) is increased, together with expression of TIEG1, a transcription factor that can induce apoptosis via the mitochondrial pathway",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23244828",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1408,
					"offsetInEndSection": 1512,
					"text": "the overexpression of TIEG1 mediated growth inhibition and apoptosis in TGF-Ξ²1-resistant HCC cell lines,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22563190",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 328,
					"offsetInEndSection": 421,
					"text": "On the other hand, KLF10 deficient keratinocytes showed increased proliferation and apoptosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22349513",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 58,
					"text": "LF10, transforming growth factor-Ξ²-inducible early gene 1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22349513",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 42,
					"text": "IEG1 can induce apoptosis of cancer cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22025675",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 7,
					"offsetInEndSection": 108,
					"text": "TGF-Ξ² inducible early gene 1) plays a significant role in regulating cell proliferation and apoptosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21524276",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 30,
					"offsetInEndSection": 178,
					"text": "TIEG1) is a KrΓΌppel-like transcription factor (KLF10) that was originally cloned from human osteoblasts as an early response gene to TGF-Ξ² treatment",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1221,
					"offsetInEndSection": 1412,
					"text": "Adenoviral delivery of TIEG1 (AdTIEG1) to TIEG1(-/-) cells reversed the RANKL-induced NFATc1 signaling defect in TIEG1(-/-) precursors and eliminated the differentiation and apoptosis defects",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 31,
					"offsetInEndSection": 170,
					"text": "(TGF)-Ξ² inducible early gene (TIEG)-1 is implicated in the control of cell proliferation, differentiation, and apoptosis in some cell types",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20945337",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 554,
					"offsetInEndSection": 685,
					"text": "TIEG1 has been shown to mimic the effects of TGF-beta in various carcinoma cells and plays a critical role in the apoptotic cascade",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20691807",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 39,
					"offsetInEndSection": 181,
					"text": "(TIEG) is a family of primary response genes induced by TGF-beta, which are well recognized in regulating cellular proliferation and apoptosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20201061",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 385,
					"offsetInEndSection": 492,
					"text": "In human and murine tissues it has been shown that TIEG1 and TIEG2 induce apoptosis and inhibit cell growth",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17308981",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 492,
					"offsetInEndSection": 550,
					"text": "overexpression of TIEG1 in OLI-neu cells induced apoptosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14743447",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 35,
					"offsetInEndSection": 215,
					"text": "(TGF-beta(1))-inducible transcription factors have recently elicited interest because of their critical role in the regulation of cell proliferation, differentiation, and apoptosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10573529",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 405,
					"offsetInEndSection": 502,
					"text": "ectopic overexpression of TIEG is sufficient to trigger the apoptotic cell program in these cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10471833",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 113,
					"text": "TGF-Ξ²1-inducible early gene (TIEG1) is another factor that induces apoptosis in breast, lung and kidney cells",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12771931",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 4668,
					"offsetInEndSection": 4801,
					"text": "TIEG1 is an early TGF-Ξ²1 upregulated transcription factor that has been documented to regulate apoptosis in several tumour cell lines",
					"beginSection": "sections.7",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12771931",
					"endSection": "sections.7"
				},
				{
					"offsetInBeginSection": 1552,
					"offsetInEndSection": 1773,
					"text": "TIEG1 is a member of the KrΓΌppel-like transcription factor family (KLF10) which is expressed in numerous tissues [15], [16], [17], [18], [19] and is involved in the regulation of cell growth, differentiation and apoptosis",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1047,
					"offsetInEndSection": 1130,
					"text": "osteoclasts lacking TIEG exhibited significantly less apoptosis than WT osteoclasts",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 1774,
					"offsetInEndSection": 1869,
					"text": "Lack of TIEG1 in osteoclast precursors delays osteoclast differentiation and apoptosis in vitro",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 12496,
					"offsetInEndSection": 12612,
					"text": "We found that restoration of TIEG1 expression in TIEG1β�’/β�’ precursors resulted in increased apoptosis of mature cells",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 872,
					"offsetInEndSection": 937,
					"text": "there was a reduction in apoptosis in TIEG1β�’/β�’ mature osteoclasts",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1015,
					"offsetInEndSection": 1114,
					"text": "the sustained number of osteoclasts in TIEG1β�’/β�’ bones is due to a reduction in osteoclast apoptosis",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 6976,
					"offsetInEndSection": 7030,
					"text": "loss of TIEG1 expression results in reduced apoptosis ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 7260,
					"offsetInEndSection": 7295,
					"text": "TIEG1 promotes osteoclast apoptosis",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 8287,
					"offsetInEndSection": 8421,
					"text": "the findings reported here support that TIEG1 expression in osteoclast precursors accelerates osteoclast differentiation and apoptosis",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21423731",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "What histone modification is recognized by the bromodomain?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23095041",
				"http://www.ncbi.nlm.nih.gov/pubmed/21851057",
				"http://www.ncbi.nlm.nih.gov/pubmed/21596426",
				"http://www.ncbi.nlm.nih.gov/pubmed/21271695",
				"http://www.ncbi.nlm.nih.gov/pubmed/21189220",
				"http://www.ncbi.nlm.nih.gov/pubmed/17049045",
				"http://www.ncbi.nlm.nih.gov/pubmed/16265664",
				"http://www.ncbi.nlm.nih.gov/pubmed/15970672",
				"http://www.ncbi.nlm.nih.gov/pubmed/15382140",
				"http://www.ncbi.nlm.nih.gov/pubmed/15143168",
				"http://www.ncbi.nlm.nih.gov/pubmed/15014446",
				"http://www.ncbi.nlm.nih.gov/pubmed/10746732",
				"http://www.ncbi.nlm.nih.gov/pubmed/10716917"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23095041",
				"http://www.ncbi.nlm.nih.gov/pubmed/21851057",
				"http://www.ncbi.nlm.nih.gov/pubmed/21596426",
				"http://www.ncbi.nlm.nih.gov/pubmed/21271695",
				"http://www.ncbi.nlm.nih.gov/pubmed/21189220",
				"http://www.ncbi.nlm.nih.gov/pubmed/17049045",
				"http://www.ncbi.nlm.nih.gov/pubmed/16265664",
				"http://www.ncbi.nlm.nih.gov/pubmed/15970672",
				"http://www.ncbi.nlm.nih.gov/pubmed/15382140",
				"http://www.ncbi.nlm.nih.gov/pubmed/15143168",
				"http://www.ncbi.nlm.nih.gov/pubmed/15014446",
				"http://www.ncbi.nlm.nih.gov/pubmed/10746732",
				"http://www.ncbi.nlm.nih.gov/pubmed/10716917"
			],
			"type": "factoid",
			"id": "53398855d6d3ac6a3400005b",
			"snippets": [
				{
					"offsetInBeginSection": 280,
					"offsetInEndSection": 361,
					"text": "acetyllysine-specific protein-protein interaction with bromodomain reader modules",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23095041",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 141,
					"offsetInEndSection": 228,
					"text": "Bromodomains bind acetylated lysines, acting as readers of the histone-acetylation code",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21851057",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 331,
					"offsetInEndSection": 472,
					"text": " three acetyllysine ligands are indentified for a PHD-adjacent bromodomain in BPTF via systematic screening and biophysical characterization.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21596426",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 673,
					"offsetInEndSection": 712,
					"text": "acetyl-lysine binding bromodomain (BRD)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21271695",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 7,
					"offsetInEndSection": 66,
					"text": "bromodomain proteins bind to acetylated lysines in histones",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21189220",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 251,
					"text": "romodomains are present in many chromatin-associated proteins such as the SWI/SNF and RSC chromatin remodelling and the SAGA HAT (histone acetyltransferase) complexes, and can bind to acetylated lysine residues in the N-terminal tails of the histones",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17049045",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 10,
					"offsetInEndSection": 60,
					"text": "recognition of acetylated histones by bromodomains",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17049045",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 130,
					"offsetInEndSection": 160,
					"text": "BRD7, a novel bromodomain gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16265664",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 675,
					"offsetInEndSection": 717,
					"text": "BRD7 interacted with H3 peptide acetylated",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16265664",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 352,
					"offsetInEndSection": 424,
					"text": "bromodomain-containing proteins that recognize histone acetylation sites",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15970672",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 581,
					"offsetInEndSection": 677,
					"text": "bromodomains of Gcn5, PCAF, TAF1 and CBP are able to recognize acetyllysine residues in histones",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15382140",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 26,
					"text": "romodomain factor 1 (Bdf1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15143168",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 223,
					"offsetInEndSection": 274,
					"text": " Bdf1 binds preferentially to acetylated histone H4",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15143168",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 118,
					"offsetInEndSection": 233,
					"text": "chromatin remodeling complex RSC bears multiple bromodomains, motifs for acetyl-lysine and histone tail interaction",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15014446",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 666,
					"offsetInEndSection": 769,
					"text": " in vitro binding of a HAT bromodomain with acetylated lysines within H3 and H4 amino-terminal peptides",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10746732",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 535,
					"offsetInEndSection": 583,
					"text": "bromodomain, that recognizes acetylated residues",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10716917",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 13,
					"offsetInEndSection": 172,
					"text": "Bromodomains are protein interaction modules\nthat recognize the\nΞµ-N-acetylation state of specific lysine residues found within\nhistone tails and other proteins",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23095041",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1371,
					"offsetInEndSection": 1461,
					"text": "Bromodomains\nare the only modules that can specifically recognize acetylated linear\nmotifs",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23095041",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 124,
					"offsetInEndSection": 285,
					"text": "the pockets for binding acetylated\nlysine within the bromodomain proteins are sufficiently deep and defined\nto potentially accommodate inhibitory small molecules",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23095041",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 879,
					"offsetInEndSection": 1024,
					"text": "Bromodomains are a family of conserved β�Ό110 amino acid modules that bind selectively to acetylated lysines present in proteins, notably histones,",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21851057",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2610,
					"offsetInEndSection": 2685,
					"text": "bromodomain binding to histones and other acetyl-lysine-containing proteins",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21851057",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "What histone variants play a role in the DNA damage reponse?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23777805",
				"http://www.ncbi.nlm.nih.gov/pubmed/23365640",
				"http://www.ncbi.nlm.nih.gov/pubmed/20703100",
				"http://www.ncbi.nlm.nih.gov/pubmed/20407219",
				"http://www.ncbi.nlm.nih.gov/pubmed/18296106",
				"http://www.ncbi.nlm.nih.gov/pubmed/16094454",
				"http://www.ncbi.nlm.nih.gov/pubmed/21383063",
				"http://www.ncbi.nlm.nih.gov/pubmed/23319141",
				"http://www.ncbi.nlm.nih.gov/pubmed/22493515",
				"http://www.ncbi.nlm.nih.gov/pubmed/22331172",
				"http://www.ncbi.nlm.nih.gov/pubmed/22253857",
				"http://www.ncbi.nlm.nih.gov/pubmed/22122340",
				"http://www.ncbi.nlm.nih.gov/pubmed/21901086",
				"http://www.ncbi.nlm.nih.gov/pubmed/21700704",
				"http://www.ncbi.nlm.nih.gov/pubmed/19896956",
				"http://www.ncbi.nlm.nih.gov/pubmed/19607843",
				"http://www.ncbi.nlm.nih.gov/pubmed/19234522",
				"http://www.ncbi.nlm.nih.gov/pubmed/19131518",
				"http://www.ncbi.nlm.nih.gov/pubmed/17851762",
				"http://www.ncbi.nlm.nih.gov/pubmed/17613284",
				"http://www.ncbi.nlm.nih.gov/pubmed/16951256",
				"http://www.ncbi.nlm.nih.gov/pubmed/16760674",
				"http://www.ncbi.nlm.nih.gov/pubmed/12202754",
				"http://www.ncbi.nlm.nih.gov/pubmed/11893489"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23777805",
				"http://www.ncbi.nlm.nih.gov/pubmed/23365640",
				"http://www.ncbi.nlm.nih.gov/pubmed/20703100",
				"http://www.ncbi.nlm.nih.gov/pubmed/20407219",
				"http://www.ncbi.nlm.nih.gov/pubmed/18296106",
				"http://www.ncbi.nlm.nih.gov/pubmed/16094454",
				"http://www.ncbi.nlm.nih.gov/pubmed/21383063",
				"http://www.ncbi.nlm.nih.gov/pubmed/23319141",
				"http://www.ncbi.nlm.nih.gov/pubmed/22493515",
				"http://www.ncbi.nlm.nih.gov/pubmed/22331172",
				"http://www.ncbi.nlm.nih.gov/pubmed/22253857",
				"http://www.ncbi.nlm.nih.gov/pubmed/22122340",
				"http://www.ncbi.nlm.nih.gov/pubmed/21901086",
				"http://www.ncbi.nlm.nih.gov/pubmed/21700704",
				"http://www.ncbi.nlm.nih.gov/pubmed/19896956",
				"http://www.ncbi.nlm.nih.gov/pubmed/19607843",
				"http://www.ncbi.nlm.nih.gov/pubmed/19234522",
				"http://www.ncbi.nlm.nih.gov/pubmed/19131518",
				"http://www.ncbi.nlm.nih.gov/pubmed/17851762",
				"http://www.ncbi.nlm.nih.gov/pubmed/17613284",
				"http://www.ncbi.nlm.nih.gov/pubmed/16951256",
				"http://www.ncbi.nlm.nih.gov/pubmed/16760674",
				"http://www.ncbi.nlm.nih.gov/pubmed/12202754",
				"http://www.ncbi.nlm.nih.gov/pubmed/11893489"
			],
			"type": "list",
			"id": "533675ced6d3ac6a34000056",
			"snippets": [
				{
					"offsetInBeginSection": 185,
					"offsetInEndSection": 333,
					"text": "H2A.Z is an evolutionarily ancient and highly conserved H2A variant that regulates processes ranging from gene expression to the DNA damage response",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22493515",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 623,
					"offsetInEndSection": 746,
					"text": "activation of DNA damage checkpoints (ataxia telangiectasia mutated (ATM) and H2A histone family, member X (H2AFX (H2AFX)))",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22331172",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 188,
					"offsetInEndSection": 349,
					"text": "the specialization imparted by histone H2A (H2A.X and H2A.Z) variants to the nucleosome core particle constitutes the earliest response to DNA damage in the cell",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22253857",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 425,
					"offsetInEndSection": 705,
					"text": "histone variants (H2AX and H2A.Z), histone post-translational modifications (acetylation, phosphorylation, methylation and ubiquitination) and chromatin-remodeling complexes (INO80, SWR1, SWI/SNF, RSC and NuRD) are important and direct players in the DNA double-strand break (DSB)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22122340",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1456,
					"offsetInEndSection": 1593,
					"text": "H2A.Z incorporation in the coding regions of genes encoding proteins involved in the regulation of meiosis and genotoxic stress responses",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21901086",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 742,
					"offsetInEndSection": 787,
					"text": " phosphorylation of H2AX, a DNA damage signal",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21700704",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 114,
					"text": "DSB) are generally considered the most critical lesion induced by ionizing radiation (IR",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19896956",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 246,
					"offsetInEndSection": 283,
					"text": "phosphorylated forms of histone H2AX ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19896956",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 579,
					"offsetInEndSection": 710,
					"text": "H2AX has a complete SQ(E/D)varphi (where varphi denotes a hydrophobic residue) known to be phosphorylated in response to DNA damage",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19607843",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 701,
					"offsetInEndSection": 774,
					"text": "H2A.X, plays a very important role in the cellular response to DNA damage",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19234522",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 201,
					"text": "H2A.X is an H2A variant present in multicellular organisms that is specifically phosphorylated on the serine in the C-terminal consensus sequence, canonically \"SQEY,\" in response to DNA damage.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19131518",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 37,
					"offsetInEndSection": 113,
					"text": "H2AFX) is important in maintaining chromatin structure and genetic stability",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17851762",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 78,
					"text": "Saccharomyces cerevisiae, the linker histone HHO1 is involved in DNA repair",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17613284",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 58,
					"text": "H1 variant, H1R is involved in DNA damage response",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17613284",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 339,
					"offsetInEndSection": 477,
					"text": "high levels of histone H2AX phosphorylation and an increased incorporation of the Htz1p histone variant into chromatin surrounding the DSB",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16951256",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 951,
					"offsetInEndSection": 1071,
					"text": "TRF2 upregulation was more dramatic in drug-resistant cells and occurred before the expression of ATM, gammaH2AX and p53",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16760674",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 213,
					"offsetInEndSection": 305,
					"text": "DNA double-strand breaks induced by anticancer drugs or irradiation increase TRF2 expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16760674",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 265,
					"offsetInEndSection": 467,
					"text": "Histone variant H2AX and core histone H2A are phosphorylated in mammals and budding yeast, respectively. We demonstrate the DSB-induced phosphorylation of histone variant H2Av in Drosophila melanogaster",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12202754",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 40,
					"offsetInEndSection": 119,
					"text": "formation of a double-strand break (DSB) in chromosomal DNA is highly conserved",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12202754",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 175,
					"offsetInEndSection": 339,
					"text": "H2A variants, H2AX and H2AZ. H2AX is phosphorylated on a serine four residues from the carboxyl terminus in response to the introduction of DNA double-strand breaks",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11893489",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 492,
					"offsetInEndSection": 649,
					"text": "In response to IR, ZNF668 knockdown reduces Tip60-H2AX interaction and impairs IR-induced histone H2AX hyperacetylation, thus impairing chromatin relaxation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23777805",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1092,
					"offsetInEndSection": 1182,
					"text": "RPA foci formation were reduced in parallel with increasing levels of H2AX phosphorylation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23365640",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 182,
					"text": "H2AX phosphorylation on a C-terminal serine residue to form \"Ξ³-H2AX\" is a critical early event in the chromatin response to chromosomal DNA double strand breaks in eukaryotes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20703100",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 936,
					"offsetInEndSection": 1075,
					"text": "The phosphorylation of the histone variant H2AX (gammaH2AX) is one of the best examples of histone PTMs in response to DNA damage induction",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20407219",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 603,
					"offsetInEndSection": 830,
					"text": "One of the most well-characterized modifications is caused by the formation of DNA double strand breaks (DSBs), resulting in phosphorylation of histone H2AX (the so-called gamma-H2AX) on the chromatin surrounding the DNA lesion",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18296106",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 588,
					"offsetInEndSection": 867,
					"text": "H2AX appears to be mainly associated with maintaining the genome integrity by participating in the repair of the double-stranded DNA breaks exogenously introduced by environmental damage (ionizing radiation, chemicals) or in the process of homologous recombination during meiosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16094454",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 527,
					"offsetInEndSection": 645,
					"text": "The sustained localization of BMI1 to damage sites is dependent on intact ATM and ATR and requires H2AX phosphorylatio",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21383063",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 886,
					"offsetInEndSection": 1114,
					"text": "unique functional interactions among various chromatin modifiers, suggesting new regulatory pathways, such as a heterochromatin-specific modulation of DNA damage response involving H2A.X and WICH, both enriched in silent domains",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23319141",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 835,
					"offsetInEndSection": 972,
					"text": " it has been proposed that Tyr142p and Ser139p (Ξ³-H2A.X) function as a molecular switch with regulatory effects on the DNA damage respons",
					"beginSection": "sections.8",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23319141",
					"endSection": "sections.8"
				},
				{
					"offsetInBeginSection": 6111,
					"offsetInEndSection": 6189,
					"text": "evidence that H2A.X Tyr142 phosphorylation decreases upon double strand breaks",
					"beginSection": "sections.12",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23319141",
					"endSection": "sections.12"
				},
				{
					"offsetInBeginSection": 2371,
					"offsetInEndSection": 2580,
					"text": " Upon DNA Double-Strand Breaks (DSBs), H2A.X histones of extensive regions flanking a damaged site become reversibly phosphorylated at their C-terminal SQEY motif (Ξ³-H2A.X) creating the so-called β€�H2A.X fociβ€™.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22253857",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2967,
					"offsetInEndSection": 3028,
					"text": "participation of H2A.Z in the maintenance of genome integrity",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22253857",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Which cyclin- dependent kinase inhibitor is regulated by Bmi-1?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20661663",
				"http://www.ncbi.nlm.nih.gov/pubmed/20591222",
				"http://www.ncbi.nlm.nih.gov/pubmed/20551323",
				"http://www.ncbi.nlm.nih.gov/pubmed/19321450",
				"http://www.ncbi.nlm.nih.gov/pubmed/18371338",
				"http://www.ncbi.nlm.nih.gov/pubmed/18371328",
				"http://www.ncbi.nlm.nih.gov/pubmed/18275833",
				"http://www.ncbi.nlm.nih.gov/pubmed/17989730",
				"http://www.ncbi.nlm.nih.gov/pubmed/17651940",
				"http://www.ncbi.nlm.nih.gov/pubmed/17145810",
				"http://www.ncbi.nlm.nih.gov/pubmed/17102614",
				"http://www.ncbi.nlm.nih.gov/pubmed/16537449",
				"http://www.ncbi.nlm.nih.gov/pubmed/16157028",
				"http://www.ncbi.nlm.nih.gov/pubmed/16155021",
				"http://www.ncbi.nlm.nih.gov/pubmed/14982841",
				"http://www.ncbi.nlm.nih.gov/pubmed/14574365",
				"http://www.ncbi.nlm.nih.gov/pubmed/12714971",
				"http://www.ncbi.nlm.nih.gov/pubmed/12482990",
				"http://www.ncbi.nlm.nih.gov/pubmed/9923679",
				"http://www.ncbi.nlm.nih.gov/pubmed/21928107",
				"http://www.ncbi.nlm.nih.gov/pubmed/18346113",
				"http://www.ncbi.nlm.nih.gov/pubmed/21496667",
				"http://www.ncbi.nlm.nih.gov/pubmed/21164364",
				"http://www.ncbi.nlm.nih.gov/pubmed/19907431",
				"http://www.ncbi.nlm.nih.gov/pubmed/19390085",
				"http://www.ncbi.nlm.nih.gov/pubmed/19389366",
				"http://www.ncbi.nlm.nih.gov/pubmed/17597110",
				"http://www.ncbi.nlm.nih.gov/pubmed/17233832",
				"http://www.ncbi.nlm.nih.gov/pubmed/16869752",
				"http://www.ncbi.nlm.nih.gov/pubmed/16778197",
				"http://www.ncbi.nlm.nih.gov/pubmed/15964994",
				"http://www.ncbi.nlm.nih.gov/pubmed/15892997",
				"http://www.ncbi.nlm.nih.gov/pubmed/14732230",
				"http://www.ncbi.nlm.nih.gov/pubmed/14536079",
				"http://www.ncbi.nlm.nih.gov/pubmed/11355949"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/20661663",
				"http://www.ncbi.nlm.nih.gov/pubmed/20591222",
				"http://www.ncbi.nlm.nih.gov/pubmed/20551323",
				"http://www.ncbi.nlm.nih.gov/pubmed/19321450",
				"http://www.ncbi.nlm.nih.gov/pubmed/18371338",
				"http://www.ncbi.nlm.nih.gov/pubmed/18371328",
				"http://www.ncbi.nlm.nih.gov/pubmed/18275833",
				"http://www.ncbi.nlm.nih.gov/pubmed/17989730",
				"http://www.ncbi.nlm.nih.gov/pubmed/17651940",
				"http://www.ncbi.nlm.nih.gov/pubmed/17145810",
				"http://www.ncbi.nlm.nih.gov/pubmed/17102614",
				"http://www.ncbi.nlm.nih.gov/pubmed/16537449",
				"http://www.ncbi.nlm.nih.gov/pubmed/16157028",
				"http://www.ncbi.nlm.nih.gov/pubmed/16155021",
				"http://www.ncbi.nlm.nih.gov/pubmed/14982841",
				"http://www.ncbi.nlm.nih.gov/pubmed/14574365",
				"http://www.ncbi.nlm.nih.gov/pubmed/12714971",
				"http://www.ncbi.nlm.nih.gov/pubmed/12482990",
				"http://www.ncbi.nlm.nih.gov/pubmed/9923679",
				"http://www.ncbi.nlm.nih.gov/pubmed/21928107",
				"http://www.ncbi.nlm.nih.gov/pubmed/18346113",
				"http://www.ncbi.nlm.nih.gov/pubmed/21496667",
				"http://www.ncbi.nlm.nih.gov/pubmed/21164364",
				"http://www.ncbi.nlm.nih.gov/pubmed/19907431",
				"http://www.ncbi.nlm.nih.gov/pubmed/19390085",
				"http://www.ncbi.nlm.nih.gov/pubmed/19389366",
				"http://www.ncbi.nlm.nih.gov/pubmed/17597110",
				"http://www.ncbi.nlm.nih.gov/pubmed/17233832",
				"http://www.ncbi.nlm.nih.gov/pubmed/16869752",
				"http://www.ncbi.nlm.nih.gov/pubmed/16778197",
				"http://www.ncbi.nlm.nih.gov/pubmed/15964994",
				"http://www.ncbi.nlm.nih.gov/pubmed/15892997",
				"http://www.ncbi.nlm.nih.gov/pubmed/14732230",
				"http://www.ncbi.nlm.nih.gov/pubmed/14536079",
				"http://www.ncbi.nlm.nih.gov/pubmed/11355949"
			],
			"type": "factoid",
			"id": "533abc76d6d3ac6a34000064",
			"snippets": [
				{
					"offsetInBeginSection": 663,
					"offsetInEndSection": 748,
					"text": "the knockdown of BMI-1 expression could lead to significant up-regulation of p16INK4a",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20661663",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1621,
					"offsetInEndSection": 1694,
					"text": "In EC9706 cells transfected by Bmi-1 siRNA, the expression levels of p16 ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20591222",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 270,
					"offsetInEndSection": 392,
					"text": "One important pathway regulated by Bmi-1 is that involving two cyclin-dependent kinase inhibitors, p16(Ink4a) and p19(Arf)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20551323",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 643,
					"offsetInEndSection": 814,
					"text": "We also observe that ROS-induced up-regulation of p16(Ink4a) occurs correlatively with ERK1/2-dependent down-regulation and subsequent dissociation from chromatin of Bmi-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19321450",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 51,
					"offsetInEndSection": 214,
					"text": "Bmi-1 is important for postnatal, but not embryonic, neural stem cell (NSC) self-renewal and have identified the cell-cycle inhibitors p16/p19 as molecular targets",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18371338",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 180,
					"offsetInEndSection": 307,
					"text": "Bmi-1 function in stem cells during development that, surprisingly, seems to involve regulation of the cell-cycle inhibitor p21",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18371328",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 823,
					"offsetInEndSection": 892,
					"text": "Our data therefore implicate p21 as an important Bmi-1 target in NSCs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18371338",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 628,
					"offsetInEndSection": 663,
					"text": "Bmi-1-mediated repression of Cdkn2A",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18275833",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 798,
					"offsetInEndSection": 894,
					"text": "decreased expression of proliferating cell nuclear antigen and Bmi-1; upregulation of p16(INK4a)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17989730",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 573,
					"offsetInEndSection": 701,
					"text": "BMI-1 promotes self-renewal of stem cells largely by interfering with two central cellular tumor suppressor pathways, p16(Ink4a)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17651940",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 104,
					"offsetInEndSection": 327,
					"text": "p16INK4a and p14ARF tumor suppressors, human telomerase reverse transcriptase (h-TERT), and oncoprotein c-Myc have been implicated in the regulation of the cell cycle and proliferation mediated by PcG proteins, mainly Bmi-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17145810",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 395,
					"offsetInEndSection": 492,
					"text": "involving the polycomb group repressor Bmi-1 and the cyclin-dependent kinase inhibitor p16(INK4a)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17102614",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 399,
					"offsetInEndSection": 596,
					"text": "increased frequency to a telomere-independent senescent state mediated by the cyclin-dependent kinase inhibitor p16(INK4a). p16(INK4a) expression was regulated by the Polycomb group repressor Bmi-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16537449",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1445,
					"offsetInEndSection": 1549,
					"text": "The antisense Bmi-1 gene can inhibit the growth of K562 cell and upgrade expression of p16 in K562 cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16157028",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 912,
					"offsetInEndSection": 989,
					"text": "overexpression of BMI-1, a transcriptional repressor of the p16(INK4a) locus,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16155021",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 800,
					"offsetInEndSection": 874,
					"text": "experimental model systems indicate that p16 is a downstream target of Bmi",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14982841",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 629,
					"offsetInEndSection": 777,
					"text": "In the absence of Bmi-1, the cyclin-dependent kinase inhibitor gene p16Ink4a is upregulated in neural stem cells, reducing the rate of proliferation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14574365",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 686,
					"offsetInEndSection": 935,
					"text": "A gene expression analysis revealed that the expression of stem cell associated genes, cell survival genes, transcription factors, and genes modulating proliferation including p16Ink4a and p19Arf was altered in bone marrow cells of the Bmi-1-/- mice",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12714971",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 106,
					"text": "polycomb protein Bmi-1 represses the INK4a locus, which encodes the tumor suppressors p16 and p14(ARF)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12482990",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 17,
					"offsetInEndSection": 110,
					"text": "Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9923679",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 777,
					"offsetInEndSection": 912,
					"text": "in bmi-1-deficient lymphocytes, the expression of the tumour suppressors p16 and p19Arf, which are encoded by ink4a, is raised markedly",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9923679",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1493,
					"offsetInEndSection": 1526,
					"text": "BMI-1-mediated INK4a/ARF pathway ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21928107",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 241,
					"offsetInEndSection": 320,
					"text": " expression of the polycomb protein BMI-1 and its downstream targets p16(Ink4a)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18346113",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 905,
					"offsetInEndSection": 1029,
					"text": "reduced expression of Bmi-1, OC, DSP, and BSP compared with rapidly proliferating cells, whereas p16(INK4A) level increased.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21496667",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 52,
					"text": "16Ink4a suppression of lung adenocarcinoma by Bmi-1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21164364",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1386,
					"offsetInEndSection": 1460,
					"text": "The suppression of p16Ink4a occurred in parallel with an increase in Bmi-1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21164364",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1224,
					"offsetInEndSection": 1282,
					"text": "Bmi-1 overexpression reduced p16(INK4a) promoter activity ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19907431",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 35,
					"text": "mi-1 regulates the Ink4a/Arf locus",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19390085",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 212,
					"offsetInEndSection": 291,
					"text": "derepression of the Ink4a/Arf locus is associated with decreased Bmi-1 binding,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19390085",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1029,
					"offsetInEndSection": 1152,
					"text": "pronounced effects of Bmi-1 over-expression in culture were largely attributable to the attenuated induction of p16(Ink4a) ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19389366",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 364,
					"offsetInEndSection": 443,
					"text": "BMI-1 is a transcriptional repressor of the Ink4a/Arf locus encoding p16(ink4a)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17597110",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 387,
					"offsetInEndSection": 442,
					"text": "introduction of Bmi-1 can inhibit p16(INK4a) expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17233832",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 635,
					"offsetInEndSection": 718,
					"text": "Bmi-1 promotes stem cell self-renewal partly by repressing the expression of Ink4a ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16869752",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 917,
					"offsetInEndSection": 1060,
					"text": "Overexpression of Bmi-1 in NPECs led to the induction of human telomerase reverse transcriptase activity and reduction of p16(INK4a) expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16778197",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 657,
					"offsetInEndSection": 742,
					"text": "Bmi-1 thus prevents the premature senescence of neural stem cells by repressing Ink4a",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15964994",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 355,
					"offsetInEndSection": 442,
					"text": "overexpression of the polycomb-group gene BMI-1 might also down-regulate p16 expression",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15892997",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 113,
					"text": "Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14732230",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 809,
					"offsetInEndSection": 925,
					"text": "modulation of Bmi-1 protein might be involved in human colorectal carcinogenesis by repressing the INK4a/ARF protein",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14732230",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 29,
					"text": "mi-1 regulation of INK4A-ARF",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14536079",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 294,
					"offsetInEndSection": 428,
					"text": "expression of BMI-1, a lymphoid oncogene whose product functions as a transcriptional repressor of the INK4A-ARF tumor suppressor locu",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14536079",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 126,
					"text": "bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11355949",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 419,
					"offsetInEndSection": 495,
					"text": "bmi-1 overexpression induces immortalization due to repression of p16/p19ARF",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11355949",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What are the biological roles proposed for proteins containing the SPRY domain?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23886867",
				"http://www.ncbi.nlm.nih.gov/pubmed/23775985",
				"http://www.ncbi.nlm.nih.gov/pubmed/23139046",
				"http://www.ncbi.nlm.nih.gov/pubmed/23091002",
				"http://www.ncbi.nlm.nih.gov/pubmed/22872646",
				"http://www.ncbi.nlm.nih.gov/pubmed/22337885",
				"http://www.ncbi.nlm.nih.gov/pubmed/21035437",
				"http://www.ncbi.nlm.nih.gov/pubmed/19184407",
				"http://www.ncbi.nlm.nih.gov/pubmed/17431422",
				"http://www.ncbi.nlm.nih.gov/pubmed/16648259",
				"http://www.ncbi.nlm.nih.gov/pubmed/16313355",
				"http://www.ncbi.nlm.nih.gov/pubmed/16226405",
				"http://www.ncbi.nlm.nih.gov/pubmed/15857996",
				"http://www.ncbi.nlm.nih.gov/pubmed/15689398",
				"http://www.ncbi.nlm.nih.gov/pubmed/12479811"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23886867",
				"http://www.ncbi.nlm.nih.gov/pubmed/23775985",
				"http://www.ncbi.nlm.nih.gov/pubmed/23139046",
				"http://www.ncbi.nlm.nih.gov/pubmed/23091002",
				"http://www.ncbi.nlm.nih.gov/pubmed/22872646",
				"http://www.ncbi.nlm.nih.gov/pubmed/22337885",
				"http://www.ncbi.nlm.nih.gov/pubmed/21035437",
				"http://www.ncbi.nlm.nih.gov/pubmed/19184407",
				"http://www.ncbi.nlm.nih.gov/pubmed/17431422",
				"http://www.ncbi.nlm.nih.gov/pubmed/16648259",
				"http://www.ncbi.nlm.nih.gov/pubmed/16313355",
				"http://www.ncbi.nlm.nih.gov/pubmed/16226405",
				"http://www.ncbi.nlm.nih.gov/pubmed/15857996",
				"http://www.ncbi.nlm.nih.gov/pubmed/15689398",
				"http://www.ncbi.nlm.nih.gov/pubmed/12479811"
			],
			"type": "list",
			"id": "533c2230c45e133714000002",
			"snippets": [
				{
					"offsetInBeginSection": 7,
					"offsetInEndSection": 141,
					"text": "monkey TRIM5Ξ± SPRY domain recognizes multiple epitopes that span several capsid monomers on the surface of the HIV-1 mature viral core",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23886867",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 876,
					"offsetInEndSection": 1033,
					"text": "These properties, which may enhance resistance of TRIM5Ξ± to capsid mutations, result in relatively low affinity of the individual SPRY domains for the capsid",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23886867",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 180,
					"text": "RIM5Ξ± is a retroviral restriction factor, in which the B30.2 (SPRY) and coiled-coil domains cooperate to determine the specificity of TRIM5Ξ±-mediated capture of retroviral capsids",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23775985",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 84,
					"text": "function of the SPRY/B30.2 domain proteins involved in innate immunity",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23139046",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 202,
					"text": "SPRY domain is a protein interaction module found in 77 murine and ~100 human proteins, and is implicated in important biological pathways, including those that regulate innate and adaptive immunity",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23139046",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 42,
					"offsetInEndSection": 136,
					"text": "TRIM5Ξ±) is a potent antiviral protein that restricts infection by HIV-1 and other retroviruses",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23091002",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 137,
					"offsetInEndSection": 257,
					"text": " TRIM5Ξ± recognizes the lattice of the retrovirus capsid through its B30.2 (PRY/SPRY) domain in a species-specific manner",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23091002",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 566,
					"offsetInEndSection": 782,
					"text": "binding of the PRY-SPRY domain from the TRIM50 C-terminal region to phosphatidylinositol species, suggesting that TRIM50 is involved in vesicular dynamics by sensing the phosphorylated state of phosphoinositol lipids",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22872646",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1093,
					"offsetInEndSection": 1159,
					"text": "TRIM50 seems to play an essential role in tubulovesicular dynamics",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22872646",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 873,
					"offsetInEndSection": 988,
					"text": "TRIM67 regulates Ras signaling via degradation of 80K-H, leading to neural differentiation including neuritogenesis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22337885",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 321,
					"offsetInEndSection": 423,
					"text": "TRIM67, which has a TRIM motif, an FN3 domain and a SPRY domain, is highly expressed in the cerebellum",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22337885",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 343,
					"offsetInEndSection": 468,
					"text": "Vasa coding region is sufficient for its selective enrichment and find that gustavus, the B30.2/SPRY and SOCS box domain gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21035437",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 887,
					"offsetInEndSection": 1011,
					"text": "We propose that Gustavus has a conserved, positive regulatory role in Vasa protein accumulation during embryonic development",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21035437",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 208,
					"offsetInEndSection": 275,
					"text": "two zebrafish genes, SSB-1 and SSB-4 (SPRY domain SOCS box proteins",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19184407",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 986,
					"offsetInEndSection": 1063,
					"text": "We hypothesize that SSB-4 plays a role in the early development of germ cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19184407",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 150,
					"text": "SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17431422",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1202,
					"offsetInEndSection": 1290,
					"text": "TRIM proteins may be conducive to the convergent evolution of virus-restricting factors.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16648259",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 21,
					"offsetInEndSection": 95,
					"text": "SPRY and B30.2 protein domains. Evolution of a component of immune defence",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16313355",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 986,
					"offsetInEndSection": 1115,
					"text": ". The combination of SPRY and PRY to produce B30.2 domains may have been selected and maintained as a component of immune defence",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16313355",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 76,
					"text": " evolution of primate TRIM5alpha, a gene restricting HIV-1 infection",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16226405",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 433,
					"offsetInEndSection": 776,
					"text": "The SPRY domain of TRIM5alpha, which may be responsible for recognition of incoming viral capsids showed higher nonsynonymous/synonymous substitution ratios than the non-SPRY domain, indicating that the adaptive evolution of TRIM5alpha in primates might be an innate strategy developed in defending retrovirus infection during primate evolutio",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16226405",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1316,
					"offsetInEndSection": 1409,
					"text": "The results are consistent with a role for TRIM5alpha in innate immunity against retroviruses",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15857996",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 70,
					"text": "B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15857996",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 22,
					"offsetInEndSection": 109,
					"text": "primate TRIM5alpha identifies a critical species-specific retroviral restriction domain",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15689398",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1207,
					"offsetInEndSection": 1426,
					"text": "By using functional studies of chimeric TRIM5alpha genes, we show that this patch is generally essential for retroviral restriction and is responsible for most of the species-specific antiretroviral restriction activity",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15689398",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1072,
					"offsetInEndSection": 1091,
					"text": "SPRY protein domain",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15689398",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 449,
					"offsetInEndSection": 569,
					"text": "Heterozygotes for gus or a deletion including gus produce embryos with fewer pole cells and posterior patterning defects",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12479811",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 31,
					"offsetInEndSection": 85,
					"text": "SPRY-domain and SOCS-box containing protein, GUSTAVUS.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12479811",
					"endSection": "title"
				}
			]
		},
		{
			"body": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24251578",
				"http://www.ncbi.nlm.nih.gov/pubmed/23788723",
				"http://www.ncbi.nlm.nih.gov/pubmed/23783574",
				"http://www.ncbi.nlm.nih.gov/pubmed/23614019",
				"http://www.ncbi.nlm.nih.gov/pubmed/23603359",
				"http://www.ncbi.nlm.nih.gov/pubmed/22209284",
				"http://www.ncbi.nlm.nih.gov/pubmed/20385601",
				"http://www.ncbi.nlm.nih.gov/pubmed/19467292",
				"http://www.ncbi.nlm.nih.gov/pubmed/19179357",
				"http://www.ncbi.nlm.nih.gov/pubmed/17901054",
				"http://www.ncbi.nlm.nih.gov/pubmed/17715293",
				"http://www.ncbi.nlm.nih.gov/pubmed/17470795",
				"http://www.ncbi.nlm.nih.gov/pubmed/15791204",
				"http://www.ncbi.nlm.nih.gov/pubmed/11839807",
				"http://www.ncbi.nlm.nih.gov/pubmed/11092556",
				"http://www.ncbi.nlm.nih.gov/pubmed/10567350",
				"http://www.ncbi.nlm.nih.gov/pubmed/10334333",
				"http://www.ncbi.nlm.nih.gov/pubmed/9256076",
				"http://www.ncbi.nlm.nih.gov/pubmed/8634917",
				"http://www.ncbi.nlm.nih.gov/pubmed/8602359",
				"http://www.ncbi.nlm.nih.gov/pubmed/8601283",
				"http://www.ncbi.nlm.nih.gov/pubmed/8955902",
				"http://www.ncbi.nlm.nih.gov/pubmed/8344267"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24251578",
				"http://www.ncbi.nlm.nih.gov/pubmed/23788723",
				"http://www.ncbi.nlm.nih.gov/pubmed/23783574",
				"http://www.ncbi.nlm.nih.gov/pubmed/23614019",
				"http://www.ncbi.nlm.nih.gov/pubmed/23603359",
				"http://www.ncbi.nlm.nih.gov/pubmed/22209284",
				"http://www.ncbi.nlm.nih.gov/pubmed/20385601",
				"http://www.ncbi.nlm.nih.gov/pubmed/19467292",
				"http://www.ncbi.nlm.nih.gov/pubmed/19179357",
				"http://www.ncbi.nlm.nih.gov/pubmed/17901054",
				"http://www.ncbi.nlm.nih.gov/pubmed/17715293",
				"http://www.ncbi.nlm.nih.gov/pubmed/17470795",
				"http://www.ncbi.nlm.nih.gov/pubmed/15791204",
				"http://www.ncbi.nlm.nih.gov/pubmed/11839807",
				"http://www.ncbi.nlm.nih.gov/pubmed/11092556",
				"http://www.ncbi.nlm.nih.gov/pubmed/10567350",
				"http://www.ncbi.nlm.nih.gov/pubmed/10334333",
				"http://www.ncbi.nlm.nih.gov/pubmed/9256076",
				"http://www.ncbi.nlm.nih.gov/pubmed/8634917",
				"http://www.ncbi.nlm.nih.gov/pubmed/8602359",
				"http://www.ncbi.nlm.nih.gov/pubmed/8601283",
				"http://www.ncbi.nlm.nih.gov/pubmed/8955902",
				"http://www.ncbi.nlm.nih.gov/pubmed/8344267"
			],
			"type": "factoid",
			"id": "533ea8fcc45e133714000010",
			"snippets": [
				{
					"offsetInBeginSection": 343,
					"offsetInEndSection": 419,
					"text": "stem-loop structure called the selenocysteine incorporating sequence (SECIS)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24251578",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 200,
					"offsetInEndSection": 270,
					"text": "3'-UTR mRNA stem-loop termed SElenoCysteine Insertion Sequence (SECIS)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23788723",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 84,
					"offsetInEndSection": 194,
					"text": "Sec is inserted by a specific translational machinery that recognizes a stem-loop structure, the SECIS element",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23783574",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 428,
					"offsetInEndSection": 509,
					"text": "Selenocysteine Insertion Sequence (SECIS) element in the 3'UTR of the transcript.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23614019",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1394,
					"offsetInEndSection": 1440,
					"text": "The proximal stem-loop promotes Sec insertion ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23614019",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 250,
					"offsetInEndSection": 379,
					"text": "Selenocysteine is encoded by an in-frame UGA codon specified by a stem-loop structure, the Sec insertion sequence element (SECIS)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23603359",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 497,
					"offsetInEndSection": 577,
					"text": "3' untranslated region RNA stem loop called a SEC incorporation sequence (SECIS)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22209284",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 266,
					"offsetInEndSection": 424,
					"text": "recoding of UGA as Sec depends on the selenocysteine insertion sequence (SECIS) element, a stem-loop structure in the 3' untranslated region of the transcript",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20385601",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 117,
					"offsetInEndSection": 223,
					"text": "this requires a dedicated machinery comprising a stem-loop structure in the 3' UTR RNA (the SECIS element)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19467292",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 206,
					"offsetInEndSection": 306,
					"text": "RNA stem-loop structure, the SECIS element in the 3 untranslated region of (UTR) selenoprotein mRNAs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179357",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 60,
					"offsetInEndSection": 248,
					"text": "recoding of the UGA stop codon to selenocysteine. In eukaryotes, this requires an RNA stem loop structure in the 3'-untranslated region, termed a selenocysteine insertion sequence (SECIS),",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17901054",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 23,
					"offsetInEndSection": 198,
					"text": " insertion into proteins is directed by translational recoding of specific UGA codons located upstream of a stem-loop structure known as Sec insertion sequence (SECIS) element",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17715293",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 125,
					"offsetInEndSection": 295,
					"text": "In eukaryotes, incorporation of Sec requires a Sec insertion sequence (SECIS) element, a stem-loop structure located in the 3'-untranslated regions of selenoprotein mRNAs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17470795",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 187,
					"offsetInEndSection": 327,
					"text": "selenocysteine insertion requires a cis-acting selenocysteine insertion sequence (SECIS) usually located in the 3'UTR of selenoprotein mRNAs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15791204",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 73,
					"offsetInEndSection": 234,
					"text": "The Sec insertion sequence (SECIS) element, which is the stem-loop structure present in 3' untranslated regions (UTRs) of eukaryotic selenoprotein-encoding genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11839807",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 306,
					"offsetInEndSection": 534,
					"text": "For eukaryotic selenoprotein mRNAs, it has been proposed that a conserved stem-loop structure designated the Sec insertion sequence (SECIS) in the 3'-untranslated (3'-UTR) region is required for recognition of UGA as a Sec codon",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11092556",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 191,
					"offsetInEndSection": 379,
					"text": "3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10567350",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 272,
					"offsetInEndSection": 566,
					"text": "Analyses of eukaryotic selenocysteine insertion sequence (SECIS) elements via computer folding programs, mutagenesis studies, and chemical and enzymatic probing has led to the derivation of a predicted consensus structural model for these elements. This model consists of a stem-loop or hairpin",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10334333",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 124,
					"text": "ECIS elements form stem-loop structures in the 3' untranslated regions (UTR) of eukaryotic mRNAs that encode selenoproteins",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9256076",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 232,
					"offsetInEndSection": 322,
					"text": "We report a detailed experimental study of the secondary structures of the SECIS elements ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8634917",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 532,
					"offsetInEndSection": 576,
					"text": "It is characterized by a stem-loop structure",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8634917",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 267,
					"offsetInEndSection": 421,
					"text": " in eukaryotic selenoprotein mRNAs, this stem-loop structure, the selenocysteine insertion sequence (SECIS) element, resides in the 3'-untranslated region",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8602359",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 119,
					"text": "ECIS elements are stem-loop structures located in the 3' untranslated regions (UTRs) of eukaryotic selenoprotein mRNAs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8601283",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 830,
					"offsetInEndSection": 974,
					"text": "eukaryotic selenocysteine UGA codons requires a stem-loop structure in the 3'UTR of mRNAs, the selenocysteine insertion sequence (SECIS) element",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8955902",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 249,
					"offsetInEndSection": 324,
					"text": "stem-loops and critical nucleotides similar to those in the SECIS elements ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8344267",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 342,
					"offsetInEndSection": 461,
					"text": "Within the selenoprotein mRNA, a stem-loop structure called the Sec Insertion Sequence (SECIS) is required for recoding",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23614019",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1028,
					"offsetInEndSection": 1131,
					"text": "The stem-loop structure indicates the location of the Selenocysteine Insertion Sequence (SECIS) element",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23614019",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 589,
					"offsetInEndSection": 763,
					"text": "UGA will be recoded as Sec when the 3β€² untranslated region (3β€²UTR) of the transcript contains a specific stem-loop structure called the Sec insertion sequence (SECIS) element",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20385601",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 502,
					"offsetInEndSection": 551,
					"text": "mammalian SECIS elements all contain a stem-loop,",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20385601",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 263,
					"offsetInEndSection": 431,
					"text": "he correct recoding of UGA to Sec requires the presence of a stem-loop structure, the SECIS element in the 3 untranslated region (UTR) of selenoprotein gene transcripts",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179357",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Which is the histone residue methylated by MLL1?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23399917",
				"http://www.ncbi.nlm.nih.gov/pubmed/23038103",
				"http://www.ncbi.nlm.nih.gov/pubmed/22666422",
				"http://www.ncbi.nlm.nih.gov/pubmed/22488473",
				"http://www.ncbi.nlm.nih.gov/pubmed/22046413",
				"http://www.ncbi.nlm.nih.gov/pubmed/21875999",
				"http://www.ncbi.nlm.nih.gov/pubmed/21124902",
				"http://www.ncbi.nlm.nih.gov/pubmed/21113167",
				"http://www.ncbi.nlm.nih.gov/pubmed/20861184",
				"http://www.ncbi.nlm.nih.gov/pubmed/19855399",
				"http://www.ncbi.nlm.nih.gov/pubmed/19818711",
				"http://www.ncbi.nlm.nih.gov/pubmed/19481096",
				"http://www.ncbi.nlm.nih.gov/pubmed/19219072",
				"http://www.ncbi.nlm.nih.gov/pubmed/19187761",
				"http://www.ncbi.nlm.nih.gov/pubmed/18838538",
				"http://www.ncbi.nlm.nih.gov/pubmed/18562676",
				"http://www.ncbi.nlm.nih.gov/pubmed/17942719",
				"http://www.ncbi.nlm.nih.gov/pubmed/17168535",
				"http://www.ncbi.nlm.nih.gov/pubmed/16651450",
				"http://www.ncbi.nlm.nih.gov/pubmed/15960975",
				"http://www.ncbi.nlm.nih.gov/pubmed/15941828"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23399917",
				"http://www.ncbi.nlm.nih.gov/pubmed/23038103",
				"http://www.ncbi.nlm.nih.gov/pubmed/22666422",
				"http://www.ncbi.nlm.nih.gov/pubmed/22488473",
				"http://www.ncbi.nlm.nih.gov/pubmed/22046413",
				"http://www.ncbi.nlm.nih.gov/pubmed/21875999",
				"http://www.ncbi.nlm.nih.gov/pubmed/21124902",
				"http://www.ncbi.nlm.nih.gov/pubmed/21113167",
				"http://www.ncbi.nlm.nih.gov/pubmed/20861184",
				"http://www.ncbi.nlm.nih.gov/pubmed/19855399",
				"http://www.ncbi.nlm.nih.gov/pubmed/19818711",
				"http://www.ncbi.nlm.nih.gov/pubmed/19481096",
				"http://www.ncbi.nlm.nih.gov/pubmed/19219072",
				"http://www.ncbi.nlm.nih.gov/pubmed/19187761",
				"http://www.ncbi.nlm.nih.gov/pubmed/18838538",
				"http://www.ncbi.nlm.nih.gov/pubmed/18562676",
				"http://www.ncbi.nlm.nih.gov/pubmed/17942719",
				"http://www.ncbi.nlm.nih.gov/pubmed/17168535",
				"http://www.ncbi.nlm.nih.gov/pubmed/16651450",
				"http://www.ncbi.nlm.nih.gov/pubmed/15960975",
				"http://www.ncbi.nlm.nih.gov/pubmed/15941828"
			],
			"type": "factoid",
			"id": "533be71dfd9a95ea0d000009",
			"snippets": [
				{
					"offsetInBeginSection": 771,
					"offsetInEndSection": 894,
					"text": "lack of interaction with the histone methyltransferase, MLL1, resulting in decreased histone H3K4me3 and gene transcription",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23399917",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1408,
					"offsetInEndSection": 1446,
					"text": "histone H3K4me3 methylase MLL1 complex",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23038103",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 165,
					"offsetInEndSection": 304,
					"text": "MEN1 encodes menin, a subunit of MLL1/MLL2-containing histone methyltransferase complexes that trimethylate histone H3 at lysine 4 (H3K4me3",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22666422",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 610,
					"offsetInEndSection": 837,
					"text": "MLL1, MLL5, Set1 and ASH1 to be highly up-regulated during transdifferentiation of HSCs. All of these histone methyltransferases regulate methylation of lysine 4 of histone H3, which is a signature of actively transcribed genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22488473",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 807,
					"offsetInEndSection": 897,
					"text": "MLL1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4 residues",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22046413",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 36,
					"offsetInEndSection": 227,
					"text": "H3K4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS, which was originally purified based on the similarity of yeast Set1 to human MLL1 and Drosophila melanogaster Trithorax (Trx)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21875999",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 170,
					"text": "istone H3 lysine 4 (K4) methylation is a prevalent mark associated with transcription activation and is mainly catalyzed by the MLL/SET1 family histone methyltransferase",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21124902",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 928,
					"offsetInEndSection": 1007,
					"text": "Mutations in the MLL1 SET domain that fail to support overall H3 K4 methylation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21124902",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 436,
					"offsetInEndSection": 562,
					"text": "MLL1, a mammalian homolog of Drosophila trithorax, is an H3K4-specific methyltransferase implicated in transcriptional control",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21113167",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 724,
					"offsetInEndSection": 827,
					"text": "We show that the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20861184",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 998,
					"offsetInEndSection": 1046,
					"text": "MLL1 histone H3 Lys4 methyltransferase complexes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19855399",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 216,
					"offsetInEndSection": 264,
					"text": "MLL1 histone methyltransferase (H3K4me3) complex",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19818711",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 315,
					"offsetInEndSection": 468,
					"text": "In the human MLL1 (mixed-lineage leukemia-1) HMT complex, DPY-30L binds to the BRE2 homolog ASH2L in order to regulate histone 3-lysine 4 trimethylation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19481096",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 936,
					"offsetInEndSection": 1097,
					"text": "MLL1 and MLL2 H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4 trimethyltransferase activity r",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19219072",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 134,
					"offsetInEndSection": 261,
					"text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19187761",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 37,
					"offsetInEndSection": 313,
					"text": "Set1/COMPASS is capable of methylating H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are multiple H3K4 methylases, including Set1A/B, forming human COMPASS complexes, and MLL1-4",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18838538",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1478,
					"offsetInEndSection": 1541,
					"text": " trimethylated H3K4 histones and histone methyltransferase MLL1",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18562676",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 640,
					"offsetInEndSection": 815,
					"text": " lacZ knock-in allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4 methylation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942719",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 105,
					"offsetInEndSection": 169,
					"text": "effectors of H3K4 methylation is mixed-lineage leukemia 1 (MLL1)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17168535",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 120,
					"offsetInEndSection": 204,
					"text": "MLL1/MLL2 histone methyltransferase complexes specific for Lys4 of histone H3 (H3K4)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16651450",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 52,
					"offsetInEndSection": 80,
					"text": "H3 K4 methyltransferase MLL1",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15960975",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 374,
					"offsetInEndSection": 508,
					"text": "purified complex has a robust MLL1-mediated histone methyltransferase activity that can effect mono-, di-, and trimethylation of H3 K4",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15960975",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 362,
					"offsetInEndSection": 501,
					"text": "MLL1 localizes with RNA polymerase II (Pol II) to the 5' end of actively transcribed genes, where histone H3 lysine 4 trimethylation occurs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15941828",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 599,
					"offsetInEndSection": 812,
					"text": "COMPASS-like (complex of proteins associated with Set1) mixed lineage leukemia (MLL) complexes that trimethylate histone H3 at lysine 4 (H3K4), specifically in MLL1/MLL2-containing complexes that trimethylate H3K4",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22666422",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2252,
					"offsetInEndSection": 2343,
					"text": "he direct role of H3K4 trimethylation (H3K4me3) catalyzed by menin-containing MLL complexes",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22666422",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4768,
					"offsetInEndSection": 4856,
					"text": "MLL complexes that are known to deposit the histone H3 lysine 4 trimethyl mark (H3K4me3)",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22666422",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 320,
					"offsetInEndSection": 504,
					"text": "MLL1 is an H3 K4 histone methyltransferase (HMT) that effect mono-, di-, and tri-methylation through its evolutionarily conserved SET (Su (var), Enhancer of Zeste and Trithorax) domain",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21124902",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1335,
					"offsetInEndSection": 1417,
					"text": "MLL1 is one of the MLL/SET1 family HMTs for H3 K4 methylation in higher eukaryotes",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21124902",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 58,
					"offsetInEndSection": 84,
					"text": "MLL/SET1 family H3 K4 HMTs",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21124902",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1427,
					"offsetInEndSection": 1532,
					"text": " MLL/SET1 family members, especially SET1A/B, the predominant H3 K4 methyltransferases in mammalian cells",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21124902",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 201,
					"offsetInEndSection": 349,
					"text": "to recruit HCF-1-Set/MLL1 histone methyl-transferase (HMT) complexes9,12 to the IE promoters, resulting in histone H3-lysine 4 (H3K4) trimethylation",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19855399",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Which factors play a role in promoter proximal pausing of RNA polymerase II?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24050178",
				"http://www.ncbi.nlm.nih.gov/pubmed/23699410",
				"http://www.ncbi.nlm.nih.gov/pubmed/23589332",
				"http://www.ncbi.nlm.nih.gov/pubmed/22549956",
				"http://www.ncbi.nlm.nih.gov/pubmed/22244331",
				"http://www.ncbi.nlm.nih.gov/pubmed/21670248",
				"http://www.ncbi.nlm.nih.gov/pubmed/17942706",
				"http://www.ncbi.nlm.nih.gov/pubmed/20534440",
				"http://www.ncbi.nlm.nih.gov/pubmed/20170405",
				"http://www.ncbi.nlm.nih.gov/pubmed/20028984",
				"http://www.ncbi.nlm.nih.gov/pubmed/19860741",
				"http://www.ncbi.nlm.nih.gov/pubmed/19245807",
				"http://www.ncbi.nlm.nih.gov/pubmed/18373978",
				"http://www.ncbi.nlm.nih.gov/pubmed/18332113",
				"http://www.ncbi.nlm.nih.gov/pubmed/17567605",
				"http://www.ncbi.nlm.nih.gov/pubmed/16880520",
				"http://www.ncbi.nlm.nih.gov/pubmed/12782658"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24050178",
				"http://www.ncbi.nlm.nih.gov/pubmed/23699410",
				"http://www.ncbi.nlm.nih.gov/pubmed/23589332",
				"http://www.ncbi.nlm.nih.gov/pubmed/22549956",
				"http://www.ncbi.nlm.nih.gov/pubmed/22244331",
				"http://www.ncbi.nlm.nih.gov/pubmed/21670248",
				"http://www.ncbi.nlm.nih.gov/pubmed/17942706",
				"http://www.ncbi.nlm.nih.gov/pubmed/20534440",
				"http://www.ncbi.nlm.nih.gov/pubmed/20170405",
				"http://www.ncbi.nlm.nih.gov/pubmed/20028984",
				"http://www.ncbi.nlm.nih.gov/pubmed/19860741",
				"http://www.ncbi.nlm.nih.gov/pubmed/19245807",
				"http://www.ncbi.nlm.nih.gov/pubmed/18373978",
				"http://www.ncbi.nlm.nih.gov/pubmed/18332113",
				"http://www.ncbi.nlm.nih.gov/pubmed/17567605",
				"http://www.ncbi.nlm.nih.gov/pubmed/16880520",
				"http://www.ncbi.nlm.nih.gov/pubmed/12782658"
			],
			"type": "list",
			"id": "533ec7abc45e133714000015",
			"snippets": [
				{
					"offsetInBeginSection": 589,
					"offsetInEndSection": 720,
					"text": "Among the factors we describe are the pausing factors--NELF (negative elongation factor) and DSIF (DRB sensitivity-inducing factor)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24050178",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 927,
					"offsetInEndSection": 1023,
					"text": "BMP target gene expression requires the pause-inducing negative elongation factor (NELF) complex",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23699410",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 151,
					"text": "NA polymerase II (Pol II) and the pausing complex, NELF and DSIF, are detected near the transcription start site (TSS) of many active and silent genes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23589332",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 68,
					"offsetInEndSection": 93,
					"text": "pausing complex NELF/DSIF",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23589332",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 919,
					"offsetInEndSection": 1013,
					"text": "knockdown of the pause-inducing factor NELF leads to broadly attenuated immune gene activation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22549956",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 464,
					"offsetInEndSection": 493,
					"text": "pausing factors NELF and DSIF",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22244331",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 810,
					"offsetInEndSection": 839,
					"text": "pausing factors NELF and DSIF",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21670248",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 708,
					"offsetInEndSection": 761,
					"text": "pausing factor DSIF (DRB sensitivity-inducing factor)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17942706",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 27,
					"offsetInEndSection": 204,
					"text": "(NELF) and 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole sensitivity-inducing factor (DSIF) are involved in pausing RNA Polymerase II (Pol II) in the promoter-proximal region",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20534440",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 381,
					"offsetInEndSection": 562,
					"text": "Pausing and resumption of the elongation of transcripts is under the control of transcription elongation factors. Three of them, P-TEFb, DSIF, and NELF have been well characterized ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20170405",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 174,
					"offsetInEndSection": 207,
					"text": "NELF-mediated stalling of RNAPII ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20028984",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 382,
					"offsetInEndSection": 525,
					"text": "At several eukaryotic promoters, DSIF, together with NELF (negative elongation factor), leads to promoter-proximal pausing of RNA polymerase II",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19860741",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 25,
					"offsetInEndSection": 70,
					"text": "negative transcription elongation factor NELF",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19245807",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 130,
					"offsetInEndSection": 366,
					"text": "(DSIF), is involved in regulating the processivity of RNA polymerase II. DSIF plays also a role in transcriptional activation, and in concert with the negative elongation factor NELF causes promoter proximal pausing of RNA polymerase II",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18373978",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 135,
					"offsetInEndSection": 194,
					"text": "NELF causes Pol II to pause in the promoter-proximal region",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18332113",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 119,
					"offsetInEndSection": 275,
					"text": "(DSIF) regulates RNA polymerase II (RNAPII) processivity by promoting, in concert with negative elongation factor (NELF), promoter-proximal pausing of RNAPI",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 83,
					"offsetInEndSection": 212,
					"text": "(DSIF) and negative elongation factor (NELF) negatively regulate transcription elongation by RNA polymerase II (RNAPII) in vitro.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16880520",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 39,
					"text": "pausing caused by NELF ",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16880520",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 1,
					"offsetInEndSection": 69,
					"text": "ELF and DSIF collaborate to inhibit elongation by RNA polymerase IIa",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12782658",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 683,
					"offsetInEndSection": 720,
					"text": "The presence of DSIF reduced pausing,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 859,
					"offsetInEndSection": 950,
					"text": "DSIF exerts both negative and positive effects on elongation by directly binding to RNAPII ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 988,
					"offsetInEndSection": 1105,
					"text": "DSIF negatively regulates transcription by acting in concert with NELF to mediate promoter proximal pausing of RNAPII",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 5020,
					"offsetInEndSection": 5114,
					"text": "DSIF supported full transcriptional activation by reducing pausing of RNAPII during elongation",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2364,
					"offsetInEndSection": 2410,
					"text": "DSIF stimulates elongation by reducing pausing",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 6762,
					"offsetInEndSection": 6798,
					"text": "DSIF reduces transcriptional pausing",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 13144,
					"offsetInEndSection": 13194,
					"text": "promoter-proximal pausing induced by NELF and DSIF",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 15516,
					"offsetInEndSection": 15578,
					"text": "occurrence of NELF- and DSIF-induced promoter-proximal pausing",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 1539,
					"offsetInEndSection": 1573,
					"text": "DSIF is required to reduce pausing",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17567605",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "Has proteomics been used in the study of Pick's disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/16987245",
				"http://www.ncbi.nlm.nih.gov/pubmed/16555340",
				"http://www.ncbi.nlm.nih.gov/pubmed/12650976",
				"http://www.ncbi.nlm.nih.gov/pubmed/11880199"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/16987245",
				"http://www.ncbi.nlm.nih.gov/pubmed/16555340",
				"http://www.ncbi.nlm.nih.gov/pubmed/12650976",
				"http://www.ncbi.nlm.nih.gov/pubmed/11880199"
			],
			"type": "yesno",
			"id": "532f05bdd6d3ac6a34000026",
			"snippets": [
				{
					"offsetInBeginSection": 776,
					"offsetInEndSection": 993,
					"text": "In Pick's disease, increased AGE, CML, CEL, HNE and MDAL bands of about 50 kDa were observed in the frontal cortex (but not in the occipital cortex) in association with increased density of glial acidic protein bands.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16987245",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 236,
					"offsetInEndSection": 529,
					"text": "Thus, brain and cerebrospinal fluid (CSF) samples from patients with Alzheimer's disease, Down syndrome, Pick's disease, Parkinson's disease, schizophrenia, and other disorders as well as brain and CSF from animals serving as models of neurological disorders have been analyzed by proteomics. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16555340",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 493,
					"offsetInEndSection": 771,
					"text": "The present study is designed to investigate expression of peroxiredoxins (Prxs), the newly characterized family of highly conserved antioxidant enzymes, and other antioxidant enzymes in frontal cortex and cerebellum of DS, AD and PD patients using the technique of proteomics. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12650976",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 326,
					"offsetInEndSection": 486,
					"text": "HMT levels were measured in the frontal cortex and cerebellum of brains of patients with AD, DS, and PiD, and normal aged subjects using proteomics techniques. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11880199",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Are there any animal models for Niemann-Pick C1 disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24044630",
				"http://www.ncbi.nlm.nih.gov/pubmed/23843985",
				"http://www.ncbi.nlm.nih.gov/pubmed/22404083",
				"http://www.ncbi.nlm.nih.gov/pubmed/22325094",
				"http://www.ncbi.nlm.nih.gov/pubmed/22198570",
				"http://www.ncbi.nlm.nih.gov/pubmed/22048958",
				"http://www.ncbi.nlm.nih.gov/pubmed/21995947",
				"http://www.ncbi.nlm.nih.gov/pubmed/21176403",
				"http://www.ncbi.nlm.nih.gov/pubmed/20864542",
				"http://www.ncbi.nlm.nih.gov/pubmed/20607864",
				"http://www.ncbi.nlm.nih.gov/pubmed/20581737",
				"http://www.ncbi.nlm.nih.gov/pubmed/19458211",
				"http://www.ncbi.nlm.nih.gov/pubmed/19875890",
				"http://www.ncbi.nlm.nih.gov/pubmed/17216601",
				"http://www.ncbi.nlm.nih.gov/pubmed/16940355",
				"http://www.ncbi.nlm.nih.gov/pubmed/12297829"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24044630",
				"http://www.ncbi.nlm.nih.gov/pubmed/23843985",
				"http://www.ncbi.nlm.nih.gov/pubmed/22404083",
				"http://www.ncbi.nlm.nih.gov/pubmed/22325094",
				"http://www.ncbi.nlm.nih.gov/pubmed/22198570",
				"http://www.ncbi.nlm.nih.gov/pubmed/22048958",
				"http://www.ncbi.nlm.nih.gov/pubmed/21995947",
				"http://www.ncbi.nlm.nih.gov/pubmed/21176403",
				"http://www.ncbi.nlm.nih.gov/pubmed/20864542",
				"http://www.ncbi.nlm.nih.gov/pubmed/20607864",
				"http://www.ncbi.nlm.nih.gov/pubmed/20581737",
				"http://www.ncbi.nlm.nih.gov/pubmed/19458211",
				"http://www.ncbi.nlm.nih.gov/pubmed/19875890",
				"http://www.ncbi.nlm.nih.gov/pubmed/17216601",
				"http://www.ncbi.nlm.nih.gov/pubmed/16940355",
				"http://www.ncbi.nlm.nih.gov/pubmed/12297829"
			],
			"type": "yesno",
			"id": "532f0ca1d6d3ac6a3400002f",
			"snippets": [
				{
					"offsetInBeginSection": 462,
					"offsetInEndSection": 528,
					"text": "Several animal models were used to analyze the impaired pathways. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24044630",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 313,
					"offsetInEndSection": 468,
					"text": "We investigated components of the surfactant system in both NPC1 mutant mice and felines and in NPC2 mutant mice near the end of their expected life span. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23843985",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 197,
					"offsetInEndSection": 383,
					"text": "Thus far, studies of NPC mice have been performed mainly to study the brain and neurodegeneration, because degeneration in the brain was known as the primary cause of death in NPC mice. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22404083",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 195,
					"offsetInEndSection": 288,
					"text": "the NPC1(-/-) mouse is available serving as an appropriate animal model of the human disease,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22325094",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 285,
					"offsetInEndSection": 481,
					"text": "o examine the onset and progression of neuropathological insults in NPC we have systematically examined the CNS of a mouse model of NPC1 (Npc1(-/-) mice) at different stages of the disease course.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22198570",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 129,
					"text": "We have identified a point mutation in Npc1 that creates a novel mouse model (Npc1(nmf164)) of Niemann-Pick type C1 (NPC) disease",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22048958",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 492,
					"offsetInEndSection": 578,
					"text": "Niemann-Pick type C1-deficient mice, which accumulate intracellular free cholesterol. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21995947",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 360,
					"offsetInEndSection": 453,
					"text": "hUCB-MSCs were transplanted into the hippocampus of NPC mice in the early asymptomatic stage.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21176403",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 126,
					"offsetInEndSection": 152,
					"text": " Niemann Pick type C1 mice",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21176403",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 380,
					"offsetInEndSection": 466,
					"text": "Three mouse models of glycosphingolipid storage diseases, namely Niemann-Pick type C1,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20864542",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 822,
					"offsetInEndSection": 879,
					"text": "Npc1(-/-) mice, a well-established model of NPC pathology",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20607864",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 346,
					"offsetInEndSection": 391,
					"text": "murine model of this disease, the npc1 mouse,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20581737",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 415,
					"offsetInEndSection": 457,
					"text": "NPC1 (Niemann-Pick type C1) knock-out mice",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19458211",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 149,
					"offsetInEndSection": 305,
					"text": "We have made transgenic mice which express the Npc1 protein exclusively in fibrillary astrocytes, using the glial fibrillary acidic protein (GFAP) promoter.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19875890",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 706,
					"offsetInEndSection": 742,
					"text": "homozygous affected (NPC1(-/-)) mice",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17216601",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 938,
					"offsetInEndSection": 967,
					"text": "heterozygous (NPC1(+/-)) mice",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17216601",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1103,
					"offsetInEndSection": 1118,
					"text": "npc1(-/-) mice,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16940355",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 314,
					"offsetInEndSection": 335,
					"text": "npc1(-/-) mouse model",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16940355",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 374,
					"offsetInEndSection": 466,
					"text": "A murine model of Niemann-Pick type C disease (NPC), the NPC1-deficient [NPC1 (-/-)] mouse, ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12297829",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2150,
					"offsetInEndSection": 2307,
					"text": "Most of our knowledge regarding NPC1 is based on cell models like human fibroblasts [21-23] and animal models like mouse [24], cat [25], and fruit fly [26]. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24044630",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2583,
					"offsetInEndSection": 2623,
					"text": "the widely used murine BALB/c NPC1 model",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24044630",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4567,
					"offsetInEndSection": 4586,
					"text": "NPC1 deficient mice",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24044630",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 1512,
					"offsetInEndSection": 1568,
					"text": "Animal models of NPC1 disease include mice and felines. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23843985",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1848,
					"offsetInEndSection": 1966,
					"text": "The feline model of NPC1 disease is a domestic short-haired cat with a spontaneous missense mutation (C955S) in NPC1. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23843985",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 308,
					"offsetInEndSection": 381,
					"text": "Npc1nih/nih and Npc2 hypomorph mice on a BALB/c background were obtained ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23843985",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 21,
					"offsetInEndSection": 40,
					"text": "Npc1 deficient mice",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22198570",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 3332,
					"offsetInEndSection": 3388,
					"text": "This was done\n                using mouse models of NPC1",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20864542",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Is RIP1 (RIP-1) part of the necrosome?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22033613",
				"http://www.ncbi.nlm.nih.gov/pubmed/22016814",
				"http://www.ncbi.nlm.nih.gov/pubmed/21749897",
				"http://www.ncbi.nlm.nih.gov/pubmed/24098568",
				"http://www.ncbi.nlm.nih.gov/pubmed/24059293",
				"http://www.ncbi.nlm.nih.gov/pubmed/23898178",
				"http://www.ncbi.nlm.nih.gov/pubmed/23612963",
				"http://www.ncbi.nlm.nih.gov/pubmed/23162759",
				"http://www.ncbi.nlm.nih.gov/pubmed/22817896",
				"http://www.ncbi.nlm.nih.gov/pubmed/22576661",
				"http://www.ncbi.nlm.nih.gov/pubmed/22421439",
				"http://www.ncbi.nlm.nih.gov/pubmed/22666585",
				"http://www.ncbi.nlm.nih.gov/pubmed/21890409"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22033613",
				"http://www.ncbi.nlm.nih.gov/pubmed/22016814",
				"http://www.ncbi.nlm.nih.gov/pubmed/21749897",
				"http://www.ncbi.nlm.nih.gov/pubmed/24098568",
				"http://www.ncbi.nlm.nih.gov/pubmed/24059293",
				"http://www.ncbi.nlm.nih.gov/pubmed/23898178",
				"http://www.ncbi.nlm.nih.gov/pubmed/23612963",
				"http://www.ncbi.nlm.nih.gov/pubmed/23162759",
				"http://www.ncbi.nlm.nih.gov/pubmed/22817896",
				"http://www.ncbi.nlm.nih.gov/pubmed/22576661",
				"http://www.ncbi.nlm.nih.gov/pubmed/22421439",
				"http://www.ncbi.nlm.nih.gov/pubmed/22666585",
				"http://www.ncbi.nlm.nih.gov/pubmed/21890409"
			],
			"type": "yesno",
			"id": "532bfd15d6d3ac6a34000017",
			"snippets": [
				{
					"offsetInBeginSection": 1179,
					"offsetInEndSection": 1272,
					"text": "formation of a different necrosome whose components, besides RIP1 and RIP3, are still unknown",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22033613",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 902,
					"offsetInEndSection": 975,
					"text": "necrosome complex consisting of RIP1, RIP3, FADD, caspase-8 and cFLIP(L).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22016814",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 477,
					"offsetInEndSection": 673,
					"text": "assembly of a supramolecular complex containing the receptor-interacting protein kinases 1 and 3 (RIP1 and RIP3) that delivers a pronecrotic signal. Such complex has recently been dubbed necrosome",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21749897",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 116,
					"offsetInEndSection": 213,
					"text": "Receptor interacting protein kinase 1 (RIPK1/RIP1) and RIP3 are key components of the necrosome. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24098568",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 189,
					"offsetInEndSection": 268,
					"text": "The phosphorylation of RIP1 and RIP3 is critical for assembly of the necrosome,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24059293",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 497,
					"offsetInEndSection": 527,
					"text": "RIP1-RIP3 \"necrosome\" complex ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23898178",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 295,
					"offsetInEndSection": 400,
					"text": "RIP1 and RIP3 mediate necrosome aggregation leading to the formation of amyloid-like signaling complexes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23612963",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 840,
					"offsetInEndSection": 894,
					"text": "Formation of the RIP1/RIP3 complex (called necrosome) ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23162759",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 24,
					"text": "The RIP1/RIP3 necrosome ",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22817896",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 966,
					"offsetInEndSection": 1001,
					"text": "Rip1-Rip3 death complex (necrosome)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22576661",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 576,
					"offsetInEndSection": 663,
					"text": "he 'necrosome', that includes receptor-interacting protein (RIP)1, RIP3 and caspase-8. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21890409",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 884,
					"offsetInEndSection": 998,
					"text": "RIP-1 kinase activity triggers formation of the necrosome (in complex with RIP-3) leading to programmed necrosis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22666585",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 5312,
					"offsetInEndSection": 5437,
					"text": " Necrosome formation was fully inhibited by Nec-1 treatment, implicating an absolute dependence on catalytically active RIP1 ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22016814",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 1869,
					"offsetInEndSection": 1955,
					"text": "The catalytic activity of RIP1 is required for the formation of the necrosome complex ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22016814",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1393,
					"offsetInEndSection": 1497,
					"text": "Besides RIP1 and RIP3, the necrosome also contains the RIP3 substrates mixed lineage kinase domain-like ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24098568",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1568,
					"offsetInEndSection": 1663,
					"text": "Upon TNF stimulation, the essential necrosome component RIP1 is recruited to the TNF receptor 1",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24098568",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 9474,
					"offsetInEndSection": 9554,
					"text": "Necrosome-associated RIP1 contains ubiquitin chains of different linkage types. ",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24098568",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 496,
					"offsetInEndSection": 740,
					"text": "several reports have suggested that the formation of a supracomplex containing the receptor-interacting protein kinase 1 (RIP1) and its homolog RIP3 (which has been named β€�necrosomeβ€�) is responsible for the switch from apoptosis to necroptosis.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23162759",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 5932,
					"offsetInEndSection": 5971,
					"text": "the RIP-1/RIP-3 complex, the necrosome,",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22666585",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 10958,
					"offsetInEndSection": 11042,
					"text": "RIP-1 kinase activity mediates the formation of the necrosome (RIP-1/RIP-3 complex) ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22666585",
					"endSection": "sections.1"
				}
			]
		},
		{
			"body": "What is the function of the protein encoded by the gene PABPC4?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23938467",
				"http://www.ncbi.nlm.nih.gov/pubmed/23181716",
				"http://www.ncbi.nlm.nih.gov/pubmed/22896784",
				"http://www.ncbi.nlm.nih.gov/pubmed/23300856",
				"http://www.ncbi.nlm.nih.gov/pubmed/22884093",
				"http://www.ncbi.nlm.nih.gov/pubmed/22530058",
				"http://www.ncbi.nlm.nih.gov/pubmed/21940797",
				"http://www.ncbi.nlm.nih.gov/pubmed/21300955",
				"http://www.ncbi.nlm.nih.gov/pubmed/20943973",
				"http://www.ncbi.nlm.nih.gov/pubmed/11328870"
			],
			"triples": [
				{
					"s": "http://purl.uniprot.org/uniprot/P21187",
					"p": "http://purl.uniprot.org/core/reviewed",
					"o": "true"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5032313138370015",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "Poly(A)-binding protein"
				},
				{
					"s": "http://purl.uniprot.org/intact/EBI-103658",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "pAbp"
				},
				{
					"s": "http://purl.uniprot.org/intact/EBI-103658",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/uniprot/P21187"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5032313138370015",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Polyadenylate-binding protein"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P21187",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_5032313138370015"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5032313138370015",
					"p": "http://purl.uniprot.org/core/shortName",
					"o": "PABP"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23938467",
				"http://www.ncbi.nlm.nih.gov/pubmed/23181716",
				"http://www.ncbi.nlm.nih.gov/pubmed/22896784",
				"http://www.ncbi.nlm.nih.gov/pubmed/23300856",
				"http://www.ncbi.nlm.nih.gov/pubmed/22884093",
				"http://www.ncbi.nlm.nih.gov/pubmed/22530058",
				"http://www.ncbi.nlm.nih.gov/pubmed/21940797",
				"http://www.ncbi.nlm.nih.gov/pubmed/21300955",
				"http://www.ncbi.nlm.nih.gov/pubmed/20943973",
				"http://www.ncbi.nlm.nih.gov/pubmed/11328870"
			],
			"type": "factoid",
			"id": "531d744c267d7dd053000009",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 121,
					"text": "In testis mRNA stability and translation initiation are extensively under the control of poly(A)-binding proteins (PABP).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11328870",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 974,
					"offsetInEndSection": 1081,
					"text": "Taken together, our findings indicate that PABPC4 may play a role in the pathogenesis of colorectal cancer.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22884093",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1170,
					"offsetInEndSection": 1447,
					"text": "Consistent with these biochemical activities, plus corresponding histological profiles, the identified RNA processing factors are predicted to collectively drive post-transcriptional expression of an alternative exome that fuels finishing steps of sperm maturation and fitness.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23938467",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1580,
					"offsetInEndSection": 1719,
					"text": "This is the first evidence that PABPCs have a targeted role in hTERT regulation leading to a growth advantage in cells expressing HPV16 E6.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20943973",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 890,
					"offsetInEndSection": 953,
					"text": "to play a role in chronic inflammation (PPP1R3B, SALL1, PABPC4,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21300955",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 385,
					"offsetInEndSection": 495,
					"text": "and with the exception of PABP4, appear to be restricted in their expression to a small number of cell types. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21940797",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1198,
					"offsetInEndSection": 1493,
					"text": "PABPC4 (p(Het) = 0.034) for HDL-C. Our findings suggest that some of the previously identified variants associate differently with lipid traits in adolescents compared to adults, either because of developmental changes or because of greater interactions with environmental differences in adults.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22530058",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1047,
					"offsetInEndSection": 1115,
					"text": "In addition, PABP4 was associated with the poly(A) tract of pre-mRNA",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23300856",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 140,
					"text": "Depletion of nuclear poly(A) binding protein PABPN1 produces a compensatory response by cytoplasmic PABP4 and PABP5 in cultured human cells.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23300856",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 5003,
					"offsetInEndSection": 5050,
					"text": "PABP4 are required for their normal development",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23300856",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 6134,
					"offsetInEndSection": 6391,
					"text": "PABP4 is highly similar to PABP1 at the protein level, sharing 75% identity and binding poly(A) with a similar affinity to PABP1 (Sladic et al., 2004), suggesting that it might function analogously in the regulation of global mRNA translation and stability.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21940797",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Name a method for enrichment of arginine-methylated peptides.",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24129315"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24129315"
			],
			"type": "factoid",
			"id": "532206819b2d7acc7e00000f",
			"snippets": [
				{
					"offsetInBeginSection": 395,
					"offsetInEndSection": 795,
					"text": "To better study protein methylation, we have developed highly specific antibodies against monomethyl arginine; asymmetric dimethyl arginine; and monomethyl, dimethyl, and trimethyl lysine motifs. These antibodies were used to perform immunoaffinity purification of methyl peptides followed by LC-MS/MS analysis to identify and quantify arginine and lysine methylation sites in several model studies. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24129315",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 17188,
					"offsetInEndSection": 17393,
					"text": "We profiled protein arginine methylation in mouse brain (from 3-month-old mice) and mouse embryo (E16β€“17) via immunoaffinity enrichment using various arginine methylation antibodies and LC-MS/MS analysis. ",
					"beginSection": "sections.8",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24129315",
					"endSection": "sections.8"
				},
				{
					"offsetInBeginSection": 2727,
					"offsetInEndSection": 2824,
					"text": "we demonstrated that the immunoaffinity enrichment method for methylated peptides is quantitative",
					"beginSection": "sections.9",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24129315",
					"endSection": "sections.9"
				}
			]
		},
		{
			"body": "Where is the protein CLIC1 localized?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/21055175",
				"http://www.ncbi.nlm.nih.gov/pubmed/15827065",
				"http://www.ncbi.nlm.nih.gov/pubmed/9880541"
			],
			"triples": [
				{
					"s": "http://purl.uniprot.org/uniprot/Q5E9B7",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_51354539423700E"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51354539423700E",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "CLIC1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51354539423700C",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Chloride intracellular channel protein 1"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q95MF9",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_5139354D463900A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5139354D463900A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "CLIC1"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_5139354D4639009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Chloride intracellular channel protein 1"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/21055175",
				"http://www.ncbi.nlm.nih.gov/pubmed/15827065",
				"http://www.ncbi.nlm.nih.gov/pubmed/9880541"
			],
			"type": "summary",
			"id": "53319916d6d3ac6a3400003f",
			"snippets": [
				{
					"offsetInBeginSection": 611,
					"offsetInEndSection": 706,
					"text": "CLIC1 expression was obtained in the cytoplasm and plasma membrane of cells in both cell lines.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21055175",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 641,
					"offsetInEndSection": 686,
					"text": "CLIC1, an intracellular chloride ion channel,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15827065",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 612,
					"offsetInEndSection": 678,
					"text": "Like NCC27/CLIC1, CLIC3 is predominantly localized in the nucleus ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9880541",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1270,
					"offsetInEndSection": 1357,
					"text": "the nuclear localization pattern of CLIC1 was remarkably changed by insulin stimulation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15827065",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Why do we use \"N-terminal proteomics\"?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23964590",
				"http://www.ncbi.nlm.nih.gov/pubmed/23745983",
				"http://www.ncbi.nlm.nih.gov/pubmed/22065552",
				"http://www.ncbi.nlm.nih.gov/pubmed/20627866",
				"http://www.ncbi.nlm.nih.gov/pubmed/19767749",
				"http://www.ncbi.nlm.nih.gov/pubmed/18836177"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23964590",
				"http://www.ncbi.nlm.nih.gov/pubmed/23745983",
				"http://www.ncbi.nlm.nih.gov/pubmed/22065552",
				"http://www.ncbi.nlm.nih.gov/pubmed/20627866",
				"http://www.ncbi.nlm.nih.gov/pubmed/19767749",
				"http://www.ncbi.nlm.nih.gov/pubmed/18836177"
			],
			"type": "summary",
			"id": "5335ebb6d6d3ac6a34000054",
			"snippets": [
				{
					"offsetInBeginSection": 1183,
					"offsetInEndSection": 1264,
					"text": "ChaFRADIC is a powerful and practicable tool for protease and peptidase research,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23964590",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 46,
					"offsetInEndSection": 138,
					"text": "systematic identification of protease cleavage events by quantitative N-terminal proteomics,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20627866",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 624,
					"offsetInEndSection": 783,
					"text": " identifying the largest set of protein protease substrates ever reported and gaining novel insight into substrate specificity differences of these cathepsins.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20627866",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1015,
					"offsetInEndSection": 1138,
					"text": "new insights into the structure-function relationship of protease targets and their validation from large-scale approaches.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19767749",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 649,
					"offsetInEndSection": 835,
					"text": "revealed unknown cleavage specificities, uncharacterized extended specificity profiles, and macromolecular determinants in substrate selection that were confirmed by molecular modeling. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18836177",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Does SCRIB deregulation promote cancer?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/14767561",
				"http://www.ncbi.nlm.nih.gov/pubmed/21549346",
				"http://www.ncbi.nlm.nih.gov/pubmed/21643016",
				"http://www.ncbi.nlm.nih.gov/pubmed/24276238",
				"http://www.ncbi.nlm.nih.gov/pubmed/23730214",
				"http://www.ncbi.nlm.nih.gov/pubmed/22169974",
				"http://www.ncbi.nlm.nih.gov/pubmed/21965329",
				"http://www.ncbi.nlm.nih.gov/pubmed/19041750",
				"http://www.ncbi.nlm.nih.gov/pubmed/18641685"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7659777",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C36345"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1514542",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7659777"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7659777",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Protein Deregulation"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/14767561",
				"http://www.ncbi.nlm.nih.gov/pubmed/21549346",
				"http://www.ncbi.nlm.nih.gov/pubmed/21643016",
				"http://www.ncbi.nlm.nih.gov/pubmed/24276238",
				"http://www.ncbi.nlm.nih.gov/pubmed/23730214",
				"http://www.ncbi.nlm.nih.gov/pubmed/22169974",
				"http://www.ncbi.nlm.nih.gov/pubmed/21965329",
				"http://www.ncbi.nlm.nih.gov/pubmed/19041750",
				"http://www.ncbi.nlm.nih.gov/pubmed/18641685"
			],
			"type": "yesno",
			"id": "53314c98d6d3ac6a3400003b",
			"snippets": [
				{
					"offsetInBeginSection": 134,
					"offsetInEndSection": 211,
					"text": "human homologs of Drosophila dlg, scrib, and lgl are cancer-associated genes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14767561",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 77,
					"text": "Aberrant overexpression of the cell polarity module scribble in human cancer.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21549346",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 140,
					"offsetInEndSection": 318,
					"text": "we show that Scrib is nearly universally overexpressed in cultured tumor cell lines and genetically disparate cancer patient series compared with matched normal tissues in vivo. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21549346",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 762,
					"offsetInEndSection": 939,
					"text": "These data uncover a previously unrecognized exploitation of Scrib for aberrant tumor cell motility and invasion, thus potentially contributing to disease progression in humans.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21549346",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 578,
					"offsetInEndSection": 737,
					"text": "oss of miR-296 causes aberrantly increased and mislocalized Scrib in human tumors, resulting in exaggerated random cell migration and tumor cell invasiveness. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21643016",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 832,
					"offsetInEndSection": 904,
					"text": "Scrib levels predict tumor relapse in hepatocellular carcinoma patients.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21643016",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 47,
					"text": "Scrib heterozygosity predisposes to lung cancer",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24276238",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 754,
					"offsetInEndSection": 859,
					"text": "loss of Scrib and activated oncogenic KRas cooperate in vivo, resulting in more aggressive lung tumors, l",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24276238",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 406,
					"offsetInEndSection": 463,
					"text": "Scribble, a product of a well-known tumor suppressor gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23730214",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 105,
					"text": "CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23730214",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 247,
					"offsetInEndSection": 358,
					"text": " scribble (SCRIB) complexes) is intricately related to advanced stages of tumour progression and invasiveness. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22169974",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 57,
					"text": "SCRIB expression is deregulated in human prostate cancer,",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21965329",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 531,
					"offsetInEndSection": 582,
					"text": "Scrib heterozygosity initiated prostate hyperplasia",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21965329",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 984,
					"offsetInEndSection": 1153,
					"text": "The clinical significance of the work in mice was highlighted by our observation that SCRIB deregulation strongly correlated with poor survival in human prostate cancer.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21965329",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 839,
					"offsetInEndSection": 1051,
					"text": "we demonstrate that scribble inhibits breast cancer formation and that deregulation of polarity pathways promotes dysplastic and neoplastic growth in mammals by disrupting morphogenesis and inhibiting cell death.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19041750",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 106,
					"text": "Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19041750",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 637,
					"offsetInEndSection": 743,
					"text": "loss of Scribble promotes invasion of cells through extracellular matrix in an organotypic culture system.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18641685",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1131,
					"offsetInEndSection": 1195,
					"text": "Scribble expression is decreased in many invasive human cancers.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18641685",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 110,
					"text": "Loss of human Scribble cooperates with H-Ras to promote cell invasion through deregulation of MAPK signalling.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18641685",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 2221,
					"offsetInEndSection": 2311,
					"text": "involves deregulation and subcellular mislocalization of Scrib in metastatic human cancer ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21643016",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 6674,
					"offsetInEndSection": 6890,
					"text": "Scrib levels were conversely upregulated in primary lesions and distant metastases of colon, lung, breast, and stomach cancer (n=18), as well as HCC (n=62) (Augello et al., 2009), compared with matched normal mucosa ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21643016",
					"endSection": "sections.1"
				}
			]
		},
		{
			"body": "What is the ubiquitin proteome?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23764619",
				"http://www.ncbi.nlm.nih.gov/pubmed/23743150",
				"http://www.ncbi.nlm.nih.gov/pubmed/22178446"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23764619",
				"http://www.ncbi.nlm.nih.gov/pubmed/23743150",
				"http://www.ncbi.nlm.nih.gov/pubmed/22178446"
			],
			"type": "factoid",
			"id": "532f1452d6d3ac6a34000030",
			"snippets": [
				{
					"offsetInBeginSection": 266,
					"offsetInEndSection": 422,
					"text": "Mass spectrometry now allows high throughput approaches for the identification of the thousands of ubiquitinated proteins and of their ubiquitination sites.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23764619",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 313,
					"offsetInEndSection": 543,
					"text": "we used Tandem repeated Ubiquitin Binding Entities (TUBEs) under non-denaturing conditions followed by mass spectrometry analysis to study global ubiquitylation events that may lead to the identification of potential drug targets.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22178446",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 174,
					"offsetInEndSection": 339,
					"text": "To study the ubiquitin proteome we have established an immunoaffinity purification method for the proteomic analysis of endogenously ubiquitinated protein complexes.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23743150",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the extracellular core \"matrisome\"?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23539364",
				"http://www.ncbi.nlm.nih.gov/pubmed/21937732",
				"http://www.ncbi.nlm.nih.gov/pubmed/22159717"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23539364",
				"http://www.ncbi.nlm.nih.gov/pubmed/21937732",
				"http://www.ncbi.nlm.nih.gov/pubmed/22159717"
			],
			"type": "summary",
			"id": "53312464d6d3ac6a3400003a",
			"snippets": [
				{
					"offsetInBeginSection": 152,
					"offsetInEndSection": 287,
					"text": "Over 300 ECM molecules have been defined as comprising the \"core matrisome\" in mammals through the analysis of whole genome sequences. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23539364",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 206,
					"text": "Completion of genome sequences for many organisms allows a reasonably complete definition of the complement of extracellular matrix (ECM) proteins. In mammals this \"core matrisome\" comprises β�Ό300 proteins. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21937732",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 456,
					"offsetInEndSection": 600,
					"text": "we have developed a bioinformatic approach to predict the in silico \"matrisome\" defined as the ensemble of ECM proteins and associated factors. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22159717",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 17,
					"offsetInEndSection": 225,
					"text": "the development of proteomics-based methods coupled with a bioinformatic definition of the β€�matrisomeβ€� (ECM and ECM-associated proteins) to analyze the protein composition of the tissue extracellular matrix. ",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22159717",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 4282,
					"offsetInEndSection": 4486,
					"text": "The β€�core matrisomeβ€� division comprises ECM glycoproteins, collagens and proteoglycans; the β€�matrisome-associatedβ€� protein division encompasses ECM-affiliated proteins, ECM regulators and Secreted factors",
					"beginSection": "sections.5",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22159717",
					"endSection": "sections.5"
				},
				{
					"offsetInBeginSection": 892,
					"offsetInEndSection": 1014,
					"text": "The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices.",
					"beginSection": "sections.6",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22159717",
					"endSection": "sections.6"
				}
			]
		},
		{
			"body": "How can the expression of SerH3 immobilization antigen be regulated?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/3336362",
				"http://www.ncbi.nlm.nih.gov/pubmed/3537733",
				"http://www.ncbi.nlm.nih.gov/pubmed/4054606",
				"http://www.ncbi.nlm.nih.gov/pubmed/3915784",
				"http://www.ncbi.nlm.nih.gov/pubmed/11973302",
				"http://www.ncbi.nlm.nih.gov/pubmed/7731807",
				"http://www.ncbi.nlm.nih.gov/pubmed/7828814",
				"http://www.ncbi.nlm.nih.gov/pubmed/8414992",
				"http://www.ncbi.nlm.nih.gov/pubmed/1522546",
				"http://www.ncbi.nlm.nih.gov/pubmed/2233735",
				"http://www.ncbi.nlm.nih.gov/pubmed/2854007",
				"http://www.ncbi.nlm.nih.gov/pubmed/3211135"
			],
			"triples": [
				{
					"s": "http://purl.uniprot.org/uniprot/Q9U697",
					"p": "http://purl.uniprot.org/core/submittedName",
					"o": "http://linkedlifedata.com/resource/#_513955363937005"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513955363937005",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "SerH3 immobilization antigen"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q22YJ5",
					"p": "http://purl.uniprot.org/core/submittedName",
					"o": "http://linkedlifedata.com/resource/#_513232594A35007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513232594A35007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "SerH3 immobilization antigen, putative"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q23VE7",
					"p": "http://purl.uniprot.org/core/submittedName",
					"o": "http://linkedlifedata.com/resource/#_513233564537007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513233564537007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "SerH3 immobilization antigen, putative"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q22TF4",
					"p": "http://purl.uniprot.org/core/submittedName",
					"o": "http://linkedlifedata.com/resource/#_513232544634007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513232544634007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "SerH3 immobilization antigen, putative"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q9U697",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_513955363937008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513955363937008",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "SerH3"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/3336362",
				"http://www.ncbi.nlm.nih.gov/pubmed/3537733",
				"http://www.ncbi.nlm.nih.gov/pubmed/4054606",
				"http://www.ncbi.nlm.nih.gov/pubmed/3915784",
				"http://www.ncbi.nlm.nih.gov/pubmed/11973302",
				"http://www.ncbi.nlm.nih.gov/pubmed/7731807",
				"http://www.ncbi.nlm.nih.gov/pubmed/7828814",
				"http://www.ncbi.nlm.nih.gov/pubmed/8414992",
				"http://www.ncbi.nlm.nih.gov/pubmed/1522546",
				"http://www.ncbi.nlm.nih.gov/pubmed/2233735",
				"http://www.ncbi.nlm.nih.gov/pubmed/2854007",
				"http://www.ncbi.nlm.nih.gov/pubmed/3211135"
			],
			"type": "factoid",
			"id": "5335f053d6d3ac6a34000055",
			"snippets": [
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 129,
					"text": "mRNA stability plays a major role in regulating the temperature-specific expression of a Tetrahymena thermophila surface protein.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/3336362",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 168,
					"text": "The presence of specific proteins (known as immobilization antigens) on the surface of the ciliated protozoan Tetrahymena thermophila is under environmental regulation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/3537733",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 156,
					"text": "A temperature shift from 40 to 28 degrees C rapidly induced expression of a specific immobilization antigen at the cell surface in Tetrahymena thermophila. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/3915784",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1016,
					"offsetInEndSection": 1163,
					"text": "Expression of each allele is regulated by temperature-sensitive mRNA stability. H mRNAs are stable at <36 degrees but are unstable at >36 degrees. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11973302",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 181,
					"text": "In Tetrahymena thermophila, the expression of the temperature-specific surface protein SerH3 is controlled primarily by a temperature-dependent change in the stability of its mRNA. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7731807",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 318,
					"offsetInEndSection": 450,
					"text": "we studied SerH3-ts1, a temperature-sensitive allele of the temperature-regulated SerH3 gene normally expressed from 20-36 degrees. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/7828814",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 214,
					"text": "In Tetrahymena thermophila, the expression of a temperature-specific surface protein known as SerH3 is primarily controlled by a temperature-dependent change in the stability of the mRNA that encodes this protein. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/8414992",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 298,
					"text": "The expression of Tetrahymena surface proteins serotype H3 (SerH3) and serotype T (SerT) is under environmental regulation. SerH3 is expressed when cells are incubated between the temperatures of 20 and 35 degrees C, while SerT is expressed when cells are grown at temperatures above 35 degrees C. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/3211135",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 131,
					"text": "The surfaces of Tetrahymena thermophila cells grown between 20 and 35 degrees C are covered by one or more variants of H antigens. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/2854007",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 30,
					"offsetInEndSection": 117,
					"text": "SerH3, a Tetrahymena thermophila gene encoding a temperature-regulated surface antigen.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/2233735",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 274,
					"offsetInEndSection": 473,
					"text": "In the holotrich Tetrahymena thermophila five alternative cell surface immobilization proteins (i-antigens) are expressed under different conditions of temperature (L, H, T) and culture media (I, S).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/1522546",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "List five applications of machine learning algorithms in medical diagnosis.",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24321226",
				"http://www.ncbi.nlm.nih.gov/pubmed/24266942",
				"http://www.ncbi.nlm.nih.gov/pubmed/24297560",
				"http://www.ncbi.nlm.nih.gov/pubmed/24290902",
				"http://www.ncbi.nlm.nih.gov/pubmed/24286700",
				"http://www.ncbi.nlm.nih.gov/pubmed/24263362",
				"http://www.ncbi.nlm.nih.gov/pubmed/23322959",
				"http://www.ncbi.nlm.nih.gov/pubmed/22606665",
				"http://www.ncbi.nlm.nih.gov/pubmed/23763826",
				"http://www.ncbi.nlm.nih.gov/pubmed/21479187",
				"http://www.ncbi.nlm.nih.gov/pubmed/15788095",
				"http://www.ncbi.nlm.nih.gov/pubmed/22606669",
				"http://www.ncbi.nlm.nih.gov/pubmed/16226240"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0730516",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "D001185"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0730516",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Learning, Machine"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7786375",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Machine Learning"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0376284",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A0730516"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0376284",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7786375"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7786375",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "D001185"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0730516",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Learning, Machine"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7786375",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Machine Learning"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0376284",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A0730516"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0376284",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7786375"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0730516",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0730516",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Learning, Machine"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7786375",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Machine Learning"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0376284",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A0730516"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0376284",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7786375"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7786375",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A0730516",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Learning, Machine"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7786375",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Machine Learning"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0376284",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A0730516"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0376284",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7786375"
				},
				{
					"s": "http://linkedlifedata.com/resource/semanticnetwork/id/T066",
					"p": "http://www.w3.org/2000/01/rdf-schema#subClassOf",
					"o": "http://linkedlifedata.com/resource/semanticnetwork/id/T052"
				},
				{
					"s": "http://linkedlifedata.com/resource/semanticnetwork/id/T066",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "Machine Activity"
				},
				{
					"s": "http://linkedlifedata.com/resource/semanticnetwork/id/T052",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "Activity"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24321226",
				"http://www.ncbi.nlm.nih.gov/pubmed/24266942",
				"http://www.ncbi.nlm.nih.gov/pubmed/24297560",
				"http://www.ncbi.nlm.nih.gov/pubmed/24290902",
				"http://www.ncbi.nlm.nih.gov/pubmed/24286700",
				"http://www.ncbi.nlm.nih.gov/pubmed/24263362",
				"http://www.ncbi.nlm.nih.gov/pubmed/23322959",
				"http://www.ncbi.nlm.nih.gov/pubmed/22606665",
				"http://www.ncbi.nlm.nih.gov/pubmed/23763826",
				"http://www.ncbi.nlm.nih.gov/pubmed/21479187",
				"http://www.ncbi.nlm.nih.gov/pubmed/15788095",
				"http://www.ncbi.nlm.nih.gov/pubmed/22606669",
				"http://www.ncbi.nlm.nih.gov/pubmed/16226240"
			],
			"type": "list",
			"id": "52ee065d98d0239505000033",
			"snippets": [
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 160,
					"text": "The ability to differentiate between brain tumor progression and radiation therapy induced necrosis is critical for appropriate patient management. I",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 522,
					"offsetInEndSection": 947,
					"text": "Experimental results on public leukemia, prostate, and colon cancer datasets show that fuzzy support vector machine applied in combination with filter or wrapper feature selection methods develops a robust model with higher accuracy than the conventional microarray classification models such as support vector machine, artificial neural network, decision trees, k nearest neighbors, and diagonal linear discriminant analysis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24266942",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 614,
					"text": "Mass spectrometry based proteomics technologies have allowed for a great progress in identifying disease biomarkers for clinical diagnosis and prognosis. However, they face acute challenges from a data reproducibility standpoint, in that no two independent studies have been found to produce the same proteomic patterns. Such reproducibility issues cause the identified biomarker patterns to lose repeatability and prevent real clinical usage. In this work, we propose a profile biomarker approach to overcome this problem from a machine-learning viewpoint by developing a novel derivative component analysis (DCA)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24297560",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 422,
					"offsetInEndSection": 517,
					"text": "In this paper, a random forest classifier (RFC) approach is proposed to diagnose lymph diseases",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24290902",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1571,
					"offsetInEndSection": 1758,
					"text": "The algorithm provides excellent discrimination of PD patients from PSP patients at an individual level, thus encouraging the application of computer-based diagnosis in clinical practice.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24286700",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 220,
					"offsetInEndSection": 430,
					"text": "The objective of this project was the development and validation of a multiparameter machine learning algorithm and system capable of predicting the need for life-saving interventions (LSIs) in trauma patients.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24263362",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 503,
					"offsetInEndSection": 889,
					"text": "Gene expression is a complicated process that allows a cell to respond both to environmental needs and to its own changing needs [1]. Upon completion of the Human Genome Project, human genome was sequenced and genes within the genome were identified [2]. Moreover, tools such as microarrays enabled scientists to study changes in expression level of a large set of genes simultaneously.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24266942",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1771,
					"offsetInEndSection": 2087,
					"text": "Many machine learning algorithms are designed and applied for microarray classification problem which some of them provided fruitful results but due to the challenges of dealing with microarrays researchers are still working on designing more accurate, robust, and interpretable models for microarray classification.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24266942",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4486,
					"offsetInEndSection": 4731,
					"text": "Various classification models have been applied on microarrays like support vector machine (SVM) [11,12], artificial neural network (ANN) [13], decision trees [10,14], k nearest neighbors (KNN) [10], diagonal linear discriminant analysis (DLDA) ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24266942",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Is cadasil syndrome a hereditary disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24274803",
				"http://www.ncbi.nlm.nih.gov/pubmed/23868154",
				"http://www.ncbi.nlm.nih.gov/pubmed/23832984",
				"http://www.ncbi.nlm.nih.gov/pubmed/23799141",
				"http://www.ncbi.nlm.nih.gov/pubmed/23705041",
				"http://www.ncbi.nlm.nih.gov/pubmed/23639391",
				"http://www.ncbi.nlm.nih.gov/pubmed/23602593",
				"http://www.ncbi.nlm.nih.gov/pubmed/23597439",
				"http://www.ncbi.nlm.nih.gov/pubmed/23584202",
				"http://www.ncbi.nlm.nih.gov/pubmed/23587639",
				"http://www.ncbi.nlm.nih.gov/pubmed/23465844",
				"http://www.ncbi.nlm.nih.gov/pubmed/23460375",
				"http://www.ncbi.nlm.nih.gov/pubmed/21197470",
				"http://www.ncbi.nlm.nih.gov/pubmed/23799017",
				"http://www.ncbi.nlm.nih.gov/pubmed/21772710",
				"http://www.ncbi.nlm.nih.gov/pubmed/23412372",
				"http://www.ncbi.nlm.nih.gov/pubmed/23394849",
				"http://www.ncbi.nlm.nih.gov/pubmed/23355563",
				"http://www.ncbi.nlm.nih.gov/pubmed/23308019",
				"http://www.ncbi.nlm.nih.gov/pubmed/23221354",
				"http://www.ncbi.nlm.nih.gov/pubmed/23649698"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "UMLS_CUI:C0751587"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "cadasil"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "MSH2010_2010_02_22:D046589"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "cadasil"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24274803",
				"http://www.ncbi.nlm.nih.gov/pubmed/23868154",
				"http://www.ncbi.nlm.nih.gov/pubmed/23832984",
				"http://www.ncbi.nlm.nih.gov/pubmed/23799141",
				"http://www.ncbi.nlm.nih.gov/pubmed/23705041",
				"http://www.ncbi.nlm.nih.gov/pubmed/23639391",
				"http://www.ncbi.nlm.nih.gov/pubmed/23602593",
				"http://www.ncbi.nlm.nih.gov/pubmed/23597439",
				"http://www.ncbi.nlm.nih.gov/pubmed/23584202",
				"http://www.ncbi.nlm.nih.gov/pubmed/23587639",
				"http://www.ncbi.nlm.nih.gov/pubmed/23465844",
				"http://www.ncbi.nlm.nih.gov/pubmed/23460375",
				"http://www.ncbi.nlm.nih.gov/pubmed/21197470",
				"http://www.ncbi.nlm.nih.gov/pubmed/23799017",
				"http://www.ncbi.nlm.nih.gov/pubmed/21772710",
				"http://www.ncbi.nlm.nih.gov/pubmed/23412372",
				"http://www.ncbi.nlm.nih.gov/pubmed/23394849",
				"http://www.ncbi.nlm.nih.gov/pubmed/23355563",
				"http://www.ncbi.nlm.nih.gov/pubmed/23308019",
				"http://www.ncbi.nlm.nih.gov/pubmed/23221354",
				"http://www.ncbi.nlm.nih.gov/pubmed/23649698"
			],
			"type": "yesno",
			"id": "532361fd9b2d7acc7e000013",
			"snippets": [
				{
					"offsetInBeginSection": 23,
					"offsetInEndSection": 487,
					"text": " CADASIL is the most frequent hereditary small-vessel disease of the brain. The clinical impact of various MR imaging markers has been repeatedly studied in this disorder, but alterations of contrast between gray matter and normal-appearing white matter remain unknown. The aim of this study was to evaluate the contrast alterations between gray matter and normal-appearing white matter on T1-weighted images in patients with CADASIL compared with healthy subjects",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23868154",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 90,
					"offsetInEndSection": 158,
					"text": " (CADASIL) is the most common form of hereditary cerebral angiopathy",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23705041",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 386,
					"text": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebral small vessel disease, clinically characterized by migraine, recurrent transient ischemic attacks or strokes, psychiatric disorders and cognitive decline. Strokes are typically ischemic, while hemorrhagic events have been only sporadically described",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23639391",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 233,
					"text": "Mutations in the TREX1 and NOTCH3 genes cause retinal vasculopathy with cerebral leukodystrophy (RVCL) and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), respectively",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23602593",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 225,
					"offsetInEndSection": 569,
					"text": "We used immunohistochemistry and immunogold electron microscopy (EM) to examine the distribution of GOM and NOTCH3 ectodomain (N3ECD) protein in microvasculature of brain gray matter and white matter in patients with CADASIL, non-CADASIL hereditary small-vessel disease and sporadic age-related degenerative disease, and comparable-age controls",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23584202",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Can adult humans be induced to produce fetal hemoglobin?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18379999",
				"http://www.ncbi.nlm.nih.gov/pubmed/17456718",
				"http://www.ncbi.nlm.nih.gov/pubmed/17486495",
				"http://www.ncbi.nlm.nih.gov/pubmed/20201948",
				"http://www.ncbi.nlm.nih.gov/pubmed/20305142",
				"http://www.ncbi.nlm.nih.gov/pubmed/17041717",
				"http://www.ncbi.nlm.nih.gov/pubmed/16735596",
				"http://www.ncbi.nlm.nih.gov/pubmed/14594506",
				"http://www.ncbi.nlm.nih.gov/pubmed/11929793",
				"http://www.ncbi.nlm.nih.gov/pubmed/11144280",
				"http://www.ncbi.nlm.nih.gov/pubmed/10908330",
				"http://www.ncbi.nlm.nih.gov/pubmed/7541126",
				"http://www.ncbi.nlm.nih.gov/pubmed/10575541",
				"http://www.ncbi.nlm.nih.gov/pubmed/21415990",
				"http://www.ncbi.nlm.nih.gov/pubmed/23997901",
				"http://www.ncbi.nlm.nih.gov/pubmed/22460946",
				"http://www.ncbi.nlm.nih.gov/pubmed/16939628",
				"http://www.ncbi.nlm.nih.gov/pubmed/24222332"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15585362",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2350438",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15585362"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15585362",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "G gamma-Globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2350438",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15591265"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15591265",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "G gamma Globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2350438",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A15585362"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15591265",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2350438",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15585362"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15585362",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "G gamma-Globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2350438",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A15591265"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A15591265",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "G gamma Globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C2350438",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A15585362"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68078",
					"p": "http://purl.uniprot.org/core/citation",
					"o": "http://purl.uniprot.org/citations/2420747"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/2420747",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Hemoglobin"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/2420747",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/2420747"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68078",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303738009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68078",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303738008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303738008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303738007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68078",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303738007"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/2420747",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/medline/86167516"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303738009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68079",
					"p": "http://purl.uniprot.org/core/citation",
					"o": "http://purl.uniprot.org/citations/511581"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68079",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303739007"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/511581",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Hemoglobin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303739008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68079",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303739008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303739009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303739007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68079",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303739009"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/511581",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/medline/80071586"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/511581",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/511581"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P02097",
					"p": "http://purl.uniprot.org/core/citation",
					"o": "http://purl.uniprot.org/citations/105752"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/105752",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/medline/79124683"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P02097",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503032303937007"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/105752",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Biochemistry"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P02097",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503032303937009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P02097",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503032303937008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503032303937007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503032303937009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/105752",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/105752"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503032303937008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68077",
					"p": "http://purl.uniprot.org/core/citation",
					"o": "http://purl.uniprot.org/citations/6157408"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68077",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303737008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303737009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/6157408",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Biochemistry"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/6157408",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/6157408"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68077",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303737009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303737008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/6157408",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/medline/81000303"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68077",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_50363830373700A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830373700A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P08225",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50303832323500A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P08225",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503038323235007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503038323235007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P08225",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503038323235008"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P08225",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503038323235009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503038323235009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503038323235008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50303832323500A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P56285",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50353632383500A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P56285",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503536323835007"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P56285",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503536323835008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503536323835008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503536323835009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P56285",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503536323835009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50353632383500A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503536323835007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68071",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830373100A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68071",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303731009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303731009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303731007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830373100A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68071",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303731008"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68071",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303731007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303731008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68078",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830373800A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830373800A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68078",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303738009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68078",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303738008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303738008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303738007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68078",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303738007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303738009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68079",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830373900A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68079",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303739007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303739008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68079",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303739008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303739009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303739007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68079",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303739009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830373900A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q27940",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_51323739343000A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513237393430009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513237393430008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q27940",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_513237393430007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513237393430007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q27940",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_513237393430008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51323739343000A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q27940",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_513237393430009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH6",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_51343558483600B"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483600B",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH6",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_513435584836008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584836008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH6",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_513435584836009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH6",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_51343558483600A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584836009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483600A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH7",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_51343558483700B"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584837009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483700B",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH7",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_51343558483700A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483700A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH7",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_513435584837008"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH7",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_513435584837009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584837008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH8",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_51343558483800B"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483800A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH8",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_51343558483800A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584838009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584838008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH8",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_513435584838008"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH8",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_513435584838009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483800B",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O77655",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_4F373736353500B"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O77655",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_4F3737363535008"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O77655",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_4F3737363535009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3737363535009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F373736353500B",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F373736353500A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/O77655",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_4F373736353500A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_4F3737363535008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P02097",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50303230393700A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P02097",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503032303937007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50303230393700A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P02097",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503032303937009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P02097",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503032303937008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503032303937007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503032303937009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503032303937008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P08224",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50303832323400A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50303832323400A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503038323234009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P08224",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503038323234007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503038323234008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P08224",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503038323234008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503038323234007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P08224",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503038323234009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P18436",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50313834333600A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503138343336009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503138343336007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P18436",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503138343336007"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50313834333600A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503138343336008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P18436",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503138343336008"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P18436",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503138343336009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P19760",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50313937363000F"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50313937363000C",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P19760",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_50313937363000C"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P19760",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_50313937363000D"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50313937363000F",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P19760",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_50313937363000B"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50313937363000B",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50313937363000D",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68030",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830333000A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68030",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303330008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303330008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830333000A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303330007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303330009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68030",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303330007"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68030",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303330009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68031",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830333100A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303331007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303331009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68031",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303331009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68031",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303331007"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68031",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303331008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303331008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830333100A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68068",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830363800C"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68068",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_50363830363800A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830363800C",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68068",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303638009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303638009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830363800A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68068",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_50363830363800B"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830363800B",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68069",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830363900A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68069",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303639008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830363900A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68069",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303639007"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68069",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303639009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303639009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303639007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303639008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68070",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830373000A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68070",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303730009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303730007",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303730009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830373000A",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68070",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303730007"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68070",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303730008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303730008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68077",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_50363830373700B"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68077",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_503638303737008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830373700B",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303737009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68077",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_503638303737009"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_503638303737008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P68077",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_50363830373700A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50363830373700A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH5",
					"p": "http://purl.uniprot.org/core/encodedBy",
					"o": "http://linkedlifedata.com/resource/#_51343558483500B"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584835009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483500B",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "HBG"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH5",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_513435584835009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH5",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_51343558483500A"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH5",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_513435584835008"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483500A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584835008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH8",
					"p": "http://purl.uniprot.org/core/mnemonic",
					"o": "HBG_LOXAF"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51343558483800A",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH8",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_51343558483800A"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584838009",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_513435584838008",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH8",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_513435584838008"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q45XH8",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_513435584838009"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P19760",
					"p": "http://purl.uniprot.org/core/citation",
					"o": "http://purl.uniprot.org/citations/1639402"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/1639402",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/medline/92347874"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50313937363000C",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Gamma-globin"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P19760",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_50313937363000C"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/1639402",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Genomics"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P19760",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_50313937363000D"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/P19760",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_50313937363000B"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/1639402",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/1639402"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50313937363000B",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin subunit gamma"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_50313937363000D",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Hemoglobin gamma chain"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/18379999",
				"http://www.ncbi.nlm.nih.gov/pubmed/17456718",
				"http://www.ncbi.nlm.nih.gov/pubmed/17486495",
				"http://www.ncbi.nlm.nih.gov/pubmed/20201948",
				"http://www.ncbi.nlm.nih.gov/pubmed/20305142",
				"http://www.ncbi.nlm.nih.gov/pubmed/17041717",
				"http://www.ncbi.nlm.nih.gov/pubmed/16735596",
				"http://www.ncbi.nlm.nih.gov/pubmed/14594506",
				"http://www.ncbi.nlm.nih.gov/pubmed/11929793",
				"http://www.ncbi.nlm.nih.gov/pubmed/11144280",
				"http://www.ncbi.nlm.nih.gov/pubmed/10908330",
				"http://www.ncbi.nlm.nih.gov/pubmed/7541126",
				"http://www.ncbi.nlm.nih.gov/pubmed/10575541",
				"http://www.ncbi.nlm.nih.gov/pubmed/21415990",
				"http://www.ncbi.nlm.nih.gov/pubmed/23997901",
				"http://www.ncbi.nlm.nih.gov/pubmed/22460946",
				"http://www.ncbi.nlm.nih.gov/pubmed/16939628",
				"http://www.ncbi.nlm.nih.gov/pubmed/24222332"
			],
			"type": "yesno",
			"id": "531481ade3eabad021000016",
			"snippets": [
				{
					"offsetInBeginSection": 243,
					"offsetInEndSection": 318,
					"text": " At the time of birth, HbF accounts for approximately 70% of the total Hb. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18379999",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 390,
					"offsetInEndSection": 521,
					"text": " whereas in the trace amounts of HbF that is found in the adult it reverses to 40:60 because of a gamma- to beta-globin gene switch",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18379999",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 734,
					"offsetInEndSection": 986,
					"text": "With the increased understanding and discovery of molecular regulators of haemoglobin switching, such as BCL11A, new avenues of research may lead ultimately to novel therapeutic, mechanism-based approaches to fetal haemoglobin reactivation in patients.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20201948",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1050,
					"offsetInEndSection": 1192,
					"text": "The data suggest that TGF-beta reactivates gamma-globin expression, combined with a sequential stimulation and suppression of erythropoiesis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14594506",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which gene is involved in CADASIL?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22664156",
				"http://www.ncbi.nlm.nih.gov/pubmed/22878905",
				"http://www.ncbi.nlm.nih.gov/pubmed/23308019",
				"http://www.ncbi.nlm.nih.gov/pubmed/21702048",
				"http://www.ncbi.nlm.nih.gov/pubmed/21038489",
				"http://www.ncbi.nlm.nih.gov/pubmed/19788051",
				"http://www.ncbi.nlm.nih.gov/pubmed/19539236",
				"http://www.ncbi.nlm.nih.gov/pubmed/19018300",
				"http://www.ncbi.nlm.nih.gov/pubmed/17622327",
				"http://www.ncbi.nlm.nih.gov/pubmed/19255248",
				"http://www.ncbi.nlm.nih.gov/pubmed/17996090",
				"http://www.ncbi.nlm.nih.gov/pubmed/17726918",
				"http://www.ncbi.nlm.nih.gov/pubmed/20224942",
				"http://www.ncbi.nlm.nih.gov/pubmed/18313300",
				"http://www.ncbi.nlm.nih.gov/pubmed/17854869"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "UMLS_CUI:C0751587"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "cadasil"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "MSH2010_2010_02_22:D046589"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "cadasil"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "MeSH"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22664156",
				"http://www.ncbi.nlm.nih.gov/pubmed/22878905",
				"http://www.ncbi.nlm.nih.gov/pubmed/23308019",
				"http://www.ncbi.nlm.nih.gov/pubmed/21702048",
				"http://www.ncbi.nlm.nih.gov/pubmed/21038489",
				"http://www.ncbi.nlm.nih.gov/pubmed/19788051",
				"http://www.ncbi.nlm.nih.gov/pubmed/19539236",
				"http://www.ncbi.nlm.nih.gov/pubmed/19018300",
				"http://www.ncbi.nlm.nih.gov/pubmed/17622327",
				"http://www.ncbi.nlm.nih.gov/pubmed/19255248",
				"http://www.ncbi.nlm.nih.gov/pubmed/17996090",
				"http://www.ncbi.nlm.nih.gov/pubmed/17726918",
				"http://www.ncbi.nlm.nih.gov/pubmed/20224942",
				"http://www.ncbi.nlm.nih.gov/pubmed/18313300",
				"http://www.ncbi.nlm.nih.gov/pubmed/17854869"
			],
			"type": "factoid",
			"id": "5323640b9b2d7acc7e000014",
			"snippets": [
				{
					"offsetInBeginSection": 71,
					"offsetInEndSection": 195,
					"text": "leukoencephalopathy (CADASIL), the most common form of familial vascular dementia, is caused by mutations of the NOTCH3 gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22664156",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 301,
					"offsetInEndSection": 594,
					"text": "Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a hereditary disease caused by mutations of the Notch3 gene encoding the Notch3 protein. Notch3 is involved in the regulation of apoptosis, modulating Fas-Ligand (Fas-L)- induced apoptosis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22878905",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 9,
					"offsetInEndSection": 189,
					"text": ": Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23308019",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 263,
					"offsetInEndSection": 467,
					"text": "Mutations in Notch3 gene are linked to cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a disorder characterized by stroke and dementia in young adults",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21702048",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 91,
					"offsetInEndSection": 252,
					"text": "(CADASIL) is caused by mutations in the NOTCH3 gene and is clinically characterized by recurrent stroke, cognitive decline, psychiatric disturbances and migraine",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21038489",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 298,
					"text": "To evaluate the role of apoptosis in the pathogenesis of brain lesions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary microangiopathy leading to cognitive decline and dementia, caused by mutations in the NOTCH3 gene.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19788051",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 467,
					"offsetInEndSection": 616,
					"text": "NOTCH3 (Notch homolog 3), the gene involved in CADASIL, encodes a transmembrane receptor primarily expressed in systemic arterial smooth-muscle cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19539236",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 91,
					"offsetInEndSection": 352,
					"text": "(CADASIL) is a vascular dementing disease caused by mutations in the NOTCH3 gene, most which are missense mutations leading to an uneven number of cysteine residues in epidermal growth factor-like repeats in the extracellular domain of Notch3 receptor (N3ECD). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17622327",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23597439",
				"http://www.ncbi.nlm.nih.gov/pubmed/23587639",
				"http://www.ncbi.nlm.nih.gov/pubmed/21616505",
				"http://www.ncbi.nlm.nih.gov/pubmed/19043263",
				"http://www.ncbi.nlm.nih.gov/pubmed/16717210",
				"http://www.ncbi.nlm.nih.gov/pubmed/15304596",
				"http://www.ncbi.nlm.nih.gov/pubmed/11706120",
				"http://www.ncbi.nlm.nih.gov/pubmed/24086431",
				"http://www.ncbi.nlm.nih.gov/pubmed/22082899",
				"http://www.ncbi.nlm.nih.gov/pubmed/21772710",
				"http://www.ncbi.nlm.nih.gov/pubmed/20224942",
				"http://www.ncbi.nlm.nih.gov/pubmed/22367627",
				"http://www.ncbi.nlm.nih.gov/pubmed/17726918",
				"http://www.ncbi.nlm.nih.gov/pubmed/23799017",
				"http://www.ncbi.nlm.nih.gov/pubmed/21038489",
				"http://www.ncbi.nlm.nih.gov/pubmed/18313300",
				"http://www.ncbi.nlm.nih.gov/pubmed/22623959",
				"http://www.ncbi.nlm.nih.gov/pubmed/18710532",
				"http://www.ncbi.nlm.nih.gov/pubmed/19006080"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "UMLS_CUI:C0751587"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "cadasil"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "MSH2010_2010_02_22:D046589"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "cadasil"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C499374"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400738",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Notch homolog 3 (Drosophila) protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8400718",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "NOTCH3 protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400718"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A8407072"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1452875",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A8400738"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A8407072",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL protein, human"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17705411",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL Syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17683439",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL Syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A12021175",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A6957136",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "CADASIL"
				},
				{
					"s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
					"p": "http://www.w3.org/2004/02/skos/core#prefLabel",
					"o": "cadasil"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CADASIL",
					"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
					"o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/genes"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CADASIL",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "CADASIL"
				},
				{
					"s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1802",
					"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
					"o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CADASIL"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23597439",
				"http://www.ncbi.nlm.nih.gov/pubmed/23587639",
				"http://www.ncbi.nlm.nih.gov/pubmed/21616505",
				"http://www.ncbi.nlm.nih.gov/pubmed/19043263",
				"http://www.ncbi.nlm.nih.gov/pubmed/16717210",
				"http://www.ncbi.nlm.nih.gov/pubmed/15304596",
				"http://www.ncbi.nlm.nih.gov/pubmed/11706120",
				"http://www.ncbi.nlm.nih.gov/pubmed/24086431",
				"http://www.ncbi.nlm.nih.gov/pubmed/22082899",
				"http://www.ncbi.nlm.nih.gov/pubmed/21772710",
				"http://www.ncbi.nlm.nih.gov/pubmed/20224942",
				"http://www.ncbi.nlm.nih.gov/pubmed/22367627",
				"http://www.ncbi.nlm.nih.gov/pubmed/17726918",
				"http://www.ncbi.nlm.nih.gov/pubmed/23799017",
				"http://www.ncbi.nlm.nih.gov/pubmed/21038489",
				"http://www.ncbi.nlm.nih.gov/pubmed/18313300",
				"http://www.ncbi.nlm.nih.gov/pubmed/22623959",
				"http://www.ncbi.nlm.nih.gov/pubmed/18710532",
				"http://www.ncbi.nlm.nih.gov/pubmed/19006080"
			],
			"type": "factoid",
			"id": "532366f09b2d7acc7e000015",
			"snippets": [
				{
					"offsetInBeginSection": 5,
					"offsetInEndSection": 253,
					"text": "missense mutations and small deletions in the NOTCH3 gene, not involving cysteine residues, have been described in patients considered to be affected by paucisymptomatic CADASIL. However, the significance of such molecular variants is still unclear",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23597439",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 267,
					"offsetInEndSection": 374,
					"text": "CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23587639",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 302,
					"text": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease due to mutations involving loss or gain of a cysteine residue in the NOTCH3 gene. A cluster of mutations around exons 3 and 4 was originally reported",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21616505",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 402,
					"offsetInEndSection": 521,
					"text": "The authors report a family with CADASIL carrying a deletion in the Notch3 gene that did not involve a cysteine residue",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15304596",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "How is the sequence variability defined in antibodies?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22863657",
				"http://www.ncbi.nlm.nih.gov/pubmed/22067045",
				"http://www.ncbi.nlm.nih.gov/pubmed/20421997",
				"http://www.ncbi.nlm.nih.gov/pubmed/18721481",
				"http://www.ncbi.nlm.nih.gov/pubmed/17353288",
				"http://www.ncbi.nlm.nih.gov/pubmed/16609350",
				"http://www.ncbi.nlm.nih.gov/pubmed/17258731",
				"http://www.ncbi.nlm.nih.gov/pubmed/16517887",
				"http://www.ncbi.nlm.nih.gov/pubmed/15613860",
				"http://www.ncbi.nlm.nih.gov/pubmed/12072528",
				"http://www.ncbi.nlm.nih.gov/pubmed/12547627",
				"http://www.ncbi.nlm.nih.gov/pubmed/11790764",
				"http://www.ncbi.nlm.nih.gov/pubmed/11292724",
				"http://www.ncbi.nlm.nih.gov/pubmed/9783696",
				"http://www.ncbi.nlm.nih.gov/pubmed/7511773",
				"http://www.ncbi.nlm.nih.gov/pubmed/8944774",
				"http://www.ncbi.nlm.nih.gov/pubmed/22661385"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22863657",
				"http://www.ncbi.nlm.nih.gov/pubmed/22067045",
				"http://www.ncbi.nlm.nih.gov/pubmed/20421997",
				"http://www.ncbi.nlm.nih.gov/pubmed/18721481",
				"http://www.ncbi.nlm.nih.gov/pubmed/17353288",
				"http://www.ncbi.nlm.nih.gov/pubmed/16609350",
				"http://www.ncbi.nlm.nih.gov/pubmed/17258731",
				"http://www.ncbi.nlm.nih.gov/pubmed/16517887",
				"http://www.ncbi.nlm.nih.gov/pubmed/15613860",
				"http://www.ncbi.nlm.nih.gov/pubmed/12072528",
				"http://www.ncbi.nlm.nih.gov/pubmed/12547627",
				"http://www.ncbi.nlm.nih.gov/pubmed/11790764",
				"http://www.ncbi.nlm.nih.gov/pubmed/11292724",
				"http://www.ncbi.nlm.nih.gov/pubmed/9783696",
				"http://www.ncbi.nlm.nih.gov/pubmed/7511773",
				"http://www.ncbi.nlm.nih.gov/pubmed/8944774",
				"http://www.ncbi.nlm.nih.gov/pubmed/22661385"
			],
			"type": "summary",
			"id": "532ad4b4d6d3ac6a34000012",
			"snippets": [
				{
					"offsetInBeginSection": 221,
					"offsetInEndSection": 399,
					"text": "Structural and immunochemical data suggest, however, that V3 contains conserved elements which explain its role in binding to virus co-receptors despite its sequence variability.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20421997",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 537,
					"offsetInEndSection": 711,
					"text": "This study, for the first time, describes an in-depth analysis of genetic variation in Vpr using information from global HIV-1 isolates involving a total of 976 Vpr sequences",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18721481",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 854,
					"offsetInEndSection": 1084,
					"text": "We investigated the possible link between enzyme secretion and variability in the linker sequence segment using site-directed mutagenesis and linker domain swapping to construct mutated and chimeric forms of the IgA1 protease from",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17353288",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 167,
					"offsetInEndSection": 457,
					"text": "We have performed low to high resolution molecular typing to assess the genetic variability of major histocompatibility complex loci (HLA-A, -B, -Cw, -DRB1, and -DQA1) in a large population of European American patients with IIM (n = 571) representing the major myositis autoantibody groups",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16609350",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 228,
					"offsetInEndSection": 518,
					"text": "In this study, we analyzed the value of IHC versus that of microsatellite instability (MSI) testing in predicting mutation status of the MLH1, MSH2, and MSH6 genes in colorectal carcinomas and adenomas, and explored the frequency and significance of immunohistochemical staining variability",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/15613860",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 720,
					"offsetInEndSection": 1004,
					"text": "Computational analyses were used to position the epitope in the context of the virion-associated envelope glycoprotein complex, to determine the variability of the surrounding surface, and to calculate the surface accessibility of possible glycan- and polypeptide-epitope components. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12072528",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1541,
					"offsetInEndSection": 1847,
					"text": "ese variations in structure of an expression site for a major, immunoprotective outer membrane protein have important implications for vaccine development and for obtaining an improved understanding of the mechanisms of persistence of ehrlichial infections in humans, domestic animals, and reservoir hosts.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11292724",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 930,
					"offsetInEndSection": 1127,
					"text": " The V3 region of the isolates used in the neutralization assay was amplified by PCR, directly sequenced, and analyzed to reveal variability between the consensus HIV-1 sequences and the isolates. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9783696",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3300,
					"offsetInEndSection": 3509,
					"text": "there is considerable structural conservation of V3, which is consistent with the requirement for V3 to participate in coreceptor binding regardless of the amino acid sequence variability this region displays.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20421997",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 1695,
					"offsetInEndSection": 1940,
					"text": "The V3 loop was identified in the late 1980s as the principle neutralizing domain of HIV-1 [24], but was considered an inappropriate target for vaccines because this region, as its name indicates, is characterized by extreme sequence variability",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20421997",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Is metabolic syndrome related with cardiovascular disease?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24328010",
				"http://www.ncbi.nlm.nih.gov/pubmed/24320038",
				"http://www.ncbi.nlm.nih.gov/pubmed/24320036",
				"http://www.ncbi.nlm.nih.gov/pubmed/24320031",
				"http://www.ncbi.nlm.nih.gov/pubmed/24290090",
				"http://www.ncbi.nlm.nih.gov/pubmed/18945929",
				"http://www.ncbi.nlm.nih.gov/pubmed/19196885",
				"http://www.ncbi.nlm.nih.gov/pubmed/21234418",
				"http://www.ncbi.nlm.nih.gov/pubmed/24287796",
				"http://www.ncbi.nlm.nih.gov/pubmed/24247648"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A2041867",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Syndrome, Metabolic Cardiovascular"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A2029581",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Cardiovascular Syndrome, Metabolic"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A2029582",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Cardiovascular Syndromes, Metabolic"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A17989670",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Metabolic Cardiovascular Syndrome"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A2035905",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Metabolic Cardiovascular Syndrome"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24328010",
				"http://www.ncbi.nlm.nih.gov/pubmed/24320038",
				"http://www.ncbi.nlm.nih.gov/pubmed/24320036",
				"http://www.ncbi.nlm.nih.gov/pubmed/24320031",
				"http://www.ncbi.nlm.nih.gov/pubmed/24290090",
				"http://www.ncbi.nlm.nih.gov/pubmed/18945929",
				"http://www.ncbi.nlm.nih.gov/pubmed/19196885",
				"http://www.ncbi.nlm.nih.gov/pubmed/21234418",
				"http://www.ncbi.nlm.nih.gov/pubmed/24287796",
				"http://www.ncbi.nlm.nih.gov/pubmed/24247648"
			],
			"type": "yesno",
			"id": "5328185dd6d3ac6a3400000e",
			"snippets": [
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 282,
					"text": "The metabolic syndrome (MetS) is characterized by a cluster of risk factors including central obesity, hypertension, dyslipidemia and insulin resistance, The MetS is associated with an increased risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24320038",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 260,
					"offsetInEndSection": 622,
					"text": "As a molecular link between metabolic signals, inflammation, and vascular dysfunction, resistin can be proposed as playing a significant role in the heightened inflammatory state induced by metabolic stress linked to excessive caloric intake, thus contributing to the risk for metabolic syndrome (MetS), type 2 diabetes (T2DM), and cardiovascular disease (CVD). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24320036",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 138,
					"text": "The metabolic syndrome (MetS) is associated with a higher risk for both, type 2 diabetes mellitus and cardiovascular disease. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24320031",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 110,
					"offsetInEndSection": 241,
					"text": "arotid intima-media thickness (CIMT) has been widely used as a surrogate marker of atherosclerosis and cardiovascular disease (CVD)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24328010",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 184,
					"offsetInEndSection": 601,
					"text": "Metabolic disturbances such as visceral obesity, hypertension, dyslipidemia, insulin resistance, and glucose intolerance are well-recognized clinical features of this syndrome. These factors, which are cluster in patients with PCOS, are also closely related to atherosclerosis.\nCarotid intima-media thickness (CIMT) has been widely used as a surrogate marker of atherosclerosis and cardiovascular disease (CVD) events",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24328010",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "What systems have been developed for the numbering of antibody residues?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23157214",
				"http://www.ncbi.nlm.nih.gov/pubmed/22390639",
				"http://www.ncbi.nlm.nih.gov/pubmed/8918594",
				"http://www.ncbi.nlm.nih.gov/pubmed/8227075",
				"http://www.ncbi.nlm.nih.gov/pubmed/12182069",
				"http://www.ncbi.nlm.nih.gov/pubmed/10592229",
				"http://www.ncbi.nlm.nih.gov/pubmed/22907343",
				"http://www.ncbi.nlm.nih.gov/pubmed/22665257",
				"http://www.ncbi.nlm.nih.gov/pubmed/19900967",
				"http://www.ncbi.nlm.nih.gov/pubmed/18503082",
				"http://www.ncbi.nlm.nih.gov/pubmed/16305737",
				"http://www.ncbi.nlm.nih.gov/pubmed/2687698",
				"http://www.ncbi.nlm.nih.gov/pubmed/9367782"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23157214",
				"http://www.ncbi.nlm.nih.gov/pubmed/22390639",
				"http://www.ncbi.nlm.nih.gov/pubmed/8918594",
				"http://www.ncbi.nlm.nih.gov/pubmed/8227075",
				"http://www.ncbi.nlm.nih.gov/pubmed/12182069",
				"http://www.ncbi.nlm.nih.gov/pubmed/10592229",
				"http://www.ncbi.nlm.nih.gov/pubmed/22907343",
				"http://www.ncbi.nlm.nih.gov/pubmed/22665257",
				"http://www.ncbi.nlm.nih.gov/pubmed/19900967",
				"http://www.ncbi.nlm.nih.gov/pubmed/18503082",
				"http://www.ncbi.nlm.nih.gov/pubmed/16305737",
				"http://www.ncbi.nlm.nih.gov/pubmed/2687698",
				"http://www.ncbi.nlm.nih.gov/pubmed/9367782"
			],
			"type": "summary",
			"id": "532ad23ad6d3ac6a34000011",
			"snippets": [
				{
					"offsetInBeginSection": 217,
					"offsetInEndSection": 771,
					"text": "IMGT is a high quality integrated knowledge resource specialized in immunoglobulins (IG), T cell receptors (TR), major histocompatibility complex (MHC) of human and other vertebrates, and related proteins of the immune system (RPI) of any species which belong to the immunoglobulin superfamily (IgSF) and to the MHC superfamily (MhcSF). IMGT consists of five databases, ten on-line tools and more than 8,000 HTML pages of Web resources. IMGT provides a common access to standardized data from genome, genetics, proteome and three-dimensional structures. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16305737",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 948,
					"offsetInEndSection": 1121,
					"text": "amino acid positions according to the IMGT unique numbering (NUMEROTATION) that are used in IMGT/3Dstructure-DB cards, results of contact analysis and renumbered flat files.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19900967",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 225,
					"offsetInEndSection": 691,
					"text": "Standardized sequence and structure analysis of antibody using IMGT(Β®) databases and tools allows one to bridge, for the first time, the gap between antibody sequences and three-dimensional (3D) structures. This is achieved through the IMGT Scientific chart rules, based on the IMGT-ONTOLOGY concepts of classification (IMGT gene and allele nomenclature), description (IMGT standardized labels), and numerotation (IMGT unique numbering and IMGT Colliers de Perles). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22907343",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 152,
					"text": "Kabat Database was initially started in 1970 to determine the combining site of antibodies based on the available amino acid sequences at that time.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/10592229",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2,
					"offsetInEndSection": 855,
					"text": "comparative analysis of the main-chain conformation of the L1, L2, L3, H1 and H2 hypervariable regions in 17 immunoglobulin structures that have been accurately determined at high resolution is described. This involves 79 hypervariable regions in all. We also analysed a part of the H3 region in 12 of the 15 VH domains considered here. On the basis of the residues at key sites the 79 hypervariable regions can be assigned to one of 18 different canonical structures. We show that 71 of these hypervariable regions have a conformation that is very close to what can be defined as a \"standard\" conformation of each canonical structure. These standard conformations are described in detail. The other eight hypervariable regions have small deviations from the standard conformations that, in six cases, involve only the rotation of a single peptide group",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9367782",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 316,
					"text": "the basis of comparative studies of known antibody structures and sequences it has been argued that there is a small repertoire of main-chain conformations for at least five of the six hypervariable regions of antibodies, and that the particular conformation adopted is determined by a few key conserved residues.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/2687698",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1579,
					"offsetInEndSection": 1854,
					"text": " Although IMGT was initially implemented for the IG, TR and MHC of human and other vertebrates [6], data and knowledge management standardization, based on the IMGT unique numbering [14-19], has now been extended to the IgSF [15-17,20-22] and MhcSF [18,23,24] of any species.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16305737",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 4369,
					"offsetInEndSection": 4615,
					"text": "The IMGT Scientific chart[2] comprises the controlled vocabulary and the annotation rules necessary for the immunogenetics data identification, description, classification and numbering and for knowledge management in the IMGT information system.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16305737",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 20101,
					"offsetInEndSection": 20386,
					"text": " A uniform numbering system for IG and TR V-DOMAINs of all vertebrate species has been established to facilitate sequence comparison and cross-referencing between experiments from different laboratories whatever the antigen receptor (IG or TR), the chain type, or the species [14-16]. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16305737",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 245,
					"offsetInEndSection": 416,
					"text": "novel functionalities that include chain sequences in IMGT format, contact analysis of paratope/epitope, β€�IMGT pMHC contact sitesβ€™ (23,34) and β€�IMGT numbering comparisonβ€™ ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19900967",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 4709,
					"offsetInEndSection": 4945,
					"text": "strands of each layer being indicated between brackets, for example [Aβ€²BDE] [Aβ€³CCβ€²Cβ€³FG], this information being deduced from the PDB file; andDomain amino acid sequence with gaps according to the IMGT numbering and region delimitations ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19900967",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 152,
					"offsetInEndSection": 391,
					"text": "The tool aligns the user amino acid sequences with the IMGT domain reference directory, identifies the closest V, C and G domains, creates gaps according to the IMGT unique numbering and highlights differences with the closest reference(s)",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19900967",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "What are the main benefits of pharmacophore models?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24294969",
				"http://www.ncbi.nlm.nih.gov/pubmed/24287559",
				"http://www.ncbi.nlm.nih.gov/pubmed/24245803",
				"http://www.ncbi.nlm.nih.gov/pubmed/24212027",
				"http://www.ncbi.nlm.nih.gov/pubmed/24140950",
				"http://www.ncbi.nlm.nih.gov/pubmed/24119198",
				"http://www.ncbi.nlm.nih.gov/pubmed/24112046",
				"http://www.ncbi.nlm.nih.gov/pubmed/22192589",
				"http://www.ncbi.nlm.nih.gov/pubmed/23662282",
				"http://www.ncbi.nlm.nih.gov/pubmed/20838973"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1308602",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "CRISP Thesaurus"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0599740",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A1308602"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1308603",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "pharmacophore"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0599740",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A1308603"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1308603",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "CRISP Thesaurus"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0599740",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A1308602"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1308603",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "pharmacophore"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0599740",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A1308603"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1308603",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "2573-1500"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0599740",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A1308602"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A1308603",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "pharmacophore"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C0599740",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A1308603"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24294969",
				"http://www.ncbi.nlm.nih.gov/pubmed/24287559",
				"http://www.ncbi.nlm.nih.gov/pubmed/24245803",
				"http://www.ncbi.nlm.nih.gov/pubmed/24212027",
				"http://www.ncbi.nlm.nih.gov/pubmed/24140950",
				"http://www.ncbi.nlm.nih.gov/pubmed/24119198",
				"http://www.ncbi.nlm.nih.gov/pubmed/24112046",
				"http://www.ncbi.nlm.nih.gov/pubmed/22192589",
				"http://www.ncbi.nlm.nih.gov/pubmed/23662282",
				"http://www.ncbi.nlm.nih.gov/pubmed/20838973"
			],
			"type": "list",
			"id": "532c0ac4d6d3ac6a3400001a",
			"snippets": [
				{
					"offsetInBeginSection": 149,
					"offsetInEndSection": 561,
					"text": "To discover novel RNAP inhibitors, a pharmacophore based on the alignment of described inhibitors was used for virtual screening. In an optimization process of hit compounds, novel derivatives with improved in vitro potency were discovered. Investigations concerning the molecular mechanism of RNAP inhibition reveal that they prevent the protein-protein interaction (PPI) between Οƒ(70) and the RNAP core enzyme.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24112046",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 777,
					"offsetInEndSection": 1190,
					"text": "the primary structural features required for estrogen receptor binding, the phenols, are not required for inhibiting parasitic growth. Significantly, the most active antileishmanial benzothiophenes lack the pharmacophore for estrogen receptor activity and therefore address potential concerns about the undesirable effects of using selective estrogen receptor modulators in women and children with leishmaniasis. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24119198",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2,
					"offsetInEndSection": 255,
					"text": "series of novel diastereoisomeric Οƒ ligands 3 was designed, synthesized and pharmacologically evaluated. The highly rigid [4.3.3]propellane scaffold was used to fix the three dimensional orientation of the pharmacophoric moieties required for Οƒ affinity",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24140950",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 143,
					"offsetInEndSection": 988,
					"text": "This study was performed to identify natural iNOS inhibitors from traditional Chinese herbs through a combination of pharmacophore modeling, molecular docking and virtual screening. First, the pharmacophore models were generated though six known iNOS inhibitors and validated by a test database. The pharmacophore model_017 showed good performance in external validation and was employed to screen Traditional Chinese Medicine Database (Version 2009), which resulting in a hit list of 498 compounds with matching score (QFIT) above 40. Then, the hits were subjected to molecular docking for further refinement. An empirical scoring function was used to evaluate the affinity of the compounds and the target protein. Parts of compounds with high docking scores have been reported to have the related pharmacological activity from the literatures.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24212027",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 327,
					"offsetInEndSection": 850,
					"text": "Hit compound 8 was identified as an inhibitor of tankyrases through a combination of substructure searching of the Amgen compound collection based on a minimal binding pharmacophore hypothesis and high-throughput screening. Herein we report the structure- and property-based optimization of compound 8 leading to the identification of more potent and selective tankyrase inhibitors 22 and 49 with improved pharmacokinetic properties in rodents, which are well suited as tool compounds for further in vivo validation studies",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24294969",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Which are the main methods for pharmacophore modelling?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23651479",
				"http://www.ncbi.nlm.nih.gov/pubmed/22650262",
				"http://www.ncbi.nlm.nih.gov/pubmed/23334436",
				"http://www.ncbi.nlm.nih.gov/pubmed/21400356",
				"http://www.ncbi.nlm.nih.gov/pubmed/18410307",
				"http://www.ncbi.nlm.nih.gov/pubmed/16783689",
				"http://www.ncbi.nlm.nih.gov/pubmed/24266725",
				"http://www.ncbi.nlm.nih.gov/pubmed/23957390",
				"http://www.ncbi.nlm.nih.gov/pubmed/23933279",
				"http://www.ncbi.nlm.nih.gov/pubmed/23862697",
				"http://www.ncbi.nlm.nih.gov/pubmed/23651486",
				"http://www.ncbi.nlm.nih.gov/pubmed/23651482",
				"http://www.ncbi.nlm.nih.gov/pubmed/23621564",
				"http://www.ncbi.nlm.nih.gov/pubmed/24504131",
				"http://www.ncbi.nlm.nih.gov/pubmed/22380004",
				"http://www.ncbi.nlm.nih.gov/pubmed/23675939",
				"http://www.ncbi.nlm.nih.gov/pubmed/16996282",
				"http://www.ncbi.nlm.nih.gov/pubmed/15807512",
				"http://www.ncbi.nlm.nih.gov/pubmed/21521148",
				"http://www.ncbi.nlm.nih.gov/pubmed/20362693"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23651479",
				"http://www.ncbi.nlm.nih.gov/pubmed/22650262",
				"http://www.ncbi.nlm.nih.gov/pubmed/23334436",
				"http://www.ncbi.nlm.nih.gov/pubmed/21400356",
				"http://www.ncbi.nlm.nih.gov/pubmed/18410307",
				"http://www.ncbi.nlm.nih.gov/pubmed/16783689",
				"http://www.ncbi.nlm.nih.gov/pubmed/24266725",
				"http://www.ncbi.nlm.nih.gov/pubmed/23957390",
				"http://www.ncbi.nlm.nih.gov/pubmed/23933279",
				"http://www.ncbi.nlm.nih.gov/pubmed/23862697",
				"http://www.ncbi.nlm.nih.gov/pubmed/23651486",
				"http://www.ncbi.nlm.nih.gov/pubmed/23651482",
				"http://www.ncbi.nlm.nih.gov/pubmed/23621564",
				"http://www.ncbi.nlm.nih.gov/pubmed/24504131",
				"http://www.ncbi.nlm.nih.gov/pubmed/22380004",
				"http://www.ncbi.nlm.nih.gov/pubmed/23675939",
				"http://www.ncbi.nlm.nih.gov/pubmed/16996282",
				"http://www.ncbi.nlm.nih.gov/pubmed/15807512",
				"http://www.ncbi.nlm.nih.gov/pubmed/21521148",
				"http://www.ncbi.nlm.nih.gov/pubmed/20362693"
			],
			"type": "list",
			"id": "532c0c21d6d3ac6a3400001b",
			"snippets": [
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 901,
					"text": "protein interactions are becoming increasingly significant as potential drug targets; however, the rational identification of small molecule inhibitors of such interactions remains a challenge. Pharmacophore modelling is a popular tool for virtual screening of compound libraries, and has previously been successfully applied to the discovery of enzymatic inhibitors. However, the application of pharmacophore modelling in the field of protein:protein interaction inhibitors has historically been considered more of a challenge and remains limited. In this review, we explore the interaction mimicry by known inhibitors that originate from in vitro screening, demonstrating the validity of pharmacophore mapping in the generation of queries for virtual screening. We discuss the pharmacophore mapping methods that have been successfully employed in the discovery of first-in-class inhibitors. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23651479",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 34,
					"offsetInEndSection": 887,
					"text": " a popular tool for virtual screening of libraries to identify novel active substances that can be potentially developed into drugs. While they have been applied for years on common drug targets, their application in the discovery of protein-protein interaction inhibitors remains limited. This review describes current pharmacophore modelling methods applied in the discovery of novel inhibitors targeting protein-protein interactions. We first address the mimicry of protein-protein interactions with their respective inhibitors as observed in crystal structure complexes. This mimicry can be exploited to derive a pharmacophore query from protein-protein complex structures. We then discuss several cases where pharmacophore queries were utilized for the discovery of first-in-class inhibitors of their respective protein-protein interaction targets.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22650262",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 283,
					"offsetInEndSection": 1068,
					"text": "The best HypoGen pharmacophore model for ACC2 inhibitors (Hypo1_ACC2) consists of one hydrogen bond acceptor, one hydrophobic aliphatic and one hydrophobic aromatic feature, whereas the best pharmacophore (Hypo1_ACC1) for ACC1 consists of one additional hydrogen-bond donor (HBD) features. The best pharmacophore hypotheses were validated by various methods such as test set, decoy set and Cat-Scramble methodology. The validated pharmacophore models were used to screen several small-molecule databases, including Specs, NCI, ChemDiv and Natural product databases to identify the potential dual ACC inhibitors. The virtual hits were then subjected to several filters such as estimated [Formula: see text] value, quantitative estimation of drug-likeness and molecular docking analysis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23334436",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2,
					"offsetInEndSection": 713,
					"text": "pharmacophore model has been developed using diverse classes of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitors useful in the treatment of human tumours. Among the top 10 generated hypotheses, the second hypothesis, with one hydrogen bond acceptor, one ring aromatic and three hydrophobic features, was found to be the best on the basis of Cat Scramble validation as well as test set prediction (r(training) = 0.89, r(test) = 0.82). The model also maps well to the external test set molecules as well as clinically active molecules and corroborates the docking studies. Finally, 10 hits were identified as potential leads after virtual screening of ZINC database for EGFR TK inhibition. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21400356",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 164,
					"offsetInEndSection": 391,
					"text": "In order to clarify the essential structure-activity relationship for the known Aurora-A inhibitors as well as identify new lead compounds against Aurora-A, 3D pharmacophore models were developed based on the known inhibitors. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18410307",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 854,
					"text": "computational methods for molecular design are well established in medicinal chemistry research, their application in the field of natural products is still not exhaustively explored. This article gives a short introduction into both the potential for the application of computer-assisted approaches, such as pharmacophore modelling, virtual screening, docking, and neural networking to efficiently access the bioactive metabolites, and the requirements and limitations related to this specific field. The challenge is which selection criteria and/or multiple filtering tools to apply for a target-oriented isolation of potentially bioactive secondary metabolites. Application examples are provided where in silico tools and classical methods used by natural product scientists are used in an effort to maximize their efficacy in drug discovery. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/16783689",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 331,
					"text": "pharmacophore models derived from protein binding site atoms without the inclusion of any ligand information have become more popular in virtual screening studies. However, the accuracy of protein-based pharmacophore models for reproducing the critical protein-ligand interactions has never been explicitly assessed. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23621564",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 868,
					"offsetInEndSection": 1259,
					"text": "Our results demonstrate that there are significant variations in the success of protein-based pharmacophore models to reproduce native contacts and consequently native ligand poses dependent on the details of the pharmacophore generation process. We show that the generation of optimized protein-based pharmacophore models is a promising approach for ligand pose prediction and pose rankings",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23621564",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2,
					"offsetInEndSection": 701,
					"text": "pharmacophore model does not describe a real molecule or a real association of functional groups but illustrates a molecular recognition of a biological target shared by a group of compounds. Pharmacophores also represent the spatial arrangement of essential interactions in a receptor-binding pocket. Structure based pharmacophores (SBPs) can work both with a free (apo) structure or a macromolecule-ligand complex (holo) structure. The SBP methods that derive pharmacophore from protein-ligand complexes use the potential interactions observed between ligand and protein, whereas, the SBP method that aims to derive pharmacophore from ligand free protein, uses only protein active site information",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23651482",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 135,
					"offsetInEndSection": 334,
					"text": "3D pharmacophore methods are now commonly used as part of more complex workflows in drug discovery campaigns, and have been successfully and extensively applied in virtual screening (VS) approaches. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23651486",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "Are there any HCV replication inhibitors available?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24165192",
				"http://www.ncbi.nlm.nih.gov/pubmed/24154738",
				"http://www.ncbi.nlm.nih.gov/pubmed/23791700",
				"http://www.ncbi.nlm.nih.gov/pubmed/23745769",
				"http://www.ncbi.nlm.nih.gov/pubmed/23688081",
				"http://www.ncbi.nlm.nih.gov/pubmed/23896953",
				"http://www.ncbi.nlm.nih.gov/pubmed/23896281",
				"http://www.ncbi.nlm.nih.gov/pubmed/23629709",
				"http://www.ncbi.nlm.nih.gov/pubmed/23453230",
				"http://www.ncbi.nlm.nih.gov/pubmed/23466233",
				"http://www.ncbi.nlm.nih.gov/pubmed/23454058",
				"http://www.ncbi.nlm.nih.gov/pubmed/23440335",
				"http://www.ncbi.nlm.nih.gov/pubmed/23431163",
				"http://www.ncbi.nlm.nih.gov/pubmed/23384816",
				"http://www.ncbi.nlm.nih.gov/pubmed/21331152",
				"http://www.ncbi.nlm.nih.gov/pubmed/21694902",
				"http://www.ncbi.nlm.nih.gov/pubmed/23230455"
			],
			"triples": [
				{
					"s": "http://data.linkedct.org/resource/intervention/24334",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_type",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/24334",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Intervention #24334 (Drug:HCV polymerase inhibitor pro-drug)"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/24334",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_name",
					"o": "HCV polymerase inhibitor pro-drug"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10759582",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/23449",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_type",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/23449",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Intervention #23449 (Drug:HCV polymerase inhibitor pro-drug)"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/23449",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_name",
					"o": "HCV polymerase inhibitor pro-drug"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10759582",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/26936",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_type",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/26936",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_name",
					"o": "HCV polymerase inhibitor pro-drug"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10759582",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/26936",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Intervention #26936 (Drug:HCV polymerase inhibitor pro-drug)"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/28754",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_type",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/28754",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Intervention #28754 (Drug:HCV polymerase inhibitor pro-drug)"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10759582",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/28754",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_name",
					"o": "HCV polymerase inhibitor pro-drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/24333",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_type",
					"o": "Drug"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/24333",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Intervention #24333 (Drug:HCV polymerase inhibitor pro-drug)"
				},
				{
					"s": "http://data.linkedct.org/resource/intervention/24333",
					"p": "http://data.linkedct.org/resource/linkedct/intervention_name",
					"o": "HCV polymerase inhibitor pro-drug"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10759582",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Drug"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24165192",
				"http://www.ncbi.nlm.nih.gov/pubmed/24154738",
				"http://www.ncbi.nlm.nih.gov/pubmed/23791700",
				"http://www.ncbi.nlm.nih.gov/pubmed/23745769",
				"http://www.ncbi.nlm.nih.gov/pubmed/23688081",
				"http://www.ncbi.nlm.nih.gov/pubmed/23896953",
				"http://www.ncbi.nlm.nih.gov/pubmed/23896281",
				"http://www.ncbi.nlm.nih.gov/pubmed/23629709",
				"http://www.ncbi.nlm.nih.gov/pubmed/23453230",
				"http://www.ncbi.nlm.nih.gov/pubmed/23466233",
				"http://www.ncbi.nlm.nih.gov/pubmed/23454058",
				"http://www.ncbi.nlm.nih.gov/pubmed/23440335",
				"http://www.ncbi.nlm.nih.gov/pubmed/23431163",
				"http://www.ncbi.nlm.nih.gov/pubmed/23384816",
				"http://www.ncbi.nlm.nih.gov/pubmed/21331152",
				"http://www.ncbi.nlm.nih.gov/pubmed/21694902",
				"http://www.ncbi.nlm.nih.gov/pubmed/23230455"
			],
			"type": "yesno",
			"id": "53353927d6d3ac6a34000043",
			"snippets": [
				{
					"offsetInBeginSection": 778,
					"offsetInEndSection": 925,
					"text": "We report here the discovery of the first small-molecule HCV infectivity inhibitor, GS-563253, also called HCV infectivity inhibitor 1 (HCV II-1). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24165192",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 140,
					"text": "Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24154738",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 525,
					"offsetInEndSection": 616,
					"text": "We tested the ability of NA808 to inhibit SPT's enzymatic activity in FLR3-1 replicon cells",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23791700",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1488,
					"offsetInEndSection": 1631,
					"text": "The SPT inhibitor NA808 prevents replication of HCV genotypes 1a, 1b, 2a, 3a, and 4a in cultured hepatocytes and in mice with humanized livers.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23791700",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 123,
					"offsetInEndSection": 263,
					"text": "Vaniprevir (phase III clinical trials) and MK-5172 (phase II clinical trials) are two potent antiviral compounds that target NS3/4A protease",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23745769",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 200,
					"text": "treatment for hepatitis C virus (HCV) infection has been significantly improved with the approval of the first two HCV NS3/4A protease inhibitors, telaprevir (Incivek) and boceprevir (Victrelis). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23688081",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 717,
					"offsetInEndSection": 1271,
					"text": "Combination therapy with telaprevir and BMS-788329 (NS5A inhibitor) reduced serum HCV RNA to undetectable levels. The presence of an NS3-V36A telaprevir resistance mutation resulted in poor response to telaprevir monotherapy but showed significant HCV reduction when telaprevir was combined with BMS-788329. However, a BMS-788329-resistant strain emerged at low frequency. Infection with a BMS-788329-resistant NS5A-L31V mutation rapidly resulted in gain of an additional NS5A-Y93A mutation that conferred telaprevir resistance during combination therapy",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23896953",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 130,
					"offsetInEndSection": 240,
					"text": "HCV NS5A replication complex inhibitors, exemplified by Daclatasvir (BMS-790052), represent a new class of DAA",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23896281",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 169,
					"offsetInEndSection": 265,
					"text": "ACH-806 (or GS-9132) is a novel, small-molecule inhibitor specific for hepatitis C virus (HCV). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23629709",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 160,
					"offsetInEndSection": 329,
					"text": "Telaprevir and boceprevir are the first two protease inhibitor (PI) DAAs to be approved for combination therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23453230",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 13,
					"offsetInEndSection": 130,
					"text": "symmetrical bidentate structure of the NS5A inhibitor BMS-790052, a series of new monodentate molecules were designed",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23466233",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1040,
					"offsetInEndSection": 1204,
					"text": "In vitro, boceprevir is more active than telaprevir against the HCV G3 NS3/4A enzyme in cell-based and biochemical assays and against G3 isolates in replicon assays",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23454058",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 351,
					"offsetInEndSection": 577,
					"text": "Alisporivir is the most advanced host-targeting antiviral in clinical development. Alisporivir blocks HCV replication by neutralizing the peptidyl-prolyl isomerase activity of the abundant host cytosolic protein, cyclophilin A",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23440335",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 102,
					"offsetInEndSection": 264,
					"text": "Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23431163",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1192,
					"offsetInEndSection": 1483,
					"text": " The recent approval of the direct-acting antiviral protease inhibitors, boceprevir and telaprevir, improved efficacy to a sustained antiviral response of 75% in patients with genotype 1 when used in combination with pegylated IFNΞ± and ribavirin, but this does not apply to other genotypes. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23440335",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 24,
					"offsetInEndSection": 201,
					"text": "\nThe first cyclophilin inhibitor shown to have in vitro anti-HCV activity was cyclosporine A, an immunosuppressant drug widely used in organ transplantation to prevent rejection",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23440335",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 34,
					"offsetInEndSection": 298,
					"text": "\nThe anti-HCV mechanism of action of alisporivir remain to be unraveled. Importantly, a number of critical discoveries have helped to guide the basic research field to understand better the mechanism of action of alisporivir as well as other cyclophilin inhibitors",
					"beginSection": "sections.5",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23440335",
					"endSection": "sections.5"
				},
				{
					"offsetInBeginSection": 1146,
					"offsetInEndSection": 1414,
					"text": "Given that the HCV therapy field is moving very quickly towards IFN-free and ribavirin-free regimens, alisporivir with all its distinctive features as described in this review represents a perfect candidate for combination with specific direct-acting antiviral agents.",
					"beginSection": "sections.8",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23440335",
					"endSection": "sections.8"
				}
			]
		},
		{
			"body": "List programs suitable for pharmacophore modelling",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22587766",
				"http://www.ncbi.nlm.nih.gov/pubmed/21143043",
				"http://www.ncbi.nlm.nih.gov/pubmed/17668276",
				"http://www.ncbi.nlm.nih.gov/pubmed/23140189",
				"http://www.ncbi.nlm.nih.gov/pubmed/22779800",
				"http://www.ncbi.nlm.nih.gov/pubmed/22553386",
				"http://www.ncbi.nlm.nih.gov/pubmed/22546667",
				"http://www.ncbi.nlm.nih.gov/pubmed/22272142",
				"http://www.ncbi.nlm.nih.gov/pubmed/21955456",
				"http://www.ncbi.nlm.nih.gov/pubmed/21342558",
				"http://www.ncbi.nlm.nih.gov/pubmed/21284830",
				"http://www.ncbi.nlm.nih.gov/pubmed/21179343",
				"http://www.ncbi.nlm.nih.gov/pubmed/21138791",
				"http://www.ncbi.nlm.nih.gov/pubmed/20621485",
				"http://www.ncbi.nlm.nih.gov/pubmed/20499259",
				"http://www.ncbi.nlm.nih.gov/pubmed/20427100",
				"http://www.ncbi.nlm.nih.gov/pubmed/20085380",
				"http://www.ncbi.nlm.nih.gov/pubmed/20055175",
				"http://www.ncbi.nlm.nih.gov/pubmed/20045317",
				"http://www.ncbi.nlm.nih.gov/pubmed/19691298",
				"http://www.ncbi.nlm.nih.gov/pubmed/18763758",
				"http://www.ncbi.nlm.nih.gov/pubmed/23202316",
				"http://www.ncbi.nlm.nih.gov/pubmed/22435086",
				"http://www.ncbi.nlm.nih.gov/pubmed/17477520",
				"http://www.ncbi.nlm.nih.gov/pubmed/9651155",
				"http://www.ncbi.nlm.nih.gov/pubmed/20116902"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/22587766",
				"http://www.ncbi.nlm.nih.gov/pubmed/21143043",
				"http://www.ncbi.nlm.nih.gov/pubmed/17668276",
				"http://www.ncbi.nlm.nih.gov/pubmed/23140189",
				"http://www.ncbi.nlm.nih.gov/pubmed/22779800",
				"http://www.ncbi.nlm.nih.gov/pubmed/22553386",
				"http://www.ncbi.nlm.nih.gov/pubmed/22546667",
				"http://www.ncbi.nlm.nih.gov/pubmed/22272142",
				"http://www.ncbi.nlm.nih.gov/pubmed/21955456",
				"http://www.ncbi.nlm.nih.gov/pubmed/21342558",
				"http://www.ncbi.nlm.nih.gov/pubmed/21284830",
				"http://www.ncbi.nlm.nih.gov/pubmed/21179343",
				"http://www.ncbi.nlm.nih.gov/pubmed/21138791",
				"http://www.ncbi.nlm.nih.gov/pubmed/20621485",
				"http://www.ncbi.nlm.nih.gov/pubmed/20499259",
				"http://www.ncbi.nlm.nih.gov/pubmed/20427100",
				"http://www.ncbi.nlm.nih.gov/pubmed/20085380",
				"http://www.ncbi.nlm.nih.gov/pubmed/20055175",
				"http://www.ncbi.nlm.nih.gov/pubmed/20045317",
				"http://www.ncbi.nlm.nih.gov/pubmed/19691298",
				"http://www.ncbi.nlm.nih.gov/pubmed/18763758",
				"http://www.ncbi.nlm.nih.gov/pubmed/23202316",
				"http://www.ncbi.nlm.nih.gov/pubmed/22435086",
				"http://www.ncbi.nlm.nih.gov/pubmed/17477520",
				"http://www.ncbi.nlm.nih.gov/pubmed/9651155",
				"http://www.ncbi.nlm.nih.gov/pubmed/20116902"
			],
			"type": "list",
			"id": "532c0d7fd6d3ac6a3400001c",
			"snippets": [
				{
					"offsetInBeginSection": 138,
					"offsetInEndSection": 260,
					"text": "Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandScout program",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22587766",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 145,
					"offsetInEndSection": 318,
					"text": "In this study, pharmacophore hypotheses based on known inhibitors were generated using common feature pharmacophore generation protocol available in Discovery Studio program",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21143043",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1083,
					"offsetInEndSection": 1163,
					"text": " A pharmacophore-based screening was then carried out using the program Catalyst",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/17668276",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1038,
					"offsetInEndSection": 1633,
					"text": "The PharmaGist employed algorithm to identify the best pharmacophores by computing multiple flexible alignments between the input ligands. The multiple alignments are generated by combining alignments pair-wise between one of the gliptin input ligands, which acts as pivot and the other gliptin as ligand. The resulting multiple alignments reveal spatial arrangements of consensus features shared by different subsets of input ligands. The best pharmacophore model has been derived using both pair-wise and multiple alignment methods, which have been weighted in Pharmacophore Generation process",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23140189",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 152,
					"offsetInEndSection": 325,
					"text": "Pharmacophore models of c-Met kinase inhibitors have been developed based on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio program package.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22779800",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 15,
					"offsetInEndSection": 179,
					"text": "chemical feature based pharmacophore models of MMP-1, MMP-8 and MMP-13 inhibitors have been developed with the aid of HypoGen module within Catalyst program package",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22553386",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 320,
					"offsetInEndSection": 458,
					"text": "Genetic Algorithm Similarity Program (GASP) was used to derive a 3D pharmacophore model which was used in effective alignment of data set.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22546667",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1085,
					"offsetInEndSection": 1255,
					"text": "Active site complimenting structure-based pharmacophore models were developed using Discovery Studio 2.5 program and validated using a dataset of known HDAC8 inhibitors. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22272142",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1314,
					"offsetInEndSection": 1438,
					"text": " pharmacophore model has been generated from the training set by means of the MOE (molecular operating environment) program.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21955456",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 982,
					"offsetInEndSection": 1169,
					"text": "A training set of 20 compounds with known experimental activity was used to generate pharmacophore hypotheses using 3D QSAR Pharmacophore Generation module available in Discovery studio. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21342558",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 529,
					"offsetInEndSection": 664,
					"text": "Pharmacophore model was developed for the first time, on a training data set of 22 CCR3 antagonists, using CATALYST HypoRefine program.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21284830",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 227,
					"offsetInEndSection": 394,
					"text": "The CatalystHipHop approach was used to generate a pharmacophore model for cyclooxygenase-2 (COX-2) inhibitors based on a training set of 15 active inhibitors (1ΓΆ15). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21179343",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 127,
					"offsetInEndSection": 305,
					"text": " Molecular modeling study, including fitting to a 3D-pharmacophore model of the designed molecules (10a-g), with HCV NS3 protease hypothesis using catalyst program was fulfilled.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21138791",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 135,
					"text": "pharmacophore model (Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst/HypoGen program. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20621485",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 225,
					"offsetInEndSection": 317,
					"text": "Three pharmacophore models of opioid agonists were generated by the Catalyst/HypoGen program",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20499259",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 229,
					"offsetInEndSection": 328,
					"text": "The superposition of the ligands was performed with the tool Pharmacophore Elucidation (MOE-package",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20427100",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 591,
					"offsetInEndSection": 738,
					"text": "Known PDE-5 inhibitors were used to construct a three dimensional quantitative structure-activity relationship (3D QSAR) model by HypoGen program. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20085380",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 18,
					"offsetInEndSection": 167,
					"text": "pharmacophore models were generated for AT1 and ET(A) receptors based on highly selective AT1 and ET(A) antagonists using the program Catalyst/HipHop",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20055175",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 132,
					"offsetInEndSection": 309,
					"text": " In this study, chemical feature based pharmacophore models of inhibitors of 5-LOX have been developed with the aid of HipHop and HypoGen modules within Catalyst program package",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20045317",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 131,
					"offsetInEndSection": 303,
					"text": "A data set consisting of 24 inhibitors was selected on the basis of the information content of the structures and activity data as required by the Catalyst/HypoGen program.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19691298",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2519,
					"offsetInEndSection": 2959,
					"text": "We therefore considered it a worthy research endeavor to study the selective COX-2 inhibitory capability of these compounds by pharmacophore analysis and docking studies.\nThe Catalyst program [17] is generally used to analyze how ligands interact with a receptor by evaluating chemical features common to a set of active ligands (HipHop) [18] or by elucidating the correlation between activity and chemical binding features (HypoGen) [19]. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21179343",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 468,
					"offsetInEndSection": 688,
					"text": "Thus, these compounds were submitted for pharmacophore model generation based on common chemical features. Diverse conformation within 20 kcal/mol energy range were generated and submitted to the Catalyst/HipHop program.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21179343",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 6494,
					"offsetInEndSection": 6597,
					"text": "In a next step we compared the binding mode obtained by docking with the Catalyst pharmacophore model. ",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21179343",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 8,
					"offsetInEndSection": 213,
					"text": "Dataset collectionIn a computerized pharmacophore generation process the accurate choice of the training set is a key issue. The built pharmacophore hypothesis can be as good as the input data information.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21342558",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 2051,
					"offsetInEndSection": 2612,
					"text": "The 2D chemical structures of 20 compounds of the training set together with their experimental IC50 values in nM.Diverse conformation generationPrior to the generation of pharmacophore hypotheses, the training set compounds, which were converted to 3D structure, were used to generate diverse conformations. Diverse Conformation Generation protocol implemented in DS was used to generate conformations using the Best conformation model generation method with CHARMM force field and Poling algorithm to ensure the energy-minimized conformation for each compound",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21342558",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 2825,
					"offsetInEndSection": 3159,
					"text": "Pharmacophore modelingThe training set comprises of 20 compounds was used in pharmacophore hypothesis generation. The HypoGen algorithm available in 3D QSAR Pharmacophore Generation protocol of DS tries to generate hypotheses with features common amongst active molecules and do not reflect the inactive molecules of the training set.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21342558",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 5860,
					"offsetInEndSection": 6125,
					"text": "The HypoGen will quit and reports the 10 top-scoring hypotheses when there is no improvement in the hypothesis score.Data analysisThe quality of a pharmacophore hypothesis is best determined by two theoretical cost calculations, which are represented in bit units [",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21342558",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 5953,
					"offsetInEndSection": 6278,
					"text": " Thus the utilization of molecular dynamic (MD) simulations to consider the flexibility of protein in the development of pharmacophore models can be a right choice and improve its reliability [30,31].\nIn this study pharmacophore models were developed using the representative structures of HDAC8 obtained from MD simulations.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22272142",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 9307,
					"offsetInEndSection": 9491,
					"text": "Structure-Based Pharmacophore ModelsPharmacophore models were generated using the two representative structures obtained from the MD simulations of HDAC8 bound C1 and C2, respectively.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22272142",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 3285,
					"offsetInEndSection": 3624,
					"text": "we have generated pharmacophore\nmodels using Catalyst [21,\n22] software for a diverse set of\ncollagenase inhibitors (MMP-1, MMP-8 and MMP-13) with an\naim to obtain pharmacophore model that would provide the\nchemical features responsible for activity. These\npharmacophore features were used to screen the databases to\nfind novel inhibitors.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22553386",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1921,
					"offsetInEndSection": 2208,
					"text": "These molecules\nwere further screened for their activities using the developed\npharmacophore models.Ligand preparation:Ligand structures were built using Maestro v9.1 and\ngeometrically minimized using OPLS_2005 force field by\nligprep module of Maestro 9.1 (SchrΓ¶dinger suite, LLC) \n[28].",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22553386",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 694,
					"offsetInEndSection": 993,
					"text": "Pharmacophore generation and validation studies using HypoGen:Ten hypotheses were generated using 21 diverse training set\nmolecules for MMP-1 and MMP-13, and 22 molecules for MMP-\n8 in HypoGen. (Figure 1 a, b & c) show some of the molecules\nselected as the training set for MMP-1, MMP-8 and MMP-13.\n",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22553386",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "How Flaviviridae family of viruses infects vertebrates?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24284878",
				"http://www.ncbi.nlm.nih.gov/pubmed/24058903",
				"http://www.ncbi.nlm.nih.gov/pubmed/23963259",
				"http://www.ncbi.nlm.nih.gov/pubmed/23738027",
				"http://www.ncbi.nlm.nih.gov/pubmed/23594175",
				"http://www.ncbi.nlm.nih.gov/pubmed/23523057",
				"http://www.ncbi.nlm.nih.gov/pubmed/23312108",
				"http://www.ncbi.nlm.nih.gov/pubmed/23242342",
				"http://www.ncbi.nlm.nih.gov/pubmed/23241081",
				"http://www.ncbi.nlm.nih.gov/pubmed/23194952",
				"http://www.ncbi.nlm.nih.gov/pubmed/23129759",
				"http://www.ncbi.nlm.nih.gov/pubmed/23110744",
				"http://www.ncbi.nlm.nih.gov/pubmed/23103288",
				"http://www.ncbi.nlm.nih.gov/pubmed/23099205",
				"http://www.ncbi.nlm.nih.gov/pubmed/23055570",
				"http://www.ncbi.nlm.nih.gov/pubmed/23030329",
				"http://www.ncbi.nlm.nih.gov/pubmed/23022371",
				"http://www.ncbi.nlm.nih.gov/pubmed/23017222",
				"http://www.ncbi.nlm.nih.gov/pubmed/22948134",
				"http://www.ncbi.nlm.nih.gov/pubmed/22981999",
				"http://www.ncbi.nlm.nih.gov/pubmed/22925932",
				"http://www.ncbi.nlm.nih.gov/pubmed/22897050",
				"http://www.ncbi.nlm.nih.gov/pubmed/22782946",
				"http://www.ncbi.nlm.nih.gov/pubmed/22627302",
				"http://www.ncbi.nlm.nih.gov/pubmed/22541792",
				"http://www.ncbi.nlm.nih.gov/pubmed/22226703",
				"http://www.ncbi.nlm.nih.gov/pubmed/22172565",
				"http://www.ncbi.nlm.nih.gov/pubmed/21994755",
				"http://www.ncbi.nlm.nih.gov/pubmed/22363822",
				"http://www.ncbi.nlm.nih.gov/pubmed/24180115",
				"http://www.ncbi.nlm.nih.gov/pubmed/24086788",
				"http://www.ncbi.nlm.nih.gov/pubmed/23965926",
				"http://www.ncbi.nlm.nih.gov/pubmed/21661323",
				"http://www.ncbi.nlm.nih.gov/pubmed/21413253",
				"http://www.ncbi.nlm.nih.gov/pubmed/20970724",
				"http://www.ncbi.nlm.nih.gov/pubmed/21216984"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24284878",
				"http://www.ncbi.nlm.nih.gov/pubmed/24058903",
				"http://www.ncbi.nlm.nih.gov/pubmed/23963259",
				"http://www.ncbi.nlm.nih.gov/pubmed/23738027",
				"http://www.ncbi.nlm.nih.gov/pubmed/23594175",
				"http://www.ncbi.nlm.nih.gov/pubmed/23523057",
				"http://www.ncbi.nlm.nih.gov/pubmed/23312108",
				"http://www.ncbi.nlm.nih.gov/pubmed/23242342",
				"http://www.ncbi.nlm.nih.gov/pubmed/23241081",
				"http://www.ncbi.nlm.nih.gov/pubmed/23194952",
				"http://www.ncbi.nlm.nih.gov/pubmed/23129759",
				"http://www.ncbi.nlm.nih.gov/pubmed/23110744",
				"http://www.ncbi.nlm.nih.gov/pubmed/23103288",
				"http://www.ncbi.nlm.nih.gov/pubmed/23099205",
				"http://www.ncbi.nlm.nih.gov/pubmed/23055570",
				"http://www.ncbi.nlm.nih.gov/pubmed/23030329",
				"http://www.ncbi.nlm.nih.gov/pubmed/23022371",
				"http://www.ncbi.nlm.nih.gov/pubmed/23017222",
				"http://www.ncbi.nlm.nih.gov/pubmed/22948134",
				"http://www.ncbi.nlm.nih.gov/pubmed/22981999",
				"http://www.ncbi.nlm.nih.gov/pubmed/22925932",
				"http://www.ncbi.nlm.nih.gov/pubmed/22897050",
				"http://www.ncbi.nlm.nih.gov/pubmed/22782946",
				"http://www.ncbi.nlm.nih.gov/pubmed/22627302",
				"http://www.ncbi.nlm.nih.gov/pubmed/22541792",
				"http://www.ncbi.nlm.nih.gov/pubmed/22226703",
				"http://www.ncbi.nlm.nih.gov/pubmed/22172565",
				"http://www.ncbi.nlm.nih.gov/pubmed/21994755",
				"http://www.ncbi.nlm.nih.gov/pubmed/22363822",
				"http://www.ncbi.nlm.nih.gov/pubmed/24180115",
				"http://www.ncbi.nlm.nih.gov/pubmed/24086788",
				"http://www.ncbi.nlm.nih.gov/pubmed/23965926",
				"http://www.ncbi.nlm.nih.gov/pubmed/21661323",
				"http://www.ncbi.nlm.nih.gov/pubmed/21413253",
				"http://www.ncbi.nlm.nih.gov/pubmed/20970724",
				"http://www.ncbi.nlm.nih.gov/pubmed/21216984"
			],
			"type": "summary",
			"id": "53340ca4d6d3ac6a34000042",
			"snippets": [
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 390,
					"text": "(WNV) is a neurotropic flavivirus that cycles between mosquitoes and birds but that can also infect humans, horses, and other vertebrate animals. In most humans, WNV infection remains subclinical. However, 20%-40% of those infected may develop WNV disease, with symptoms ranging from fever to meningoencephalitis. A large variety of WNV strains have been described worldwide",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24284878",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 32,
					"offsetInEndSection": 958,
					"text": "can be parasitized by Ixodid ticks, which may be infected with tick-borne pathogens, like Borrelia spp., Babesia spp., Anaplasma, Rickettsia/Coxiella, and tick-borne encephalitis virus. The prevalence of ticks on birds varies over years, season, locality and different bird species. The prevalence of ticks on different species depends mainly on the degree of feeding on the ground. In Europe, the Turdus spp., especially the blackbird, Turdus merula, appears to be most important for harboring ticks. Birds can easily cross barriers, like fences, mountains, glaciers, desserts and oceans, which would stop mammals, and they can move much faster than the wingless hosts. Birds can potentially transport tick-borne pathogens by transporting infected ticks, by being infected with tick-borne pathogens and transmit the pathogens to the ticks, and possibly act as hosts for transfer of pathogens between ticks through co-feeding.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24058903",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 423,
					"offsetInEndSection": 811,
					"text": "The dengue viruses (DENVs) are mosquito-borne flaviviruses transmitted by infected Aedes mosquitoes. Illness manifests across a clinical spectrum with severe disease characterized by intravascular volume depletion and hemorrhage. Recent estimates on the burden of DENV infection determined that there are 390 million dengue infections per year, three times the current estimate by the WHO",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23963259",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 127,
					"text": "(WNV), an arbovirus maintained in a bird-mosquito enzootic cycle, can infect other vertebrates including humans",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738027",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 347,
					"text": "(WNV), a mosquito-borne flavivirus in the Japanese encephalitis antigenic group, has caused sporadic outbreaks in humans, horses and birds throughout many of the warmer regions of Europe for at least 20 years. Occasional cases of West Nile encephalitis have also been associated with infected blood transfusions and organ donations",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23594175",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 432,
					"text": "Dengue is the most important vector-borne disease in many different parts of the world and is expanding into other areas of the globe without hindrance. The morbidity and mortality due to dengue complications are increasing globally at an alarming rate. Although transmission of the dengue virus has been documented in well-characterized areas of Pakistan, its incidence in Khyber Pakhtunkhawa has not been characterized",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23523057",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 136,
					"offsetInEndSection": 789,
					"text": " A rising incidence of acute hepatitis C virus (HCV) in HIV-infected MSM has been observed since 2000 in Europe, Australia, USA and Asia. Transmission appears to occur through the permucosal rather than the more usual parenteral route. Although often multifactorial, permucosal risk factors can be classified as behavioural (sexual practices and mucosally administered drugs) and biological (HIV and sexually transmitted infections). This review will describe the epidemiology of HCV infection in this cohort. Current and future treatment strategies will also be outlined in the context of novel, orally bioavailable, directly acting antiviral therapies",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23242342",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 713,
					"text": "The genus Flavivirus currently consists of approximately 80 single-strand positive-sense RNA viruses. These replicate in a range of hosts including myriad vertebrate, insect, and tick species. As a consequence of this broad host range, the majority of flaviviruses can be propagated in most vertebrate and insect cell cultures. This ability to infect arthropods and vertebrates usually is essential for maintenance of these viruses in nature. But recently, there has been the discovery of a number of flaviviruses that infect mosquitoes but not vertebrates. It remains largely unknown why certain flaviviruses infect vertebrates and mosquitoes while others infect mosquitoes or vertebrates exclusively",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23241081",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 269,
					"text": "Hepatitis C virus (HCV) transmission among people who inject drugs remains a challenging public health problem. We investigated the risk of HCV transmission by analyzing the direct association of HCV with filters, water to dilute drugs, and water containers",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23129759",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 6,
					"offsetInEndSection": 117,
					"text": " is a mosquito-borne disease caused by four closely related dengue virus (genus Flavivirus)serotypes (DENV-1β€“4)",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23110744",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 10,
					"offsetInEndSection": 186,
					"text": " West Nile viruses are enveloped RNA viruses that belong to genus Flavivirus (family Flaviviridae) and are considered important mosquito-borne viral pathogenic agents worldwide",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23099205",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 27,
					"offsetInEndSection": 126,
					"text": " (JEV) is a mosquito-borne pathogenic flavivirus responsible for acute viral encephalitis in humans",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23055570",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 242,
					"text": "Hepatitis C virus infection (HCV) is not infrequent among haemodialysis patients. Most published reports suggest that patient-to-patient spread, either directly or indirectly, is the most common mode of transmission in renal units",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23022371",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 161,
					"text": "POWV) is a rare tick-borne agent of encephalitis in North America. Historically, confirmed cases occurred mainly in the northeastern United State",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23017222",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 257,
					"text": "(WNV) is a zoonotic arthropod-borne pathogen with continued geographical expansion in Europe. We present and evaluate data on the temporal, spatial and bird species focus of the WNV surveillance programme in dead wild birds in Great Britain ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22948134",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 20,
					"offsetInEndSection": 567,
					"text": "YFV) is historically one of the most important viruses to affect human populations. Despite the existence of highly effective vaccines for over 70 years, yellow fever remains a significant and re-emerging cause of morbidity and mortality in endemic and high-risk regions of South America and Africa. The virus may be maintained in sylvatic enzootic/epizootic, transitional and urban epidemic transmission cycles with geographic variation in terms of levels of genetic diversity, the nature of transmission cycles and patterns of outbreak activity.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22981999",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 7,
					"offsetInEndSection": 310,
					"text": "is a systemic arthropod-borne viral disease of major global public health importance. At least 2.5 billion people who live in areas of the world where dengue occurs are at risk of developing dengue fever (DF) and its severe complications, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22782946",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 6,
					"offsetInEndSection": 153,
					"text": " is a mosquito-transmitted infection that poses significant global health risks for travelers and individuals living in the tropics and subtropics.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22541792",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 142,
					"text": "(WNV) (Flaviviridae: Flavivirus) is transmitted from mosquitoes to birds, but can cause fatal encephalitis in infected humans.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22226703",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 15,
					"offsetInEndSection": 277,
					"text": "West Nile virus (WNV) is a member of the genus Flavivirus within the Japanese encephalitis antigenic complex. The enzootic virus cycle involves transmission between avian hosts and ornithophilic mosquitoes, whereas humans and horses are considered dead-end hosts",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22172565",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 230,
					"text": " four major flavivirus clades are transmitted by mosquitoes, ticks, directly between vertebrates or directly between arthropods, respectively, but the molecular determinants of mode of transmission in flaviviruses are unknown. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21216984",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 42,
					"offsetInEndSection": 307,
					"text": " Tick-borne encephalitis virus (TBEV), one of the most prevalent arboviruses in Europe and in many parts of Asia. Transmission of TBEV to humans usually occurs by bite of an infected tick or rarely by ingestion of unpasteurized milk products of infected livestock. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20970724",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1995,
					"offsetInEndSection": 2419,
					"text": "Most alphaviruses and flaviviruses survive in nature by replicating alternately in a vertebrate host and a hematophagous arthropod (mosquitoes or, for some flaviviruses, ticks). Arthropod vectors acquire the viral infection by biting a viremic host, and after an extrinsic incubation period during which the virus replicates in the vector's tissues, they transmit virus through salivary secretions to another vertebrate host",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21413253",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 55,
					"offsetInEndSection": 751,
					"text": "Western Hemisphere have drawn attention to West Nile virus (WNV) as an international public health problem. Of particular concern has been the ability for the virus to cause outbreaks of disease in highly populated urban centers. Incrimination of Australian mosquito species is an essential component in determining the receptivity of Australia to the introduction and/or establishment of an exotic strain of WNV and can guide potential management strategies. Based on vector competence experiments and ecological studies, we suggest candidate Australian mosquito species that would most likely be involved in urban transmission of WNV, along with consideration of the endemic WNV subtype, Kunjin",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23965926",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 15,
					"offsetInEndSection": 412,
					"text": "West Nile virus (WNV) is a member of the genus Flavivirus within the Japanese encephalitis antigenic complex. The enzootic virus cycle involves transmission between avian hosts and ornithophilic mosquitoes, whereas humans and horses are considered dead-end hosts. Given the recent increase of WNV infection in humans and horses in Europe, concern has been raised regarding public and animal health",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22172565",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 6111,
					"offsetInEndSection": 6715,
					"text": "Selection bias in identifying the infection may exist, diminishing the reported incidence to only patients with severe disease. Results of seroprevalence studies in Canada and the northeastern United States are variable but include seroprevalence estimates as high as 5.8% in Canada (3) and 0.7% in New York State (4). Small and medium-sized mammals are common reservoirs (notably, woodchucks [Marmota monax] and white-footed mice [Peromyscus leucopus]), and several species of tick (4 Ixodes spp., 2 Dermacentor spp.) act as vectors (5β€“7). Human infection has been documented in North America and Russia",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23017222",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 7867,
					"offsetInEndSection": 8044,
					"text": "Geographic distribution of confirmed Powassan virus (POWV) infections (diagnosis made by serology, reverse transcription PCR) and counties with POWVβ€“infected ticks in Minnesota.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23017222",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 288,
					"text": "POWV is causing an emerging and potentially severe tick-borne infection in Minnesota and Wisconsin. POWV infection should be suspected when tick-exposed patients exhibit viral encephalitis, especially those with cerebellar symptoms and/or thalamus/midbrain gray matter disease",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23017222",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 3057,
					"offsetInEndSection": 3406,
					"text": " the virus efficiently infected mosquito cells. In addition, mosquitoes within the Culex pipiens complex supported replication of RABV but displayed poor peroral vector competence for this virus as compared to wild type WNV, and the same mosquitoes vertically transmitted the virus at a much higher rate than what had been reported for wild type WNV",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23241081",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 23,
					"offsetInEndSection": 328,
					"text": "Influence of temperature on virus growth on mammalian cellsPreviously, we reported that RABV97-103 was unable to infect mammalian or avian cell cultures, house sparrows or chickens, but the virus efficiently infected mosquito cells\n[14], i.e., it displayed characteristics of a host-restricted flavivirus.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23241081",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 13,
					"offsetInEndSection": 348,
					"text": "West Nile virus (WNV; genus Flavivirus, family Flaviviridae) is a mosquito-borne virus that is maintained in a bird-mosquito enzootic cycle, and is considered the most widely distributed flavivirus in the world [1], [2]. WNV can infect a broad range of vertebrate species including horses and humans which are considered dead-end hosts",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23738027",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 876,
					"offsetInEndSection": 1407,
					"text": "as described by Russell and Kay [12], a viremic host or, perhaps more likely, an infected mosquito would most likely enter Australia via the eastern seaboard, where, until recently, WNVKUN has seldom been active [13] and where little protective immunity would naturally exist in the vertebrate fauna or humans. Indeed, the apparent rarity of detectable flavivirus infection in urban mosquito populations in eastern Australia suggests that endemic urban flaviviruses would have minimal influence on potential exotic WNV transmission",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23965926",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 345,
					"offsetInEndSection": 614,
					"text": "In addition to physiologically supporting virus amplification, an effective reservoir for WNV must be relatively abundant in comparison with other avian species, have frequent exposure to infection via mosquitoes, and be biologically capable of infecting vector species",
					"beginSection": "sections.4",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23965926",
					"endSection": "sections.4"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 1393,
					"text": "\nThere is ample evidence that birds, particularly passerines, can be parasitized by Ixodid ticks (Hoogstraal et al., 1961, 1963; Nuorteva and Hoogstraal, 1963; Anderson and Magnarelli, 1984; Mehl et al., 1984; Weisbrod and Johnson, 1989; Stafford et al., 1995; Olsen et al., 1995a; Nicholls and Callister, 1996; Smith et al., 1996; Ishiguro et al., 2000; Alekseev et al., 2001; BjΓ¶ersdorff et al., 2001; Scharf, 2004; Comstedt et al., 2006; Poupon et al., 2006; Ogden et al., 2008; Hasle et al. 2009). These ticks may be infected with tick-borne pathogens, like Borrelia spp. (Olsen et al., 1995a,b; Gylfe et al., 2000; Hanincova et al., 2003; Comstedt et al., 2006; Poupon et al., 2006; Ogden et al., 2008; Hasle et al. 2010; Kjelland et al., 2010; Franke et al., 2012; Socolovschi et al., 2012), Anaplasma spp. (Alekseev et al., 2001; BjΓ¶ersdorff et al., 2001; Daniels et al., 2002; Ogden et al., 2008; Franke et al., 2012), Babesia spp. (Hasle et al., 2011), Rickettsia/Coxiella (Elfving et al., 2010; Socolovschi et al., 2012) and Tick-borne encephalitis virus (TBEV) (WaldenstrΓ¶m et al., 2007; Geller et al., 2013). The prevalence of ticks on birds varies between years, season, locality and different bird species. The prevalence of ticks on different species depends mainly on the degree of feeding on the ground (Mehl et al., 1984; Hasle et al. 2009; Marsot et al., 2012). ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24058903",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 34,
					"offsetInEndSection": 690,
					"text": "Birds can potentially transport tick-borne pathogens by transport of infected ticks. In addition, the birds may act as amplifying host by being infected with tick-borne pathogens that can infect their parasitizing ticks, which can transmit the pathogens to subsequent hosts, or by hosting co-feeding ticks, i.e., ticks that feed near each other on the same host, when pathogens may pass from one tick to the other.\nTransport of infected ticksTransport of already infected ticks is an obvious mechanism of transporting tick-borne pathogens by birds, as most tick-borne pathogens survive transstadially, i.e., from larvae to nymphs, and from nymphs to adults",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24058903",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 872,
					"offsetInEndSection": 1463,
					"text": "WNV is maintained in an enzootic cycle between mosquitoes and birds [3] but can also infect and cause disease in other vertebrate animals, including horses and humans. In most humans, WNV infection is subclinical, but approximately 20%β€“40% of those infected may develop symptoms of WNV disease ranging from West Nile fever (fever, headache, malaise, lymphadenopathy, myalgia, fatigue, skin rash, diarrhoea, and vomiting) to meningoencephalitis (muscle weakness, tremors, paralysis, and cognitive impairment) or flaccid paralysis (a polio-like syndrome), and, less frequently, death [1,4,5,6]",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24284878",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 292,
					"text": "WNV Dissemination and Entry into the Central Nervous System\nAfter an organism is intradermally inoculated with WNV by infected mosquitoes, WNV is thought to initially replicate in keratinocytes, newly recruited neutrophils and skin dendritic cells, specifically in Langherhans cells (LCs) ",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24284878",
					"endSection": "sections.2"
				}
			]
		},
		{
			"body": "Is there a phylogenetic analysis for HIV?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23015735",
				"http://www.ncbi.nlm.nih.gov/pubmed/22996031",
				"http://www.ncbi.nlm.nih.gov/pubmed/22981618",
				"http://www.ncbi.nlm.nih.gov/pubmed/22978157",
				"http://www.ncbi.nlm.nih.gov/pubmed/22924643",
				"http://www.ncbi.nlm.nih.gov/pubmed/22918554",
				"http://www.ncbi.nlm.nih.gov/pubmed/22903393",
				"http://www.ncbi.nlm.nih.gov/pubmed/22899432",
				"http://www.ncbi.nlm.nih.gov/pubmed/24273040",
				"http://www.ncbi.nlm.nih.gov/pubmed/24223905",
				"http://www.ncbi.nlm.nih.gov/pubmed/24220189",
				"http://www.ncbi.nlm.nih.gov/pubmed/24205972",
				"http://www.ncbi.nlm.nih.gov/pubmed/24171696",
				"http://www.ncbi.nlm.nih.gov/pubmed/23555203",
				"http://www.ncbi.nlm.nih.gov/pubmed/19245688",
				"http://www.ncbi.nlm.nih.gov/pubmed/22162803",
				"http://www.ncbi.nlm.nih.gov/pubmed/23555898"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7584997",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C18940"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7584997",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Phylogenetics"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7658697"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7658697"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7584997"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7658697",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Phylogenetic Analysis"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7658697",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C18940"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7584997",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Phylogenetics"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7658697"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7658697"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7584997"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7658697",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Phylogenetic Analysis"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7584997",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "NCI Thesaurus"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7584997",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Phylogenetics"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7658697"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7658697"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7584997"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7658697",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Phylogenetic Analysis"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7658697",
					"p": "http://www.w3.org/2004/02/skos/core#note",
					"o": "NCI Thesaurus"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7584997",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Phylogenetics"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7658697"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A7658697"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1519068",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7584997"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7658697",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Phylogenetic Analysis"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23015735",
				"http://www.ncbi.nlm.nih.gov/pubmed/22996031",
				"http://www.ncbi.nlm.nih.gov/pubmed/22981618",
				"http://www.ncbi.nlm.nih.gov/pubmed/22978157",
				"http://www.ncbi.nlm.nih.gov/pubmed/22924643",
				"http://www.ncbi.nlm.nih.gov/pubmed/22918554",
				"http://www.ncbi.nlm.nih.gov/pubmed/22903393",
				"http://www.ncbi.nlm.nih.gov/pubmed/22899432",
				"http://www.ncbi.nlm.nih.gov/pubmed/24273040",
				"http://www.ncbi.nlm.nih.gov/pubmed/24223905",
				"http://www.ncbi.nlm.nih.gov/pubmed/24220189",
				"http://www.ncbi.nlm.nih.gov/pubmed/24205972",
				"http://www.ncbi.nlm.nih.gov/pubmed/24171696",
				"http://www.ncbi.nlm.nih.gov/pubmed/23555203",
				"http://www.ncbi.nlm.nih.gov/pubmed/19245688",
				"http://www.ncbi.nlm.nih.gov/pubmed/22162803",
				"http://www.ncbi.nlm.nih.gov/pubmed/23555898"
			],
			"type": "yesno",
			"id": "53354eafd6d3ac6a34000044",
			"snippets": [
				{
					"offsetInBeginSection": 668,
					"offsetInEndSection": 859,
					"text": "The results of Burst and phylogenetic analysis suggested that the C. neoformans var. grubii strains could be separated into three nonredundant evolutionary groups (Burst group 1 to group 3). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23015735",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 338,
					"offsetInEndSection": 424,
					"text": "Phylogenetic trees were constructed to evaluate the relationships between the variants",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22996031",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 213,
					"offsetInEndSection": 663,
					"text": "We analyzed pol (protease/reverse transcriptase) sequences from 135 newly diagnosed HIV-1-infected patients during the years 2009-2011. For phylogenetic relationships, sequences were aligned to the most recent reference data set from the Los Alamos database using BioEdit (version 7.1.3). The resulting alignment was analyzed with the Phylip package (version 3.67) building a neighbor-joining tree based on the Kimura two-parameter substitution model",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22981618",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 402,
					"offsetInEndSection": 663,
					"text": ". Phylogenetic analysis of gag gene were then performed using the MEGA 3.1 software, the gene distances were calculated by Distance program. There were three different HIV-1 subtypes including B, CRF01-AE and CRF07-BC present among twenty four MSMs in Zhengzhou",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22978157",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 785,
					"offsetInEndSection": 883,
					"text": "Phylogenetic analysis showed interpatient and intrapatient clustering of LTR nucleotide sequences.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22924643",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 246,
					"offsetInEndSection": 423,
					"text": " We evaluated the risk factors for intrafamilial transmission of HIV-1 infection through qualitative epidemiology following pol and env gene sequencing and phylogenetic analysis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22918554",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 424,
					"offsetInEndSection": 587,
					"text": "Phylogenetic analysis has shown that the Siberian 10.RU.6637 isolate displays the highest sequence identity to the HIV-1 subtype AG forms circulating in Uzbekistan",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22903393",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 333,
					"offsetInEndSection": 546,
					"text": "Phylogenetic analysis showed that the evolutionary relationship of Env between HIV and SIV was the closest and they appeared to descend from a common ancestor, and the relationship of HIV and EIAV was the furthest",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22899432",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 499,
					"offsetInEndSection": 601,
					"text": "DI was confirmed when maximum sequence divergence was excessive and supported by phylogenetic analysis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24273040",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 47,
					"offsetInEndSection": 219,
					"text": " (HIV-1) dual infection (DI) has been associated with decreased CD4 T-cell counts and increased viral loads; however, the frequency of intrasubtype DI is poorly understood.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24273040",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 289,
					"offsetInEndSection": 574,
					"text": "The aim of this study was to investigate the phylogenetic relationships of HIV-1 subtype C strains from Bangladesh and related strains from other countries, and thereby clarify when and from where subtype C was introduced in the country and how it subsequently spread within Bangladesh",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24223905",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 190,
					"offsetInEndSection": 521,
					"text": " This study characterized HCV genotype 5 sequences from South Africa, including six near full-length genomes, as well as the E1 region from an additional 12 genotype 5 samples. Phylogenetic analysis of these near full-length genome sequences revealed that all genotype 5 sequences formed a close cluster with high bootstrap support",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24220189",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 453,
					"offsetInEndSection": 603,
					"text": " The evolutionary history of the B subregion was not as clear as the C subregion, as the short length of this region yielded poor phylogenetic results",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24205972",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 668,
					"offsetInEndSection": 758,
					"text": " Finally, a phylogenetic tree was constructed to elucidate the observed pattern of HIV TDR",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24171696",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1514,
					"offsetInEndSection": 1751,
					"text": "Phylogenetic analysis of the studied HIV-1 02_AG variants has shown that the recombinant forms comprise at least three groups of viruses: (1) rare HIV isolates that are genetically related to the HIV-1 02_AG forms widespread in Cameroon,",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22903393",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2569,
					"offsetInEndSection": 2786,
					"text": "This isolate was recovered from an HIV-infected Novosibirsk citizen, its genetic properties were comprehensively analyzed, its phylogenetic relationships were determined, and recombination breakpoints were identified.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22903393",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2320,
					"offsetInEndSection": 2563,
					"text": "The constructed phylogenetic tree suggests that the HIV-1 02.UZ.AY829214 variant from Uzbekistan displays the highest similarity to our HIV-1 10.RU.6637 isolate; correspondingly, the breakpoint positions of these genome sequences were compared",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22903393",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 6862,
					"offsetInEndSection": 7052,
					"text": "Phylogenetic analyses, including maximum parsimony, maximum likelihood, and bootstrap analyses, were performed on the concatenated sequences of MLST loci for the 15 identified sequence types",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23015735",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 2354,
					"offsetInEndSection": 2700,
					"text": "Phylogenetic analysisGenotype sequences were edited, and aligned using Muscle\n[13], then trimmed to identical lengths (986 bp) within Geneious 5.4.3\n[14]. 136 reference pol sequences from the Los Alamos HIV Sequence database\n[15] and 119 pol sequences from the Canadian national HIV drug resistance surveillance were aligned and trimmed as above.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24171696",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 1777,
					"offsetInEndSection": 2072,
					"text": "The aim of this study was to investigate the phylogenetic relationship between HIV-1 subtype C strains from Bangladesh and related strains from other countries, and thereby elucidate when and from where subtype C was introduced in the country and how it has subsequently spread within Bangladesh",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24223905",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "Why graphics processing units (GPU) are more suitable for biological tasks than central processing units (CPU)?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23391255",
				"http://www.ncbi.nlm.nih.gov/pubmed/23281733",
				"http://www.ncbi.nlm.nih.gov/pubmed/22149859",
				"http://www.ncbi.nlm.nih.gov/pubmed/21357575",
				"http://www.ncbi.nlm.nih.gov/pubmed/20715052",
				"http://www.ncbi.nlm.nih.gov/pubmed/20357844",
				"http://www.ncbi.nlm.nih.gov/pubmed/18061402",
				"http://www.ncbi.nlm.nih.gov/pubmed/22537298",
				"http://www.ncbi.nlm.nih.gov/pubmed/22759575",
				"http://www.ncbi.nlm.nih.gov/pubmed/20589122",
				"http://www.ncbi.nlm.nih.gov/pubmed/18070356"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23391255",
				"http://www.ncbi.nlm.nih.gov/pubmed/23281733",
				"http://www.ncbi.nlm.nih.gov/pubmed/22149859",
				"http://www.ncbi.nlm.nih.gov/pubmed/21357575",
				"http://www.ncbi.nlm.nih.gov/pubmed/20715052",
				"http://www.ncbi.nlm.nih.gov/pubmed/20357844",
				"http://www.ncbi.nlm.nih.gov/pubmed/18061402",
				"http://www.ncbi.nlm.nih.gov/pubmed/22537298",
				"http://www.ncbi.nlm.nih.gov/pubmed/22759575",
				"http://www.ncbi.nlm.nih.gov/pubmed/20589122",
				"http://www.ncbi.nlm.nih.gov/pubmed/18070356"
			],
			"type": "summary",
			"id": "53355714d6d3ac6a34000045",
			"snippets": [
				{
					"offsetInBeginSection": 759,
					"offsetInEndSection": 995,
					"text": "The global speedups of 22.11, 38.80, and 44.80 are found comparing the parallel computation of one GPU, two GPUs by exact rotational operator, and two GPU versions by an approximate rotational operator with serial computation of the CPU",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23391255",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 195,
					"text": "evaluate the use of general-purpose graphics processing units (GPGPUs) to improve the performance of MODFLOW, an unstructured preconditioned conjugate gradient (UPCG) solver has been developed",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23281733",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 201,
					"offsetInEndSection": 541,
					"text": "UPCG solver uses a compressed sparse row storage scheme and includes Jacobi, zero fill-in incomplete, and modified-incomplete lower-upper (LU) factorization, and generalized least-squares polynomial preconditioners. The UPCG solver also includes options for sequential and parallel solution on the central processing unit (CPU) using OpenMP",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23281733",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1052,
					"offsetInEndSection": 1544,
					"text": "Testing indicates GPGPU speedups on the order of 2 to 8, relative to the standard MODFLOW preconditioned conjugate gradient (PCG) solver, can be achieved when (1) memory copies between the CPU and GPGPU are optimized, (2) the percentage of time performing memory copies between the CPU and GPGPU is small relative to the calculation time, (3) high-performance GPGPU cards are utilized, and (4) CPU-GPGPU combinations are used to execute sequential operations that are difficult to parallelize",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23281733",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2052,
					"offsetInEndSection": 2305,
					"text": "A list-mode ToF OSEM library was developed on the GPU-CUDA platform. Our studies show that the GPU reformulation is considerably faster than a single-threaded reference CPU method especially for ToF processing, while producing virtually identical images",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22149859",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1253,
					"offsetInEndSection": 1420,
					"text": "When applied to line projection operations for non-ToF list-mode PET, this new GPU-CUDA method is >200 times faster than a single-threaded reference CPU implementation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22149859",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 564,
					"offsetInEndSection": 841,
					"text": "The GPU-based parallel implementation of the Gillespie stochastic simulation algorithm (SSA), the logarithmic direct method (LDM) and the next reaction method (NRM) is approximately 85 times faster than the sequential implementation of the NRM on a central processing unit (CPU",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21357575",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 296,
					"text": "exploration of fundamental biological processes involving the forced unraveling of multimeric proteins, the sliding motion in protein fibers and the mechanical deformation of biomolecular assemblies under physiological force loads is challenging even for distributed computing systems",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20715052",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 468,
					"offsetInEndSection": 692,
					"text": "We assessed the computational performance of an end-to-end application of the program, where all the steps of the algorithm are running on a GPU, by profiling the simulation time and memory usage for a number of test systems",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20715052",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 754,
					"offsetInEndSection": 847,
					"text": "Our results show that the GPGPUs can provide significant speedup over conventional processors",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20357844",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 17,
					"offsetInEndSection": 207,
					"text": "explore the power and feasibility of using programmable graphics processing units (GPUs) for real-time rendering and displaying large 3D medical datasets for stereoscopic display workstation",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18061402",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 401,
					"offsetInEndSection": 691,
					"text": "The performance of rendering and displaying was measured and compared between GPU-based and central processing unit (CPU)-based programming. The results indicate that GPU-based programming was capable of rendering large 3D datasets at real-time interactive rates with stereographic displays",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18061402",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "How is yellow fever virus transmitted?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24056028",
				"http://www.ncbi.nlm.nih.gov/pubmed/24027319",
				"http://www.ncbi.nlm.nih.gov/pubmed/23980723",
				"http://www.ncbi.nlm.nih.gov/pubmed/23967358",
				"http://www.ncbi.nlm.nih.gov/pubmed/23740065",
				"http://www.ncbi.nlm.nih.gov/pubmed/23697028",
				"http://www.ncbi.nlm.nih.gov/pubmed/23523817",
				"http://www.ncbi.nlm.nih.gov/pubmed/23411863",
				"http://www.ncbi.nlm.nih.gov/pubmed/23133693",
				"http://www.ncbi.nlm.nih.gov/pubmed/22999801",
				"http://www.ncbi.nlm.nih.gov/pubmed/22966141",
				"http://www.ncbi.nlm.nih.gov/pubmed/22897918",
				"http://www.ncbi.nlm.nih.gov/pubmed/22594140",
				"http://www.ncbi.nlm.nih.gov/pubmed/22377581",
				"http://www.ncbi.nlm.nih.gov/pubmed/22264275",
				"http://www.ncbi.nlm.nih.gov/pubmed/21723310",
				"http://www.ncbi.nlm.nih.gov/pubmed/21413253",
				"http://www.ncbi.nlm.nih.gov/pubmed/21199140",
				"http://www.ncbi.nlm.nih.gov/pubmed/21143108",
				"http://www.ncbi.nlm.nih.gov/pubmed/20874041",
				"http://www.ncbi.nlm.nih.gov/pubmed/20513550",
				"http://www.ncbi.nlm.nih.gov/pubmed/18645665",
				"http://www.ncbi.nlm.nih.gov/pubmed/16913829",
				"http://www.ncbi.nlm.nih.gov/pubmed/15705322",
				"http://www.ncbi.nlm.nih.gov/pubmed/16707042"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24056028",
				"http://www.ncbi.nlm.nih.gov/pubmed/24027319",
				"http://www.ncbi.nlm.nih.gov/pubmed/23980723",
				"http://www.ncbi.nlm.nih.gov/pubmed/23967358",
				"http://www.ncbi.nlm.nih.gov/pubmed/23740065",
				"http://www.ncbi.nlm.nih.gov/pubmed/23697028",
				"http://www.ncbi.nlm.nih.gov/pubmed/23523817",
				"http://www.ncbi.nlm.nih.gov/pubmed/23411863",
				"http://www.ncbi.nlm.nih.gov/pubmed/23133693",
				"http://www.ncbi.nlm.nih.gov/pubmed/22999801",
				"http://www.ncbi.nlm.nih.gov/pubmed/22966141",
				"http://www.ncbi.nlm.nih.gov/pubmed/22897918",
				"http://www.ncbi.nlm.nih.gov/pubmed/22594140",
				"http://www.ncbi.nlm.nih.gov/pubmed/22377581",
				"http://www.ncbi.nlm.nih.gov/pubmed/22264275",
				"http://www.ncbi.nlm.nih.gov/pubmed/21723310",
				"http://www.ncbi.nlm.nih.gov/pubmed/21413253",
				"http://www.ncbi.nlm.nih.gov/pubmed/21199140",
				"http://www.ncbi.nlm.nih.gov/pubmed/21143108",
				"http://www.ncbi.nlm.nih.gov/pubmed/20874041",
				"http://www.ncbi.nlm.nih.gov/pubmed/20513550",
				"http://www.ncbi.nlm.nih.gov/pubmed/18645665",
				"http://www.ncbi.nlm.nih.gov/pubmed/16913829",
				"http://www.ncbi.nlm.nih.gov/pubmed/15705322",
				"http://www.ncbi.nlm.nih.gov/pubmed/16707042"
			],
			"type": "summary",
			"id": "533aaab6d6d3ac6a34000062",
			"snippets": [
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 472,
					"text": "Yellow Fever (YF) is an acute viral communicable disease transmitted by an arbovirus of the flavivirus genus. It is primarily a zoonotic disease, especially the monkeys. Worldwide, an estimated 200β€‰000 cases of yellow fever occurred each year, and the case-fatality rate is ~15%. Forty-five endemic countries in Africa and Latin America, with a population of close to 1 billion, are at risk. Up to 50% of severely affected persons from YF die without treatment",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24056028",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 20,
					"offsetInEndSection": 565,
					"text": "yellow fever virus (YFV) are transmitted between arthropod vectors and vertebrate hosts. While barriers limiting arbovirus population diversity have been observed in mosquitoes, whether barriers exist in vertebrate hosts is unclear. To investigate whether arboviruses encounter bottlenecks during dissemination in the vertebrate host, we infected immunocompetent mice and immune-deficient mice lacking alpha/beta interferon (IFN-Ξ±/Ξ²) receptors (IFNARβ�»/β�» mice) with a pool of genetically marked viruses to evaluate dissemination and host barriers",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24027319",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 190,
					"text": "Re-emergence of vector-borne diseases such as dengue and yellow fever, which are both transmitted by the Aedes aegypti mosquito, has been correlated with insecticide resistance. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23980723",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 393,
					"text": "Arthropod-borne viruses are important emerging pathogens world-wide. Viruses transmitted by mosquitoes, such as dengue, yellow fever, and Japanese encephalitis viruses, infect hundreds of millions of people and animals each year. Global surveillance of these viruses in mosquito vectors using molecular based assays is critical for prevention and control of the associated diseases",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23967358",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 204,
					"offsetInEndSection": 489,
					"text": "fever and dengue fever are mosquito-borne infectious diseases transmitted by Aedes aegyptii, the presence of yellow fever in Sudan and dengue fever in Saudi Arabia are threats to Egypt with the reemerging of Ae. aegyptii in Southern Egypt, larvae control is feasible than flying adults",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23697028",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 39,
					"offsetInEndSection": 282,
					"text": "dengue virus (DENV) and yellow fever virus (YFV), that originated in sylvatic cycles maintained in non-human primates and forest-dwelling mosquitoes have emerged repeatedly into sustained human-to-human transmission by Aedes aegypti mosquitoes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23523817",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 284,
					"offsetInEndSection": 439,
					"text": "Sylvatic cycles of both viruses remain active, and where the two viruses overlap in West Africa they utilize similar suites of monkeys and Aedes mosquitoes",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23523817",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 572,
					"offsetInEndSection": 1098,
					"text": "First, the sylvatic cycle of YFV originated in Africa and was introduced into the New World, probably as a result of the slave trade, but is absent in Asia; in contrast, sylvatic DENV likely originated in Asia and has spread to Africa but not to the New World. Second, while sylvatic YFV can emerge into extensive urban outbreaks in humans, these invariably die out, whereas four different types of DENV have established human transmission cycles that are ecologically and evolutionarily distinct from their sylvatic ancestors",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23523817",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1100,
					"offsetInEndSection": 1358,
					"text": "Finally, transmission of YFV among humans has been documented only in Africa and the Americas, whereas DENV is transmitted among humans across most of the range of competent Aedes vectors, which in the last decade has included every continent save Antarctica",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23523817",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 114,
					"offsetInEndSection": 237,
					"text": "Mosquito-transmitted diseases such as malaria, dengue, yellow fever and filariasis are the main contributors to this burden",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23411863",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 67,
					"offsetInEndSection": 272,
					"text": "yellow fever (YFV) viruses is increasing in many parts of the world. The viruses are primarily transmitted by Aedes aegypti, a highly domesticated mosquito species that is notoriously difficult to control.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23133693",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 72,
					"offsetInEndSection": 202,
					"text": "The first of these to be discovered was yellow fever virus in 1901, and three to four new species are still being found every year",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22966141",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 540,
					"text": "The causative agent of yellow fever is an arbovirus of the Flaviviridae family transmitted by infected Aedes mosquitoes, particularly in Africa. In the Central African Republic since 2006, cases have been notified in the provinces of Ombella-Mpoko, Ouham-Pende, Basse-Kotto, Haute-Kotto and in Bangui the capital. As the presence of a vector of yellow fever virus (YFV) represents a risk for spread of the disease, we undertook entomological investigations at these sites to identify potential vectors of YFV and their abundance",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22897918",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 21,
					"offsetInEndSection": 203,
					"text": " family Flaviviridae, includes a number of important arthropod-transmitted human pathogens such as dengue viruses, West Nile virus, Japanese encephalitis virus and yellow fever virus",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22377581",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 502,
					"offsetInEndSection": 948,
					"text": "Reports of the detection of these viruses with no recognized pathogenic role in humans are increasing in mosquitoes collected around the world, particularly in those sampled in entomological surveys targeting pathogenic flaviviruses. The presence of six potential flaviviruses, detected from independent European arbovirus surveys undertaken in the Czech Republic, Italy, Portugal, Spain and the UK between 2007 and 2010, is reported in this work",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22377581",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 416,
					"text": "Yellow Fever virus (YFV) is an important arboviral pathogen in much of sub-Saharan Africa and the tropical Americas. It is the prototype member of the genus Flavivirus and is transmitted primarily by Aedes (Stegomyia) mosquitoes. The incidence of human infections in endemic areas has risen in recent years. Prompt and dependable identification of YFV is a critical component of response to suspect cases",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22264275",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 358,
					"text": "Health-care professionals can help travelers by providing accurate pre-travel counseling for mosquito-transmitted diseases such as malaria, yellow fever, and dengue fever. Governments and international organizations will benefit from knowledge survey among health professionals in this field to promote the development of travel health profession",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21199140",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 26,
					"offsetInEndSection": 165,
					"text": "United States made 12 million visits to developing countries in Asia, South America, Central America, Oceania, the Middle East, and Africa.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20874041",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 13,
					"offsetInEndSection": 223,
					"text": " Yellow fever is a serious illness public health importance and is transmitted by mosquitoes of the genera Haemagogus and Sabethes in the rural and forest environments, and by Aedes aegypti in the urban setting",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18645665",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1657,
					"offsetInEndSection": 1976,
					"text": "At present, diagnosis of YF is routinely accomplished through conventional RT-PCR, immunoassay or by virus isolation. The genome based molecular assays are key to diagnosis in the acute phase of infection, before the appearance of antibody. The assays can also be used for detection of virus in field-caught mosquitoes ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22264275",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2740,
					"offsetInEndSection": 2915,
					"text": "he assay was optimized with orally infected Ae. aegypti mosquitoes and used to monitor the relative infectivity of a Cameroon isolate of YFV in different Ae. aegypti colonies.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22264275",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 19,
					"offsetInEndSection": 349,
					"text": "Yellow fever is an acute, often fatal infectious disease caused by a flavivirus (Flaviviridae family) transmitted by mosquitoes and occurring in sub-Saharan Africa and tropical America. Each year, yellow fever virus (YFV) causes an estimated 200 000 cases, of which about 30 000 are fatal, even though an effective vaccine exists.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22897918",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 826,
					"offsetInEndSection": 1184,
					"text": "FV occurs naturally in an enzootic cycle involving monkey populations such as Cercopithecus aethiopsC. nictitans, Colobus polykomos and Papio doguera[4] and sylvatic mosquito species such as Aedes africanus, Ae. opok, Ae. simpsoni, Ae. luteocephalus, Ae. taylori and Ae. vittatus, which breed in natural sites (e.g. bamboo stumps, bromeliads and tree holes) ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22897918",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 582,
					"offsetInEndSection": 919,
					"text": "Many specialist human viruses also have mammalian or avian origins. Indeed, a substantial proportion of mammalian viruses may be capable of crossing the species barrier into humans, although only around half of these are capable of being transmitted by humans and around half again of transmitting well enough to cause major outbreaks. A",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22966141",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2974,
					"offsetInEndSection": 3408,
					"text": "he subset of viruses that can not only infect humans but can also be transmitted from one human to another (by whatever route, including via arthropod vectors). Again, this will mainly reflect the hostβ€“pathogen interaction, especially whether it is possible for the virus to access tissues from which it can exit the host, such as the upper respiratory tract, lower gut, urogenital tract, skin or (for some transmission routes) blood.",
					"beginSection": "sections.2",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22966141",
					"endSection": "sections.2"
				},
				{
					"offsetInBeginSection": 13,
					"offsetInEndSection": 223,
					"text": "Arthropod-borne viruses (arboviruses) are important human and veterinary pathogens that are biologically transmitted to vertebrates by hematophagous (blood feeding) arthropod vectors, such as female mosquitoes.",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23967358",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 685,
					"offsetInEndSection": 1119,
					"text": "Mosquito-borne flaviviruses are phylogenetically divided into two groups: those transmitted by Aedes species mosquitoes, such as dengue virus (DENV) and yellow fever virus (YFV), and those transmitted by Culex species mosquitoes, such as Japanese encephalitis virus (JEV) and West Nile virus (WNV). Additionally, flaviviruses continue to be isolated from mosquitoes without a known vertebrate host, termed arthropod-specific viruses [",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23967358",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 2030,
					"offsetInEndSection": 2290,
					"text": "The majority of phleboviruses use phlebotomine sand flies as their primary vectors, but many can also be transmitted by mosquitoes. One notable example is Rift Valley fever virus (RVFV), which is transmitted by a number of different mosquito species in nature ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23967358",
					"endSection": "sections.0"
				}
			]
		},
		{
			"body": "List programs suitable for protein docking",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24266324",
				"http://www.ncbi.nlm.nih.gov/pubmed/24187131",
				"http://www.ncbi.nlm.nih.gov/pubmed/24123140",
				"http://www.ncbi.nlm.nih.gov/pubmed/24108416",
				"http://www.ncbi.nlm.nih.gov/pubmed/24063890",
				"http://www.ncbi.nlm.nih.gov/pubmed/24050689",
				"http://www.ncbi.nlm.nih.gov/pubmed/23873600",
				"http://www.ncbi.nlm.nih.gov/pubmed/23862697",
				"http://www.ncbi.nlm.nih.gov/pubmed/23836482",
				"http://www.ncbi.nlm.nih.gov/pubmed/23829357",
				"http://www.ncbi.nlm.nih.gov/pubmed/23818491",
				"http://www.ncbi.nlm.nih.gov/pubmed/23813626",
				"http://www.ncbi.nlm.nih.gov/pubmed/23812908",
				"http://www.ncbi.nlm.nih.gov/pubmed/23808933",
				"http://www.ncbi.nlm.nih.gov/pubmed/23775700",
				"http://www.ncbi.nlm.nih.gov/pubmed/23712937",
				"http://www.ncbi.nlm.nih.gov/pubmed/23647909",
				"http://www.ncbi.nlm.nih.gov/pubmed/23633577",
				"http://www.ncbi.nlm.nih.gov/pubmed/23590204",
				"http://www.ncbi.nlm.nih.gov/pubmed/23451944",
				"http://www.ncbi.nlm.nih.gov/pubmed/23436713",
				"http://www.ncbi.nlm.nih.gov/pubmed/23351099",
				"http://www.ncbi.nlm.nih.gov/pubmed/23198780",
				"http://www.ncbi.nlm.nih.gov/pubmed/15215358",
				"http://www.ncbi.nlm.nih.gov/pubmed/16933295",
				"http://www.ncbi.nlm.nih.gov/pubmed/11841293",
				"http://www.ncbi.nlm.nih.gov/pubmed/17444519"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24266324",
				"http://www.ncbi.nlm.nih.gov/pubmed/24187131",
				"http://www.ncbi.nlm.nih.gov/pubmed/24123140",
				"http://www.ncbi.nlm.nih.gov/pubmed/24108416",
				"http://www.ncbi.nlm.nih.gov/pubmed/24063890",
				"http://www.ncbi.nlm.nih.gov/pubmed/24050689",
				"http://www.ncbi.nlm.nih.gov/pubmed/23873600",
				"http://www.ncbi.nlm.nih.gov/pubmed/23862697",
				"http://www.ncbi.nlm.nih.gov/pubmed/23836482",
				"http://www.ncbi.nlm.nih.gov/pubmed/23829357",
				"http://www.ncbi.nlm.nih.gov/pubmed/23818491",
				"http://www.ncbi.nlm.nih.gov/pubmed/23813626",
				"http://www.ncbi.nlm.nih.gov/pubmed/23812908",
				"http://www.ncbi.nlm.nih.gov/pubmed/23808933",
				"http://www.ncbi.nlm.nih.gov/pubmed/23775700",
				"http://www.ncbi.nlm.nih.gov/pubmed/23712937",
				"http://www.ncbi.nlm.nih.gov/pubmed/23647909",
				"http://www.ncbi.nlm.nih.gov/pubmed/23633577",
				"http://www.ncbi.nlm.nih.gov/pubmed/23590204",
				"http://www.ncbi.nlm.nih.gov/pubmed/23451944",
				"http://www.ncbi.nlm.nih.gov/pubmed/23436713",
				"http://www.ncbi.nlm.nih.gov/pubmed/23351099",
				"http://www.ncbi.nlm.nih.gov/pubmed/23198780",
				"http://www.ncbi.nlm.nih.gov/pubmed/15215358",
				"http://www.ncbi.nlm.nih.gov/pubmed/16933295",
				"http://www.ncbi.nlm.nih.gov/pubmed/11841293",
				"http://www.ncbi.nlm.nih.gov/pubmed/17444519"
			],
			"type": "list",
			"id": "53355befd6d3ac6a34000046",
			"snippets": [
				{
					"offsetInBeginSection": 786,
					"offsetInEndSection": 935,
					"text": "We present CSBB-ConeExclusion, a methodology and computer program which provides a measure of the applicability of solution dockings to solid support",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24266324",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 110,
					"offsetInEndSection": 409,
					"text": "The structure of the Ξ±1I-peptide complex was investigated using data from NMR, small angle x-ray scattering, and size exclusion chromatography that were used to generate and validate a model of the complex using the data-driven docking program, HADDOCK (High Ambiguity Driven Biomolecular Docking). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24187131",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 218,
					"text": "We report the performance of our approaches for protein-protein docking and interface analysis in CAPRI rounds 20-26. At the core of our pipeline was the ZDOCK program for rigid-body protein-protein docking",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24123140",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 40,
					"offsetInEndSection": 281,
					"text": "GalaxyDock protein-ligand docking program is introduced. GalaxyDock performs conformational space annealing (CSA) global optimization to find the optimal binding pose of a ligand both in the rigid-receptor mode and the flexible-receptor mode",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24108416",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 630,
					"offsetInEndSection": 858,
					"text": "Utilizing NMR titration data, we generated the structural models of S100B-FGF2 complex from the computational docking program, HADDOCK which were further proved stable during 15ns unrestrained molecular dynamics (MD) simulations",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24063890",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 470,
					"offsetInEndSection": 720,
					"text": "Thereafter, all molecules were docked into the newly generated active site environment of the selected protein using glide docking program, and the 3D-QSAR analysis was performed in PHASE program utilizing the docking based alignment of the molecules",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24050689",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 351,
					"offsetInEndSection": 908,
					"text": "DockRank uses interface residues predicted by partner-specific sequence homology-based protein-protein interface predictor (PS-HomPPI), which predicts the interface residues of a query protein with a specific interaction partner. We compared the performance of DockRank with several state-of-the-art docking scoring functions using Success Rate (the percentage of cases that have at least one near-native conformation among the top m conformations) and Hit Rate (the percentage of near-native conformations that are included among the top m conformations). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23873600",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 175,
					"offsetInEndSection": 520,
					"text": "In this study, we developed a novel scoring program, HotLig, which applies the Connolly surface of a protein to calculate hydrophobic interaction and paired pharmacophore interactions with ligands. In addition to molecular surface distance, ligand-contacting areas and hydrogen-bond angles were also introduced to the scoring functions in HotLig",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23862697",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 13,
					"offsetInEndSection": 182,
					"text": "a method called residue contact frequency (RCF), which uses the complex structures generated by the protein-protein docking algorithm ZDOCK to predict interface residues",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23836482",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 14,
					"offsetInEndSection": 470,
					"text": "devoted to results obtained by the docking program SOL and the post-processing program DISCORE at the CSAR benchmark. SOL and DISCORE programs are described. SOL is the original docking program developed on the basis of the genetic algorithm, MMFF94 force field, rigid protein, precalculated energy grid including desolvation in the frame of simplified GB model, vdW, and electrostatic interactions and taking into account the ligand internal strain energy",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23829357",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 579,
					"offsetInEndSection": 747,
					"text": "improves the binding energy scoring by the local energy optimization of the ligand docked pose and a simple linear regression on the base of available experimental data",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23829357",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 296,
					"offsetInEndSection": 567,
					"text": "The template-based methods showed similar performance to a docking method (ZDOCK) when the latter was allowed one prediction for each complex, but when the same number of predictions was allowed for each method, the docking approach outperformed template-based approaches",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23818491",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 207,
					"offsetInEndSection": 441,
					"text": "VinaMPI is a massively parallel Message Passing Interface (MPI) program based on the multithreaded virtual docking program AutodockVina, and is used to distribute tasks while multithreading is used to speed-up individual docking tasks",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23813626",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 791,
					"offsetInEndSection": 978,
					"text": "Prime and the binding energy function in YASARA suggested it could be possible to evaluate the quality of the orthosteric binding site based on the prediction of relative binding energies",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23812908",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 10,
					"offsetInEndSection": 188,
					"text": " is a free and open source application that unifies a suite of software programs within a user-friendly graphical user interface (GUI) to facilitate molecular docking experiments",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23808933",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 824,
					"offsetInEndSection": 955,
					"text": "This article presents DockTrina, a novel protein docking method for modeling the 3D structures of nonsymmetrical triangular trimers",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23775700",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 279,
					"offsetInEndSection": 606,
					"text": "To account for the important docking interactions between the UBSAs ligand and hCA II enzyme, a molecular docking program AutoDock Vina is used. The molecular docking results obtained by AutoDock Vina revealed that the docked conformer has root mean square deviation value less than 1.50 Γ… compared to X-ray crystal structures.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23712937",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 423,
					"offsetInEndSection": 564,
					"text": "Four possible binding pockets (Pocket A, B, C, and D) at the stalk region of hemagglutinin were detected and defined using the CAVITY program",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23647909",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 291,
					"offsetInEndSection": 527,
					"text": "Within this context, low-resolution shape data obtained from either ion-mobility mass spectrometry (IM-MS) or SAXS experiments have been integrated into the conventional scoring function of the information-driven docking program HADDOCK",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23633577",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 16,
					"offsetInEndSection": 199,
					"text": "a novel de novo design program, called LiGen, we developed a docking program, LiGenDock, based on pharmacophore models of binding sites, including a non-enumerative docking algorithm.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23590204",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 215,
					"offsetInEndSection": 379,
					"text": "we present the functionalities of LiGenDock and its accompanying module LiGenPocket, aimed at the binding site analysis and structure-based pharmacophore definition",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23590204",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 171,
					"offsetInEndSection": 443,
					"text": "Here we describe the application of the program AutoDock to the design of a focused library that was used in the \"click chemistry in-situ\" generation of the most potent noncovalent inhibitor of the native enzyme acetylcholinesterase (AChE) yet developed (K(d) = ~100 fM). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23451944",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 782,
					"offsetInEndSection": 989,
					"text": " the method yields improved success over the standard DOCK energy function for pose identification across a large test set of experimental co-crystal structures, for crossdocking, and for database enrichment",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23436713",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 597,
					"offsetInEndSection": 739,
					"text": "The pose prediction success rate of each docking program alone was found in this trial to be 55% for Autodock, 58% for DOCK, and 64% for Vina.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23351099",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 13321,
					"offsetInEndSection": 13749,
					"text": "he quality of the orthosteric binding site was further probed by docking the muscarinic antagonist N-methylscopolamine (NMS), using either Glide [20] or Autodock [21]. Docking NMS produced reasonable poses with hydrogen bonding to Asn404 (except ver01 and ver02, data not shown). NMS docking to ver04 produced better hydrogen bonding of NMS to Asp103, while NMS docking to model ver05 produced better hydrogen bonding to Asn404.",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23812908",
					"endSection": "sections.1"
				},
				{
					"offsetInBeginSection": 15864,
					"offsetInEndSection": 16259,
					"text": "As a preliminary test of the concept, induced fit docking of the antagonists NMS to homology models produced better results than mere docking using Glide or Autodock. Therefore, induced fit docking was implemented using either SchrΓ¶dingerβ€™s β€�Induced Fit Docking Workflowβ€� or according to the procedure of Naburs et al. [24] of four non-selective antagonists of muscarinic acetylcholine receptors",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23812908",
					"endSection": "sections.1"
				}
			]
		},
		{
			"body": "What genes are related to breast cancer?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24327800",
				"http://www.ncbi.nlm.nih.gov/pubmed/24324792",
				"http://www.ncbi.nlm.nih.gov/pubmed/24319537",
				"http://www.ncbi.nlm.nih.gov/pubmed/24302665",
				"http://www.ncbi.nlm.nih.gov/pubmed/24296317",
				"http://www.ncbi.nlm.nih.gov/pubmed/23678008",
				"http://www.ncbi.nlm.nih.gov/pubmed/23358415",
				"http://www.ncbi.nlm.nih.gov/pubmed/21123097",
				"http://www.ncbi.nlm.nih.gov/pubmed/24298072",
				"http://www.ncbi.nlm.nih.gov/pubmed/24289229",
				"http://www.ncbi.nlm.nih.gov/pubmed/24272208",
				"http://www.ncbi.nlm.nih.gov/pubmed/24183724",
				"http://www.ncbi.nlm.nih.gov/pubmed/24026986",
				"http://www.ncbi.nlm.nih.gov/pubmed/22695536",
				"http://www.ncbi.nlm.nih.gov/pubmed/18485221",
				"http://www.ncbi.nlm.nih.gov/pubmed/23318652",
				"http://www.ncbi.nlm.nih.gov/pubmed/17132159"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24327800",
				"http://www.ncbi.nlm.nih.gov/pubmed/24324792",
				"http://www.ncbi.nlm.nih.gov/pubmed/24319537",
				"http://www.ncbi.nlm.nih.gov/pubmed/24302665",
				"http://www.ncbi.nlm.nih.gov/pubmed/24296317",
				"http://www.ncbi.nlm.nih.gov/pubmed/23678008",
				"http://www.ncbi.nlm.nih.gov/pubmed/23358415",
				"http://www.ncbi.nlm.nih.gov/pubmed/21123097",
				"http://www.ncbi.nlm.nih.gov/pubmed/24298072",
				"http://www.ncbi.nlm.nih.gov/pubmed/24289229",
				"http://www.ncbi.nlm.nih.gov/pubmed/24272208",
				"http://www.ncbi.nlm.nih.gov/pubmed/24183724",
				"http://www.ncbi.nlm.nih.gov/pubmed/24026986",
				"http://www.ncbi.nlm.nih.gov/pubmed/22695536",
				"http://www.ncbi.nlm.nih.gov/pubmed/18485221",
				"http://www.ncbi.nlm.nih.gov/pubmed/23318652",
				"http://www.ncbi.nlm.nih.gov/pubmed/17132159"
			],
			"type": "list",
			"id": "53357c98d6d3ac6a3400004a",
			"snippets": [
				{
					"offsetInBeginSection": 1055,
					"offsetInEndSection": 1279,
					"text": "Network analysis showed increased expression of a majority of components in p53 and BRCA1 subnetworks in AA breast tumor samples, and members of the aurora B and polo-like kinase signaling pathways were also highly expressed",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324792",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1211,
					"offsetInEndSection": 1453,
					"text": "These results indicate that nuclear NRF2 protein plays important roles in the proliferation and/or progression of breast carcinoma, and nuclear NRF2 immunoreactivity is therefore considered a potent prognostic factor in breast cancer patients",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24302665",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 401,
					"offsetInEndSection": 535,
					"text": "Our previous studies in breast cancer cells indicate that 2CdA and F-ara-A are involved in epigenetic regulation of gene transcription",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24296317",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1642,
					"offsetInEndSection": 1833,
					"text": " It seems to be a new important element of ClF anticancer activity and may indicate its potential efficacy in epigenetic therapy of solid tumours, especially at early stages of carcinogenesis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24296317",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 275,
					"offsetInEndSection": 558,
					"text": "many molecular components that regulate HR are tumour suppressors p53, a negative regulator and breast cancer early-onset (BRCA)2, a positive regulator. Both the players not only interact with each other but also directly interact with human RAD51 (hRAD51), the key recombinase in HR",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23678008",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1158,
					"offsetInEndSection": 1270,
					"text": " Our findings suggest a rigorous p53-mediated regulation on hRAD51 functions in HR even in the presence of BRCA2",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23678008",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4,
					"offsetInEndSection": 460,
					"text": "coordinated replication and transcription of pericentromeric repeats enable RNA interference (RNAi)-mediated transmission of pericentromeric heterochromatin in fission yeast, which is essential for the proper function of centromeres. Rad3/ATR kinase phosphorylates histone H2A on serine-128/-129 to create Ξ³H2A in pericentromeric heterochromatin during S phase, which recruits Brc1 through its breast cancer gene 1 protein (BRCA1) C-terminal (BRCT) domains",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23358415",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 70,
					"offsetInEndSection": 186,
					"text": "protein BRCA2 affect its interactions with the recombinase RAD51 and are associated with an increased risk of cancer",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21123097",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 501,
					"offsetInEndSection": 765,
					"text": " serial deletion mutation experiments, binding strengths were increased when the C-terminal BRC repeat was removed from BRC1-8, BRC1-5 and BRC1-3. These results may provide an insight into the effects of missense or truncation mutations in BRCA2 in canine tumours.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21123097",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 504,
					"text": "Triple-negative breast cancers (TNBC) do not represent a single disease subgroup and are often aggressive breast cancers with poor prognoses. Unlike estrogen/progesterone receptor and HER2 (human epidermal growth factor receptor 2) breast cancers, which are responsive to targeted treatments, there is no effective targeted therapy for TNBC, although approximately 50% of patients respond to conventional chemotherapies, including taxanes, anthracyclines, cyclophosphamide, and platinum salts",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24298072",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 197,
					"text": "Genetic BRCA2 insufficiency is associated with breast cancer development; however, in sporadic breast cancer cases, high BRCA2 expression is paradoxically correlated with poor prognosis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24289229",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1429,
					"offsetInEndSection": 1749,
					"text": "HER-2 and TOP2A gene amplification showed a tendency to be associated with larger tumor size, positive lymph node status, high level of apoptotic and proliferative indexes, and low level of p53 and Bcl-2 expression, which all together indicate group of patients with similar outcome during the progression of the disease",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24272208",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 4886,
					"offsetInEndSection": 5234,
					"text": "This study represents, to our knowledge, the first time that NGS data was used in combination with a large patient cohort to investigate expression differences of genes and other transcripts between AA and CA BRCa patients, and to our knowledge, this work represents the largest and most comprehensive study on health disparity in AA BRCa to date. ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324792",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 18561,
					"offsetInEndSection": 19603,
					"text": "The number of genes in parentheses refers to the number of genes in common with the presented results compared to the total number of differentially expressed genes from each study. Gene names: AK2 - adenylate kinase 2; APP - amyloid beta (A4) precursor protein; BUB1 - BUB1 mitotic checkpoint serine/threonine kinase; CKS2 - CDC28 protein kinase regulatory subunit 2; CRYBB2 - crystallin, beta B2; CXCL10 - chemokine (C-X-C motif) ligand 10; DNAJC15 - DnaJ (Hsp40) homolog, subfamily C, member 15; DUT - deoxyuridine triphosphatase; ESPL1 - extra spindle pole bodies homolog 1 (S. cerevisiae); ESR1 - estrogen receptor 1; HLA-DQB1 - major histocompatibility complex, class II, DQ beta 1; ISG20 - interferon stimulated exonuclease gene 20kDa; KIF20A - kinesin family member 20A; MRPL48 - mitochondrial ribosomal protein L48; SNED1 - sushi, nidogen and EGF-like domains 1; TAP2 - transporter 2, ATP-binding cassette, sub-family B (MDR/TAP); UBE2C - ubiquitin-conjugating enzyme E2C; ZIC1 - Zic family member 1; ZNF395 - zinc finger protein 395",
					"beginSection": "sections.1",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324792",
					"endSection": "sections.1"
				}
			]
		},
		{
			"body": "Is signal transducer and activator of transcription-3 (STAT3) critical for tumor angiogenesis progression?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24324713",
				"http://www.ncbi.nlm.nih.gov/pubmed/24307888",
				"http://www.ncbi.nlm.nih.gov/pubmed/24305878",
				"http://www.ncbi.nlm.nih.gov/pubmed/24274066",
				"http://www.ncbi.nlm.nih.gov/pubmed/24238495",
				"http://www.ncbi.nlm.nih.gov/pubmed/24231788",
				"http://www.ncbi.nlm.nih.gov/pubmed/24200081",
				"http://www.ncbi.nlm.nih.gov/pubmed/24199193",
				"http://www.ncbi.nlm.nih.gov/pubmed/24178245",
				"http://www.ncbi.nlm.nih.gov/pubmed/24116074",
				"http://www.ncbi.nlm.nih.gov/pubmed/24058783",
				"http://www.ncbi.nlm.nih.gov/pubmed/24042330",
				"http://www.ncbi.nlm.nih.gov/pubmed/24005169",
				"http://www.ncbi.nlm.nih.gov/pubmed/23962559",
				"http://www.ncbi.nlm.nih.gov/pubmed/23903834",
				"http://www.ncbi.nlm.nih.gov/pubmed/23848964",
				"http://www.ncbi.nlm.nih.gov/pubmed/23848338",
				"http://www.ncbi.nlm.nih.gov/pubmed/20204067",
				"http://www.ncbi.nlm.nih.gov/pubmed/20052595",
				"http://www.ncbi.nlm.nih.gov/pubmed/18498667",
				"http://www.ncbi.nlm.nih.gov/pubmed/9091577",
				"http://www.ncbi.nlm.nih.gov/pubmed/17610223",
				"http://www.ncbi.nlm.nih.gov/pubmed/22076197",
				"http://www.ncbi.nlm.nih.gov/pubmed/19566485",
				"http://www.ncbi.nlm.nih.gov/pubmed/15665295",
				"http://www.ncbi.nlm.nih.gov/pubmed/16061629"
			],
			"triples": [
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10788344",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C39238"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1514955",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A10788344"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1514955",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A10788344"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10788344",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Stat3 Signaling Pathway"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1514955",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7663266"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A7663266",
					"p": "http://www.w3.org/2004/02/skos/core#notation",
					"o": "C39238"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1514955",
					"p": "http://www.w3.org/2008/05/skos-xl#altLabel",
					"o": "http://linkedlifedata.com/resource/umls/label/A10788344"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1514955",
					"p": "http://linkedlifedata.com/resource/umls/altMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A10788344"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/label/A10788344",
					"p": "http://www.w3.org/2008/05/skos-xl#literalForm",
					"o": "Stat3 Signaling Pathway"
				},
				{
					"s": "http://linkedlifedata.com/resource/umls/id/C1514955",
					"p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
					"o": "http://linkedlifedata.com/resource/umls/label/A7663266"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q7Z4H9",
					"p": "http://purl.uniprot.org/core/citation",
					"o": "http://purl.uniprot.org/citations/12853948"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/12853948",
					"p": "http://purl.uniprot.org/core/name",
					"o": "Nature"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51375A34483900F",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "STAT3-interacting protein as a repressor"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/12853948",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/pubmed/12853948"
				},
				{
					"s": "http://purl.uniprot.org/pubmed/12853948",
					"p": "http://www.w3.org/2004/02/skos/core#exactMatch",
					"o": "http://purl.uniprot.org/medline/22737999"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q7Z4H9",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_51375A34483900F"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q3ZN08",
					"p": "http://linkedlifedata.com/resource/relationontology/expressedInCellLine",
					"o": "http://purl.uniprot.org/tissues/597"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q3ZN08",
					"p": "http://purl.uniprot.org/core/alternativeName",
					"o": "http://linkedlifedata.com/resource/#_51335A4E30380015"
				},
				{
					"s": "http://purl.uniprot.org/tissues/597",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Breast tumor"
				},
				{
					"s": "http://purl.uniprot.org/tissues/597",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Mammary tumour"
				},
				{
					"s": "http://purl.uniprot.org/uniprot/Q3ZN08",
					"p": "http://purl.uniprot.org/core/recommendedName",
					"o": "http://linkedlifedata.com/resource/#_51335A4E30380014"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51335A4E30380014",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "STAT3-interacting protein as a repressor"
				},
				{
					"s": "http://linkedlifedata.com/resource/#_51335A4E30380015",
					"p": "http://purl.uniprot.org/core/fullName",
					"o": "Acrosomal protein ACPIN1"
				},
				{
					"s": "http://purl.uniprot.org/tissues/597",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Mammary tumor"
				},
				{
					"s": "http://purl.uniprot.org/tissues/597",
					"p": "http://www.w3.org/2000/01/rdf-schema#label",
					"o": "Mammary gland tumor"
				}
			],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/24324713",
				"http://www.ncbi.nlm.nih.gov/pubmed/24307888",
				"http://www.ncbi.nlm.nih.gov/pubmed/24305878",
				"http://www.ncbi.nlm.nih.gov/pubmed/24274066",
				"http://www.ncbi.nlm.nih.gov/pubmed/24238495",
				"http://www.ncbi.nlm.nih.gov/pubmed/24231788",
				"http://www.ncbi.nlm.nih.gov/pubmed/24200081",
				"http://www.ncbi.nlm.nih.gov/pubmed/24199193",
				"http://www.ncbi.nlm.nih.gov/pubmed/24178245",
				"http://www.ncbi.nlm.nih.gov/pubmed/24116074",
				"http://www.ncbi.nlm.nih.gov/pubmed/24058783",
				"http://www.ncbi.nlm.nih.gov/pubmed/24042330",
				"http://www.ncbi.nlm.nih.gov/pubmed/24005169",
				"http://www.ncbi.nlm.nih.gov/pubmed/23962559",
				"http://www.ncbi.nlm.nih.gov/pubmed/23903834",
				"http://www.ncbi.nlm.nih.gov/pubmed/23848964",
				"http://www.ncbi.nlm.nih.gov/pubmed/23848338",
				"http://www.ncbi.nlm.nih.gov/pubmed/20204067",
				"http://www.ncbi.nlm.nih.gov/pubmed/20052595",
				"http://www.ncbi.nlm.nih.gov/pubmed/18498667",
				"http://www.ncbi.nlm.nih.gov/pubmed/9091577",
				"http://www.ncbi.nlm.nih.gov/pubmed/17610223",
				"http://www.ncbi.nlm.nih.gov/pubmed/22076197",
				"http://www.ncbi.nlm.nih.gov/pubmed/19566485",
				"http://www.ncbi.nlm.nih.gov/pubmed/15665295",
				"http://www.ncbi.nlm.nih.gov/pubmed/16061629"
			],
			"type": "yesno",
			"id": "533d0f44c45e13371400000e",
			"snippets": [
				{
					"offsetInBeginSection": 50,
					"offsetInEndSection": 345,
					"text": " (STAT3) is critical for cancer progression by regulating tumor cell survival, proliferation, and angiogenesis. Herein, we investigated the regulation of STAT3 activation and the therapeutic effects of Icaritin, a prenyl flavonoid derivative from Epimedium Genus, in renal cell carcinoma (RCC). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324713",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1205,
					"offsetInEndSection": 1377,
					"text": " Overall, these results suggest that Icaritin strongly inhibits STAT3 activation and is a potentially effective therapeutic option for the treatment of renal cell carcinoma",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324713",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 476,
					"offsetInEndSection": 664,
					"text": "we have reviewed important signaling pathways that are closely related to radiosensitization, such as cell cycle arrest, tumor angiogenesis, JAK/STAT3 signaling pathway and Mismatch repair",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24307888",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 270,
					"text": "Interleukin-27 signaling is mediated by the JAK-STAT pathway via activation of STAT1 and STAT3, which have tumor suppressive and oncogenic activities, respectively. Epithelial-mesenchymal transition (EMT) and angiogenesis are key processes in carcinogenesis.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24274066",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1813,
					"offsetInEndSection": 1909,
					"text": "The inhibition of STAT3 activation had no effect on the development of the epithelial phenotype.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24274066",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 254,
					"text": "STAT3 plays a vital role in inducing and maintaining a pro-carcinogenic inflammatory microenvironment and is reported to be a critical mediator of the oncogenic effects of EGFR mutations. STAT3 activation is mediated through JAK family kinases",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24238495",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1551,
					"offsetInEndSection": 2061,
					"text": " EESB treatment could significantly suppress the activation of several CRC-related pathways, including STAT3, Erk, and p38 signalings in tumor tissues, and alter the expression of multiple critical target genes such as Bcl-2, Bax, Cyclin D1, CDK4, and p21. These molecular effects lead to the induction of cancer cell apoptosis and inhibition of cell proliferation. Our findings demonstrate that SB possesses a broad range of antitumor activities because of its ability to affect multiple intracellular targets",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24231788",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1063,
					"offsetInEndSection": 1554,
					"text": "Western immunoblotting analyses of mouse lung tissues indicated significantly lower level of pSTAT3 and Mcl-1 in the carcinogen plus DMAPT group relative to the group treated with the carcinogen only. Given the evidence that STAT3 is activated in more than half of lung cancers and it regulates genes involved in cell proliferation, survival and angiogenesis, DMAPT is a promising agent for lung cancer chemoprevention in subjects who are at high risk of developing this devastating disease.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24200081",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 51,
					"offsetInEndSection": 702,
					"text": "(STAT3) is a latent cytoplasmic transcription factor, originally discovered as a transducer of signal from cell surface receptors to the nucleus. It is activated by tyrosine phosphorylation at position 705 leading to its dimerization, nuclear translocation, DNA binding, and activation of gene transcription. Under normal physiological conditions, STAT3 activation is tightly regulated. However, compelling evidence suggests that STAT3 is constitutively activated in many cancers and plays a pivotal role in tumor growth and metastasis. It regulates cellular proliferation, invasion, migration, and angiogenesis that are critical for cancer metastasis",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24199193",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 70,
					"offsetInEndSection": 251,
					"text": "STAT3) signaling pathway plays important roles in oncogenesis, angiogenesis, immunity, and tumor cell invasion. In the present study, we investigated the association of interleukin ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24116074",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 346,
					"offsetInEndSection": 585,
					"text": " Phosphorylated STAT3 (pSTAT3) regulates many genes that are necessarily expressed in cancer initiation, development, and progression, being involved in proliferation, anti-apoptosis, invasion, angiogenesis, and immune surveillance evasion",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24005169",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 405,
					"offsetInEndSection": 586,
					"text": "Signal transducer and activator of transcription 3 (STAT3) is a transcription factor, which can be activated by tyrosine phosphorylation in response to growth factors and cytokines ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24116074",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1383,
					"offsetInEndSection": 1968,
					"text": "Upon activation, STAT3 rapidly translocates into nucleus, and binds to recognition sequence in the promoter of target genes (e.g., cyclin D1, Bcl-2, Bcl-xL, matrix metalloproteinases and vascular endothelial growth factor [VEGF]), thereby increasing their transcription [8-10]. All these target genes are implicated in regulation of cell survival, angiogenesis, immune evasion, and inflammation in tumor microenvionment.\nSTAT3 activation contributes to growth stimulation, anti-apoptosis, and angiogenesis, which is signiο¬�cantly associated with inflammation, immunity, and oncogenesis ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24116074",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 1979,
					"offsetInEndSection": 2859,
					"text": "Consequently, constitutive activation of STAT3 is responsible for a variety of human cancers, including ovarian cancer, breast cancer, leukemia, prostate cancer, head and neck cancer, and pancreatic cancer [13-17]. Blockade of the JAK/STAT3 signal may inhibit the growth of human cancers [17]. Recently, STAT3 has been demonstrated to play a pivotal role in the maintenance of gastric cancer cells survival [18-22]. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer [23-25]. However, it still remains unknown how activated STAT3 via interleukin (IL)-6-type cytokine signaling associates with T lymphocyte alteration during the progression of human gastric cancer. The purpose of this study was to determine whether IL-6/STAT3 signaling pathway associates with T lymphocyte changes, and correlates with the progression of human gastric cancer",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24116074",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 795,
					"text": "IL-6 and its downstream signals, such as STAT3, play essential roles in the process of inο¬‚ammation and aberrant immunity as well as carcinogenesis [28-30]. STAT3 is activated for a few seconds or hours and then is deactivated to maintain homeostasis under normal circumstance. However, STAT3 activation continues, which triggers oncogene transcription under abnormal conditions [25,31]. Accumulating evidence indicates increased expression and activation of STAT3 in human gastric carcinoma [18-25,32]. It remains unclear whether increased IL-6/STAT3 activation correlates with aberrant immunity in the progression and invasion of gastric cancer. In the present study, we observed the levels of IL-6, IL-10 and VEGF in serum were significant decreased after removal of gastric cancer.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24116074",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 3352,
					"offsetInEndSection": 3556,
					"text": "It has been shown that STAT3 activation in tumor cells can mediate an immune response by inhibiting the activity of immune cells through inflammatory cytokines probably release from invading tumor tissue ",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24116074",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 3079,
					"offsetInEndSection": 3464,
					"text": "It is observed that aberrant STAT3 activation in tumor cells is associated with cell proliferation, cell survival, invasion, angiogenesis, and metastasis [11] (Figure 1). Conversely, targeting STAT3 activation inhibits tumor growth and metastasis both in vitro and in vivo without affecting normal cells, thus suggesting that STAT3 could be a valid molecular target for cancer therapy ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24199193",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3,
					"offsetInEndSection": 349,
					"text": "Role of STAT3 in Cancer Metastasis\nCancer metastasis is a complex, multistep process in which tumor cells primarily invades surrounding tissue and basement membrane, thus entering into blood circulation; while surviving during circulation, the tumor cells extravasate and adhere into distant organ and induce angiogenesis to form secondary tumor.",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24199193",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 350,
					"offsetInEndSection": 541,
					"text": "Compelling evidence supports the fact that STAT3 activation plays a critical role in every step of metastasis including cell proliferation and survival, invasion, migration, and angiogenesis ",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24199193",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 21,
					"offsetInEndSection": 370,
					"text": "Translational Advances\nSTAT3 is excessively active in many cancers and plays a central role in tumorigenesis. Several lines of evidence have implicated that inhibition of STAT3 with a dominant negative form of STAT3 or other inhibitors attenuates the proliferation and survival of a wide variety of cancers with little or no effects on normal cells ",
					"beginSection": "sections.4",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24199193",
					"endSection": "sections.4"
				},
				{
					"offsetInBeginSection": 750,
					"offsetInEndSection": 1198,
					"text": "IL-27 elicits its effects through activation of both STAT1 and STAT3, which have opposing roles in carcinogenesis [1,2,8,11-15]. Activated STAT1 signaling has tumor suppressive roles by inhibiting angiogenesis, tumor growth and metastasis as well as promoting apoptosis [12,16]. Alternatively, the STAT3 pathway has been shown to be constitutively activated in many human cancers and has been implicated in oncogenic transformation and progression ",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24274066",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 596,
					"offsetInEndSection": 769,
					"text": "In cancer, STAT3 has been implicated in EGF-mediated EMT in ovarian cancer cell lines and STAT1 has been reported to inhibit angiogenesis in murine fibrosarcoma tumor cells ",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24274066",
					"endSection": "sections.3"
				},
				{
					"offsetInBeginSection": 12,
					"offsetInEndSection": 552,
					"text": "We report that IL-27-mediated induction of MET and inhibition of angiogenic factors is STAT1-dependent, and inhibition of STAT1 activity results in induction of a mesenchymal phenotype and angiogenic factors above basal levels implicating an overwhelming STAT3 effect. These findings suggest that STAT1 activation may play an important role in repressing STAT3 in lung carcinogenesis, and suggest that better understanding of STAT signaling by cytokines such as IL-27 may shed light to potential new targets in cancer prevention and therapy",
					"beginSection": "sections.4",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24274066",
					"endSection": "sections.4"
				},
				{
					"offsetInBeginSection": 1562,
					"offsetInEndSection": 1949,
					"text": "STAT3 is also reported to have a leading role in cancer inflammation and immunity [19], [20], [21], [22]. Many tumor-derived factors, such as IL-10, IL-6 and VEGF that are crucial for both tumor growth and immunosuppression, activate STAT3 to create an efficient β€�feed-forwardβ€� loop to induce persistent STAT3 activity in tumor cells and the tumor microenvironment [19], [23], [24], [25]",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324713",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 3638,
					"offsetInEndSection": 3944,
					"text": "Additionally, Icaritin inhibited tumor angiogenesis, potently suppressed STAT3 activation, and significantly reduced RCC tumor growth in vivo. These data suggest that Icaritin is a specific inhibitor of JAK2/STAT3 activation and may represent a viable therapeutic strategy for the treatment of advanced RCC",
					"beginSection": "sections.0",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324713",
					"endSection": "sections.0"
				},
				{
					"offsetInBeginSection": 11,
					"offsetInEndSection": 392,
					"text": "Activated STAT3 promotes tumorigenesis by preventing apoptosis and enhancing proliferation, angiogenesis, invasiveness, and immune evasion [21], [45], [46], [47], [48]. In various cancer types, including leukemias and solid cancers of the breast, head and neck, melanoma, prostate, pancreas, and colon, aberrant activation of STAT3 crucially contributes to cancer progression [13].",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324713",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "What is known about the economic cost of urinary incontinence?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23369111",
				"http://www.ncbi.nlm.nih.gov/pubmed/22500250",
				"http://www.ncbi.nlm.nih.gov/pubmed/24198618",
				"http://www.ncbi.nlm.nih.gov/pubmed/12809878",
				"http://www.ncbi.nlm.nih.gov/pubmed/11386591",
				"http://www.ncbi.nlm.nih.gov/pubmed/11183903",
				"http://www.ncbi.nlm.nih.gov/pubmed/9510336"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23369111",
				"http://www.ncbi.nlm.nih.gov/pubmed/22500250",
				"http://www.ncbi.nlm.nih.gov/pubmed/24198618",
				"http://www.ncbi.nlm.nih.gov/pubmed/12809878",
				"http://www.ncbi.nlm.nih.gov/pubmed/11386591",
				"http://www.ncbi.nlm.nih.gov/pubmed/11183903",
				"http://www.ncbi.nlm.nih.gov/pubmed/9510336"
			],
			"type": "summary",
			"id": "5335c938d6d3ac6a34000052",
			"snippets": [
				{
					"offsetInBeginSection": 1581,
					"offsetInEndSection": 1634,
					"text": "urgency UI also results in substantial economic costs",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23369111",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1739,
					"offsetInEndSection": 1796,
					"text": "substantial economic burden attributable to UI due to NDO",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23369111",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 523,
					"offsetInEndSection": 806,
					"text": "The estimated total economic cost in treating overactive bladder was 117 billion Korean Won (KRW, the currency of South Koea) in 2006 and 145 billion KRW in 2007. The estimated total cost in treating stress urinary incontinence was 122 billion KRW in 2006 and 59 billion KRW in 2007.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22500250",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 177,
					"offsetInEndSection": 275,
					"text": "OAB may severely impair quality of life, and its overall economic costs to society are substantial",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/24198618",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 926,
					"offsetInEndSection": 1372,
					"text": "The estimated total economic cost of OAB was 12.02 billion dollars in 2000, with 9.17 and 2.85 billion dollars incurred in the community and institutions, respectively. Community female and male OAB costs totaled 7.37 and 1.79 billion dollars, respectively. The estimated total cost was sensitive to the estimated prevalence of OAB; therefore, we calculated the average cost per community-dwelling person with OAB, which was 267 dollars per year.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12809878",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1554,
					"offsetInEndSection": 1681,
					"text": "The conservative estimates of the total cost of OAB were comparable to those of osteoporosis and gynecologic and breast cancer.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/12809878",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 487,
					"offsetInEndSection": 1133,
					"text": "An estimated 1835628 community-dwelling women over the age of 18 years had urinary incontinence in 1998. The total annual cost of this urinary incontinence is estimated at $710.44 million, or $387 per incontinent woman, comprising $338.47 million in treatment costs and $371.97 million in personal costs. An estimated 60% of women with incontinence in 1998 were aged 40 years or over. Assuming the prevalence of incontinence remains constant and, allowing for inflation, we project that the total annual cost in 20 years' time will be $1267.85 million, 93% ($1.18 billion) of which will constitute costs associated with women aged over 40 years. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11386591",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 178,
					"text": "Overactive bladder (OAB) is a highly prevalent condition among older patients, and its presence is associated with the use of substantial healthcare resources and economic costs.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11183903",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 907,
					"offsetInEndSection": 1021,
					"text": "Caring for incontinent patients in the long-term care setting was shown to result in substantial additional costs,",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/11183903",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 122,
					"offsetInEndSection": 270,
					"text": "For individuals 65 years of age and older these costs are substantial, increasing from $8.2 billion (1984 dollars) to $16.4 billion (1993 dollars). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9510336",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 417,
					"offsetInEndSection": 565,
					"text": "The 1995 societal cost of incontinence for individuals aged 65 years and older was $26.3 billion, or $3565 per individual with urinary incontinence.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/9510336",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 931,
					"offsetInEndSection": 1055,
					"text": "In the United States (US), the socioeconomic cost for OAB and SUI was 24 billion Dollars (USD, United States Dollar) in 2004",
					"beginSection": "sections.3",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22500250",
					"endSection": "sections.3"
				}
			]
		},
		{
			"body": "Can administration of the thyrotropin releasing hormone reduce fatigue in cancer patients?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23387883",
				"http://www.ncbi.nlm.nih.gov/pubmed/21947558",
				"http://www.ncbi.nlm.nih.gov/pubmed/19761698"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23387883",
				"http://www.ncbi.nlm.nih.gov/pubmed/21947558",
				"http://www.ncbi.nlm.nih.gov/pubmed/19761698"
			],
			"type": "yesno",
			"id": "5314d0e4dae131f84700000e",
			"snippets": [
				{
					"offsetInBeginSection": 1228,
					"offsetInEndSection": 1482,
					"text": "TRH administration was associated with significant improvement (p < 0.05) in fatigue levels as measured by the Visual Analog Scale-Energy (VAS-E), was associated with significant (p < 0.05) improvement in sleep disturbances and improved quality of life. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23387883",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1601,
					"offsetInEndSection": 1727,
					"text": "This decrease in CRP level with TRH administration was associated with improvement in energy levels as measured by the VAS-E. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23387883",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 343,
					"offsetInEndSection": 483,
					"text": "In the present pilot, randomized, placebo-controlled, crossover study, we investigated the efficacy and safety of TRH as a treatment for CF.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21947558",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1090,
					"offsetInEndSection": 1289,
					"text": "TRH administration was associated with significant improvement in fatigue level as measured by the VAS-E, the fatigue and vigor subscales of the POMS, and the fatigue subscale of FACIT-F (p < 0.05). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21947558",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1461,
					"offsetInEndSection": 1665,
					"text": "TRH administration was efficacious, safe, and tolerable in the treatment of CF with a positive impact on quality of life. These results provide a crucial impetus for pursuing TRH therapeutics to treat CF.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21947558",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 0,
					"offsetInEndSection": 106,
					"text": "Thyrotropin-releasing hormone can relieve cancer-related fatigue: hypothesis and preliminary observations.",
					"beginSection": "title",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19761698",
					"endSection": "title"
				},
				{
					"offsetInBeginSection": 657,
					"offsetInEndSection": 808,
					"text": "Global assessment using both subjective and objective parameters showed that TRH exerted clear anti-fatigue effects in four of the six TRH treatments. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19761698",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1029,
					"offsetInEndSection": 1120,
					"text": "These initial findings support the proposal that TRH can ameliorate cancer-related fatigue.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19761698",
					"endSection": "abstract"
				}
			]
		},
		{
			"body": "What is the effect of ivabradine in heart failure after myocardial infarction?",
			"documents": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23536611",
				"http://www.ncbi.nlm.nih.gov/pubmed/23394554",
				"http://www.ncbi.nlm.nih.gov/pubmed/23096376",
				"http://www.ncbi.nlm.nih.gov/pubmed/21878041",
				"http://www.ncbi.nlm.nih.gov/pubmed/21838751",
				"http://www.ncbi.nlm.nih.gov/pubmed/22416440",
				"http://www.ncbi.nlm.nih.gov/pubmed/20000882",
				"http://www.ncbi.nlm.nih.gov/pubmed/19664404",
				"http://www.ncbi.nlm.nih.gov/pubmed/19514618",
				"http://www.ncbi.nlm.nih.gov/pubmed/19074674",
				"http://www.ncbi.nlm.nih.gov/pubmed/18310678",
				"http://www.ncbi.nlm.nih.gov/pubmed/14981003",
				"http://www.ncbi.nlm.nih.gov/pubmed/19129742",
				"http://www.ncbi.nlm.nih.gov/pubmed/18757088",
				"http://www.ncbi.nlm.nih.gov/pubmed/18621770",
				"http://www.ncbi.nlm.nih.gov/pubmed/20028694",
				"http://www.ncbi.nlm.nih.gov/pubmed/19411283",
				"http://www.ncbi.nlm.nih.gov/pubmed/23067195"
			],
			"triples": [],
			"concepts": [
				"http://www.ncbi.nlm.nih.gov/pubmed/23536611",
				"http://www.ncbi.nlm.nih.gov/pubmed/23394554",
				"http://www.ncbi.nlm.nih.gov/pubmed/23096376",
				"http://www.ncbi.nlm.nih.gov/pubmed/21878041",
				"http://www.ncbi.nlm.nih.gov/pubmed/21838751",
				"http://www.ncbi.nlm.nih.gov/pubmed/22416440",
				"http://www.ncbi.nlm.nih.gov/pubmed/20000882",
				"http://www.ncbi.nlm.nih.gov/pubmed/19664404",
				"http://www.ncbi.nlm.nih.gov/pubmed/19514618",
				"http://www.ncbi.nlm.nih.gov/pubmed/19074674",
				"http://www.ncbi.nlm.nih.gov/pubmed/18310678",
				"http://www.ncbi.nlm.nih.gov/pubmed/14981003",
				"http://www.ncbi.nlm.nih.gov/pubmed/19129742",
				"http://www.ncbi.nlm.nih.gov/pubmed/18757088",
				"http://www.ncbi.nlm.nih.gov/pubmed/18621770",
				"http://www.ncbi.nlm.nih.gov/pubmed/20028694",
				"http://www.ncbi.nlm.nih.gov/pubmed/19411283",
				"http://www.ncbi.nlm.nih.gov/pubmed/23067195"
			],
			"type": "summary",
			"id": "532f062ad6d3ac6a34000027",
			"snippets": [
				{
					"offsetInBeginSection": 1290,
					"offsetInEndSection": 1515,
					"text": "Ivabradine may be important for the improvement of clinical outcomes in patients with LV systolic dysfunction and heart rate β‰¥ 70 b.p.m., whatever the primary clinical presentation (CAD or HF) or clinical status (NYHA class).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536611",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 662,
					"offsetInEndSection": 888,
					"text": "Treatment with ivabradine was associated with a 13% relative risk reduction for the composite of cardiovascular mortality or HF hospitalization (P < 0.001 vs. placebo); this was driven by HF hospitalizations (19%, P < 0.001). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536611",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1437,
					"offsetInEndSection": 1766,
					"text": "Ivabradine (IVA), a pure HR lowering drug, reduces the demand of myocardial oxygen during exercise, contributes to the restoration of oxygen balance and is therefore beneficial in chronic CVD. No relevant negative effects have been observed on cardiac conduction, contractility, relaxation, repolarization or blood pressure (BP).",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23394554",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 2149,
					"offsetInEndSection": 2651,
					"text": "The most significant results were obtained in the subgroup of patients with life-limiting exertional angina. In this group, ivabradine significantly reduced the primary endpoint, a composite of cardiovascular death, hospitalization for fatal and nonfatal acute myocardial infarction (AMI) or heart failure, by 24%, and hospitalizations for AMI by 42%. In the subgroup of patients with baseline heart rate >70 bpm, hospitalizations for AMI and revascularization were reduced by 73% and 59%, respectively",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/23096376",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 406,
					"offsetInEndSection": 975,
					"text": "Indeed, heart rate reduction with ivabradine, a selective and specific I(f) inhibitor, reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate β‰¥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21878041",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1531,
					"offsetInEndSection": 1790,
					"text": "The beneficial effects of ivabradine may be due to the reversal of electrophysiological cardiac remodelling in post-MI rats by reduction of functional overexpression of HCN channels. This is attributable to transcriptional and post-transcriptional mechanisms.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/21838751",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1545,
					"offsetInEndSection": 1758,
					"text": "Addition of ivabradin to standard treatment of SCCF after MI promoted less frequency of hospitalizations, recurrent non-fatal MI, fatal cardiovascular events. This effect was especially strong in high baseline HR.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/22416440",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 864,
					"offsetInEndSection": 1447,
					"text": "The most important finding of the study was that patients with high baseline HR had an increase in serious cardiovascular events including death (34%), hospital admission secondary to congestive heart failure (53%), acute myocardial infarction (46%), or revascularization procedure (38%). In addition, in the subset analysis focusing on patients with baseline HR > or =70 bpm and left ventricular ejection fraction <40% the agent resulted in a 36% decrease in hospital admissions secondary to fatal and nonfatal myocardial infarction and a 30% decrease in coronary revascularization.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/20000882",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 708,
					"offsetInEndSection": 1078,
					"text": "In the subgroup of patients with a baseline heart rate > or =70 bpm, treatment with ivabradine resulted in a significant, 36% reduction in the risk of myocardial infarction and a 20% reduction in the need for coronary revascularisation. Ivabradine was well tolerated, with an increased rate of treatment discontinuation, mainly due to bradycardia, compared with placebo.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19664404",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1015,
					"offsetInEndSection": 1289,
					"text": "Ivabradine did not significantly affect the combined primary endpoint. Significant reduction by 36% (p = 0.001) in myocardial infarction and by 30% (p = 0.016) in coronary revascularization was observed in the pre-defined subgroup of patients with heart rate > or = 70/min. ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19514618",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1460,
					"offsetInEndSection": 1677,
					"text": "In conclusion, these data indicated that HR reduction by Iva prevents the worsening of LV dysfunction and remodeling that may be related to a downregulation of cardiac renin-angiotensin-aldosterone system transcripts.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19074674",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1229,
					"offsetInEndSection": 1342,
					"text": "Interstitial fibrosis in the MI-remote LV was markedly reduced by Iva (4.0 +/- 0.1 vs. 1.8 +/- 0.1%, P < 0.005). ",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/19074674",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1352,
					"offsetInEndSection": 1729,
					"text": "Although both metoprolol and ivabradine comparably prevented post-MI deterioration of haemodynamic function in the rat, metoprolol had additional potentially beneficial effects; it prevented LV dilation and hypertrophy, chronotropic incompetence, strongly increased contractility of isolated cardiomyocytes, and prevented the potentially proarrhythmic increase in NCX activity.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/18310678",
					"endSection": "abstract"
				},
				{
					"offsetInBeginSection": 1413,
					"offsetInEndSection": 1779,
					"text": "In rats with CHF, long-term HRR induced by the selective I(f) inhibitor ivabradine improves LV function and increases stroke volume, preserving cardiac output despite the HRR. The improvement of cardiac function is related not only to the HRR per se but also to modifications in the extracellular matrix and/or function of myocytes as a consequence of long-term HRR.",
					"beginSection": "abstract",
					"document": "http://www.ncbi.nlm.nih.gov/pubmed/14981003",
					"endSection": "abstract"
				}
			]
		}
	]
}